
<html lang="en"     class="pb-page"  data-request-id="1887f0cf-44a7-434c-9f49-6d4517aec841"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b00702"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists" /></meta><meta name="dc.Creator" content="Francisco&#xA;O.  Battiti" /></meta><meta name="dc.Creator" content="Sophie L.  Cemaj" /></meta><meta name="dc.Creator" content="Adrian M.  Guerrero" /></meta><meta name="dc.Creator" content="Anver Basha  Shaik" /></meta><meta name="dc.Creator" content="Jenny  Lam" /></meta><meta name="dc.Creator" content="Rana  Rais" /></meta><meta name="dc.Creator" content="Barbara S.  Slusher" /></meta><meta name="dc.Creator" content="Jeffery R.  Deschamps" /></meta><meta name="dc.Creator" content="Greg H.  Imler" /></meta><meta name="dc.Creator" content="Amy Hauck  Newman" /></meta><meta name="dc.Creator" content="Alessandro  Bonifazi" /></meta><meta name="dc.Description" content="Because of the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge...." /></meta><meta name="Description" content="Because of the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge...." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 19, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00702" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00702" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00702" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00702" /></link>
        
    
    

<title>The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00702" /></meta><meta property="og:title" content="The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0018.jpeg" /></meta><meta property="og:description" content="Because of the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike. Inspired by the potential for chemical modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity. We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R. In addition, a cyclopropyl moiety incorporated into the linker and full resolution of the chiral centers resulted in lead compound 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the reference compounds. Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00702"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00702">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00702&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00702&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00702&amp;href=/doi/10.1021/acs.jmedchem.9b00702" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6287-6314</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00657" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00717" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D<sub>3</sub> Receptor (D<sub>3</sub>R) Selective Agonists</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Francisco O. Battiti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francisco O. Battiti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francisco%0AO.++Battiti">Francisco O. Battiti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sophie L. Cemaj</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sophie L. Cemaj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sophie+L.++Cemaj">Sophie L. Cemaj</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adrian M. Guerrero</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adrian M. Guerrero</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adrian+M.++Guerrero">Adrian M. Guerrero</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anver Basha Shaik</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anver Basha Shaik</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anver+Basha++Shaik">Anver Basha Shaik</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jenny Lam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jenny Lam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div><div class="loa-info-affiliations-info">Johns Hopkins Drug Discovery Program, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jenny++Lam">Jenny Lam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rana Rais</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rana Rais</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Johns Hopkins Drug Discovery Program, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rana++Rais">Rana Rais</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4059-2453" title="Orcid link">http://orcid.org/0000-0003-4059-2453</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara S. Slusher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara S. Slusher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Johns Hopkins Drug Discovery Program, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara+S.++Slusher">Barbara S. Slusher</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9814-4157" title="Orcid link">http://orcid.org/0000-0001-9814-4157</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffery R. Deschamps</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffery R. Deschamps</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Naval Research Laboratory, Code 6910, 4555 Overlook Avenue, Washington, DC 20375, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffery+R.++Deschamps">Jeffery R. Deschamps</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Greg H. Imler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Greg H. Imler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Naval Research Laboratory, Code 6910, 4555 Overlook Avenue, Washington, DC 20375, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Greg+H.++Imler">Greg H. Imler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy Hauck Newman</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Hauck Newman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#c1a0afa4b6aca0af81a8afb5b3a0efafa8a5a0efafa8a9efa6aeb7"><span class="__cf_email__" data-cfemail="4a2b242f3d272b240a23243e382b6424232e2b64242322642d253c">[email protected]</span></a>. Phone: (443)-740-2887. Fax: (443)-740-2111 (A.H.N.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy+Hauck++Newman">Amy Hauck Newman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9065-4072" title="Orcid link">http://orcid.org/0000-0001-9065-4072</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Alessandro Bonifazi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alessandro Bonifazi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#5e3f323b2d2d3f303a2c31703c313037383f24376c1e30373670393128"><span class="__cf_email__" data-cfemail="b5d4d9d0c6c6d4dbd1c7da9bd7dadbdcd3d4cfdc87f5dbdcdd9bd2dac3">[email protected]</span></a>. Phone: (443)-740-2897. Fax: (443)-740-2111 (A.B.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alessandro++Bonifazi">Alessandro Bonifazi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7306-0114" title="Orcid link">http://orcid.org/0000-0002-7306-0114</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00702&amp;href=/doi/10.1021%2Facs.jmedchem.9b00702" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6287–6314</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 19, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 April 2019</li><li><span class="item_label"><b>Published</b> online</span>19 June 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00702</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6287%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DFrancisco%250AO.%2BBattiti%252C%2BSophie%2BL.%2BCemaj%252C%2BAdrian%2BM.%2BGuerrero%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D13%26contentID%3Dacs.jmedchem.9b00702%26title%3DThe%2BSignificance%2Bof%2BChirality%2Bin%2BDrug%2BDesign%2Band%2BSynthesis%2Bof%2BBitopic%2BLigands%2Bas%2BD3%2BReceptor%2B%2528D3R%2529%2BSelective%2BAgonists%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6314%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00702"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1812</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00702" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Francisco\nO.&quot;,&quot;last_name&quot;:&quot;Battiti&quot;},{&quot;first_name&quot;:&quot;Sophie&quot;,&quot;last_name&quot;:&quot;L. Cemaj&quot;},{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;M. Guerrero&quot;},{&quot;first_name&quot;:&quot;Anver&quot;,&quot;last_name&quot;:&quot;Basha Shaik&quot;},{&quot;first_name&quot;:&quot;Jenny&quot;,&quot;last_name&quot;:&quot;Lam&quot;},{&quot;first_name&quot;:&quot;Rana&quot;,&quot;last_name&quot;:&quot;Rais&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;S. Slusher&quot;},{&quot;first_name&quot;:&quot;Jeffery&quot;,&quot;last_name&quot;:&quot;R. Deschamps&quot;},{&quot;first_name&quot;:&quot;Greg&quot;,&quot;last_name&quot;:&quot;H. Imler&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Hauck Newman&quot;},{&quot;first_name&quot;:&quot;Alessandro&quot;,&quot;last_name&quot;:&quot;Bonifazi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6287-6314&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00702&quot;},&quot;abstract&quot;:&quot;Because of the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike. Inspired by the potential for chemical modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity. We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R. In addition, a cyclopropyl moiety incorporated into the linker and full resolution of the chiral centers resulted in lead compound 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the reference compounds. Moreover, the favorable metabolic stability in rat liver microsomes supports future studies &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00702&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00702" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00702&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00702" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00702&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00702" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00702&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00702&amp;href=/doi/10.1021/acs.jmedchem.9b00702" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00702" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00702" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26pmid%3D31257877%26genre%3Darticle%26aulast%3DBattiti%26date%3D2019%26atitle%3DThe%2BSignificance%2Bof%2BChirality%2Bin%2BDrug%2BDesign%2Band%2BSynthesis%2Bof%2BBitopic%2BLigands%2Bas%2BD3%2BReceptor%2B%2528D3R%2529%2BSelective%2BAgonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D13%26spage%3D6287%26epage%3D6314%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/jmcmar.2019.62.issue-13/20190711/jmcmar.2019.62.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Because of the large degree of homology among dopamine D<sub>2</sub>-like receptors, discovering ligands capable of discriminating between the D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor subtypes remains a significant challenge. Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike. Inspired by the potential for chemical modification of the D<sub>3</sub> preferential agonists (+)-PD128,907 (<b>1</b>) and PF592,379 (<b>2</b>), we synthesized bitopic structures to further improve their D<sub>3</sub>R selectivity. We found that the (2<i>S</i>,5<i>S</i>) conformation of scaffold <b>2</b> resulted in a privileged architecture with increased affinity and selectivity for the D<sub>3</sub>R. In addition, a cyclopropyl moiety incorporated into the linker and full resolution of the chiral centers resulted in lead compound <b>53</b> and eutomer <b>53a</b> that demonstrate significantly higher D<sub>3</sub>R binding selectivities than the reference compounds. Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Dopamine (DA) D<sub>3</sub> receptors (D<sub>3</sub>Rs) belong to the same D<sub>2</sub>-like receptor family as D<sub>2</sub>R and D<sub>4</sub>R subtypes, sharing a high level of homology with them.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6">(1−6)</a> Hypo- or hyperalteration of the D<sub>3</sub>R functionality with consequent changes in brain plasticity is associated with multiple neuropsychiatric disorders.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> D<sub>3</sub>Rs have recently been targeted for therapeutic potential, especially directed toward substance use disorders because of their discrete localization in the central nervous system (CNS).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, the development of small drug-like molecules able to activate (agonists and partial agonists) or block (antagonists) the signaling pathways regulated by these receptors, namely, Gi/o-protein-mediated inhibition of adenylyl cyclase or β-arrestin recruitment, has remained a challenge.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">The quest toward developing high affinity and selective D<sub>3</sub>R antagonists has been one of the successful focuses of our research laboratory, as well as for multiple other academic labs and pharmaceutical companies, over the last decade.<a onclick="showRef(event, 'ref3 ref8 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref3 ref8 ref11 ref12 ref13">(3,8,11−13)</a> D<sub>3</sub>R antagonists have been designed and pharmacologically evaluated, mainly for treatment of schizophrenia, psychosis, and substance use disorders.<a onclick="showRef(event, 'ref9 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref9 ref14 ref15 ref16">(9,14−16)</a> Little success has been achieved in advancing these compounds toward large clinical trials or FDA approval. For example, because of the high receptor expression in both CNS and periphery, most of the antipsychotic drugs acting as D<sub>2</sub>-like antagonists or partial agonists show significant side effects, including cardiovascular hypertension<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> and metabolic syndrome<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> associated with the blockade of dopaminergic receptors expressed in the β-pancreatic islets.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Similarly, D<sub>3</sub>R-selective antagonists have been extensively assessed preclinically for the treatment of psychostimulant use disorders.<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25">(21−25)</a> However, increase in blood pressure observed in dog models,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> when combined with cocaine, halted the development of GSK598,809 for this patient population.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Nevertheless, we have recently demonstrated that new generations of D<sub>3</sub>R antagonists may have potential in the treatment of opioid use disorders,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> significantly reducing self-administration of opioids in animal models, without detectable abuse liability.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a></div><div class="NLM_p">Various D<sub>3</sub>R agonists have been developed for the treatment of Parkinson’s disease and its locomotor-associated disorders.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Despite extensive efforts over the years, the design of D<sub>2</sub>-like receptor selective agonists has proven to be an elusive challenge.<a onclick="showRef(event, 'ref2 ref9 ref31'); return false;" href="javascript:void(0);" class="ref ref2 ref9 ref31">(2,9,31)</a> As mentioned above, this is likely due to the high degree of homology between the receptors’ orthosteric binding sites (OBS) recognized by the endogenous agonist DA to initiate physiological signaling activation. Indeed, most of the agonists currently used in therapies or as tools for in vitro and in vivo drug development [i.e., pramipexole ((<i>S</i>)-<i>N</i><sup>6</sup>-propyl-4,5,6,7-tetrahydrobenzo[<i>d</i>]thiazole-2,6-diamine), 7-OH-DPAT (7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol), ergoline derivatives and (+)-PD128,907 ((4a<i>R</i>,10b<i>R</i>)-4-propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-ol) (<b>1</b>)] show very limited D<sub>3</sub>R selectivity,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> with D<sub>3</sub>R over D<sub>2</sub>R selectivity of ∼10-fold. This could not only partially explain the cross-activation side effects observed in in vivo studies but could also limit validation of studies, where it is difficult to discern the effects from activation of similarly co-expressed receptor subtypes.</div><div class="NLM_p">Additionally, assessing agonist affinity and selectivity in binding studies could be challenging and radioligand-probe dependent, as we have discussed previously.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In fact, some of the high binding selectivities reported in the past for promising D<sub>3</sub>R agonists often do not directly translate into functional studies; this may be a consequence of the radiotracer probes and assay conditions used in radioligand competition experiments.</div><div class="NLM_p">With the goal of developing a new generation of improved D<sub>3</sub>R selective agonists, we have applied a well-established bitopic molecular approach to our drug design.<a onclick="showRef(event, 'ref11 ref12 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref33 ref34 ref35 ref36">(11,12,33−36)</a> We have previously demonstrated how combining a primary pharmacophore (PP) (recognizing the OBS) with a secondary pharmacophore (SP) [inspired by privileged structural synthons that are able to bind a secondary binding pocket (SBP) or an allosteric binding site (ABS)] can generate compounds with high subtype affinity, selectivity, as well as unique pharmacological behaviors (allosterism or biased agonism) as a consequence of highly specific ligand-induced receptor conformations.<a onclick="showRef(event, 'ref12 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref12 ref35 ref36">(12,35,36)</a> Among the multiple possible reasons for designing drugs targeting SBP and ABS, as mentioned before, one of the most obvious is selectivity. It is well known that GPCR OBS within receptor subfamilies activated by the same endogenous ligands are highly conserved, making it very difficult to develop drugs that can discriminate among them. ABS, SBP, and receptor pockets accommodating linkers with diverse chemical structures can be more specific for each protein, thus improving the odds of increased subtype selectivities, when specifically targeted in drug design. We have already demonstrated that the presence of specific SPs, and connecting linkers, is the key to achieving affinity, selectivity, and efficacy modulation, while the nature of the PP remains responsible for the retention of efficacy.<a onclick="showRef(event, 'ref11 ref12 ref36'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref36">(11,12,36)</a></div><div class="NLM_p">In particular, bitopic ligands presenting well-known OBS antagonist or partial agonist PPs, such as (2,3-dichlorophenyl)piperazine (e.g., aripiprazole (7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one), PG648 (<i>N</i>-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)-1<i>H</i>-indole-2-carboxamide), PG1037 ((<i>E</i>)-<i>N</i>-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-en-1-yl)-[1,1′-biphenyl]-4-carboxamide), BAK2-66 (<i>N</i>-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-fluorobutyl)benzofuran-2-carboxamide)),<a onclick="showRef(event, 'ref3 ref35 ref37'); return false;" href="javascript:void(0);" class="ref ref3 ref35 ref37">(3,35,37)</a> 1-(3-chloro-5-ethyl-2-methoxyphenyl)piperazine (e.g., eticlopride (5-chloro-3-ethyl-<i>N</i>-[[(2<i>S</i>)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide), VK4-116 (<i>N</i>-(4-(4-(3-chloro-5-ethyl-2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)-1<i>H</i>-indole-2-carboxamide)),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> 1-(2-chloro-3-ethylphenyl)piperazine (e.g., VK4-40 (<i>N</i>-(4-(4-(2-chloro-3-ethylphenyl)piperazin-1-yl)-3-hydroxybutyl)-1<i>H</i>-indole-2-carboxamide)),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (e.g., SB269,652 (1<i>H</i>-indole-2-carboxylic acid {4-[2-(cyano-3,4-dihydro-1<i>H</i>-isoquinolin-2-yl)-ethyl]-cyclohexyl}-amide)),<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> all maintained the functional profiles of their PPs, with a variety of allosteric pharmacological behaviors specifically induced by their linkers and SPs. Analogously, D<sub>2</sub>R-selective bitopic ligands built around the full agonist PP (e.g., sumanirole ((<i>R</i>)-5-(methylamino)-5,6-dihydro-4<i>H</i>-imidazo[4,5,1-<i>ij</i>]quinolin-2(1<i>H</i>)-one)),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> retained full agonism functionality with unique biased functional selectivity.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a></div><div class="NLM_p">Inspired by these findings, we selected two D<sub>3</sub>R preferential full agonists as our main PP scaffolds for chemical modification guided by structure–activity relationship (SAR) studies. Compound <b>1</b> is probably the most widely used D<sub>3</sub>R agonist for in vitro and in vivo studies. Despite its moderate subtype selectivity, and some preliminary SAR already reported,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> its structure showed multiple potential positions for additional synthetic modifications (e.g., phenolic alcohol and morpholine ring—<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In addition, compound PF592,379 (5-((2<i>R</i>,5<i>S</i>)-5-methyl-4-propylmorpholin-2-yl)pyridin-2-amine) (<b>2</b>)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> was reported by Pfizer Research and Development in early 2000s. As part of their work directed toward a new generation of D<sub>3</sub>R selective agonists, based on aminopyridine derivatives, they developed therapeutic agents for the treatment of multiple female sexual dysfunctions (i.e., female arousal disorder, hypoactive sexual desire disorder, and female orgasmic disorder), male erectile and ejaculatory dysfunctions, and pain.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Despite the discontinuation of its development, <b>2</b> caught our attention due to multiple functional groups in its core PP moiety which could be readily alkylated to generate the desired bitopic analogues (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), increasing its structural complexity to study multiple aspects of receptor–drug interactions. A similar approach, in modifying morpholine and/or aminopyridine nuclei of <b>2</b>, has been used by both Pfizer and Merck to generate libraries of molecules and SAR, which further informed our work and the choice of the structural synthons.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Moreover, the available extensive pharmacokinetic studies on <b>2</b>,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> particularly focused on absorption routes, bioavailability, metabolic pathways, and elimination in rats, dogs, and humans, enhanced our interest, and provided valuable information for drug design and future potential characterization of our identified leads. Drug self-administration and drug discrimination studies in rats<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> also confirmed the lack of abuse potential for <b>2</b>, which is an important requirement in the development of compounds enhancing dopaminergic signaling with potential therapeutic applications. Finally, the complex but efficient synthetic scheme reported for <b>2</b>, and its derivatives,<a onclick="showRef(event, 'ref42 ref43 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref45">(42,43,45)</a> was an excellent starting point, allowing us to chemically intervene in some of the key steps to obtain different chirality and regiochemistry according to our synthetic needs. Extensive stereochemical modifications were not pursued with <b>1</b>, which is commercially available as the D<sub>3</sub>R eutomer in the (4a<i>R</i>,10b<i>R</i>) absolute configuration, and thus this stereochemistry was retained for initial drug design and synthesis.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bitopic drug design based on <b>1</b> as the PP scaffold. The PPs are highlighted in red, the linker portion of the new bitopic analogues is highlighted in green, and all different SPs are highlighted in blue. The SAR studies were focused on (i) O-alkylation of the phenolic region of <b>1</b>, (ii) structural simplification of the PP via removal of the morpholine ring, (iii) preparation of <b>15</b> and subsequent <i>N</i>-alkylation at the morpholine nitrogen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Bitopic drug design based on PP scaffold <b>2</b>. The PP is highlighted in magenta, the linker portions of the new bitopic analogues are highlighted in green, and all the different SPs are highlighted in blue. The structural modifications of the PP focused on <i>N</i>-<i>n</i>-dipropylation at the aniline nitrogen, preparation of the nor-diastereoisomers, and subsequent <i>N</i>-alkylation at the morpholine nitrogen with different linkers and SPs. The linkers used in the SAR studies, to combine PP and SPs, included: (i) <i>n</i>-butyl, (ii) <i>E</i>-butenyl, (iii) <i>cis</i>- and <i>trans</i>-(methyl)cyclopropyl-methyl, and (iv) <i>trans</i>-(methyl)cyclopropyl-ethyl. When necessary, to further investigate SAR, all stereochemical combinations of diastereoisomers and/or enantiomers were prepared.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As depicted in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, the bitopic drug design based on scaffold <b>1</b> focused on (i) O-alkylation of the phenolic oxygen of <b>1</b>, (ii) structural simplification of the PP via removal of the morpholine ring, (iii) preparation of the nor-analogue <b>15</b> and subsequent (iv) N-alkylation of the morpholine nitrogen. Analogously, the structural modifications based on scaffold <b>2</b> as the PP (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) were directed toward (i) <i>N</i>,<i>N</i>-dipropylation at the aniline nitrogen, (ii) preparation of the nor-diastereoisomers, and subsequent (iii) N-alkylation of the morpholine nitrogen with the desired linkers and SPs. The linkers used in the SAR studies, to connect PP and SPs, included: (i) <i>n</i>-butyl,<a onclick="showRef(event, 'ref3 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref3 ref35 ref36">(3,35,36)</a> (ii) <i>E</i>-butenyl,<a onclick="showRef(event, 'ref3 ref49'); return false;" href="javascript:void(0);" class="ref ref3 ref49">(3,49)</a> (iii) <i>cis</i>- and <i>trans</i>-(methyl)cyclopropyl-methyl,<a onclick="showRef(event, 'ref12 ref50'); return false;" href="javascript:void(0);" class="ref ref12 ref50">(12,50)</a> and (iv) <i>trans</i>-(methyl)cyclopropyl-ethyl.<a onclick="showRef(event, 'ref12 ref50'); return false;" href="javascript:void(0);" class="ref ref12 ref50">(12,50)</a> The choice of linkers and SPs, as privileged synthons and molecular fragments, is a result of previous research which highlighted their essential role in modulating pharmacological properties of new compounds in unique directions, otherwise not obtainable via canonical agonist–OBS interaction.<a onclick="showRef(event, 'ref11 ref12 ref36 ref37 ref44 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref36 ref37 ref44 ref50 ref51">(11,12,36,37,44,50,51)</a> When necessary, all stereochemical combinations of diastereoisomers and/or enantiomers were prepared.</div><div class="NLM_p">All the newly synthesized compounds were tested in radioligand competition binding studies for on-target affinities (D<sub>2</sub>R, D<sub>3</sub>R, and D<sub>4</sub>R). Selected leads were further evaluated for metabolic stability in rat liver microsomes and metabolite identification to assess their applicability in future in vivo studies, in rodents.</div><div class="NLM_p last">The objective of this work was to generate new, small-molecule, D<sub>3</sub>R agonists with improved affinity, subtype selectivity, and high structural complexity (presence of multiple chiral centers fully resolved). These molecules and the SAR described will serve as tools for molecular biology, computational chemistry, and in vivo and in vitro pharmacology to disentangle questions about D<sub>3</sub>R dopaminergic signaling, otherwise difficult to address with the currently available ligands.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">We were interested in the potential of scaffold <b>1</b> as the PP and proceeded to synthesize a series of bitopic compounds with various canonical aromatic SPs. As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A, we initially envisioned connecting the linker at the phenolic oxygen through standard alkylation with <i>N</i>-(4-bromobutyl)phthalimide in the presence of excess potassium carbonate under reflux. Deprotection of the resulting phthalimide (<b>3</b>) yielded primary amine <b>4</b> which was used as a common intermediate to achieve compounds <b>5–10</b> via standard 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-mediated amide coupling with the appropriate carboxylic acid. Incorporation of the dihydroquinolin-2(1<i>H</i>)-one motif as SP (<b>11</b>) was achieved via alkylation of the phenol with 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one under standard basic conditions with potassium carbonate at reflux (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, KI, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (b) NH<sub>2</sub>NH<sub>2</sub>, EtOH, reflux; (c) DIPEA, EDC, HOBt, ArCOOH, 0 °C to RT; (d) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, KI, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux.</p></p></figure><div class="NLM_p">We envisioned the linker could also connect to scaffold <b>1</b> at the morpholine nitrogen via reductive amination, effectively substituting the propyl side chain of <b>1</b> with the linker and SP of choice. Aldehyde <b>14</b> was thus synthesized from the commercially available dihydroquinolin-2(1<i>H</i>)-one through alkylation of the phenol with (4-bromobutoxy)(<i>tert</i>-butyl)dimethylsilane and potassium carbonate, followed by deprotection of the (<i>tert</i>-butyl)dimethylsilane (TBDMS) group in <b>12</b> and Dess–Martin oxidation of resulting primary alcohol <b>13</b> to yield precursor aldehyde <b>14</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>A). We then proceeded to remove the propyl side chain of <b>1</b> by treatment with cyanogen bromide under exposure to microwave irradiation at elevated temperature and pressure (120 °C, 275 psi) to yield <b>15</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>B). Compound <b>16</b> was readily prepared, starting from <b>14</b> and <b>15</b>, via reductive amination with sodium triacetoxyborohydride (STAB) and catalytic acetic acid. Substitution at the N position in <b>16</b> was detrimental to the affinity of the <b>1</b> scaffold (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), and therefore, no more analogues were attempted.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (4-Bromobutoxy)(<i>tert</i>-butyl)dimethylsilane, K<sub>2</sub>CO<sub>3</sub>, EtOH, reflux; (b) 1 M TBAF, THF, RT; (c) DMP, DCM, 0 °C to RT; (d) (i) BrCN, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, microwave 120 °C, 275 psi, 75 W; (ii) 37% HCl/H<sub>2</sub>O (e) cat. AcOH, Na(OAc)<sub>3</sub>BH, <b>14</b>.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinity Data for Compounds Derived from <b>1</b> PP<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0014.gif" alt="" id="gr14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0015.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Radioligand competition binding assays performed on HEK293 cells stably expressing hD<sub>2</sub>R, hD<sub>3</sub>R, and hD<sub>4</sub>R in the presence of [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Equilibrium dissociation constants (<i>K</i><sub>i</sub>) were derived from IC<sub>50</sub> values using the Cheng–Prusoff equation. Each <i>K</i><sub>i</sub> value represents the arithmetic mean ± SEM; <i>n</i> = number of independent experiments, each performed in triplicate. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">Intrigued by the prospect of testing structurally simplified analogues of <b>1</b>, we proceeded to synthesize <b>19</b>, where the morpholine ring was removed while retaining the oxygen and nitrogen heteroatoms in the same position to preserve their H-bond accepting activity (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Intermediate <b>17</b> was synthesized via Neber rearrangement from commercially available 6-methoxy-4-chromanone as reported in the literature.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Subsequent HBr-assisted O-demethylation of <b>17</b> afforded <b>18</b>, which was used to form compound <b>19</b> via reductive amination with <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The enantiomers of the resulting analogue [enantiomeric separation achieved via preparative chiral high-pressure liquid chromatography (HPLC) as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Methods">Experimental Methods</a> section] exhibited decreased affinity in radioligand binding studies relative to the parent compound (<b>1</b>); therefore, no further analogues were synthesized.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 48% HBr in water, reflux; (b) AcOH, Na(OAc)<sub>3</sub>BH, <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> DCE, RT.</p></p></figure><div class="NLM_p">Relaying our efforts to scaffold <b>2</b>,<a onclick="showRef(event, 'ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44">(42−44)</a> we began by examining substitution at the aniline nitrogen (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>A), where the aniline was dialkylated using propionaldehyde and STAB at reflux. Substitution at the aniline nitrogen showed a detrimental effect on the binding profile of pharmacophore <b>2</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) redirecting us to the morpholine nitrogen for further manipulations (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>B). Starting from the <b>nor-21</b> mixture of diastereomers, achieved in a ∼3:1 mixture of (2<i>R</i>,5<i>S</i>)/(2<i>S</i>,5<i>S</i>) by reported synthetic methods,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><b>22</b> was synthesized via traditional alkylation with 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one and potassium carbonate at reflux. Encouraged by the affinity of <b>22</b>, the two diastereomers of <b>nor-21</b>, <b>23a</b>, and <b>23b</b> were separated via flash chromatography and used independently thereafter. Their diastereomeric purity was assessed via chiral analytical HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S1</a>); meanwhile, their absolute stereochemistry was confirmed via X-ray crystallography (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) of <b>23a</b> and by comparison with the previously reported spectroscopic data.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Starting from the two pure diastereomers, their respective bitopic compounds were synthesized in parallel. Compounds <b>24</b> and <b>26</b> were synthesized from their respective <b>nor-21</b> diastereomer via alkylation, analogous to <b>22</b> (chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S2</a>). Compounds <b>25</b> and <b>27</b> were constructed via reductive amination with <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S3</a>).</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) X-ray crystal structure of <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> [C8(<i>R</i>)–C6(<i>S</i>)]; (B) X-ray crystal structure of <b>23a</b>. The assigned absolute configuration for <b>(2<i>R</i>,5<i>S</i>)-23a</b> [C8(<i>R</i>)–C11(<i>S</i>)] and its spectroscopic data matches with the literature.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) AcOH, Na(OAc)<sub>3</sub>BH, propionaldehyde, ACN, reflux; (b) resolution via flash chromatography; (c) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, KI (cat.), K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (d) AcOH, Na(OAc)<sub>3</sub>BH, <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> DCE, RT.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Binding Affinity Data for Compounds Derived from <b>2</b> PP<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0016.gif" alt="" id="gr16" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0017.gif" alt="" id="gr17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Radioligand competition binding assays performed on HEK293 cells stably expressing hD<sub>2</sub>R, hD<sub>3</sub>R, and hD<sub>4</sub>R, in the presence of [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Equilibrium dissociation constants (<i>K</i><sub>i</sub>) were derived from IC<sub>50</sub> values using the Cheng–Prusoff equation. Each <i>K</i><sub>i</sub> value represents arithmetic mean ± SEM; <i>n</i> = number of independent experiments, each performed in triplicate. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">Having confirmed the privileged stereochemistry of the morpholine ring (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) with the compounds in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, we proceeded to examine the effect of structural changes on the linker. Initial efforts were aimed at synthesizing compounds <b>30</b> and <b>31</b>, the unsaturated analogues of <b>24</b> and <b>26</b>, respectively. As shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, allyl bromide was dimerized via cross olefin metathesis using Hoveyda–Grubbs catalyst second generation to form (<i>E</i>)-1,4-dibromobut-2-ene, <b>28</b>, in a 9:1 (<i>E</i>/<i>Z</i>) ratio.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Alkylation of 3,4-dihydroquinolin-2(1<i>H</i>)-one at the phenolic oxygen was accomplished with a slight excess of dibromobutene under gentle reflux conditions with potassium carbonate to yield <b>29</b>. Lastly, <b>30</b> and <b>31</b> were achieved from alkylation of <b>23a</b> and <b>23b</b> with <b>29</b>, respectively (chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S4</a>). The <i>E</i> stereochemistry of the olefin in the linker was further confirmed through nuclear Overhauser effect analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figures S5 and S6</a>).</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) HG-II Grubb’s catalyst, DCM; (b) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, KI, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (c) <b>23a</b> or <b>23b</b>, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux.</p></p></figure><div class="NLM_p">We were also interested in investigating the addition of a cyclopropyl ring to the linker. As reported in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, we began by constructing a 4-carbon linker with a cyclopropyl ring separated by one methylene unit from both pharmacophores. Similar to what has been previously described,<a onclick="showRef(event, 'ref12 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref12 ref55 ref56">(12,55,56)</a> starting from the mixture of isomers of ethyl 2-cyanocyclopropanecarboxylate, reduction with lithium aluminum hydride afforded amino alcohol <b>32</b>, which was then subjected to EDC-mediated amide coupling with indole-2 carboxylic acid, yielding <b>33</b>, establishing the SP in the desired position and preparing the alcohol necessary for the aldehyde intermediate. Previous efforts at accessing the separate <i>cis</i> and <i>trans</i> indole-cyclopropyl-alcohol intermediate in <b>33</b> have relied on distillation of the ethyl 2-cyanocyclopropanecarboxylate starting material to separate the <i>cis</i> and <i>trans</i> cyclopropyl moieties;<a onclick="showRef(event, 'ref12 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref12 ref55 ref56">(12,55,56)</a> however, we observed that <i>cis</i> and <i>trans</i><b>33</b> were readily separable by standard flash chromatography, allowing the use of the racemic ethyl 2-cyanocyclopropanecarboxylate starting material and circumventing less efficient distillation procedures. Having separated <i>cis</i> and <i>trans</i> cyclopropyl intermediates, we continued to prepare the desired aldehyde by Dess–Martin oxidation of the alcohol to achieve the exclusively <i>trans</i>-<b>34</b> and <i>cis</i>-<b>35</b> aldehydes. Reductive amination of the <i>cis</i> and <i>trans</i> aldehydes with <b>23a</b> and <b>23b</b> yielded four sets of diastereomers: <b>36</b>, <b>37</b>, <b>38</b>, and <b>39</b>. Compounds <b>36</b> and <b>39</b> have a fixed (2<i>R</i>,5<i>S</i>) stereochemistry at the morpholine ring, and both consist of two sets of enantiomers at the cyclopropyl ring: <b>36</b>, the two <i>trans</i>-cyclopropyl enantiomers, <b>39</b>, the two <i>cis</i>-cyclopropyl enantiomers. The same is true for compounds <b>37</b> and <b>38</b>; however, the morpholine ring in these is fixed with (2<i>S</i>,5<i>S</i>) stereochemistry. To extend our study of the effect of the structural configuration of the linker on the affinity of these bitopic ligands, when possible, we proceeded to separate the enantiomeric pairs across the cyclopropyl ring for <b>37</b>, <b>38</b>, and <b>39</b>. Using chiral preparative HPLC, these three diastereomeric sets were separated to yield the individual enantiomers. Six of the total eight possible enantiomers (one chiral center was fixed allowing for a total of eight enantiomers) were thus isolated (analytical chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S7</a>). Because of the challenges in achieving sufficient enantiomeric separation via preparative HPLC and being aware of the unfavorable conformation of its (2<i>R</i>,5<i>S</i>)-morpholine ring for binding pose, compound <b>36</b> was tested as the <i>trans</i> diastereomeric mixture (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S7</a>). Because of the moderate affinities observed (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), absolute stereochemistry of the individual enantiomers was not explored. Previous studies by our group had revealed that addition of the cyclopropyl ring to the linker may render the four-carbon length too short, and incorporation of an additional methylene unit between the cyclopropyl ring and SP yielded improved D<sub>3</sub>R binding selectivities and also produced intriguing pharmacological allosteric properties.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Consequently, the results from compounds <b>36</b>, <b>37</b>, <b>38</b>, and <b>39</b> suggested that the homologated analogues of these compounds had great potential as lead targets.</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) LiAlH<sub>4</sub>, THF, 0 °C to RT; (b) indole-2-carboxylic acid, DIPEA, EDC, HOBt, DCM, 0 °C to RT; (c) diastereoisomer separation via flash chromatography; (d) DMP, DCM, 0 °C to RT; (e) cat. AcOH, Na(OAc)<sub>3</sub>BH, <b>23a</b> or <b>23b</b>, DCE; (f) chiral resolution via preparative chiral HPLC (AD-H column) or flash chromatography.</p></p></figure><div class="NLM_p">Binding data collected from compounds <b>24</b>, <b>25</b>, <b>26</b>, <b>27</b>, <b>30</b>, and <b>31</b> had conclusively shown the (2<i>S</i>,5<i>S</i>) stereochemistry at the morpholine to be significantly privileged over the (2<i>R</i>,5<i>S</i>) stereochemistry. As a result, we were poised to optimize a new diastereoselective synthetic strategy that would access the desired (2<i>S</i>,5<i>S</i>) diastereomer, <b>23b</b>, selectively, given the current synthetic strategy to access the <b>nor-21</b> scaffold yielded a 3:1 ratio in favor of the undesired diastereomer.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Rapid access to large amounts of the desired (2<i>S</i>,5<i>S</i>) diastereomer became particularly important as we endeavored to develop a new set of compounds containing a five carbon-length linker with a cyclopropyl ring. Thus, we adapted the diastereoselective synthetic scheme already reported for the synthesis of the (2<i>R</i>,5<i>S</i>)-diatereoisomer<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> toward obtaining the desired (2<i>S</i>,5<i>S</i>) absolute configuration.</div><div class="NLM_p">Our new diastereoselective approach to access <b>23b</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>A) features the enantioselective reduction of the α-chloroketone 2-chloro-1-(6-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)pyridin-3-yl)ethan-1-one, synthesized in two steps from readily available materials,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> with (+)-<i>B</i>-chlorodiisopinocampheylborane ((+)-DIP-Cl) to yield <b>47</b> selectively in a 97.5:2.5 enantiomeric ratio as determined by analytical chiral HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S8</a>). This reduction step allowed the installation of the right stereochemistry at the key chiral center in <b>23b</b>. Compound <b>47</b> was then treated with potassium carbonate to yield epoxide <b>48</b> quantitatively and then achieve <b>49</b> via epoxide opening with (<i>S</i>)-(+)-2-aminopropanol (<span class="smallcaps smallerCapital">l</span>-alaninol). Formation of intermediate epoxide <b>48</b> was found to be crucial for the successful nucleophilic attack of the <span class="smallcaps smallerCapital">l</span>-alaninol amine; nucleophilic displacement of the chlorine did not occur under any conditions tested with <b>47</b> and <span class="smallcaps smallerCapital">l</span>-alaninol. With <b>49</b> successfully synthesized, both key chiral centers of <b>23b</b> had been established with the desired <i>S</i> stereochemistry. Following carboxybenzyl (Cbz) protection of the secondary amine in <b>49</b> with <i>N</i>-(benzyloxycarbonyloxy)succinimide, the morpholine ring was closed under traditional Mitsunobu conditions to displace the less hindered primary alcohol and yield the fully constructed scaffold of <b>23b</b>. Deprotection of the 2,5-dimethylpyrrole protecting group with hydroxylamine hydrochloride followed by deprotection of the Cbz group via palladium hydroxide on carbon (Pd(OH)<sub>2</sub>/C)-catalyzed hydrogenation yielded <b>23b</b>. With this rapid diastereoselective route, we could now proceed to synthesize the desired bitopic compounds with a five-carbon cyclopropyl linker.</div><div class="NLM_p">Our group had previously shown the trans conformation across the cyclopropyl ring to be favorable over the cis conformation for an array of bitopic compounds.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> As a result, we began by synthesizing racemic <i>trans</i> bitopic compound <b>53</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>A). Starting with trans aldehyde <i>N</i>-(2-(2-formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide, synthesized selectively with trans stereochemistry, from our previously reported procedure,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> standard reductive amination conditions with <b>23b</b> gave us access to <b>53</b> in good yields. We further separated the <i>trans</i>-<b>53</b> racemic mixture with preparative chiral HPLC to isolate two trans cyclopropyl enantiomers <b>53a</b> and <b>53b</b> (analytical chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S9</a>).</div><div class="NLM_p">The excellent affinity and selectivity exhibited by <b>53a</b> over <b>53b</b> prompted us to determine the absolute stereochemistry of these two diastereoisomers. We identified the absolute stereochemistry of the <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> intermediate, isolated via chiral HPLC resolution (analytical chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S10</a>), in the synthesis of the linker (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>), by X-ray crystallography (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). As a result, we had HPLC and optical rotation information of the two <i>trans</i> enantiomers of alcohols <b>(+)-(1<i>S</i>,2<i>R</i>)-43</b> and <b>(−)-(1<i>R</i>,2<i>S</i>)-44</b> (analytical chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S11</a>), and aldehydes <b>(−)-(1<i>S</i>,2<i>R</i>)-45</b> and <b>(+)-(1<i>R</i>,2<i>S</i>)-46</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Separation of the two trans enantiomers could also be readily accomplished for alcohol intermediate <b>54</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>B), which was separated via preparative chiral HPLC into <b>(+)-43</b> and <b>(−)-44</b> (analytical chiral HPLC chromatograms in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S12</a>), from which the absolute stereochemistry of both was determined comparing to reported analytical HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figure S12</a>) and specific optical rotation, with the same compounds prepared as in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Knowing the absolute configuration of both enantiomers of alcohol <b>54</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>B), <b>(+)-43</b> and <b>(−)-44</b> were converted to the corresponding aldehydes by Dess–Martin oxidation, followed by reductive amination with <b>23b</b> to yield <b>53a,b</b>, with the stereochemistry at all four chiral centers fully resolved and assigned (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>B). The use of analytical HPLC was essential at every step of this sequence to ensure that the correct stereochemistry was assigned (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Figures S13 and S14</a>).</div><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>a) CH<sub>3</sub>NO<sub>2</sub>, <i>t</i>-BuOLi, <i>t</i>-BuOH/THF, 0 °C to RT; (b) MsCl, TEA, DCM, 0 °C to RT, followed by preparative chiral HPLC resolution; (c) LAH, THF, 0 °C to reflux; (d) EDC, HOBt, DIPEA, THF, 0 °C to RT; (e) DMP, DCM, RT.</p></p></figure><figure id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (+)-DIP, <sup><i>t</i></sup>BuOMe/THF (7:3), −40 °C to RT; (b) K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (c) (<i>S</i>)-2-aminopropan-1-ol, toluene, reflux; (d) <i>N</i>-(benzyloxycarbonyloxy)succinimide, THF, −40 °C to RT; (e) DIAD, PPh<sub>3</sub>, toluene, RT; (f) hydroxylamine hydrochloride (NH<sub>2</sub>OH·HCl), EtOH, reflux; (g) H<sub>2</sub> (50 psi), Pd(OH)<sub>2</sub>/C; (h) cat. AcOH, Na(OAc)<sub>3</sub>BH, <i>N</i>-(2-(2-formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref12 ref36'); return false;" href="javascript:void(0);" class="ref ref12 ref36">(12,36)</a> DCE; (i) chiral resolution via preparative chiral HPLC-ADH; (j) chiral resolution via preparative chiral HPLC-ADH; (k) DMP, DCM, 0 °C to RT; (l) cat. AcOH, Na(OAc)<sub>3</sub>BH.</p></p></figure><div class="NLM_p">Further, we wished to investigate the importance of the PP in the activity observed by these bitopic molecules. Thus, as additional SAR investigations on the nature of the PP to induce agonist or antagonist profiles, we proceeded to synthesize bitopic molecules containing the same initial linker and SP used in scaffolds <b>1</b> and <b>2</b>, with PPs widely characterized as D<sub>3</sub>R-selective antagonists.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> As shown in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>, from standard alkylation of two substituted phenylpiperazines with 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, we synthesized compounds <b>57</b> and <b>58</b>, respectively.</div><figure id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) K<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-DMF, 90 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Radioligand Binding Data</h3><div class="NLM_p last">The affinities of the new compounds were tested by radioligand competition binding assays at hD<sub>2</sub>R, hD<sub>3</sub>R, and hD<sub>4</sub>R using agonist [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT as the radiotracer. We have previously demonstrated and established how competition against an agonist radioligand allows a more accurate determination of affinities for novel unlabeled D<sub>2</sub>-like agonists.<a onclick="showRef(event, 'ref31 ref32 ref57'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref57">(31,32,57)</a> Importantly, affinities of D<sub>2</sub>-like agonists and partial agonists, when determined in competition against an agonist radioligand probe, reflect binding the receptors in their “active” state. The D<sub>3</sub>R preferential agonists, pramipexole <b>1</b> and the diastereomeric mixture of <b>2</b> (synthesized as reported<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>), were tested in parallel with the new bitopic analogues, and in the same assay conditions, to allow a direct comparison of affinities and receptor subtype selectivity.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> SAR Based on <b>1</b> as the PP</h3><div class="NLM_p last">Consistent with the literature, <b>1</b> showed low nanomolar affinity for D<sub>3</sub>R (<i>K</i><sub>i</sub> = 1.69 nM) but only a moderate 12-fold selectivity over D<sub>2</sub>R. A very similar profile was observed for pramipexole as well, (D<sub>3</sub>R <i>K</i><sub>i</sub> = 1.69 nM; D<sub>2</sub>R/D<sub>3</sub>R = 8.41), confirming the need for more selective D<sub>3</sub>R agonists as pharmacological tools for in vitro and in vivo studies. Our studies proved that every structural modification that was made to scaffold <b>1</b> markedly reduced or completely prevented binding at either D<sub>2</sub>R and/or D<sub>3</sub>R (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Indeed, phenolic −OH is essential for high D<sub>3</sub>R binding affinity because all O-alkylated derivatives completely lost affinity (D<sub>3</sub>R <i>K</i><sub>i</sub>s ranging from 613 to 11 300 nM) and subtype selectivity (D<sub>2</sub>R/D<sub>3</sub>R ratios <10-fold), independent from the structure of the SPs. Analogously, the tertiary basic center is also essential for high affinity at D<sub>3</sub>R of <b>1</b>. Indeed, the nor-analogue <b>15</b> showed >200-fold reduced affinity at both D<sub>2</sub>R and D<sub>3</sub>R, despite maintaining a similar 10-fold selectivity over D<sub>2</sub>R. The replacement of the <i>n</i>-propyl chain with the <i>n</i>-butyl linker and SP was also detrimental. Particularly, introducing 3,4-dihydroquinolin-2(1<i>H</i>)-one, which is known to be a D<sub>2</sub>-like privileged SP,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> present in the structure of the D<sub>2</sub>R partial agonist aripiprazole, resulted in complete loss of affinity (<b>16</b>; <i>K</i><sub>i</sub>s > 5000 nM at both D<sub>2</sub>R and D<sub>3</sub>R), confirming that <b>1</b> is a privileged pharmacophore with structural features that cannot be altered to pursue more complex derivatives in its currently available geometrical configuration. Even the simplification of the scaffold, by removal of the morpholine ring, as depicted in enantiomers <b>19a</b> and <b>19b</b>, induced >100–1000-fold loss of affinity at both receptor subtypes, independently from the absolute configuration of the stereocenter. However, in the design of bitopic antagonists, alkylation of the phenyl-piperazine basic nitrogen with different eticlopride (known potent D<sub>2</sub>/D<sub>3</sub> orthosteric antagonist)-inspired PPs<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> seems to be better tolerated. Indeed, both compounds <b>57</b> and <b>58</b>, sharing the same 3,4-dihydroquinolin-2(1<i>H</i>)-one SP showed high affinities at both receptor subtypes (<b>57</b>: D<sub>2</sub>R <i>K</i><sub>i</sub> = 1.86 nM, D<sub>3</sub>R <i>K</i><sub>i</sub> = 40.9 nM; <b>58</b>: D<sub>2</sub>R <i>K</i><sub>i</sub> = 0.844 nM, D<sub>3</sub>R <i>K</i><sub>i</sub> = 2.42 nM), and <b>57</b> presented 22-fold selectivity for D<sub>2</sub>R over D<sub>3</sub>R. This selectivity profile also confirmed that the 3,4-dihydroquinolin-2(1<i>H</i>)-one SP promotes better recognition of the D<sub>2</sub>R, as observed in previously reported aripiprazole-based SARs.<a onclick="showRef(event, 'ref35 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref35 ref58 ref59">(35,58,59)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> SAR Based on <b>2</b> as the PP</h3><div class="NLM_p">Compound <b>2</b> was presented for the first time by Pfizer, as part of a new series of selective D<sub>3</sub>R agonists, based on variously substituted aminopyridines, as potential therapeutic agents for the treatment of female sexual dysfunctions.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Pfizer explored the structural requirements of the orthosteric PP scaffold of <b>2</b> in SAR studies based on regiochemical substitutions on the morpholine ring, modulation of the basic nature of the morpholine by converting it to cyclic amides, as well as introducing alkyl and aromatic groups in both aniline and morpholine nitrogen, respectively.<a onclick="showRef(event, 'ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44">(42−44)</a> Compound <b>2</b> presents two chiral centers in the morpholine moiety, and Pfizer focused their initial work on the development of the (2<i>R</i>,5<i>S</i>)-enantiomer. In order to better evaluate the significance of the chirality on the morpholine ring and understand how the new extended bitopic molecules would change the stereochemical requirements for optimal recognition of the D<sub>3</sub>R OBS and SBP, we prepared and tested all possible diastereomeric combinations.</div><div class="NLM_p">We synthesized and tested <b>2</b> as a 3:1 diastereomeric mixture of (2<i>R</i>,5<i>S</i>) and (2<i>S</i>,5<i>S</i>), following the synthetic schemes previously described.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The affinity observed in our binding assays was consistent with those previously reported,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> confirming a moderate D<sub>3</sub>R affinity (<i>K</i><sub>i</sub> = 185 nM) and a preferential selectivity for D<sub>3</sub>R over D<sub>2</sub>R (9.4-fold D<sub>3</sub>R selective). Although its D<sub>3</sub>R affinity was not comparable to <b>1</b>, <b>2</b> showed more versatility in terms of chemical modifications, and its lower affinity and selectivity implied significant room for pharmacological improvements. In order to identify the positions that better tolerated substitutions, the affinities of <b>20</b> (presenting <i>n</i>-dipropyl substituents on the aniline nitrogen) and the two nor-diastereoisomers <b>(2<i>R</i>,5<i>S</i>)-23a</b> and <b>(2<i>S</i>,5<i>S</i>)-23b</b> were assessed and compared. As expected, alkylation of the aniline nitrogen resulted in complete loss of D<sub>2</sub>-like affinity (<i>K</i><sub>i</sub> > 5000 nM and >10 000 nM for D<sub>2</sub>R and D<sub>3</sub>R, respectively). Dealkylation of the morpholine nitrogen also decreased affinity for both receptor subtypes of ∼3–9 fold, suggesting that a tertiary nitrogen is preferred. However, the first interesting observation was that among the two nor-analogues, the <b>(2<i>S</i>,5<i>S</i>)-23b</b> diastereoisomer was the one showing a slightly higher affinity for D<sub>3</sub>R (<i>K</i><sub>i</sub> = 424 nM), giving a first indication of a preferential enantiospecificity. The importance of the morpholine ring chirality and its high enantiospecificity in binding D<sub>3</sub>R was highlighted in a definitive manner by the affinity profiles of all newly prepared bitopic analogues. Indeed, when comparing couples of diastereoisomers <b>(2<i>R</i>,5<i>S</i>)-24</b> and <b>(2<i>S</i>,5<i>S</i>)-26</b> (presenting the 3,4-dihydroquinolin-2(1<i>H</i>)-one SP), and <b>(2<i>R</i>,5<i>S</i>)-25</b> and <b>(2<i>S</i>,5<i>S</i>)-27</b> (presenting the 2-indole butylamide SP), we observed how (2<i>S</i>,5<i>S</i>) stereochemistry is privileged for high D<sub>3</sub>R affinity. Particularly, <b>(2<i>S</i>,5<i>S</i>)-27</b> showed low nanomolar D<sub>3</sub>R affinity (<i>K</i><sub>i</sub> = 5.96 nM), >1000-fold higher when compared to its <b>(2<i>R</i>,5<i>S</i>)-25</b> inactive diastereoisomer, and 30-fold higher when compared to parent molecule <b>2</b>. This observation not only confirmed the success of the bitopic molecular approach in achieving high affinity but also <b>(2<i>S</i>,5<i>S</i>)-27</b> presented an improved D<sub>3</sub>R subtype selectivity (22.5-fold selective over D<sub>2</sub>R) and underscored the significance of the stereochemistry for the morpholine ring position-2 in order to obtain optimal binding interactions. Similarly, <b>(2<i>S</i>,5<i>S</i>)-26</b> has a D<sub>3</sub>R affinity 775-fold better with respect to its <b>(2<i>R</i>,5<i>S</i>)-24</b> diastereoisomer, but an overall lack of subtype selectivity, consistent with the presence of 3,4-dihydroquinolin-2(1<i>H</i>)-one SP, which, as discussed above, improves D<sub>2</sub>R subtype binding.</div><div class="NLM_p">Having identified the best stereochemical combination for the PP, we focused our attention on the nature of the linker portion of the molecules. We have published extensively on the role of the linkers as critical modulators of the pharmacological profiles of bitopic ligands.<a onclick="showRef(event, 'ref11 ref12 ref35 ref36 ref37 ref49'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref35 ref36 ref37 ref49">(11,12,35−37,49)</a> We assessed how linkers differing in length, rigidity, and chirality can help improve binding affinities, receptor subtype selectivity, and enhance allosteric properties and biased agonism. Among multiple structural manipulations of linkers, introduction of rigid elements, such as a double bond or cyclopropyl ring is some of the most well-studied functionalizations used in developing SARs.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In this new series of analogues, the presence of a trans double bond resulted in a complete loss of binding at both D<sub>2</sub>R and D<sub>3</sub>R [<b>(2<i>R</i>,5<i>S</i>)-30</b> and <b>(2<i>S</i>,5<i>S</i>)-31</b>]. However, we were intrigued by assessing the potential of a cyclopropyl ring in the linker. The addition of either <i>cis</i> or <i>trans</i> cyclopropyl rings introduced two extra chiral centers in the bitopic compounds, increasing the total number of the possible diastereoisomers but allowing a detailed screening of the spatial requirements needed to maximize ligand–receptor interactions. Consistent with previous studies performed on D<sub>3</sub>R antagonists, when the cyclopropyl was embedded in a butyl chain,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> the linker was too short for optimal binding, and all compounds, independent from the stereochemical combinations tested, resulted in moderate or poor D<sub>3</sub>R affinity and selectivity. However, the resolved diastereoisomers rel-<b><i>trans</i>-(2<i>S</i>,5<i>S</i>)-37a</b> and rel-<b><i>trans</i>-(2<i>S</i>,5<i>S</i>)-37b</b>, despite their relatively low D<sub>3</sub>R affinity, showed some indications that <i>trans</i>-cyclopropyl is the preferred binding configuration, and that among the two <i>trans</i> enantiomers, there might be enantiospecificity toward receptor subtype recognition. Indeed, <b><i>trans</i>-(2<i>S</i>,5<i>S</i>)-37a</b> showed a slightly preferential (∼5-fold) affinity for D<sub>2</sub>R (<i>K</i><sub>i</sub> = 216 nM); meanwhile, <b><i>trans</i>-(2<i>S</i>,5<i>S</i>)-37b</b> preferentially binds D<sub>3</sub>R (<i>K</i><sub>i</sub> = 404 nM). Based on these observations, extending the cyclopropyl linker by one extra methylene unit, reaching the optimal linker length and regiochemistry,<a onclick="showRef(event, 'ref12 ref36'); return false;" href="javascript:void(0);" class="ref ref12 ref36">(12,36)</a> successfully yielded rel-<b><i>trans</i>-(2<i>S</i>,5<i>S</i>)-53</b>, which showed a significantly improved D<sub>3</sub>R affinity (<i>K</i><sub>i</sub> = 2.84 nM) and selectivity over D<sub>2</sub>R (D<sub>2</sub>R/D<sub>3</sub>R = 37.3).</div><div class="NLM_p last">To further disentangle the importance of the chirality of the cyclopropyl ring, its two enantiomers were resolved; compounds obtained presented four chiral centers with all absolute configurations assigned. Binding studies on these analogues provided critical insights on how specific stereochemistry at the PP, as well as in the linker, is essential to achieve the highest affinities in this new series of compounds and the highest D<sub>3</sub>R selectivity observed for bitopic agonists. Compound <b>53a</b>, presenting (2<i>S</i>,5<i>S</i>)-PP configuration and (1<i>R</i>,2<i>S</i>)-<i>trans</i>-cylopropyl stereochemistry, showed D<sub>3</sub>R <i>K</i><sub>i</sub> = 1.85 nM and an unprecedented 47.5-fold selectivity for D<sub>3</sub>R over D<sub>2</sub>R (D<sub>2</sub>R <i>K</i><sub>i</sub> = 87.8 nM). Instead, its (1<i>S</i>,2<i>R</i>)-<i>trans</i>-cyclopropyl diastereoisomer <b>53b</b> showed 152-fold reduced affinity for D<sub>3</sub>R (<i>K</i><sub>i</sub> = 282 nM) and complete loss of selectivity (D<sub>2</sub>R <i>K</i><sub>i</sub> = 831 nM, D<sub>2</sub>R/D<sub>3</sub>R = 2.95). Moreover, competition binding experiments for <b>53</b>, <b>53a</b>, <b>53b</b>, and <b>27</b> in the presence of antagonist [<sup>3</sup>H]-<i>N</i>-methylspiperone (similar assay conditions to previously described protocols)<a onclick="showRef(event, 'ref11 ref13 ref31'); return false;" href="javascript:void(0);" class="ref ref11 ref13 ref31">(11,13,31)</a> provided initial evidence of the new compounds’ agonist profile. Indeed, their affinities were significantly reduced for all D<sub>2</sub>-like receptor subtypes, and their D<sub>3</sub>R selectivity increased, (<b>53</b>: D<sub>2</sub>R <i>K</i><sub>i</sub> = 8280 ± 462 nM (<i>n</i> = 3), D<sub>3</sub>R <i>K</i><sub>i</sub> = 34 ± 2.23 nM (<i>n</i> = 3), D<sub>4</sub>R <i>K</i><sub>i</sub> = 6650 ± 662 nM (<i>n</i> = 3), D<sub>2</sub>R/D<sub>3</sub>R = 244, D<sub>4</sub>R/D<sub>3</sub>R = 196; <b>53a</b>: D<sub>2</sub>R <i>K</i><sub>i</sub> = 1610 ± 94 nM (<i>n</i> = 3), D<sub>3</sub>R <i>K</i><sub>i</sub> = 5.36 ± 0.522 nM (<i>n</i> = 3), D<sub>4</sub>R <i>K</i><sub>i</sub> = 1520 ± 109 nM (<i>n</i> = 3), D<sub>2</sub>R/D<sub>3</sub>R = 300, D<sub>4</sub>R/D<sub>3</sub>R = 284; <b>53b</b>: D<sub>2</sub>R <i>K</i><sub>i</sub> = 70 600 ± 15 900 nM (<i>n</i> = 3), D<sub>3</sub>R <i>K</i><sub>i</sub> = 2900 ± 463 nM (<i>n</i> = 3), D<sub>4</sub>R <i>K</i><sub>i</sub> = 62 700 ± 25 600 nM (<i>n</i> = 3), D<sub>2</sub>R/D<sub>3</sub>R = 24, D<sub>4</sub>R/D<sub>3</sub>R = 22; <b>27</b>: D<sub>2</sub>R <i>K</i><sub>i</sub> = 21 000 ± 1160 nM (<i>n</i> = 3), D<sub>3</sub>R <i>K</i><sub>i</sub> = 182 ± 28.3 nM (<i>n</i> = 3), D<sub>4</sub>R <i>K</i><sub>i</sub> = 16 800 ± 3470 nM (<i>n</i> = 3), D<sub>2</sub>R/D<sub>3</sub>R = 115, D<sub>4</sub>R/D<sub>3</sub>R = 92) when compared to the <i>K</i><sub>i</sub> obtained in competition versus agonist [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This is consistent with our extensive experimental observations<a onclick="showRef(event, 'ref32 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref32 ref35 ref36">(32,35,36)</a> on how agonists cannot compete in the same way with antagonist radiotracers, thus highlighting the need for accurate assay conditions to determine affinity and receptor subtype selectivities, which could be otherwise under- and overestimated, respectively. Moreover, these data seem to suggest that while D<sub>2</sub>R and D<sub>3</sub>R adopt different antagonist-bound conformations, facilitating the development of selective antagonists, the higher similarity of their agonist-bound states is reflected in the inherent difficulty of developing subtype selective agonists.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Phase I Metabolic Stability of <b>53</b> in Rat Liver Microsomes and Metabolite Identification</h3><div class="NLM_p">Compound <b>53</b> presented affinity and selectivity profiles very similar to eutomer <b>53a</b>; thus, it was selected for metabolic stability evaluation and to be considered as a candidate for future in vivo studies. Compound <b>53</b> showed moderate stability to phase I metabolism in rat liver microsomes fortified with NADPH with 53 ± 1% intact remaining at 60 min, post incubation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). The compound shows complete stability controls without NADPH suggesting specific CYP-dependent metabolism. Lastly, the metabolites formed due to phase I metabolism were identified using high-resolution mass spectrometry (MS) and are reported in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B.</div><figure id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Metabolic stability of <b>53</b>. The compound shows moderate instability to phase I metabolism in rat liver microsomes fortified with NADPH. Compound <b>53</b> shows complete stability in the negative control without NADPH. (B) Metabolite Identification of <b>53</b> following phase I metabolic stability using high-resolution MS. The major phase I metabolite was determined to be the hydroxylated product (<i>m</i>/<i>z</i> = 450.2498; *note the position assigned to the hydroxyl group is arbitrary). Minor metabolites were identified to be N-dealkylation (<i>m</i>/<i>z</i> = 194.1288) and the oxidation (<i>m</i>/<i>z</i> = 432.2293) products.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Herein, we demonstrated how SAR studies based on well-defined stereochemistry led to the identification of new high affinity and selectivity D<sub>3</sub>R agonist <b>53a</b>. In particular, we observed that (i) <b>1</b> is a unique compound, and in its current structural conformations, it cannot be altered or simplified to pursue more complex derivatives, (ii) a complete inversion of configuration at the chiral center in position-2 is essential to successfully develop new bitopic ligands based on <b>2</b> [(2<i>S</i>,5<i>S</i>)- is the only morpholine ring configuration tolerated, for optimal D<sub>3</sub>R binding, by all bitopic analogues studied]; (iii) cyclopropyl linkers optimized in their length, relative regiochemical positions of PP and SP, and relative and absolute stereochemistry [(1<i>R</i>,2<i>S</i>) is the privileged cyclopropyl configuration] can dramatically modulate pharmacological profiles.</div><div class="NLM_p">The high molecular complexity of <b>53a</b>, combined with its fully resolved tridimensional structure, and unprecedented D<sub>3</sub>R agonist affinity/selectivity will undoubtedly aid computational studies to better understand D<sub>3</sub>R ligand–receptor interactions, as well as underscore potential biased agonism as a consequence of specific receptor conformations.</div><div class="NLM_p last">Moreover, because of the large degree of homogeneity among the D<sub>2</sub>-like family of DA receptors and consequent lack of selective agonists, <b>53</b> and eutomer <b>53a</b>, presenting the highest D<sub>3</sub>R to D<sub>2</sub>R binding selectivity reported for agonists, to date, may have the potential to become the main pharmacological reference tools for future D<sub>3</sub>R in vitro and/or in vivo studies, taking into account the promising metabolic stability of <b>53</b> in rat liver microsomes.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p last">All chemicals and solvents were purchased from chemical suppliers unless otherwise stated and used without further purification. All melting points were determined on an OptiMelt automated melting point system and are uncorrected. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Varian Mercury Plus 400 instrument. Proton chemical shifts are reported as parts per million (δ ppm) relative to tetramethylsilane (0.00 ppm) as an internal standard or to deuterated solvents. Coupling constants are measured in hertz. Chemical shifts for <sup>13</sup>C NMR spectra are reported as parts per million (δ ppm) relative to deuterated CHCl<sub>3</sub> or deuterated MeOH (CDCl<sub>3</sub> 77.5 ppm, CD<sub>3</sub>OD 49.3 ppm). Chemical shifts, multiplicities, and coupling constants (<i>J</i>) have been reported and calculated using VnmrJ Agilent-NMR 400MR or MNova 9.0 software. Gas chromatography–MS (GC/MS) data were acquired (where obtainable) using Agilent Technologies (Santa Clara, CA) 7890B GC equipped with an HP-5MS column (cross-linked 5% PH ME siloxane, 30 m × 0.25 mm i.d. × 0.25 μm film thickness) and a 5977B mass-selective ion detector in the electron-impact mode. Ultrapure grade helium was used as the carrier gas at a flow rate of 1.2 mL/min. The injection port and transfer line temperatures were 250 and 280 °C, respectively, and the oven temperature gradient used was as follows: the initial temperature (70 °C) was held for 1 min and then increased to 300 °C at 20 °C/min and maintained at 300 °C for 4 min, with a total run time of 16.5 min. Column chromatography was performed using a Teledyne Isco CombiFlash RF flash chromatography system or a Teledyne Isco EZ-Prep chromatography system. Preparative thin layer chromatography was performed on Analtech silica gel plates (1000 μm). Preparative chiral HPLC was performed using a Teledyne Isco EZ-Prep chromatography system or an Agilent Technologies HP series 1200 system, with the diode array detector (DAD) and ELS detectors. HPLC analysis was performed using an Agilent Technologies 1260 Infinity system coupled with the DAD. Separation of the analyte, purity, and enantiomeric/diastereomeric excess determinations was achieved at 40 °C using the methods reported in each detailed reaction description. Preparative and analytical HPLC columns were purchased from Daicel Corporation or Phenomenex. HPLC methods and conditions are reported in the descriptions of the chemical reactions where they were applied. Microanalyses were performed by Atlantic Microlab, Inc. (Norcross, GA) and agree with ±0.4% of calculated values. HRMS (mass error within 5 ppm) and MS/MS fragmentation analysis were performed on LTQ-Orbitrap Velos (Thermo-Scientific, San Jose, CA) coupled with an ESI source in the positive ion mode to confirm the assigned structures and regiochemistry. Optical rotations were determined using a Jasco DIP-370 polarimeter. Unless otherwise stated, all test compounds were evaluated to be >95% pure on the basis of combustion analysis, NMR, GC/MS, and HPLC-DAD. The detailed analytical results are reported in the characterization of each final compound and summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Table S1</a>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 2-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butyl)isoindoline-1,3-dione (<b>3</b>)</h3><div class="NLM_p last">To a solution of (4a<i>R</i>,10b<i>R</i>)-4-propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-ol (<b>1</b>) (0.50 g, 1.7 mmol) in acetonitrile (AcOH, 10 mL), K<sub>2</sub>CO<sub>3</sub> (4.8 g, 17 mmol) was added followed by 2-(4-bromobutyl)isoindoline-1,3-dione (0.65 g, 8.2 mmol) and KI (5.4 mg, 0.053 mmol). The reaction mixture was stirred under an inert atmosphere at reflux overnight. The reaction mixture was cooled, filtered, and the solvent was removed in vacuo. The crude material was purified via flash column chromatography, eluting with 5% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 95:5:0.5) to afford the product as a white solid, in 58% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.88–7.80 (m, 2H), 7.74–7.67 (m, 2H), 6.91 (s, 1H), 6.74–6.63 (m, 2H), 4.47 (dd, <i>J</i> = 10.7, 3.7 Hz, 1H), 4.39 (d, <i>J</i> = 9.2 Hz, 1H), 4.11–4.02 (m, 1H), 3.96–3.80 (m, 5H), 3.75 (t, <i>J</i> = 6.8 Hz, 2H), 2.89 (d, <i>J</i> = 11.5 Hz, 1H), 2.68 (td, <i>J</i> = 11.2, 10.4, 6.0 Hz, 1H), 2.57–2.40 (m, 2H), 1.90–1.81 (m, 2H), 1.59–1.54 (m, 3H), 1.48 (dq, <i>J</i> = 15.1, 6.9 Hz, 1H), 0.95–0.86 (m, 3H). The free base was converted into the corresponding oxalate salt. CHN Anal (C<sub>26</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>·H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·0.5 H<sub>2</sub>O) Calcd: C, 61.19; H, 6.05; N, 5.10. Found: C, 60.87; H, 5.78; N, 5.00. mp 158–159 °C.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butan-1-amine (<b>4</b>)</h3><div class="NLM_p last">To a solution of <b>3</b> (0.5 mg, 1.1 mmol) in EtOH (50 mL), hydrazine (36 mg, 14 mL, 1.1 mmol) was added under an inert atmosphere and was stirred at reflux overnight. The reaction mixture was cooled to room temperature, and the solvent was removed in vacuo. The product was resuspended in DCM, and the organic fraction was extracted (3×) with 75 mL portions of aqueous K<sub>2</sub>CO<sub>3</sub>, which after drying over anhydrous MgSO<sub>4</sub> was concentrated in vacuo to afford the crude product as a white solid, in 89% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.93 (d, <i>J</i> = 2.7 Hz, 1H), 6.76–6.65 (m, 2H), 4.48 (dd, <i>J</i> = 10.8, 3.7 Hz, 1H), 4.41 (d, <i>J</i> = 9.2 Hz, 1H), 4.07 (dd, <i>J</i> = 11.4, 3.3 Hz, 1H), 3.99–3.81 (m, 4H), 2.90 (d, <i>J</i> = 11.7 Hz, 1H), 2.79–2.70 (m, 2H), 2.67 (dd, <i>J</i> = 10.4, 6.2 Hz, 1H), 2.58–2.41 (m, 2H), 2.33–2.21 (m, 1H), 1.78 (p, <i>J</i> = 6.6 Hz, 2H), 1.48 (ddd, <i>J</i> = 29.8, 16.3, 6.9 Hz, 4H), 0.91 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>N</i>-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butyl)-9<i>H</i>-fluorene-2-carboxamide (<b>5</b>)</h3><div class="NLM_p last">To a solution of 9H-fluorene-2-carboxylic acid (72 mg, 0.34 mmol) in DCM (10 mL) under an inert atmosphere at 0 °C, EDC (76 mg, 0.39 mmol) and HOBt (53 mg, 0.39 mmol) were added. After 30 min of vigorous stirring, <b>4</b> (0.10 g, 0.31 mmol) and DIPEA (0.075 mL, 0.42 mmol) were added to the reaction mixture. The reaction stirred overnight gradually warming to RT. The solvent was evaporated, and the compound was purified via flash chromatography, eluting with EtOAc/hexanes (9:1) to give the 68 mg product as tan-colored powder in 43% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.93 (s, 1H), 7.86–7.71 (m, 3H), 7.57 (d, <i>J</i> = 7.3 Hz, 1H), 7.38–7.26 (m, 2H), 6.99 (s, 1H), 6.72 (q, <i>J</i> = 9.1 Hz, 2H), 6.38 (s, 1H), 4.48 (dd, <i>J</i> = 10.8, 3.6 Hz, 1H), 4.39 (d, <i>J</i> = 9.2 Hz, 1H), 4.04–4.00 (m, 3H), 3.88 (m, 4H), 3.56 (q, <i>J</i> = 6.4 Hz, 2H), 2.92–2.80 (m, 1H), 2.67 (s, 1H), 2.55–2.38 (m, 2H), 2.27 (d, <i>J</i> = 14.2 Hz, 1H), 1.86 (m, 4H), 1.57 (m, 2H), 0.90 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 167.73, 153.02, 147.26, 144.69, 144.00, 143.38, 140.70, 133.00, 127.55, 126.93, 125.71, 125.15, 123.71, 122.73, 120.49, 119.65, 116.43, 116.04, 110.48, 75.54, 68.16, 67.24, 66.00, 59.44, 55.57, 51.99, 39.75, 36.86, 26.86, 26.46, 19.07, 11.82. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20, flow rate 1 mL/min), total run time of 40 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm; RT 17.073 min, purity > 99%, de > 95% (absorbance at 280 nm). HRMS (ESI) C<sub>32</sub>H<sub>36</sub>O<sub>4</sub>N<sub>2</sub> + H<sup>+</sup> calcd, 513.27478; found, 513.27432 (−0.9 ppm). CHN Anal (C<sub>32</sub>H<sub>36</sub>N<sub>2</sub>O<sub>4</sub>·0.75H<sub>2</sub>O) Calcd: C, 73.05; H, 7.18; N, 5.32. Found: C, 73.11; H, 7.03; N, 5.17. mp 165–166 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: +38.83 (0.065 g/100 mL in DCM).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>N</i>-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butyl)-1<i>H</i>-indole-2-carboxamide (<b>6</b>)</h3><div class="NLM_p last">The compound was prepared following the same procedure described for <b>5</b>, starting from 1<i>H</i>-indole-2-carboxylic acid (55 mg, 0.34 mmol). The compound was purified via flash chromatography, eluting with EtOAc/hexanes (9:1) to give the 0.10 g product as a white solid in 69% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.11 (s, 1H), 7.62 (d, <i>J</i> = 8.1 Hz, 1H), 7.42 (d, <i>J</i> = 8.3 Hz, 1H), 7.26 (m, 1H), 7.13 (t, <i>J</i> = 7.5 Hz, 1H), 6.95 (s, 1H), 6.79–6.67 (m, 3H), 6.35 (s, 1H), 4.49 (dd, <i>J</i> = 10.8, 3.7 Hz, 1H), 4.40 (d, <i>J</i> = 9.2 Hz, 1H), 4.15–3.96 (m, 3H), 3.89 (q, <i>J</i> = 11.3, 10.9 Hz, 2H), 3.61–3.52 (m, 2H), 2.89 (d, <i>J</i> = 11.7 Hz, 1H), 2.67 (d, <i>J</i> = 15.1 Hz, 1H), 2.58–2.41 (m, 2H), 2.27 (s, 1H), 1.90–1.80 (m, 3H), 0.91 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.45, 152.97, 147.33, 136.03, 130.79, 127.71, 124.41, 122.75, 121.90, 120.61, 116.46, 116.07, 111.79, 110.44, 101.64, 75.55, 68.08, 67.25, 66.02, 59.43, 55.60, 52.01, 39.30, 26.75, 26.55, 19.07, 11.82. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20, flow rate 1 mL/min), total run time of 40 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm; RT 29.973 min, purity > 95%, de > 90% (absorbance at 230 nm). HRMS (ESI) C<sub>27</sub>H<sub>33</sub>O<sub>4</sub>N<sub>3</sub> + H<sup>+</sup> calcd, 464.25438; found, 464.25347 (−1.9 ppm). CHN Anal (C<sub>27</sub>H<sub>33</sub>N<sub>3</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) Calcd: C, 69.28; H, 7.21; N, 8.98. Found: C, 69.40; H, 7.33; N, 9.07. mp 143–144 °C; [α]<sub class="stack">D</sub><sup class="stack">24</sup>: +35.4 (0.130 g/100 mL in DCM).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butyl)benzofuran-2-carboxamide (<b>7</b>)</h3><div class="NLM_p last">The compound was prepared following the same procedure described for <b>5</b>, starting from benzofuran-2-carboxylic acid (55 mg, 0.34 mmol). The compound was purified via flash chromatography, eluting with EtOAc/hexanes (9:1) to give a 0.13 g of the product as yellow oil in 86% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 7.8 Hz, 1H), 7.49–7.35 (m, 3H), 7.33–7.23 (m, 1H), 6.95 (s, 1H), 6.82 (s, 1H), 6.79–6.66 (m, 2H), 4.48 (dd, <i>J</i> = 11.0, 3.7 Hz, 1H), 4.39 (d, <i>J</i> = 9.2 Hz, 1H), 4.15–4.02 (m, 2H), 4.01–3.91 (m, 2H), 3.91–3.81 (m, 2H), 3.56 (q, <i>J</i> = 6.2 Hz, 2H), 2.89 (d, <i>J</i> = 11.6 Hz, 1H), 2.68 (dd, <i>J</i> = 17.8, 10.9 Hz, 1H), 2.57–2.41 (m, 2H), 1.85 (s, 2H), 1.56 (s, 3H), 1.47 (s, 1H), 1.26 (t, <i>J</i> = 7.1 Hz, 1H), 0.91 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 158.87, 154.67, 153.08, 148.85, 147.24, 127.65, 126.69, 123.59, 122.68, 122.64, 116.40, 116.03, 111.71, 110.36, 110.16, 75.57, 68.02, 67.26, 66.01, 59.43, 55.61, 52.02, 38.97, 26.78, 26.45, 19.07, 11.84. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20, flow rate 1 mL/min), total run time of 40 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm; RT 17.984 min, purity > 99%, de > 95% (absorbance at 273 nm). HRMS (ESI) C<sub>27</sub>H<sub>32</sub>O<sub>5</sub>N<sub>2</sub> + H<sup>+</sup> calcd, 465.23840; found, 465.23812 (−0.6 ppm). CHN Anal (C<sub>27</sub>H<sub>32</sub>N<sub>2</sub>O<sub>5</sub>) Calcd: C, 69.81; H, 6.94; N, 6.03. Found: C, 70.09; H, 7.12; N, 6.01. [α]<sub class="stack">D</sub><sup class="stack">24</sup>: +45.3 (0.225 g/100 mL in DCM).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butyl)benzo[<i>d</i>]thiazole-2-carboxamide (<b>8</b>)</h3><div class="NLM_p last">The compound was prepared following the same procedure described for <b>5</b>, starting from benzo(<i>d</i>)thiazole-2-carboxylic (43 mg, 0.24 mmol). The compound was purified via flash chromatography, eluting with EtOAc/hexanes (9:1) to give 83 mg of the product as clear wax in 79% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.93 (dd, <i>J</i> = 26.8, 8.1 Hz, 2H), 7.45 (dt, <i>J</i> = 23.7, 7.4 Hz, 2H), 6.86 (d, <i>J</i> = 2.9 Hz, 1H), 6.71–6.57 (m, 2H), 4.45–4.29 (m, 2H), 4.03–3.72 (m, 5H), 3.48 (s, 2H), 3.35–3.26 (m, 1H), 2.83 (d, <i>J</i> = 11.7 Hz, 1H), 2.70–2.55 (m, 1H), 2.42 (dtd, <i>J</i> = 24.0, 11.9, 10.8, 3.6 Hz, 2H), 2.26–2.16 (m, 1H), 1.84 (m, 3H), 1.50 (dt, <i>J</i> = 11.3, 6.2 Hz, 1H), 1.44–1.33 (m, 1H), 0.83 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 164.06, 159.89, 153.11, 152.88, 147.21, 137.11, 126.70, 126.57, 124.24, 122.64, 122.36, 116.37, 116.08, 110.32, 75.59, 67.92, 67.26, 66.01, 59.45, 55.61, 52.04, 39.48, 26.74, 26.35, 19.09, 11.83. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20 + 0.1% DEA, flow rate 1 mL/min), total run time of 40 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm; RT 16.477 min, purity > 99%, de > 95% (absorbance at 280 nm). HRMS (ESI) C<sub>26</sub>H<sub>31</sub>O<sub>4</sub>N<sub>3</sub>S + H<sup>+</sup> calcd, 482.21080; found, 482.21006 (−1.5 ppm). CHN Anal (C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>S) Calcd: C, 64.84; H, 6.49; N, 8.73. Found: C, 64.64; H, 6.51; N, 8.44. [α]<sub class="stack">D</sub><sup class="stack">24</sup>: +37.3 (0.215 g/100 mL in DCM).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butyl)benzo[<i>d</i>]thiazole-5-carboxamide (<b>9</b>)</h3><div class="NLM_p last">The compound was prepared following the same procedure described for <b>5</b>, starting from benzo[<i>d</i>]thiazole-5-carboxylic acid (84 mg, 0.47 mmol). The compound was purified via flash chromatography, eluting with EtOAc/hexanes (9:1) to give 100 mg of the product as clear viscous oil in 44% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.06 (d, <i>J</i> = 1.4 Hz, 1H), 8.47 (s, 1H), 8.00 (d, <i>J</i> = 8.4 Hz, 1 H), 7.88 (dd, <i>J</i> = 8.7, 1.8 Hz, 1H), 6.98–6.90 (m, 1H), 6.70 (q, <i>J</i> = 8.8 Hz, 2H), 6.46 (s, 1H), 4.52–4.43 (m, 1H), 4.39 (d, <i>J</i> = 9.2 Hz, 1H), 4.09–3.95 (m, 2H), 3.94–3.8 (m, 2H), 3.58 (q, <i>J</i> = 6.3, 2H), 2.89 (d, <i>J</i> = 11.7 Hz, 1H), 2.68 (td, <i>J</i> = 11.1, 6.1 Hz, 1H), 2.55–2.39 (m, 2H), 2.31–2.20 (m, 1H), 1.85 (d, <i>J</i> = 9.4 Hz, 4H), 1.66 (s, 1H), 1.60–1.39 (m, 2H), 0.91 (t, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 167.16, 155.34, 153.31, 153.16, 147.44, 136.85, 133.52, 124.51, 122.87, 122.25, 122.01, 116.60, 116.24, 110.55, 75.74, 67.44, 66.18, 59.60, 55.78, 52.20, 40.05, 26.95, 26.63, 19.26, 12.01. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20 + 0.1% DEA, flow rate 1 mL/min), total run time of 40 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm; RT 25.177 min, purity > 95%, de > 90% (absorbance at 230 nm). HRMS (ESI) C<sub>26</sub>H<sub>31</sub>O<sub>4</sub>N<sub>3</sub>S + H<sup>+</sup> calcd, 482.21080; found, 482.20892 (−3.9 ppm). CHN Anal (C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>S) Calcd: C, 64.84; H, 6.49; N, 8.73. Found: C, 64.93; H, 6.77; N, 8.46. [α]<sub class="stack">D</sub><sup class="stack">26</sup>: +41.7 (0.255 g/100 mL in DCM).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxamide (<b>10</b>)</h3><div class="NLM_p last">The compound was prepared following the same procedure described for <b>5</b>, starting from 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid (77 mg, 0.47 mmol). The compound was purified via flash chromatography, eluting with 2% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2 + 0.1% NH<sub>4</sub>OH) to give 90 mg of the product as clear viscous oil in 41% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 4.8 Hz, 1H) 7.95 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.16–7.02 (m, 2H), 6.91 (d, <i>J</i> = 2.8 Hz, 1H), 6.83 (d, <i>J</i> = 0.9 Hz, 1H), 6.75–6.60 (m, 2H), 4.46 (dd, <i>J</i> = 10.8, 3.7 Hz, 1H), 4.38 (d, <i>J</i> = 9.2 Hz, 1H), 4.03 (dd, <i>J</i> = 11.5, 3.5 Hz, 1H), 3.98–3.78 (m, 4H), 3.51 (q, <i>J</i> = 6.2 Hz, 2H), 2.88 (d, <i>J</i> = 11.7 Hz, 1H), 2.76–2.57 (m, 1H), 2.53–2.40 (m, 3H), 2.30–2.18 (m, 1H), 1.80 (dt, <i>J</i> = 12.8, 6.4 Hz, 4H), 1.61–1.36 (m, 2H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.43, 161.35, 153.09, 147.92, 147.40, 145.65, 131.62, 130.85, 122.71, 120.41, 110.64, 101.61, 75.58, 68.31, 67.27, 65.96, 59.56, 55.72, 52.08, 39.45, 26.86, 26.37, 19.03, 11.90. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20 + 0.1% DEA, flow rate 1 mL/min), total run time of 40 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm; RT 35.552 min, purity > 95%, de > 90% (absorbance at 230 nm). HRMS (ESI) C<sub>26</sub>H<sub>32</sub>O<sub>4</sub>N<sub>4</sub> + H<sup>+</sup> calcd, 465.24963; found, 465.24713 (−5.2 ppm). CHN Anal (C<sub>26</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>) Calcd: C, 67.22; H, 6.94; N, 12.06. Found: C, 67.39; H, 7.10; N, 11.89. [α]<sub class="stack">D</sub><sup class="stack">26</sup>: +38.2 (0.211 g/100 mL in DCM).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 7-(4-(((4a<i>R</i>,10b<i>R</i>)-4-Propyl-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-yl)oxy)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>11</b>)</h3><div class="NLM_p last">The compound was prepared following the same procedure described for <b>3</b>, starting from <b>1</b> (0.150 g, 0.5 mmol) and 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (0.158 g, 0.5 mmol). The compound was purified via flash chromatography, eluting with 5% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2 + 0.1% NH<sub>4</sub>OH) to give 100 mg of the product as a clear viscous oil in 43% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.59 (s, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 6.94 (s, 1H), 6.77–6.65 (m, 2H) 6.52 (d, <i>J</i> = 8.3 Hz, 1H), 6.28 (s, 1H), 4.48 (d <i>J</i> = 10.6 Hz, 1H), 4.41 (d, <i>J</i> = 9.2 Hz, 1H), 4.08 (d, <i>J</i> = 11.4 Hz, 1H), 4.02–3.75 (m, 6H), 2.89 (t, <i>J</i> = 7.9 Hz, 3H), 2.73–2.64 (m, 1H), 2.61 (t, <i>J</i> = 7.5 Hz, 2H), 2.57–2.44 (m, 2H), 2.33–2.22 (m, 1H), 1.99–1.86 (m, 4H), 1.53–1.46 (m, 2H), 0.91 (t, <i>J</i> = 7.3 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.42, 158.79, 153.38, 147.36, 138.20, 128.86, 122.82, 116.56, 116.20, 115.93, 110.50, 108.84, 102.32, 75.84, 68.17, 67.94, 67.50, 66.19, 59.64, 55.79, 52.21, 31.29, 26.19, 26.13, 24.79, 19.27, 12.01. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20 + 0.1% DEA, flow rate 1 mL/min), total run time of 40 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm; RT 24.783 min, purity > 95%, de > 90% (absorbance at 214 nm). HRMS (ESI) C<sub>27</sub>H<sub>34</sub>O<sub>5</sub>N<sub>2</sub> + H<sup>+</sup> found, 467.25295 (−2.3 ppm). CHN Anal (C<sub>27</sub>H<sub>34</sub>N<sub>2</sub>O<sub>5</sub>) Calcd: C, 69.51; H, 7.35; N, 6.00. Found: C, 69.77; H, 7.55; N, 5.84. [α]<sub class="stack">D</sub><sup class="stack">26</sup>: +25.5 (0.335 g/100 mL in DCM).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 7-(4-((<i>tert</i>-Butyldimethylsilyl)oxy)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>12</b>)</h3><div class="NLM_p last">To a stirring solution of 7-hydroxy-3,4-dihydroquinolin-2(1<i>H</i>)-one (0.5 g, 3.1 mmol) and K<sub>2</sub>CO<sub>3</sub> (10 equiv) in ethanol (20 mL), (4-bromobutoxy)(<i>tert</i>-butyl)dimethylsilane (0.82 g, 3.1 mmol) was added portion-wise, and the mixture was stirred at reflux overnight. The solvent was evaporated; the residue was dissolved with DCM and washed with water and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated in vacuo to afford the crude product. The compound was purified via flash chromatography, eluting with EtOAc/hexanes (5:5) to give 0.91 g of product as colorless viscous oil in 84% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75 (s, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H) 6.52 (d, <i>J</i> = 8.1 Hz, 1H), 6.29 (d, <i>J</i> = 3.3 Hz, 1H), 3.67 (br s, 2H), 2.89 (br s, 2H), 2.61 (br s, 2H), 1.82 (br s, 2H), 1.67 (br s, 2H), 0.90 (q, <i>J</i> = 2.2 Hz, 9H), 0.05 (q, <i>J</i> = 2.2 Hz, 6H).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 7-(4-Hydroxybutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>13</b>)</h3><div class="NLM_p last">A solution of <b>12</b> (0.91 g, 2.6 mmol) and 1 M TBAF (2 equiv) in THF (30 mL) was stirred at room temperature for 4 h. The reaction mixture was washed with water, dried over MgSO<sub>4</sub>, filtered, and evaporated in vacuo to afford 0.5 g of the desired product as colorless viscous oil in 82% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.04 (d, <i>J</i> = 8.2 Hz, 1H), 6.53 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 6.36 (d, <i>J</i> = 2.4 Hz, 1H), 3.98 (t, <i>J</i> = 6.2 Hz, 2H), 3.69 (t, <i>J</i> = 6.4 Hz, 2H), 2.88 (dd, <i>J</i> = 8.5, 6.5 Hz, 2H), 2.64–2.56 (m, 2H), 2.33 (br s, 1H), 1.87 (tt, <i>J</i> = 8.2, 5.9 Hz, 2H), 1.78–1.68 (m, 2H).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 4-((2-Oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy)butanal (<b>14</b>)</h3><div class="NLM_p last">To solution of <b>13</b> (0.5 g, 2.1 mmol) in DCM (10 mL) at 0 °C, Dess–Martin periodinane (DMP, 1 g, 2.4 mmol) was added portion-wise. The reaction mixture was stirred at 0 °C for 1 h, and then allowed to warm to room temperature and washed with 2 N NaHCO<sub>3</sub> water solution. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated in vacuo to afford the crude product. The compound was purified via flash chromatography, eluting with EtOAc/hexanes (3:7) to give 0.27 g of the product as colorless viscous oil in 55% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.84 (s, 1H), 8.02 (br s, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 6.50 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 6.30 (d, <i>J</i> = 2.5 Hz, 1H), 3.97 (t, <i>J</i> = 6.0 Hz, 2H), 2.89 (dd, <i>J</i> = 8.4, 6.6 Hz, 2H), 2.70–2.57 (m, 4H), 2.16–2.05 (m, 2H).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (4a<i>R</i>,10b<i>R</i>)-3,4,4a,10b-Tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-ol (<b>15</b>)</h3><div class="NLM_p last">To a stirred solution of <b>1</b> (0.23 g, 0.92 mmol) in 1 M BrCN (0.29 g, 2.8 mmol) in acetonitrile, K<sub>2</sub>CO<sub>3</sub> (0.38 g, 2.8 mmol) was added. The solution was stirred for 40 min in a microwave at 120 °C, 275 psi, 75 W. The reaction was analyzed with GC to confirm that intermediate cyanate was formed. The reaction mixture was filtered and concentrated in vacuo. A solution of 5 mL of concentrated HCl in 5 mL of H<sub>2</sub>O was prepared and added to the dry crude material. The reaction solution was stirred at reflux overnight. The reaction solution was concentrated in vacuo. A solution of ammonia in methanol was added until a pH of 8 was reached. The solution mixture was concentrated in vacuo and was purified via flash column chromatography, eluting with 5% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 95:5:0.5) to afford 60 mg of the product as tan viscous oil in 31% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.85 (d, <i>J</i> = 1.2 Hz, 1H), 6.67 (d, <i>J</i> = 1.5 Hz, 2H), 4.32 (d, <i>J</i> = 9.2 Hz, 1H), 4.16–4.03 (m, 2H), 3.99–3.82 (m, 2H), 3.20–2.97 (m, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 149.69, 147.61, 122.92, 116.98, 116.10, 111.71, 76.40, 68.10, 67.97, 54.39, 46.30. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20 flow rate 1 mL/min), total run time of 70 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm; RT 40.879 min, purity > 95%, de > 90% (absorbance at 230 nm). GC/MS (EI) RT 10.360 min, 207.1 <i>m</i>/<i>z</i>.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 7-(4-((4a<i>R</i>,10b<i>R</i>)-9-Hydroxy-2,3,4a,10b-tetrahydro-4<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-4-yl)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>16</b>)</h3><div class="NLM_p last">To a stirred solution of (4a<i>R</i>,10b<i>R</i>)-3,4,4a,10b-tetrahydro-2<i>H</i>,5<i>H</i>-chromeno[4,3-<i>b</i>][1,4]oxazin-9-ol (<b>15</b>) (0.060 g, 0.29 mmol) in 1,2-dichloroethane (10 mL) were added <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide (0.068 g, 0.29 mmol) and catalytic amounts of AcOH. Na(OAc)<sub>3</sub>BH (0.093 g, 0.44 mmol) was added after solution was stirred for 1 h. Solution was left at room temperature and allowed to stir overnight. The solution mixture was concentrated in vacuo and was purified twice via flash column chromatography, eluting with 10% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 95:5:0.5) and EtOAc/hexanes (6:4), respectively. The partially purified product was purified again with preparative TLC eluting with 5% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 95:5:0.5) to afford 10 mg of the product as a white solid in 8.1% yield, after all combined purification steps. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 6.83 (d, <i>J</i> = 2.7 Hz, 1H), 6.69–6.60 (m, 2H), 6.52 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 6.34 (d, <i>J</i> = 2.4 Hz, 1H), 4.47 (dd, <i>J</i> = 10.7, 3.6 Hz, 1H), 4.40 (d, <i>J</i> = 9.2 Hz, 1H), 4.08–4.03 (m, 1H), 3.95 (t, <i>J</i> = 6.0 Hz, 2H), 3.91–3.81 (m, 2H), 2.95–2.85 (m, 3H), 2.85–2.76 (m, 1H), 2.64–2.42 (m, 5H), 1.86–1.61 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 172.19, 158.61, 150.57, 146.59, 138.09, 128.76, 122.57, 116.49, 116.11, 115.93, 111.63, 108.89, 102.30, 75.7, 67.89, 67.29, 65.85, 59.71, 53.34, 52.08, 31.06, 27.20, 24.58, 22.66; HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (80:20 flow rate 1 mL/min), total run time of 70 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm; RT 27.262 min, purity > 99%, de > 95% (absorbance at 214 nm). HRMS (ESI) C<sub>24</sub>H<sub>28</sub>O<sub>5</sub>N<sub>2</sub> + H<sup>+</sup> calcd, 425.20710; found, 425.20788 (1.8 ppm). mp 185–186 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: +43.3 (0.060 g/100 mL in MeOH).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-Amino-6-hydroxychroman-4-one (<b>18</b>)</h3><div class="NLM_p last">3-Amino-6-methoxychroman-4-one hydrochloride (<b>17</b>) (0.94 g, 4.1 mmol) was dissolved in 48% hydrobromic acid (23 mL) and stirred at 120 °C for 8 h and 60 °C overnight. The reaction mixture was cooled to room temperature and neutralized with 7 N ammonia solution in methanol until a pH of 8 was reached. The solution mixture was concentrated in vacuo and filtered on a silica plug, washing with EtOAc/hexanes (9:1) to give 0.27 g of the product as yellow viscous oil, in 37% yield, which was used in the next step without further purification. GC/MS (EI) RT 9.203 min, 179.0 <i>m</i>/<i>z</i>.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(4-((6-Hydroxy-4-oxochroman-3-yl)amino)butyl)-1<i>H</i>-indole-2-carboxamide (<b>19</b>)</h3><div class="NLM_p last">To a stirred solution of 3-amino-6-hydroxychroman-4-one (<b>18</b>) (0.12 g, 0.70 mmol) in 1–2 dichloroethane (10 mL) were added <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide (0.15 g, 0.70 mmol) and catalytic amounts of AcOH. Na(OAc)<sub>3</sub>BH (0.21 g, 1.0 mmol) was added after solution was stirred for 1 h. Solution was left at room temperature and allowed to stir overnight. The solution mixture was concentrated in vacuo and was purified via flash column chromatography, eluting with EtOAc/hexanes (7:3). HRMS (ESI) C<sub>22</sub>H<sub>23</sub>O<sub>4</sub>N<sub>3</sub> + H<sup>+</sup> calcd, 394.17613; found, 394.17640 (0.6 ppm). The racemic mixture was purified via preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm; 5 μm), eluting with <i>n</i>-hexane/2-propanol (70:30, flow rate 20 mL/min) to yield two different fractions (6 and 4 mg of yellow solid, respectively), enriched of the corresponding enantiomers. <b>19a</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>CN): δ 9.27 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 1H), 7.24–7.19 (m, 2H), 7.07 (t, <i>J</i> = 7.5 Hz, 1H), 6.98 (dd, <i>J</i> = 8.9, 3.1 Hz, 1H), 6.85–6.77 (m, 2H), 6.71 (s, 1H), 4.45 (dd, <i>J</i> = 11.1, 5.3 Hz, 1H), 4.04 (t, <i>J</i> = 11.4 Hz, 1H), 3.57 (dd, <i>J</i> = 11.7, 5.3 Hz, 1H), 3.44 (q, <i>J</i> = 6.5 Hz, 2H), 2.73 (ddt, <i>J</i> = 23.7, 11.7, 5.8 Hz, 2H), 1.63 (dq, <i>J</i> = 28.0, 7.3 Hz, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>CN): δ 161.59, 155.67, 152.87, 150.95, 136.10, 131.02, 127.68, 124.72, 124.21, 121.85, 120.45, 119.44, 118.74, 111.85, 111.22, 102.05, 70.80, 60.62, 47.94, 39.30, 27.45, 27.23, 27.17, 26.29. <b>19b</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>CN): δ 9.29 (s, 1H), 7.59 (d, <i>J</i> = 8.1 Hz, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 1H), 7.27–7.21 (m, 1H), 7.09 (t, <i>J</i> = 7.5 Hz, 1H), 7.00 (dd, <i>J</i> = 8.9, 3.1 Hz, 1H), 6.84–6.79 (m, 2H), 6.67 (s, 1H), 4.47 (dd, <i>J</i> = 11.1, 5.3 Hz, 1H), 4.06 (t, <i>J</i> = 11.4 Hz, 1H), 3.58 (dd, <i>J</i> = 11.7, 5.3 Hz, 1H), 3.47 (q, <i>J</i> = 6.5 Hz, 2H) 2.84–2.61 (m, 2H), 1.66 (dp, <i>J</i> = 29.1, 7.2 Hz, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>CN): δ 192.85, 161.72, 155.81, 150.93, 136.19, 130.98, 127.74, 124.84, 124.37, 121.93, 120.58, 119.92, 119.56, 118.87, 111.34, 107.91, 102.14, 70.87, 60.71, 48.02, 39.43, 27.52, 27.26. Analytical HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30 flow rate 1 mL/min), total run time of 90 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm; enantiomer <b>19a</b>: RT 48.546 min, purity > 90%, er 70:30 (absorbance at 214 nm); enantiomer <b>19b</b>: RT 54.171 min, purity > 90%, er 90:10 (absorbance at 214 nm). [α] values for compounds <b>19a</b> and <b>19b</b> were not determined.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 5-((5<i>S</i>)-5-Methyl-4-propylmorpholin-2-yl)-<i>N</i>,<i>N</i>-dipropylpyridin-2-amine (<b>20</b>)</h3><div class="NLM_p last">To a solution of <b>2</b>, the diastereomeric mixture<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (50 mg, 0.21 mmol) in acetonitrile (10 mL), propionaldehyde (49 mg, 0.84 mmol) was added, followed by the catalytic amount of glacial acetic acid. The reaction mixture was stirred at reflux for 2 h, cooled to room temperature, followed by portion-wise addition of STAB (178 mg, 0.84 mmol). The mixture was stirred at reflux overnight. The reaction was monitored via GC/MS until complete consumption of the starting material. The solvent was evaporated in vacuo to give a crude product, which was purified via flash chromatography, eluting with 5% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 95:5 + 0.5% NH<sub>4</sub>OH). The pure compound was obtained as the diastereomeric mixture, as yellow oil, in 22% yield (15 mg) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.12 (s, 1H), 7.44 (d, <i>J</i> = 9.2 Hz, 1H), 6.40 (d, <i>J</i> = 8.9 Hz, 1H), 4.48 (br s, 1H), 3.93 (br s, 1H), 3.77 (d, <i>J</i> = 11.3 Hz, 1H), 3.38 (t, <i>J</i> = 7.7 Hz, 4H), 2.93 (br s, 1H), 2.62 (br s, 2H), 2.43 (br s, 2H), 1.60 (h, <i>J</i> = 7.7 Hz, 6H) 1.13 (br s, 3H), 0.97–0.82 (m, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 158.08, 147.95, 146.78, 135.68, 129.00, 126.10, 105.33, 77.36, 56.53, 53.02, 51.43, 50.75, 29.86, 20.93, 12.00, 11.61. GC/MS (EI) RT 11.905 min, 319.3 <i>m</i>/<i>z</i>. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (95:5 flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 250–273 nm, RT 5.907 min and 6.267 min, purity > 95%, dr 1:1 (absorbance at 254 nm). HRMS (ESI) C<sub>19</sub>H<sub>33</sub>ON<sub>3</sub> + H<sup>+</sup> calcd, 320.26964; found, 320.26896 (−2.1 ppm).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 7-(4-((5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>22</b>)</h3><div class="NLM_p last">To a solution of <b>21</b> (65:35 diastereomeric mixture, 50 mg, 0.26 mmol) in acetonitrile (5 mL), was added K<sub>2</sub>CO<sub>3</sub> (10 equiv) and KI (cat.), followed by 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (92.6 mg, 0.31 mmol). The reaction mixture was stirred at reflux overnight. The solvent was evaporated in vacuo, and the crude residue was purified via flash chromatography, eluting with 10% CMA (CHCl<sub>3</sub>/MeOH 9:1 + 0.1% NH<sub>4</sub>OH). The pure product was obtained as the 2:1 diastereomeric mixture, as yellow oil, in 28% yield (30 mg). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.94 (s, 1H, 33% isomer), 8.65 (s, 1H, 66% isomer), 8.12 (s, 1H, 33% isomer), 8.03 (s, 1H, 66% isomer), 7.50–7.38 (m, 1H), 7.02 (d, <i>J</i> 8.3 Hz, 1H) 6.49 (td, <i>J</i> = 10.8, 8.8, 5.9 Hz, 1H), 6.36–6.32 (m, 1H), 4.75 (s, 2H, 33% isomer), 4.62 (s, 2H, 66% isomer), 4.46 (t, <i>J</i> = 10.0 Hz, 1H), 4.00–3.91 (m, 3H, 66% isomer), 3.86–3.77 (m, 3H, 33% isomer), 3.69 (d, <i>J</i> = 11.6 Hz, 1H, 33% isomer), 3.38 (t, <i>J</i> = 10.8 Hz, 1H, 66% isomer), 2.98–2.76 (m, 4H), 2.71–2.48 (m, 3H), 2.47–2.37 (m, 2H), 2.29 (dt, <i>J</i> = 13.1, 6.7 Hz, 2H, 33% isomer), 2.19 (t, <i>J</i> = 11.0 Hz, 2H, 66% isomer), 1.91–1.69 (m, 4H), 1.08 (d, <i>J</i> = 6.6 Hz, 3H, 33% isomer), 1.01 (d, <i>J</i> = 6.2 Hz, 3H, 66% isomer), <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.14, 171.97, 158.75, 158.50, 158.46, 146.46, 146.35, 138.44, 138.40, 136.95, 136.41, 128.79, 128.76, 126.08, 126.05, 115.96, 115.91, 109.15, 108.63, 108.47, 102.45, 102.24, 76.65, 75.88, 73.48, 71.58, 68.18, 67.97, 58.60, 55.04, 54.15, 53.14, 53.02, 52.21, 31.27, 31.24, 27.36, 27.35, 24.75, 23.60, 22.17, 15.09, 8.96. HPLC method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30 + 0.1% DEA, flow rate 1 mL/min), total run time of 50 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 22.568 min and 27.336 min, purity > 95%, dr 65:35 (absorbance at 230 nm). HPLC method B: column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30 + 0.1% DEA, flow rate 1 mL/min), total run time of 50 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 16.751 min and 29.776 min, purity > 95%, dr 35:65 (absorbance at 230 nm). HRMS (ESI) C<sub>23</sub>H<sub>30</sub>O<sub>3</sub>N<sub>4</sub> + H<sup>+</sup> calcd, 411.23907; found, 411.23863 (−1.0 ppm). CHN Anal (C<sub>23</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub>·0.4CH<sub>2</sub>Cl<sub>2</sub>·0.2CH<sub>3</sub>OH) Calcd: C, 62.87; H, 7.06; N, 12.43. Found: C, 63.06; H, 6.83; N, 12.09.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 5-((2<i>R</i>,5<i>S</i>)-5-Methylmorpholin-2-yl)pyridin-2-amine (<b>23a</b>) and 5-((2<i>S</i>,5<i>S</i>)-5-Methylmorpholin-2-yl)pyridin-2-amine (<b>23b</b>)</h3><div class="NLM_p last">The diastereomeric mixture [65:35 ratio of (2<i>R</i>,5<i>S</i>)/(2<i>S</i>,5<i>S</i>)] was separated via flash chromatography, eluting with 5–10% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH + 0.5% NH<sub>4</sub>OH). GC/MS (EI) RT 9.494 min and 9.540 min, 193.1 <i>m</i>/<i>z</i>. The (2<i>R</i>,5<i>S</i>)-diastereoisomer eluted first as a white solid. All spectroscopic data were consistent with the reported ones.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.91 (d, <i>J</i> = 2.3 Hz, 1H), 7.51 (dd, <i>J</i> = 8.7, 2.3, 1H), 6.61 (d, <i>J</i> = 8.6 Hz, 1H), 4.33 (dd, <i>J</i> = 10.7, 2.5 Hz, 1H), 3.95 (dd, <i>J</i> = 11.4, 3.3 Hz, 1H), 3.37–3.33 (m, 2H), 3.11–2.92 (m, 1H), 2.83 (dd, <i>J</i> = 12.7, 10.7 Hz, 1H), 1.07 (d, <i>J</i> = 6.5 Hz, 3H). HPLC method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (85:15 flow rate 1 mL/min), total run time of 50 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 19.193 min, purity > 99%, de > 99% (absorbance at 230 nm). HPLC method B: column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (90:10 flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 42.578 min, purity > 95%, de > 95% (absorbance at 230 nm). CHN Anal (C<sub>10</sub>H<sub>15</sub>N<sub>3</sub>O·0.1 H<sub>2</sub>O) Calcd: C, 61.58; H, 7.86; N, 21.54. Found: C, 61.35; H, 7.46; N, 21.31. The (2<i>S</i>,5<i>S</i>)-diastereoisomer eluted second as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.88 (d, <i>J</i> = 2.3 Hz, 1H), 7.49 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.58 (d, <i>J</i> = 8.6 Hz, 1H), 4.35 (dd, <i>J</i> = 10.0, 2.9 Hz, 1H), 3.84 (dd, <i>J</i> = 11.5, 3.0 Hz, 1H), 3.74–3.63 (m, 1H), 3.11–2.91 (m, 2H), 2.73 (dd, <i>J</i> = 13.2, 3.0 Hz, 1H), 1.33 (d, <i>J</i> = 7.1 Hz, 3H). HPLC method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (85:15 flow rate 1 mL/min), total run time of 50 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 20.228 min, purity > 95%, de > 99% (absorbance at 230 nm). HPLC method B: column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (90:10 flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 38.246 min, purity > 99%, de > 99% (max absorbance at 230 nm). CHN Anal (C<sub>10</sub>H<sub>15</sub>N<sub>3</sub>O·0.1 H<sub>2</sub>O) Calcd: C, 61.58; H, 7.86; N, 21.54. Found: C, 61.71; H, 7.61; N, 21.33.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 5-((2<i>S</i>,5<i>S</i>)-5-Methylmorpholin-2-yl)pyridin-2-amine (<b>23b</b>)</h3><div class="NLM_p last">Compound <b>52</b> (0.320 g, 0.977 mmol) was dissolved in 30 mL of ethanol and added to a hydrogenation flask, followed by the addition of Pearlman’s catalyst (Pd(OH)<sub>2</sub>/C 20 wt %, 0.350 g, 0.498 mmol). The reaction mixture was charged and shaken in a Parr apparatus under 50 psi of the hydrogen gas atmosphere. The reaction was allowed to proceed for 1 h. The reaction mixture was subsequently filtered through a wet Celite plug, rinsed with ethanol, and evaporated to yield 75 mg of the desired product as a white solid in 39.7% yield. All spectroscopic and HPLC data were consistent with the ones described for <b>23b</b>. GC/MS (EI) RT 9.533 min, 207.0 <i>m</i>/<i>z</i>. HPLC column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (90:10 flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 31.552 min, purity 94.5%, de > 99% (absorbance at 230.4 nm). Diastereomeric excess was determined via HPLC comparison (same HPLC method described above) with the (<i>R</i>,<i>S</i>)-diastereoisomer <b>23a</b> previously described (RT 37.332 min, purity > 99, ee > 99%).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 7-(4-((2<i>R</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>24</b>)</h3><div class="NLM_p last">The desired product was prepared following the same procedure described for <b>22</b>, starting from <b>23a</b> (30 mg, 0.16 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.04 (s, 1H), 7.77 (s, 1H), 7.45 (d, <i>J</i> = 8.5 Hz, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 6.49 (t, <i>J</i> = 9.4 Hz, 2H), 6.25 (s, 1H), 4.54 (s, 2H), 4.45 (d, <i>J</i> = 10.3 Hz, 1H), 3.98–3.89 (m, 2H), 3.83 (d, <i>J</i> = 11.3 Hz, 1H), 3.39 (t, <i>J</i> = 10.8 Hz, 1H), 2.99–2.83 (m, 4H), 2.61 (t, <i>J</i> = 7.5 Hz, 2H), 2.47–2.37 (m, 1H), 2.29 (dt, <i>J</i> = 12.9, 6.8 Hz, 1H), 2.19 (t, <i>J</i> = 11.1 Hz, 1H), 1.88–1.57 (m, 4H), 1.02 (d, <i>J</i> = 6.2 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.50, 158.77, 158.41, 146.39, 138.29, 136.45, 128.86, 126.15, 116.03, 108.54, 108.47, 102.43, 76.64, 73.50, 68.00, 58.58, 55.06, 53.12, 31.27, 27.32, 24.78, 22.15, 15.10. HPLC method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 28.163 min, purity > 95%, de > 99% (absorbance at 230 nm). HPLC method B: column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 33.735 min, purity > 99%, de > 99% (absorbance at 230 nm). The free base was converted into the corresponding oxalate salt. HRMS (ESI) C<sub>23</sub>H<sub>30</sub>O<sub>3</sub>N<sub>4</sub> + H<sup>+</sup> calcd, 411.23907; found, 411.23818 (−0.2 ppm). CHN Anal (C<sub>23</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub>·3 H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·0.75 H<sub>2</sub>O) Calcd: C, 50.18; H, 5.45; N, 8.07. Found: C, 50.09; H, 5.64; N, 8.46. mp 178–179 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: +24.8 (0.295 g/100 mL in MeOH).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(4-((2<i>R</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)butyl)-1<i>H</i>-indole-2-carboxamide (<b>25</b>)</h3><div class="NLM_p last">To a solution of <b>23a</b> (60 mg, 0.31 mmol) in 1,2-dichloroethane (10 mL), <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (71 mg, 0.31 mmol) was added, followed by the catalytic amount of glacial acetic acid. The reaction mixture was stirred at room temperature for 2 h, followed by portion-wise addition of STAB (178 mg, 0.84 mmol). The reaction was stirred at room temperature overnight, and the solvent was evaporated in vacuo to give a crude product, which was purified via flash chromatography, eluting with 15% DMA (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 85:15 + 0.1% NH<sub>4</sub>OH). The pure compound was obtained as 62 mg of colorless viscous oil in 47% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.31 (s, 1H), 8.03 (d, <i>J</i> = 2.2 Hz, 1H), 7.64 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.47–7.40 (m, 2H), 7.31–7.26 (m, 1H), 7.14 (ddd, <i>J</i> = 8.0, 7.0, 1.0 Hz, 1H), 6.82 (dd, <i>J</i> = 2.2, 0.9 Hz, 1H), 6.47–6.44 (m, 1H), 6.32 (s, 1H), 4.55 (s, 2H), 4.46 (dd, <i>J</i> = 10.5, 2.3 Hz, 1H), 3.83 (dd, <i>J</i> = 11.3, 3.4 Hz, 1H), 3.53–3.49 (m, 2H), 3.43–3.37 (m, 1H), 2.97–2.80 (m, 2H), 2.42 (ddd, <i>J</i> = 10.0, 6.3, 3.5 Hz, 1H), 2.26 (ddd, <i>J</i> = 12.9, 7.7, 5.6 Hz, 1H), 2.18 (dd, <i>J</i> = 11.7, 10.5 Hz, 1H), 1.58 (qd, <i>J</i> = 8.0, 3.6 Hz, 4H), 1.02 (d, <i>J</i> = 6.2 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.73, 158.29, 146.17, 136.52, 136.31, 130.93, 127.79, 126.01, 124.64, 122.04, 120.83, 112.06, 108.56, 101.89, 76.60, 73.41, 58.25, 53.12, 51.01, 27.95, 23.29, 15.09. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30 to 50:50, flow rate 1 mL/min), total run time of 120 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 80.465 min, purity > 99%, de > 99% (absorbance at 230 nm). The free base was converted into the corresponding oxalate salt. HRMS (ESI) C<sub>23</sub>H<sub>29</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> found, 408.23917 (−0.6 ppm). CHN Anal (C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>·2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·0.85H<sub>2</sub>O) Calcd: C, 53.79; H, 5.80; N, 11.62. Found: C, 54.19; H, 6.05; N, 11.22. mp 176–177 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: +30.8 (0.055 g/100 mL in MeOH).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 7-(4-((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>26</b>)</h3><div class="NLM_p last">The desired product was prepared following the same procedure described for <b>22</b>, starting from <b>23b</b> (30 mg, 0.16 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.36 (s, 1H), 7.99 (s, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 6.50 (dd, <i>J</i> = 12.5, 8.0 Hz, 2H), 6.31 (s, 1H), 5.27 (br s, 2H), 4.47 (t, <i>J</i> = 6.3 Hz, 1H), 3.96 (t, <i>J</i> = 6.5 Hz, 2H), 3.85 (d, <i>J</i> = 11.1 Hz, 1H), 3.72 (d, <i>J</i> = 11.2 Hz, 1H), 2.89 (t, <i>J</i> = 7.5 Hz, 3H), 2.61 (dt, <i>J</i> = 7.9, 4.7 Hz, 4H), 2.50 (hept, <i>J</i> = 7.1, 6.2 Hz, 2H), 1.87–1.75 (m, 2H), 1.67 (q, <i>J</i> = 7.4 Hz, 2H), 1.11 (d, <i>J</i> = 6.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.19, 158.77, 158.24, 144.39, 138.18, 137.62, 128.86, 125.74, 115.93, 109.36, 109.13, 102.31, 75.62, 71.72, 68.09, 54.05, 52.78, 51.78, 31.19, 27.31, 24.70, 23.34, 8.65. HPLC method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 35.369 min, purity > 95%, de > 90% (absorbance at 230 nm). HPLC method B: column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 18.507 min, purity 94.2%, de 88.4% (absorbance at 230.4 nm). The free base was converted into the corresponding oxalate salt. HRMS (ESI) C<sub>23</sub>H<sub>30</sub>O<sub>3</sub>N<sub>4</sub> + H<sup>+</sup> calcd, 411.23907; found, 411.23798 (−1.6 ppm). CHN Anal (C<sub>23</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub>·2 H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·2 H<sub>2</sub>O) Calcd: C, 51.75; H, 6.11; N, 8.94. Found: C, 51.58; H, 5.94; N, 8.77. Salt was highly hygroscopic; therefore, the melting point could not be determined; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: −1.37 (0.085 g/100 mL in MeOH).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(4-((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)butyl)-1<i>H</i>-indole-2-carboxamide (<b>27</b>)</h3><div class="NLM_p last">The desired product was prepared following the same procedure described for <b>25</b>, starting from <b>23b</b> (30 mg, 0.16 mmol). The pure compound was obtained as 43 mg of colorless viscous oil in 63% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.28 (s, 1H), 8.06 (d, <i>J</i> = 2.3 Hz, 1H), 7.64 (dd, <i>J</i> = 8.1, 1.0 Hz, 1H), 7.48–7.40 (m, 2H), 7.28 (ddd, <i>J</i> = 8.3, 7.0, 1.2 Hz, 1H), 7.14 (ddd, <i>J</i> = 8.0, 7.0, 1.0 Hz, 1H), 6.83 (d, <i>J</i> = 1.5 Hz, 1H), 6.51–6.44 (m, 1H), 6.41 (s, 1H), 4.51 (br s, 2H), 4.47 (dd, <i>J</i> = 9.4, 3.6 Hz, 1H), 3.87 (dd, <i>J</i> = 11.2, 2.8 Hz, 1H), 3.74 (dd, <i>J</i> = 11.2, 2.1 Hz, 1H), 3.52 (q, <i>J</i> = 6.6 Hz, 2H), 2.92–2.83 (m, 1H), 2.66–2.52 (m, 2H), 2.49 (t, <i>J</i> = 7.1 Hz, 2H), 1.65 (dq, <i>J</i> = 37.1, 7.5 Hz, 4H), 1.10 (d, <i>J</i> = 6.6, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.69, 158.20, 146.44, 136.64, 136.27, 131.03, 127.82, 126.27, 124.64, 122.05, 120.85, 112.02, 108.52, 101.88, 76.14, 72.18, 53.85, 53.09, 51.57, 39.65, 27.75, 24.52, 8.24. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30 to 50:50, flow rate 1 mL/min), total run time of 120 min, and multiple DAD λ absorbance signals were measured in the range of 230–280 nm, RT 89.625 min, purity > 99%, de > 99% (absorbance at 230 nm). The free base was converted into the corresponding oxalate salt. HRMS (ESI) C<sub>23</sub>H<sub>29</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> found, 408.23994 (1.3 ppm). CHN Anal (C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>·2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·0.5H<sub>2</sub>O) Calcd: C, 54.36; H, 5.74; N, 11.74. Found: C, 54.45; H, 5.85; N, 11.86. mp 132–133 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: −7.27 (0.055 g/100 mL in MeOH).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>E</i>)-1,4-Dibromobut-2-ene (<b>28</b>)</h3><div class="NLM_p last">To a two-neck round-bottom flask was added Hoveyda–Grubbs catalyst second generation (25.0 mg, 0.04 mmol) and subsequently purged with argon. Degassed dichloromethane (6 mL) was added via syringe to the flask to form a green solution of the catalyst. To the solution was added freshly distilled allyl bromide<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> (5.0 mL, 52.1 mmol); gas evolution from the reaction was observed and within a minute, the reaction mixture turned brown in color. The reaction mixture was allowed to stir for approximately 10 more min after which the solvent was removed under reduced pressure, and the product was purified by standard flash chromatography with hexanes/EtOAc (95:5) to yield 1.70 g of 1,4-dibromobut-2-ene as a white crystal in 15% yield, and in a 9:1 ratio of the <i>E</i>/<i>Z</i> product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.98 (br s, 2H), 4.03–3.90 (m, 4H).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>E</i>)-7-((4-Bromobut-2-en-1-yl)oxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>29</b>)</h3><div class="NLM_p last">(<i>E</i>)-1,4-Dibromobut-2-ene (<b>28</b>) (0.200 g, 0.94 mmol) and 7-hydroxy-3,4-dihydroquinolin-2(1<i>H</i>)-one (0.155 g, 5.55 mmol) were dissolved in acetonitrile (5 mL) with gentle heating; to the reaction mixture were added anhydrous K<sub>2</sub>CO<sub>3</sub> (1.29 g, 9.40 mmol) and a catalytic amount of KI (approx 25.0 mg). The reaction was subsequently refluxed for 1.5 h and then allowed to stir overnight at room temperature. The solvent was then removed under reduced pressure and the crude material was purified via flash chromatography, eluting with hexanes/EtOAc (75:25), to yield 0.060 g of the product as a white solid in 22% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.77 (s, 1H), 7.04 (d, <i>J</i> = 8.4 Hz, 1H), 6.52 (d, <i>J</i> = 8.2 Hz, 1H), 6.39 (s, 1H), 6.13–6.01 (m, 1H), 6.02–5.89 (m, 1H), 4.52 (s, 1H), 3.98 (d, <i>J</i> = 5.6 Hz, 2H), 2.96–2.84 (m, 2H), 2.70–2.55 (m, 2H).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 7-(((<i>E</i>)-4-((2<i>R</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)but-2-en-1-yl)oxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>30</b>)</h3><div class="NLM_p last">To a round-bottom flask were added <b>29</b> (0.0342 g, 0.115 mmol) and <b>23a</b> (0.0220 g, 0.110 mmol) and subsequently dissolved with acetonitrile (5 mL). To the solution was added anhydrous K<sub>2</sub>CO<sub>3</sub> (0.150 g, 1.20 mmol), and the reaction was set to reflux for 50 min and then allowed to return to room temperature to be stirred overnight. The solvent was removed under reduced pressure, and the crude mixture was purified via flash chromatography eluting with 5% DMA (DCM/MeOH 95:5 + 0.5% NH<sub>4</sub>OH), to yield 0.0365 g of the desired product, as a white solid in 78% yield. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.81 (s, 1H), 7.38 (d, <i>J</i> = 8.7 Hz, 1H), 6.99 (d, <i>J</i> = 8.5 Hz, 1H), 6.53 (t, <i>J</i> = 7.9 Hz, 2H), 6.45 (s, 1H), 5.86 (br s, 2H), 4.54 (s, 2H), 4.37 (d, <i>J</i> = 10.5 Hz, 1H), 3.81 (d, <i>J</i> = 11.5 Hz, 1H), 3.56 (d, <i>J</i> = 14.0 Hz, 1H), 3.37 (d, <i>J</i> = 11.0 Hz, 1H), 2.95 (dd, <i>J</i> = 13.9, 7.3 Hz, 1H), 2.82 (d, <i>J</i> = 9.6 Hz, 3H), 2.51 (t, <i>J</i> = 7.8 Hz, 2H), 2.43 (s, 1H), 2.15 (t, <i>J</i> = 11.3 Hz, 1H), 1.05 (d, <i>J</i> = 6.0 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 174.05, 160.69, 159.26, 146.18, 139.73, 137.84, 131.45, 129.87, 129.54, 125.80, 117.41, 111.43, 110.45, 109.89, 103.78, 77.39, 73.85, 68.79, 59.19, 56.12, 56.08, 31.90, 25.39, 14.68. HPLC method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 31.234 min, purity > 95%, de > 99% (absorbance at 214 nm). HPLC method B: column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 31.721 min, purity > 99%, de > 99% (absorbance at 214 nm). HPLC method C: column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 130 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 46.609 min, purity > 95%, de > 99% (max absorbance at 214 nm). The free base was converted into the corresponding oxalate salt. HRMS (ESI) C<sub>23</sub>H<sub>28</sub>O<sub>3</sub>N<sub>4</sub> + H<sup>+</sup> calcd, 409.22342; found, 409.22293 (−1.1 ppm). CHN Anal (C<sub>23</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>·3H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·2.5H<sub>2</sub>O) Calcd: C, 48.13; H, 5.43; N, 7.74. Found: C, 47.96; H, 5.31; N, 7.42. mp 123–124 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: +20.0 (0.080 g/100 mL in MeOH).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 7-(((<i>E</i>)-4-((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)but-2-en-1-yl)oxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>31</b>)</h3><div class="NLM_p last">The desired product was prepared following the same procedure described for <b>30</b>, starting from <b>23b</b> (0.0200 g, 0.103 mmol). The crude material was purified via flash chromatography, eluting with 5% DMA (DCM/MeOH 95:5 + 0.5% NH<sub>4</sub>OH), to yield 0.0379 g of the desired product as a white solid, in 90% yield. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.85 (s, 1H), 7.43 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 7.00 (d, <i>J</i> = 8.5 Hz, 1H), 6.53 (t, <i>J</i> = 8.5 Hz, 2H), 6.45 (d, <i>J</i> = 2.5 Hz, 1H), 5.85 (br s, 2H), 4.52 (s, 2H), 4.37 (dt, <i>J</i> = 7.9, 3.4 Hz, 1H), 3.84 (d, <i>J</i> = 11.5 Hz, 1H), 3.70 (d, <i>J</i> = 10.6 Hz, 1H), 3.13 (q, <i>J</i> = 13.5 Hz, 2H), 2.91–2.77 (m, 3H), 2.59–2.45 (m, 4H), 1.10 (d, <i>J</i> = 4.4 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 173.99, 160.59, 159.32, 146.23, 139.70, 137.96, 131.19, 130.62, 129.56, 126.04, 117.38, 110.44, 109.91, 103.71, 77.04, 72.69, 68.90, 57.21, 52.86, 31.89, 25.37, 8.50. HPLC method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 37.386 min, purity 92.6%, de 86.3% (absorbance at 214 nm). HPLC method B: column Chiralcel OD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 19.762 min, purity 91.5%, de > 83.4% (absorbance at 214.4 nm). The free base was converted into the corresponding oxalate salt. HRMS (ESI) C<sub>23</sub>H<sub>28</sub>O<sub>3</sub>N<sub>4</sub> + H<sup>+</sup> calcd, 409.22342; found, 409.22282 (−2.8 ppm). CHN Anal (C<sub>23</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>·2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·2H<sub>2</sub>O) Calcd: C, 51.92; H, 5.81; N, 8.97. Found: C, 51.85; H, 5.71; N, 8.93. mp 110–111 °C; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: −5.33 (0.075 g/100 mL in MeOH).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (2-(Aminomethyl)cyclopropyl)methanol (<b>32</b>)</h3><div class="NLM_p last">To a round-bottom flask was added lithium aluminum hydride (LAH, 2.106 g, 55.5 mmol) and subsequently purged with argon. Anhydrous tetrahydrofuran (25 mL) was added to the flask to form a gray suspension, and the solution was subsequently cooled to 0 °C in an ice bath. Ethyl 2-cyanocyclopropanecarboxylate<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (2.57 g, 18.5 mmol) was then dissolved in 5 mL of anhydrous tetrahydrofuran and added dropwise to the solution of LAH via a syringe. Upon complete addition of ethyl 2-cyanocyclopropanecarboxylate, the reaction mixture was removed from the ice bath and allowed to reach room temperature and stirred with moderate heating for 2 h. The reaction mixture was then removed from the heating source and stirred at room temperature overnight. Ice cold water (3 mL) was added to the reaction, followed by 3 mL of 15% NaOH which resulted in the formation of a white solid precipitate. An additional 15 mL of water was added to the reaction mixture, and it was then stirred for 30 min. Excess MgSO<sub>4</sub> was added to the reaction mixture to absorb water, and the suspension was stirred for additional 30 min. The suspension was then filtered over Celite, and the solvent was removed under reduced pressure to yield 1.801 g of the desired product as colorless oil, in 96% yield, which was carried on to the next step without further purification.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-((2-(Hydroxymethyl)cyclopropyl)methyl)-1<i>H</i>-indole-2-carboxamide (<b>33</b>)</h3><div class="NLM_p last">Indole-2-carboxylic acid (3.220 g, 20.0 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL) and cooled to 0 °C in an ice bath. To this solution were subsequently added EDC (hydrochloride) (4.14 g, 21.6 mmol) and hydroxybenzotriazole (3.16 g, 23.4 mmol) in one portion and allowed to stir for 30 min at 0 °C. A solution of <b>32</b> (1.801 g, 17.8 mmol, 1.78 M) in DCM was added dropwise, followed by <i>N</i>,<i>N</i>-diisoproylethylamine (Hünig’s base or DIPEA) (4.4 mL, 25.2 mmol). The reaction mixture was then removed from the ice bath and allowed to reach room temperature and stirred overnight. The reaction mixture was quenched with the addition of 50 mL of saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (3 × 50 mL); the combined organic phases were dried with Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and the crude was purified by flash chromatography, gradually increasing the mobile phase polarity up to hexanes/EtOAc (2:3) (EtOAc/Hex), followed by isocratic elution. The diastereoisomers <b>33b</b> and <b>33a</b> were separated with R<sub>f</sub>: 0.25 and R<sub>f</sub>: 0.20, respectively; first, <b>33b</b> eluted as colorless oil (0.241 g, 5.5% yield); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.59 (d, <i>J</i> = 8.0 Hz, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 1H), 7.21 (t, <i>J</i> = 7.7 Hz, 1H), 7.09–6.99 (m, 2H), 3.96–3.87 (m, 1H), 3.73 (dd, <i>J</i> = 14.3, 4.8 Hz, 1H), 3.45 (t, <i>J</i> = 9.8 Hz, 1H), 3.23 (dd, <i>J</i> = 14.3, 7.0 Hz, 1H), 1.25 (br s, 2H), 0.82 (q, <i>J</i> = 7.5 Hz, 1H), 0.26 (d, <i>J</i> = 5.6 Hz, 1H); second, <b>33a</b> eluted as colorless oil (0.117 g, 2.7% yield), and its spectroscopic data were consistent with the previously reported data;<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.56 (d, <i>J</i> = 7.9 Hz, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.17 (t, <i>J</i> = 7.7 Hz, 1H), 7.10–6.97 (m, 2H), 3.44 (dd, <i>J</i> = 11.6, 5.8 Hz, 1H), 3.31 (p, <i>J</i> = 5.4, 4.4 Hz, 2H), 3.23 (dd, <i>J</i> = 13.8, 6.4 Hz, 1H), 0.99 (d, <i>J</i> = 6.0 Hz, 2H), 0.50 (d, <i>J</i> = 6.7 Hz, 1H), 0.44 (d, <i>J</i> = 6.7 Hz, 1H).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>trans</i>-<i>N</i>-((2-Formylcyclopropyl)methyl)-1<i>H</i>-indole-2-carboxamide (<b>34</b>)</h3><div class="NLM_p last">The desired product was prepared following the same procedure described for <b>35</b> starting from <b>33a</b> (0.117 g, 0.50 mmol) to yield 99.0 mg as colorless viscous oil in 81.7% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.12 (s, 1H), 8.99 (dd, <i>J</i> = 3.8, 1.5 Hz, 1H), 7.59 (s, 1H), 7.52 (d, <i>J</i> = 8.2 Hz, 1H), 7.33 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (t, <i>J</i> = 7.8 Hz, 1H), 7.03–6.87 (m, 2H), 3.48 (dt, <i>J</i> = 12.7, 5.8 Hz, 1H), 3.24 (dt, <i>J</i> = 13.8, 6.5 Hz, 1H), 1.82 (s, 1H), 1.75 (s, 1H), 1.24 (d, <i>J</i> = 4.2 Hz, 1H), 1.05 (d, <i>J</i> = 6.6 Hz, 1H).</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>cis</i>-<i>N</i>-((2-Formylcyclopropyl)methyl)-1<i>H</i>-indole-2-carboxamide (<b>35</b>)</h3><div class="NLM_p last">Compound <b>33b</b> (0.241 g, 0.99 mmol) was dissolved in DCM (20 mL) and cooled to −78 °C under an argon atmosphere. To the solution was added DMP (0.636 g, 1.50 mmol) in one portion, and the reaction was allowed to warm to room temperature. The reaction mixture was then stirred for 1.5 h, at which point the solvent was removed under reduced pressure and the crude mixture was partially purified by flash chromatography, eluting with hexanes/EtOAc (7:3) to yield 45 mg of the desired product as viscous colorless oil, in 18.8% yield, and used directly in the following step.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>trans</i>-<i>N</i>-((2-(((2<i>R</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)methyl)-1<i>H</i>-indole-2-carboxamide (<b>36</b>)</h3><div class="NLM_p last">Compound <b>36</b> was synthesized following the same procedure described for <b>39</b>, starting from <b>23a</b> (30.0 mg, 0.16 mmol) and <b>34</b> (37.5 mg, 0.16 mmol) to yield 36.6 mg of the final product, as colorless oil, in 54.5% yield. The mixture was additionally purified via preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm; 5 μm), eluting with <i>n</i>-hexane/2-propanol (from 70:30 up to 50:50, flow rate 25 mL/min) to yield the desired product as a 1:1.6 mixture of the two diastereoisomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.33 (s, 1H), 8.00 (d, <i>J</i> = 16.4 Hz, 1H), 7.65 (d, <i>J</i> = 8.2 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.42–7.21 (m, 2H), 7.14 (t, <i>J</i> = 7.6 Hz, 1H), 6.84 (d, <i>J</i> = 27.7 Hz, 1H), 6.43 (d, <i>J</i> = 59.1 Hz, 1H), 6.26 (dd, <i>J</i> = 18.3, 8.5 Hz, 1H), 4.45 (d, <i>J</i> = 10.6 Hz, 1H), 4.39 (s, 2H), 3.82 (t, <i>J</i> = 10.0 Hz, 1H), 3.73 (s, 1H, 38% isomer), 3.49 (s, 1H, 62% isomer), 3.40 (t, <i>J</i> = 11.4 Hz, 3H), 3.10 (t, <i>J</i> = 13.5 Hz, 1H, 62% isomer), 2.90 (d, <i>J</i> = 13.6 Hz, 1H, 38% isomer), 2.65 (dd, <i>J</i> = 13.2, 6.7 Hz, 1H, 38% isomer), 2.48 (s, 1H, 62% isomer), 2.30 (t, <i>J</i> = 11.0 Hz, 2H, 62% isomer), 2.09 (dd, <i>J</i> = 15.0, 8.4 Hz, 2H, 38% isomer), 1.21 (d, <i>J</i> = 5.9 Hz, 3H, 38% isomer), 1.01 (d, <i>J</i> = 6.0 Hz, 3H, 62% isomer), 0.92 (br s, 2H), 0.56 (d, <i>J</i> = 19.1 Hz, 1H), 0.42 (s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.58, 158.24, 146.41, 146.36, 136.34, 136.26, 130.91, 130.82, 127.86, 125.97, 124.65, 122.11, 120.85, 120.83, 112.06, 112.05, 108.34, 102.11, 102.00, 92.67, 73.37, 59.04, 58.90, 57.43, 57.33, 54.81, 43.71, 19.07, 17.42, 15.13, 15.01, 14.51, 14.21, 10.93, 9.11. HRMS (ESI) C<sub>24</sub>H<sub>29</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> calcd, 420.23940; found, 420.23979 (0.9 ppm). Analytical HPLC for <b><i>trans</i>-36</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (60:40, flow rate 1 mL/min), total run time of 170 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 66.064 min, purity > 99% (absorbance at 230 nm).</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>trans</i>-<i>N</i>-((2-(((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)methyl)-1<i>H</i>-indole-2-carboxamide (<b>37</b>)</h3><div class="NLM_p last">Compound <b>37</b> was synthesized following the same procedure described for <b>39</b>, starting from <b>23b</b> (30.0 mg, 0.16 mmol) and <b>34</b> (37.6 mg, 0.16 mmol) to yield 35.0 mg of the final product as colorless oil in 52% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.34 (s, 1H, 50% isomer), 10.05 (s, 1H), 50% isomer, 8.10 (s, 1H, 50% isomer), 7.88 (d, <i>J</i> = 6.7 Hz, 1H, 50% isomer), 7.67 (t, <i>J</i> = 8.0 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.32–7.19 (m, 2H), 7.11 (q, <i>J</i> = 10.1, 9.4 Hz, 2H), 6.24 (d, <i>J</i> = 8.6 Hz, 1H, 50% isomer), 6.03 (d, <i>J</i> = 8.6 Hz, 1H, 50% isomer), 5.05 (br s, 2H), 4.66 (d, <i>J</i> = 10.5 Hz, 1H, 50% isomer), 4.60 (d, <i>J</i> = 10.5 Hz, 1H, 50% isomer), 4.16–3.83 (m, 2H), 3.72–3.62 (m, 1H), 3.47–3.27 (m, 2H), 3.10 (d, <i>J</i> = 13.2 Hz, 1H, 50% isomer), 2.94 (dd, <i>J</i> = 22.9, 12.5 Hz, 1H), 2.77 (s, 1H, 50% isomer), 2.69–2.49 (m, 1H), 2.32 (t, <i>J</i> = 11.0 Hz, 1H, 50% isomer), 2.19 (d, <i>J</i> = 11.3 Hz, 1H, 50% isomer), 1.26 (d, <i>J</i> = 6.4 Hz, 3H, 50% isomer), 1.18 (d, <i>J</i> = 7.0 Hz, 3H, 50% isomer), 1.14–0.79 (m, 2H), 0.65 (s, 1H), 0.52 (s, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.73, 161.70, 158.29, 144.49, 144.24, 137.05, 136.94, 136.70, 136.59, 131.31, 131.13, 127.86, 127.82, 124.53, 124.42, 124.29, 123.73, 122.24, 122.18, 120.64, 120.51, 112.03, 112.00, 109.04, 108.94, 104.76, 103.90, 74.58, 74.45, 70.14, 58.29, 57.59, 51.97, 51.85, 51.75, 51.46, 43.48, 43.42, 29.85, 22.46, 19.12, 18.23, 14.07, 13.52, 10.09, 9.44, 9.28, 9.11. HRMS (ESI) C<sub>24</sub>H<sub>29</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> calcd, 420.23940; found, 420.23976 (0.8 ppm). The racemic mixture was purified via preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm; 5 μm), eluting with <i>n</i>-hexane/2-propanol (from 70:30 up to 50:50, flow rate 25 mL/min) to yield two different fractions corresponding to the two enantiomers <b>37a</b> and <b>37b</b>. Analytical HPLC for <b>37a</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (60:40, flow rate 1 mL/min), total run time of 70 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 37.316 min, purity > 95%, de > 99% (absorbance at 230 nm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.22 (s, 1H), 8.07 (s, 1H), 7.65 (d, <i>J</i> = 8.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.30 (d, <i>J</i> = 7.6 Hz, 1H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 6.83 (s, 1H), 6.43 (d, <i>J</i> = 8.6 Hz, 1H), 6.37 (s, 1H), 4.46 (d, <i>J</i> = 10.0 Hz, 1H), 4.40 (s, 2H), 3.87 (d, <i>J</i> = 11.2 Hz, 1H), 3.69 (d, <i>J</i> = 11.1 Hz, 1H), 3.39 (q, <i>J</i> = 7.6 Hz, 2H), 2.97 (d, <i>J</i> = 6.9 Hz, 1H), 2.69 (d, <i>J</i> = 12.0 Hz, 1H), 2.60 (t, <i>J</i> = 10.9 Hz, 1H), 2.39 (s, 2H), 1.26 (br s, 1H), 1.10–1.04 (m, 3H), 0.98 (br s, 1H), 0.57 (d, <i>J</i> = 6.7 Hz, 1H), 0.45 (t, <i>J</i> = 6.6 Hz, 1H). Analytical HPLC for <b>37b</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (60:40, flow rate 1 mL/min), total run time of 70 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 42.160 min, purity 92.9%, de 89.4% (max absorbance at 230.4 nm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.28 (s, 1H), 8.06 (s, 1H), 7.65 (d, <i>J</i> = 8.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (d, <i>J</i> = 7.6 Hz, 1H), 7.14 (t, <i>J</i> = 7.6 Hz, 1H), 6.83 (s, 1H), 6.46 (s, 1H), 6.32 (d, <i>J</i> = 8.4 Hz, 1H), 4.46 (d, <i>J</i> = 9.9 Hz, 1H), 4.36 (s, 2H), 3.87 (d, <i>J</i> = 11.3 Hz, 1H), 3.71 (d, <i>J</i> = 11.1 Hz, 1H), 3.46 (dt, <i>J</i> = 12.7, 5.9 Hz, 1H), 3.29 (dt, <i>J</i> = 13.8, 6.7 Hz, 1H), 2.99 (d, <i>J</i> = 7.3 Hz, 1H), 2.69 (d, <i>J</i> = 11.9 Hz, 1H), 2.65–2.53 (m, 2H), 2.19 (dd, <i>J</i> = 12.7, 7.4 Hz, 1H), 1.26 (s, 1H), 1.08 (d, <i>J</i> = 6.6 Hz, 3H), 0.94 (d, <i>J</i> = 6.8 Hz, 1H), 0.56 (dd, <i>J</i> = 8.6, 4.8 Hz, 1H), 0.51–0.42 (m, 1H). [α] values for compounds <b>37a</b> and <b>37b</b> were not determined.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>cis</i>-<i>N</i>-((2-(((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)methyl)-1<i>H</i>-indole-2-carboxamide (<b>38</b>)</h3><div class="NLM_p last">Compound <b>38</b> was synthesized following the same procedure described for <b>39</b>, starting from <b>23b</b> (11.0 mg, 0.06 mmol) and <b>35</b> (37.5 mg, 0.16 mmol) to yield 12.3 mg of the final product as colorless oil in 48% yield. HRMS (ESI) C<sub>24</sub>H<sub>29</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> calcd, 420.23940; found, 420.24047 (2.5 ppm). The racemic mixture was purified via preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm; 5 μm), eluting with <i>n</i>-hexane/2-propanol (from 70:30 up to 50:50, flow rate 25 mL/min) to yield two different fractions corresponding to the two diastereoisomers <b>38a</b> and <b>38b</b>. Analytical HPLC for <b>38a</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (60:40, flow rate 1 mL/min), total run time of 100 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 78.730 min, purity > 95%, de > 99% (absorbance at 230 nm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.17 (s, 1H), 7.98 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.59–7.35 (m, 3H), 7.29 (d, <i>J</i> = 7.5 Hz, 1H), 7.14 (t, <i>J</i> = 7.5 Hz, 1H), 6.82 (s, 1H), 6.43 (d, <i>J</i> = 8.5 Hz, 1H), 4.57 (d, <i>J</i> = 9.4 Hz, 1H), 4.39 (s, 2H), 4.31 (dt, <i>J</i> = 13.9, 6.7 Hz, 1H), 4.02 (d, <i>J</i> = 10.8 Hz, 1H), 3.81 (d, <i>J</i> = 11.4 Hz, 1H), 3.15 (s, 1H), 2.82 (ddd, <i>J</i> = 39.5, 26.2, 13.0 Hz, 3H), 2.51 (d, <i>J</i> = 12.1 Hz, 1H), 2.20 (t, <i>J</i> = 12.0 Hz, 1H), 1.26 (br s, 2H), 1.15 (d, <i>J</i> = 6.6 Hz, 3H), 0.94–0.83 (m, 1H), 0.22 (d, <i>J</i> = 5.4 Hz, 1H); analytical HPLC for <b>38b</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (60:40, flow rate 1 mL/min), total run time of 100 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 82.436 min, purity > 99%, de > 99% (absorbance at 230 nm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.19 (s, 1H), 8.08 (s, 1H), 7.67 (d, <i>J</i> = 8.1 Hz, 1H), 7.46 (dd, <i>J</i> = 15.8, 8.4 Hz, 3H), 7.30 (d, <i>J</i> = 7.5 Hz, 1H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 7.01 (s, 1H), 6.49 (d, <i>J</i> = 8.5 Hz, 1H), 4.63 (d, <i>J</i> = 10.5 Hz, 1H), 4.46 (s, 2H), 4.26 (dd, <i>J</i> = 14.4, 7.0 Hz, 1H), 3.97 (d, <i>J</i> = 12.0 Hz, 1H), 3.72 (d, <i>J</i> = 11.3 Hz, 1H), 2.98–2.83 (m, 3H), 2.78 (t, <i>J</i> = 12.1 Hz, 1H), 2.58 (t, <i>J</i> = 11.3 Hz, 1H), 2.21 (t, <i>J</i> = 11.9 Hz, 1H), 1.26 (br s, 1H), 1.17 (d, <i>J</i> = 6.8 Hz, 3H), 1.14 (br s, 1H), 0.87 (d, <i>J</i> = 5.8 Hz, 1H), 0.21 (d, <i>J</i> = 5.3 Hz, 1H). [α] values for compounds <b>38a</b> and <b>38b</b> were not determined.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>cis</i>-<i>N</i>-((2-(((2<i>R</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)methyl)-1<i>H</i>-indole-2-carboxamide (<b>39</b>)</h3><div class="NLM_p last">Compound <b>35</b> (37.5 mg, 0.155 mmol) was dissolved in 1,2-dichloroethane (6 mL) and to the mixture was added <b>23a</b> (30.0 mg, 0.155 mmol). To the stirring solution was added catalytic amount of acetic acid, and the reaction was allowed to stir for 30 min, after which STAB (50.0 mg, 0.23 mmol) was added in one portion, and the reaction mixture was allowed to stir at room temperature overnight. The solvent was removed under reduced pressure, and the crude residue was purified via flash chromatography, gradually increasing the polarity of the mobile phase, with two fractions of the desired product, enriched with the respective diastereoisomer, eluting with 10% DMA (DCM/MeOH 9:1 + 0.5% NH<sub>4</sub>OH) to yield colorless oils. The diastereoisomers were further purified via preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm; 5 μm), eluting with <i>n</i>-hexane/2-propanol (from 70:30 up to 50:50, flow rate 25 mL/min) to yield two different fractions corresponding to two diastereoisomers <b>39a</b> (5.7 mg; 8.7%) and <b>39b</b> (7.6 mg; 12% yield). Analytical HPLC for <b>39a</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (60:40, flow rate 1 mL/min), total run time of 90 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 38.626 min, purity > 99%, de > 99% (absorbance at 230 nm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.49 (s, 1H), 7.95 (s, 1H), 7.68 (d, <i>J</i> = 7.9 Hz, 1H), 7.46 (d, <i>J</i> = 8.2 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 1H), 7.29 (br s, 2H), 7.15 (s, 1H), 7.05 (s, 1H), 6.45 (d, <i>J</i> = 8.5 Hz, 1H), 4.64 (d, <i>J</i> = 13.5 Hz, 2H), 4.48 (s, 1H), 3.89 (d, <i>J</i> = 11.9 Hz, 1H), 3.56 (t, <i>J</i> = 11.3 Hz, 1H), 3.32 (d, <i>J</i> = 11.9 Hz, 1H), 2.68 (t, <i>J</i> = 12.2 Hz, 1H), 2.59 (t, <i>J</i> = 12.6 Hz, 1H), 2.47–2.28 (m, 2H), 2.18–2.05 (m, 2H), 1.13 (br s, 2H), 1.03–0.98 (m, 3H), 0.88 (br s, 1H), 0.24 (br s, 1H). HRMS (ESI) C<sub>24</sub>H<sub>29</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> calcd, 420.23940; found, 420.23983 (1 ppm). Analytical HPLC for <b>39b</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (60:40, flow rate 1 mL/min), total run time of 90 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 48.157 min, purity > 99%, de > 99% (absorbance at 230 nm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.38 (s, 1H), 7.90 (s, 1H), 7.66 (d, <i>J</i> = 8.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 2H), 7.18–7.10 (m, 1H), 6.90 (s, 1H), 6.84 (s, 1H), 6.33 (d, <i>J</i> = 8.4 Hz, 1H), 4.48–4.34 (m, 3H), 4.09–3.95 (m, 1H), 3.82 (t, <i>J</i> = 10.1 Hz, 2H), 3.49 (t, <i>J</i> = 10.9 Hz, 1H), 3.44–3.30 (m, 1H), 3.14 (t, <i>J</i> = 12.9 Hz, 1H), 2.96 (d, <i>J</i> = 10.6 Hz, 2H), 2.55–2.47 (m, 1H), 2.42–2.22 (m, 2H), 1.11 (d, <i>J</i> = 6.3 Hz, 3H), 1.01 (d, <i>J</i> = 6.2 Hz, 1H), 0.18 (q, <i>J</i> = 5.5 Hz, 1H); HRMS (ESI) C<sub>24</sub>H<sub>29</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> calcd, 420.23940; found, 420.23976 (0.8 ppm). [α] values for compounds <b>39a</b> and <b>39b</b> were not determined.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Enantiomeric Resolution of the Racemic Nitro–Olefin Intermediate <b>(±)-41</b><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h3><div class="NLM_p last">Chiral HPLC separation was performed on the racemic mixture, synthesized as previously reported<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> using an Agilent system coupled with the UV–vis/DAD. Separation of the analyte, purity, and enantiomeric excess determinations were achieved at 40 °C using the Chiralcel OZ-H (Daicel Corporation CPI Company) column (20 mm × 250 mm, 5 μm). The mobile phase used (10 mL/min flow rate) was composed of 10% 2-propanol in hexanes with isocratic elution. The total run time was 60 min, eluting first <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> [α]<sub class="stack">D</sub><sup class="stack">23</sup>: −224.76 (0.860 g/100 mL in MeOH), followed by <b>(+)-(1<i>S</i>,2<i>R</i>)-41b</b> [α]<sub class="stack">D</sub><sup class="stack">23</sup>: +208.94 (0.760 g/100 mL in MeOH) with a separation time between peaks of approximately 2 min. Analytical HPLC for <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b>: column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (90:10), total run time of 40 min, RT 21.021 min, purity 96.1%, ee 92.3% (absorbance at 254 nm). Analytical HPLC for <b>(+)-(1<i>S</i>,2<i>R</i>)-41b</b>: column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (90:10), total run time of 40 min, RT 27.677 min, purity 97.1%, ee 94.2% (absorbance at 254 nm). Spectroscopic data for both enantiomers were identical to the racemic mixture.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (2-(2-Aminoethyl)cyclopropyl)methanol (<b>(1<i>R</i>,2<i>S</i>)-42a</b>)</h3><div class="NLM_p last">Compound was prepared following the synthetic procedure described for <b>(1<i>S</i>,2<i>R</i>)-42b</b> below, starting from <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b>.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (2-(2-Aminoethyl)cyclopropyl)methanol (<b>(1<i>S</i>,2<i>R</i>)-42b</b>)</h3><div class="NLM_p last">Lithium aluminum hydride (0.205 g, 5.40 mmol), as a mineral oil dispersion, was added to a vacuum-purged round-bottom flask, cooled on a 0 °C ice bath, slowly suspended with the dropwise addition of anhydrous THF (10 mL), and stirred vigorously for 1 h. A solution of <b>(+)-(1<i>S</i>,2<i>R</i>)-41b</b> (0.33 g, 1.80 mmol) in anhydrous THF (10 mL) was then added dropwise to the stirring suspension over 15 min. Upon completion of the addition, reaction flask was removed from the ice bath and allowed to gradually warm to room temperature overnight with constant stirring. Upon completion, reaction was again cooled to 0 °C on the ice bath and subsequently quenched with the dropwise addition of a 1:1 mixture of MeOH/2 N aqueous NaOH. Precipitated solids were then filtered and washed repeatedly with ethyl acetate, collecting and concentrating the resultant filtrate under vacuo to afford the crude amino alcohol product without further purification (0.189 g/92% yield).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(2-(2-(Hydroxymethyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>(+)-(1<i>S</i>,2<i>R</i>)-43</b>)</h3><div class="NLM_p last">Compound was prepared following the synthetic procedure described for <b>(−)-(1<i>R</i>,2<i>S</i>)-44</b>, starting from <b>(1<i>R</i>,2<i>S</i>)-42a</b> (0.130 g, 1.10 mmol). Upon reaction completion, solvent was evaporated under vacuo, and the crude material was purified by Combiflash chromatography, eluting in 75% EtOAc/hexanes to afford the desired product as pale viscous yellow oil (0.065 g/22% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 9.58 δ (s, 1H), 7.61 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.40 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.27–7.23 (m, 1H), 7.12–7.08 (m, 1H), 7.06 (bt, <i>J</i> = 5.2 Hz, 1H), 6.97 (dd, <i>J</i> = 2.0, 0.8 Hz, 1H), 3.98–3.88 (m, 2H), 3.38–3.32 (m, 1H), 3.19 (br s, 1H), 1.99–1.93 (m, 2H), 1.12–1.03 (m, 1H), 0.97–0.90 (m, 1H), 0.71–0.65 (m, 1H), 0.43–0.34 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.1, 136.3, 130.9, 127.6, 124.4, 121.9, 120.5, 112.0, 102.5, 67.1, 39.8, 34.0, 20.9, 16.0, 9.0. GC/MS (EI) <i>m</i>/<i>z</i> 258.1 (M+). [α]<sub class="stack">D</sub><sup class="stack">23</sup>: +42.258 (0.310 g/100 mL in MeOH). Analytical HPLC column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (from 90:10 up to 70:30), total run time of 60 min, RT 19.654 min, ee 88.5% (absorbance at 254.4 nm).</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(2-(2-(Hydroxymethyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>(−)-(1<i>R</i>,2<i>S</i>)-44</b>)</h3><div class="NLM_p last">To a well stirring solution of indole-2-carboxylic acid (0.307 g, 1.9 mmol) dissolved in anhydrous THF (10 mL), cooled to 0 °C on an ice bath, and under inert atmosphere, were added EDC hydrochloride (0.416 g, 2.10 mmol) and HOBt (0.281 g, 2.00 mmol) together as a single portion. The reaction mixture was subsequently removed from ice and allowed to stir, warming to room temperature over the following hour. <b>(1<i>S</i>,2<i>R</i>)-42b</b> (0.200 g, 1.70 mmol) was dissolved in anhydrous THF (15 mL) and then added dropwise into the vigorously stirring solution. <i>N</i>,<i>N</i>-Diisopropylethylamine (0.297 g, 0.401 mL, 2.30 mmol) was then added via the syringe as a single portion, and the reaction was allowed to proceed at room temperature over the following 4 h. Upon reaction completion, solvent was evaporated under vacuo, and the crude material was purified by Combiflash chromatography, eluting in 75% EtOAc/hexanes to afford the desired product as pale viscous yellow oil (0.075 g/16.7% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 9.58 δ (s, 1H), 7.61 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.40 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.27–7.23 (m, 1H), 7.12–7.08 (m, 1H), 7.06 (bt, <i>J</i> = 5.2 Hz, 1H), 6.97 (dd, <i>J</i> = 2.0, 0.8 Hz, 1H), 3.98–3.88 (m, 2H), 3.38–3.32 (m, 1H), 3.19 (br s, 1H), 1.99–1.93 (m, 2H), 1.12–1.03 (m, 1H), 0.97–0.90 (m, 1H), 0.71–0.65 (m, 1H), 0.43–0.34 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.1, 136.3, 130.9, 127.6, 124.4, 121.9, 120.5, 112.0, 102.5, 67.1, 39.8, 34.0, 20.9, 16.0, 9.0. GC/MS (EI) <i>m</i>/<i>z</i> 258.1 (M+). [α]<sub class="stack">D</sub><sup class="stack">23</sup>: −38.378 (0.185 g/100 mL in MeOH). Analytical HPLC column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (from 90:10 up to 70:30), total run time of 40 min, RT 26.135 min, ee 88.5% (absorbance at 254 nm).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (−)-<i>N</i>-(2-((1<i>R</i>,2<i>S</i>)-2-(Hydroxymethyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>44</b>) and (+)-<i>N</i>-(2-((1<i>S</i>,2<i>R</i>)-2-(Hydroxymethyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>43</b>)</h3><div class="NLM_p last">Racemic mixture <b><i>trans</i>-54</b> was resynthesized as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The racemic mixture was separated via preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm; 5 μm), eluting with <i>n</i>-hexane/2-propanol (from 90:10 up to 80:20, flow rate 18 mL/min) to yield two different fractions corresponding to the two enantiomers <b>(−)-44</b> and <b>(+)-43</b>. Analytical HPLC for <b>(−)-44</b>, method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (from 90:10 up to 80:20, flow rate 1 mL/min), total run time of 100 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 35.599 min, purity 88.8%, ee 78.5% (absorbance at 214 nm); method B: column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (from 90:10 up to 70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 47.728 min, purity 89.5%, ee 79% (max absorbance at 214 nm). The results of the HPLC analysis performed on the OZ-H column matched with the analysis performed on the same <b>(−)-(1<i>R</i>,2<i>S</i>)-44</b> resolved as described in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Spectroscopic data and optical rotation were consistent with the ones reported above for the same <b>(−)-(1<i>R</i>,2<i>S</i>)-44</b>. Analytical HPLC for <b>(+)-43</b>, method A: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (from 90:10 up to 80:20, flow rate 1 mL/min), total run time of 100 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 40.379 min, purity > 95%, ee > 99% (absorbance at 214 nm); method B: column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (from 90:10 up to 70:30, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 33.440 min, purity > 95%, ee > 99% (absorbance at 214 nm). The results of the HPLC analysis performed on OZ-H column matched with the analysis performed on the same <b>(+)-(1<i>S</i>,2<i>R</i>)-43</b> resolved as described in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Spectroscopic data and optical rotation were consistent with the ones reported above for the same <b>(+)-(1<i>S</i>,2<i>R</i>)-43</b>.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(2-(2-Formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>(−)-(1<i>S</i>,2<i>R</i>)-45</b>)</h3><div class="NLM_p last">Compound was prepared following the synthetic procedure described for <b>(+)-(1<i>R</i>,2<i>S</i>)-46</b>, starting from <b>(+)-(1<i>S</i>,2<i>R</i>)-43</b> (0.065 g, 0.26 mmol). The crude material was purified by Combiflash chromatography, eluting in 50% EtOAc/hexanes to afford the desired product as a pale white solid (0.45 g/68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.54 (s, 1H), 9.08 (d, <i>J</i> = 5.2 Hz, 1H), 7.64 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.29 (dd, <i>J</i> = 7.0, 0.8 Hz, 1H), 7.15–7.11 (m, 1H), 6.85 (m, 1H), 6.46 (bt, <i>J</i> = 5.2 Hz, 1H), 3.59 (dd, <i>J</i> = 12.8, 7.0 Hz, 2H), 1.76–1.68 (m, 3H), 1.58–1.53 (m, 1H), 1.37–1.32 (m, 1H), 1.02–0.98 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 200.7, 161.8, 136.3, 130.5, 127.6, 124.6, 121.9, 120.7, 112.0, 102.0, 39.3, 32.8, 29.9, 20.2, 14.6. [α]<sub class="stack">D</sub><sup class="stack">23</sup>: −30.352 (0.425 g/100 mL in MeOH).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-(2-((1<i>S</i>,2<i>R</i>)-2-Formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>45</b>)</h3><div class="NLM_p last">Compound <b>45</b> was synthesized following the same procedure described for <b>35</b>, starting from <b>(+)-43</b> (62.20 mg, 0.24 mmol). Spectroscopic data and optical rotation were consistent with the ones reported above for the same <b>(−)-(1<i>S</i>,2<i>R</i>)-45</b>.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>N</i>-(2-(2-Formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>(+)-(1<i>R</i>,2<i>S</i>)-46</b>)</h3><div class="NLM_p last">To a well stirring solution of <b>(−)-(1<i>R</i>,2<i>S</i>)-44</b> (0.075 g, 0.29 mmol) in anhydrous DCM (10 mL) and under an inert atmosphere was added DMP (0.142 g, 0.33 mmol) as a single portion. The reaction was then allowed to proceed at room temperature over the following 1.5 h with vigorous stirring. Upon completion, the reaction mixture was diluted with additional DCM (50 mL) and decanted to a separatory funnel, wherein the organic phase was washed repeatedly with 10 mL portions of an aqueous 10% NaHCO<sub>3</sub> solution. The organic phase was then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuo to afford the crude product as viscous red oil. The crude material was subsequently purified by Combiflash chromatography, eluting in 50% EtOAc/hexanes to afford the desired product as a pale white solid (0.035 g/47% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.54 (s, 1H), 9.08 (d, <i>J</i> = 5.2 Hz, 1H), 7.64 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 7.29 (dd, <i>J</i> = 7.0, 0.8 Hz, 1H), 7.15–7.11 (m, 1H), 6.85 (m, 1H), 6.46 (bt, <i>J</i> = 5.2 Hz, 1H), 3.59 (dd, <i>J</i> = 12.8, 7.0 Hz, 2H), 1.76–1.68 (m, 3H), 1.58–1.53 (m, 1H), 1.37–1.32 (m, 1H), 1.02–0.98 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 200.7, 161.8, 136.3, 130.5, 127.6, 124.6, 121.9, 120.7, 112.0, 102.0, 39.3, 32.8, 29.9, 20.2, 14.6. [α]<sub class="stack">D</sub><sup class="stack">23</sup>: +22.58 (0.124 g/100 mL in MeOH).</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-(2-((1<i>R</i>,2<i>S</i>)-2-Formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>46</b>)</h3><div class="NLM_p last">Compound <b>46</b> was synthesized following the same procedure described for <b>35</b>, starting from <b>(−)-44</b> (60 mg, 0.23 mmol). Spectroscopic data and optical rotation were consistent with the ones reported above for the same <b>(+)-(1<i>R</i>,2<i>S</i>)-46</b>.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>S</i>)-2-Chloro-1-(6-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)pyridin-3-yl)ethan-1-ol (<b>47</b>)</h3><div class="NLM_p last">In a round-bottom flask covered in aluminum foil, (+)-<i>B</i>-chlorodiisopinocampheylborane ((+)-DIP-Cl) (3.37 g, 10.5 mmol) was weighed quickly and with limited exposure to light, dissolved with <sup><i>t</i></sup>BuOMe/THF (3:7, 10 mL), placed under an argon atmosphere, and subsequently cooled to −40 °C in a dry ice/acetonitrile bath. Compound 2-chloro-1-(6-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)pyridin-3-yl)ethan-1-one<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (2.06 g, 8.2 mmol) was then dissolved in THF (4 mL) and added dropwise to the solution of (+)-DIP-Cl. The reaction was allowed to stir overnight, slowly warming to room temperature. The reaction completion was monitored via thin layer chromatography (TLC) and GC/MS, and then 30 mL of saturated NH<sub>4</sub>Cl aqueous solution was added to the reaction mixture and allowed to stir for 1 h at room temperature. The organic phase was collected, and the aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was removed under reduced pressure. The crude residue was purified via flash chromatography, eluting with hexanes/EtOAc (75:25), to yield 2.07 g of the desired compound as yellow oil, in 78.6% yield. Spectroscopic data were concurrent with the previously reported ones.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> GC/MS (EI) RT 10.785 min, 250.1 <i>m</i>/<i>z</i>. HPLC column Chiralcel OZ-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (from 90:10 up to 80:20, flow rate 1 mL/min), total run time of 50 min, RT 18.163 min, purity > 95%, ee > 99% (absorbance at 230 nm). [α]<sub class="stack">D</sub><sup class="stack">23</sup>: +23.3 (0.645 g/100 mL in CHCl<sub>3</sub>). Enantiomeric excess and absolute configuration were confirmed via HPLC comparison (same HPLC methods described above) with the (<i>R</i>)-enantiomer (RT 13.056 min, purity 94.7%, ee 90.3%), resynthesized, as standard, using (−)-DIP-Cl as previously reported.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> [α]<sub class="stack">D</sub><sup class="stack">23</sup>: −21.1 (0.620 g/100 mL in CHCl<sub>3</sub>).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>S</i>)-2-(2,5-Dimethyl-1<i>H</i>-pyrrol-1-yl)-5-(oxiran-2-yl)pyridine (<b>48</b>)</h3><div class="NLM_p last">Compound <b>47</b> (2.06 g, 0.0082 mol) was dissolved in acetonitrile (200 mL), anhydrous K<sub>2</sub>CO<sub>3</sub> was added to the solution, (21.3 g, 0.154 mol) and it was stirred overnight at reflux. The reaction mixture was allowed to cool to room temperature, and the suspension was filtered. The solvent was removed under reduced pressure to yield 1.59 g of the desired compound as brown oil, which was used in the next step without further purification. GC/MS (EI) RT 9.672 min, 214.1 <i>m</i>/<i>z</i>.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>S</i>)-2-(((<i>S</i>)-2-(6-(2,5-Dimethyl-1<i>H</i>-pyrrol-1-yl)pyridin-3-yl)-2-hydroxyethyl)amino)propan-1-ol (<b>49</b>)</h3><div class="NLM_p last">Compound <b>48</b> (1.59 g, 7.39 mmol) was dissolved in 150 mL of toluene, and the solution was stirred to homogeneity. (<i>S</i>)-2-Aminopropan-1-ol (2.77 g, 36.9 mmol) was added to the solution, and the reaction mixture was then heated to reflux and stirred overnight. The reaction was cooled to room temperature, and the solvent was removed under reduced pressure. The crude residue was dissolved in DCM (30 mL) and washed with water (5 mL). The organic phase was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude material was purified via flash chromatography with gradient elution, increasing the polarity of the mobile phase up to 20% DMA (DCM/MeOH + 0.5% NH<sub>4</sub>OH), to yield 450 mg of the desired compound as an off-white solid, in 21% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 8.58 (s, 1H), 7.87 (d, <i>J</i> = 8.5 Hz, 1H), 7.22 (d, <i>J</i> = 8.4 Hz, 1H), 5.89 (s, 2H), 4.81 (d, <i>J</i> = 9.5 Hz, 1H), 3.66 (d, <i>J</i> = 10.8 Hz, 1H), 3.4 (t, <i>J</i> = 9.4 Hz, 1H), 2.99 (d, <i>J</i> = 12.1 Hz, 1H), 2.87 (dt, <i>J</i> = 21.7, 10.3 Hz, 2H), 2.11 (s, 6H), 1.47 (d, <i>J</i> = 6.6 Hz, 3H).</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Benzyl ((<i>S</i>)-2-(6-(2,5-Dimethyl-1<i>H</i>-pyrrol-1-yl)pyridin-3-yl)-2-hydroxyethyl)((<i>S</i>)-1-hydroxypropan-2-yl)carbamate (<b>50</b>)</h3><div class="NLM_p last">Compound <b>49</b> (0.450 g, 1.55 mmol) was dissolved in 25 mL of anhydrous tetrahydrofuran and subsequently cooled to −40 °C with a cryocooler. In a separate vial, a solution of <i>N</i>-(benzyloxycarbonyloxy)succinimide in anhydrous tetrahydrofuran (0.465 g, 1.87, 0.2 M) was prepared and transferred dropwise into the reaction flask. Upon completion of the <i>N</i>-(benzyloxycarbonyloxy)succinimide solution addition, the cryocooler was powered off to allow the reaction mixture to slowly reach room temperature. Following overnight stirring at room temperature, an additional equivalent of <i>N</i>-(benzyloxycarbonyloxy)succinimide (0.386 g, 1.55 mmol) was added to the reaction mixture, and the reaction was stirred at room temperature for an additional 2 h. The reaction was quenched with the addition of saturated NaHCO<sub>3</sub> aqueous solution (25 mL) and methanol (20 mL) and stirred at room temperature for 1 h. The organic solvents were removed under reduced pressure, and the remaining aqueous layer was extracted with DCM (3 × 30 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. The crude material was partially purified via flash chromatography, gradually increasing the mobile phase polarity up to hexanes/EtOAc (4:6), to yield 505 mg of the desired product as colorless oil, in 76.9% yield.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Benzyl (2<i>S</i>,5<i>S</i>)-2-(6-(2,5-Dimethyl-1<i>H</i>-pyrrol-1-yl)pyridin-3-yl)-5-methylmorpholine-4-carboxylate (<b>51</b>)</h3><div class="NLM_p last">Triphenylphosphine (0.38 g, 1.44 mmol) and 50 (0.500 g, 1.20 mmol) were dissolved in toluene (20 mL). The solution was stirred at room temperature while diisopropyl azodicarboxylate (DIAD) (0.28 mL, 1.44 mmol) was added dropwise. The reaction mixture was then stirred for 20 h at room temperature. The reaction mixture was evaporated under reduced pressure, and the crude residue was purified via flash chromatography, gradually increasing the mobile phase polarity up to hexanes/EtOAc (8:2), to yield 363 mg of the desired product as colorless viscous oil, in 74.6% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 8.61 (d, <i>J</i> = 12.4 Hz, 1H), 7.86 (d, <i>J</i> = 8.3 Hz, 1H), 7.38 (br s, 5H), 7.23 (d, <i>J</i> = 8.5 Hz, 1H), 5.90 (s, 2H), 5.19 (d, <i>J</i> = 9.8 Hz, 2H), 5.11–4.96 (m, 1H), 4.37–3.99 (m, 2H), 3.89 (d, <i>J</i> = 15.6 Hz, 2H), 3.32–2.96 (m, 1H), 2.12 (s, 6H), 1.32 (d, <i>J</i> = 5.8 Hz, 3H).</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Benzyl (2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholine-4-carboxylate (<b>52</b>)</h3><div class="NLM_p last">Compound <b>51</b> (0.363 g, 0.895 mmol) was dissolved in 10 mL of ethanol; hydroxylamine hydrochloride (0.522 g, 7.52 mmol) was then added to the solution in one portion, and the reaction mixture was heated to reflux. After 4 h, additional 8 equiv of hydroxylamine hydrochloride was added to the flask, and the reaction mixture was allowed to stir at reflux overnight. The solvent was removed under reduced pressure, the crude mixture was dissolved in DCM and washed with saturated NaHCO<sub>3</sub> aqueous solution. The organic phase was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude mixture was purified via flash chromatography, eluting with 2% DMA (DCM/MeOH + 1% NH<sub>4</sub>OH), to yield desired product as purple oil, in quantitative yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (d, <i>J</i> = 9.8 Hz, 1H), 7.47 (d, <i>J</i> = 8.6 Hz, 1H), 7.35 (d, <i>J</i> = 9.4 Hz, 5H), 6.49 (d, <i>J</i> = 8.5 Hz, 1H), 5.16 (d, <i>J</i> = 10.8 Hz, 2H), 5.09–5.01 (m, 1H), 4.51 (s, 2H), 4.38–4.11 (m, 2H), 3.81 (d, <i>J</i> = 16.1 Hz, 2H), 3.06 (dt, <i>J</i> = 25.5, 12.3 Hz, 1H), 1.32 (d, <i>J</i> = 6.2 Hz, 3H).</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>trans-N</i>-(2-(2-(((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>53</b>)</h3><div class="NLM_p last"><i>N</i>-(2-(2-Formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide<a onclick="showRef(event, 'ref12 ref36'); return false;" href="javascript:void(0);" class="ref ref12 ref36">(12,36)</a> was added to a solution of <b>23b</b> (0.075 g, 0.388 mmol) in 1,2-dichloroethane (50 mL). The catalytic amount of glacial acetic acid was added to the stirring solution, and the reaction mixture was allowed to stir for 30 min at room temperature before adding STAB (0.123 g, 0.582 mmol) in one portion. The reaction was stirred for additional 30 min at room temperature, after which the solvent was removed under reduced pressure. The crude mixture was purified via flash chromatography, gradually increasing the mobile phase polarity from 100% DCM to 10% DMA (DCM/MeOH + 0.5% NH<sub>4</sub>OH) to afford 150 mg of the desired product as a 50:50 diastereomeric mixture, as an off-white solid, in 89.2% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.61 (s, 1H, 50% isomer), 9.57 (s, 1H, 50% isomer), 8.06 (d, <i>J</i> = 8.7 Hz, 1H), 7.64 (d, <i>J</i> = 8.1 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 2H), 7.32–7.23 (m, 2H), 7.13 (t, <i>J</i> = 7.6 Hz, 1H), 6.94 (s, 1H, 50% isomer), 6.87 (s, 1H, 50% isomer), 6.47 (d, <i>J</i> = 8.4 Hz, 1H), 4.62 (br s, 2H), 4.50 (d, <i>J</i> = 10.0 Hz, 1H), 3.94 (t, <i>J</i> = 11.6 Hz, 1H), 3.72 (t, <i>J</i> = 9.1 Hz, 1H), 3.66–3.47 (m, 2H), 3.03 (d, <i>J</i> = 31.6 Hz, 1H), 2.75 (d, <i>J</i> = 12.5 Hz, 1H), 2.60 (dt, <i>J</i> = 21.5, 11.0, Hz, 1H), 2.47 (dd, <i>J</i> = 12.6, 6.2 Hz, 1H, 50% isomer), 2.34 (t, <i>J</i> = 9.7 Hz, 1H, 50% isomer), 2.22 (dd, <i>J</i> = 12.7, 7.5 Hz, 1H, 50% isomer), 2.10 (s, 1H, 50% isomer), 1.70–1.49 (m, 2H), 1.11 (dd, <i>J</i> = 1.6, 6.66, 3H), 0.71 (d, <i>J</i> = 36.6 Hz, 2H), 0.43 (t, <i>J</i> = 7.0 Hz, 2H); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>): δ 161.75, 161.72, 158.28, 158.25, 146.23, 146.15, 136.75, 136.43, 131.20, 131.10, 127.82, 126.13, 124.60, 124.54, 122.02, 120.81, 120.76, 112.10, 108.66, 108.59, 102.45, 102.05, 75.89, 75.55, 71.93, 71.58, 58.84, 53.15, 52.82, 52.17, 51.91, 39.85, 39.82, 33.86, 33.72, 22.21, 16.50, 16.18, 15.37, 11.52, 10.78, 8.63, 8.53. HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (50:50 flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 21.873 min and 36.176, purity > 95%, dr 50:50 (absorbance at 230 nm). The free base was converted into the corresponding oxalate salt. HRMS (ESI) C<sub>25</sub>H<sub>31</sub>O<sub>2</sub>N<sub>5</sub> + H<sup>+</sup> calcd, 434.25505; found, 434.25604 (2.3 ppm). CHN Anal (C<sub>25</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub>·2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>·H<sub>2</sub>O) Calcd: C, 55.15; H, 5.90; N, 11.09. Found: C, 55.55; H, 5.75; N, 11.12. About 50 mg the oxalate salt was free-based, and the diastereomeric mixture was separated via preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm; 5 m), eluting with <i>n</i>-hexane/2-propanol (from 40:60 up to 50:50, flow rate 20 mL/min) to yield two different fractions corresponding to the two diastereoisomers (<b>53a</b>) <i>N</i>-(2-((1<i>R</i>,2<i>S</i>)-2-(((2<i>S</i>,5<i>S</i>)-2-(6-aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide and (<b>53b</b>) <i>N</i>-(2-((1<i>S</i>,2<i>R</i>)-2-(((2<i>S</i>,5<i>S</i>)-2-(6-aminopyridin-3-yl)-5 methylmorpholino)methyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide. Analytical HPLC for <b>53a</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (50:50, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 21.362 min, purity > 99%, de > 99% (absorbance at 230 nm). mp 83–84 °C with prior decomposition; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: +17.8 (0.045 g/100 mL in MeOH). Analytical HPLC for <b>53b</b>: column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (50:50, flow rate 1 mL/min), total run time of 70 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 35.338 min, purity > 95%, de > 99% (absorbance at 230 nm). mp 63–64 °C with prior decomposition; [α]<sub class="stack">D</sub><sup class="stack">25</sup>: −14.3 (0.06 g/100 mL in MeOH).</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>N</i>-(2-((1<i>R</i>,2<i>S</i>)-2-(((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>53a</b>)</h3><div class="NLM_p last">Compound <b>53a</b> was synthesized following the same procedure described for <b>53</b>, starting from <b>46</b> (40 mg, 0.16 mmol). Spectroscopic data were consistent with the ones obtained for <b>53</b> and HPLC analyses, using <b>53a</b> as standard, were consistent to the results previously obtained, and reported above, obtained for <b>53a</b>, confirming the assigned absolute configuration. Analytical HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (50:50, flow rate 1 mL/min), total run time of 45 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 20.626 min, purity > 99%, ee > 99% (absorbance at 230 nm).</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i>-(2-((1<i>S</i>,2<i>R</i>)-2-(((2<i>S</i>,5<i>S</i>)-2-(6-Aminopyridin-3-yl)-5-methylmorpholino)methyl)cyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide (<b>53b</b>)</h3><div class="NLM_p last">Compound <b>53b</b> was synthesized following the same procedure described for <b>53</b>, starting from <b>45</b> (3.20 mg, 0.02 mmol). Spectroscopic data were consistent with the ones obtained for <b>53</b> and HPLC analyses, using <b>53b</b> as the standard, were consistent to the results previously obtained, and reported above, for <b>53b</b>, confirming the assigned absolute configuration. Analytical HPLC column Chiralpak AD-H (4.6 mm × 250 mm; particle size 5 μm), elution with <i>n</i>-hexane/2-propanol (50:50, flow rate 1 mL/min), total run time of 60 min, and multiple DAD λ absorbance signals were measured in the range of 210–280 nm, RT 35.991 min, purity > 99%, ee > 99% (absorbance at 230 nm).</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 7-(4-(4-(3-Chloro-5-ethyl-2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>57</b>)</h3><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (2.173 g, 15.7 mmol) was added to a solution of 1-(3-chloro-5-ethyl-2-methoxyphenyl)piperazine<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (0.50 g, 1.97 mmol) in <i>N</i>,<i>N</i>-dimethylformamide, followed by 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (0.70 g, 2.37 mmol) at room temperature. The reaction mixture was warmed to 90 °C and stirred for 6 h. The reaction mixture was diluted with ice-cold water and extracted with chloroform. The combined organic phase was washed with ice-cold water (4 × 200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude compound was purified by flash chromatography, eluting with 20% acetone in chloroform, to obtain the desired product in 67% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.82 (br s, 1H), 7.04 (d, <i>J</i> = 8.2 Hz, 1H), 6.84 (s, 1H), 6.61 (s, 1H), 6.52 (d, <i>J</i> = 8.3 Hz, 1H), 6.30 (s, 1H), 3.97 (dd, <i>J</i> = 13.2, 6.6 Hz, 2H), 3.81 (d, <i>J</i> = 22.7 Hz, 3H), 3.14 (s, 3H), 3.00–2.83 (m, 3H), 2.74–2.38 (m, 8H), 1.99–1.50 (m, 6H), 1.21 (dd, <i>J</i> = 18.6, 11.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.38, 158.65, 146.37, 146.16, 140.77, 138.04, 128.67, 128.20, 122.16, 116.65, 115.72, 108.61, 102.09, 67.91, 58.99, 58.26, 53.75, 50.27, 31.09, 29.37, 28.45, 27.25, 25.73, 24.59, 23.40, 15.38. The free base was converted into the corresponding hydrochloride salt, which was precipitated from acetone. HRMS (ESI) C<sub>26</sub>H<sub>34</sub>O<sub>3</sub>N<sub>3</sub>Cl + H<sup>+</sup> calcd, 472.23615; found, 472.23603 (−1.4 ppm). mp 193–194 °C, Anal (C<sub>26</sub>H<sub>34</sub>ClN<sub>3</sub>O<sub>3</sub>·HCl·1.25H<sub>2</sub>O) Calcd: C, 58.81; H, 7.12; N, 7.91. Found: C, 58.71; H, 6.66; N, 7.52.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 7-(4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>58</b>)</h3><div class="NLM_p last">The compound was synthesized according to the same method described for <b>57</b>, starting from 1-(2-chloro-3-ethylphenyl)piperazine<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (0.50 g, 2.23 mmol) and 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (0.80 g, 2.67 mmol). The desired product was obtained in 74% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.68 (s, 1H), 7.16 (t, <i>J</i> = 7.8 Hz, 1H), 7.05 (d, <i>J</i> = 8.1 Hz, 1H), 6.94 (t, <i>J</i> = 8.1 Hz, 2H), 6.53 (d, <i>J</i> = 8.1 Hz, 1H), 6.30 (s, 1H), 3.97 (t, <i>J</i> = 6.1 Hz, 2H), 3.07 (s, 3H), 2.90 (t, <i>J</i> = 7.4 Hz, 2H), 2.84–2.71 (m, 2H), 2.63 (dd, <i>J</i> = 16.9, 9.3 Hz, 5H), 2.56–2.38 (m, 2H), 1.83 (dd, <i>J</i> = 14.0, 7.1 Hz, 2H), 1.77–1.66 (m, 2H), 1.62 (s, 2H), 1.23 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.70, 158.67, 149.62, 143.20, 138.11, 128.68, 126.86, 123.93, 117.97, 115.67, 108.77, 108.67, 102.18, 67.93, 58.25, 53.46, 51.56, 31.08, 27.45, 27.29, 24.58, 23.44, 14.08. The free base was converted into the corresponding hydrochloride salt, which was precipitated from acetone. mp 197–198 °C, Anal (C<sub>25</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>2</sub>·HCl·0.5H<sub>2</sub>O) Calcd: C, 61.60; H, 6.69; N, 8.62. Found: C, 61.60; H, 7.03; N, 8.62.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Radioligand Binding Studies</h3><div class="NLM_p last">Radioligand binding assays were conducted similarly as previously described.<a onclick="showRef(event, 'ref31 ref36'); return false;" href="javascript:void(0);" class="ref ref31 ref36">(31,36)</a> HEK293 cells stably expressing human D<sub>2L</sub>R or D<sub>3</sub>R or D<sub>4.4</sub> were grown in a 50:50 mix of DMEM and Ham’s F12 culture media, supplemented with 20 mM HEPES, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 0.1 mM non-essential amino acids, 1× antibiotic/antimycotic, 10% heat-inactivated fetal bovine serum, and 200 μg/mL hygromycin (Life Technologies, Grand Island, NY) and kept in an incubator at 37 °C and 5% CO<sub>2</sub>. Upon reaching 80–90% confluence, cells were harvested using premixed Earle’s balanced salt solution with 5 mM EDTA (Life Technologies) and centrifuged at 3000 rpm for 10 min at 21 °C. The supernatant was removed, and the pellet was resuspended in 10 mL hypotonic lysis buffer (5 mM MgCl<sub>2</sub>, 5 mM Tris, pH 7.4 at 4 °C) and centrifuged at 14 500 rpm (∼25 000<i>g</i>) for 30 min at 4 °C. The pellet was then resuspended in fresh binding buffer. Bradford protein assay (Bio-Rad, Hercules, CA) was used to determine the protein concentration. For [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT binding studies, membranes were harvested fresh; the binding buffer was made from 50 mM Tris, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, pH 7.4. On the test day, each test compound was diluted into half-log serial dilutions using the 30% dimethyl sulfoxide (DMSO) vehicle. When it was necessary to assist solubilization of the drugs at the highest tested concentration, 0.1% acetic acid (final concentration v/v) was added alongside the vehicle. Membranes were diluted in fresh binding buffer. Radioligand competition experiments were conducted in 96-well plates containing 300 μL fresh binding buffer, 50 μL of the diluted test compound, 100 μL of membranes (40–80, 20–40, and 30–60 μg/well total protein for hD<sub>2L</sub>R, hD<sub>3</sub>R, and hD<sub>4.4</sub>R respectively), and 50 μL of radioligand diluted in binding buffer ([<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT: 1.5 nM final concentration for hD<sub>2L</sub>, 0.5 nM final concentration for hD<sub>3</sub>, and 3 nM final concentration for hD<sub>4.4</sub> ARC, Saint Louis, MO). Aliquots of [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT solution were also quantified accurately to determine how much radioactivity was added, taking in account the experimentally determined counter efficiency. Nonspecific binding was determined using 10 μM (+)-butaclamol (Sigma-Aldrich, St. Louis, MO), and total binding was determined with the 30% DMSO vehicle. All compound dilutions were tested in duplicate or triplicate, and the reaction incubated for 90 min at room temperature. The reaction was terminated by filtration through PerkinElmer Uni-Filter-96 GF/B, presoaked for 90 min in 0.5% polyethylenimine, using a Brandel 96-Well Plates Harvester Manifold (Brandel Instruments, Gaithersburg, MD). The filters were washed thrice with 3 mL (3 × 1 mL/well) of ice-cold binding buffer. PerkinElmer MicroScint 20 Scintillation Cocktail (65 μL) was added to each well, and filters were counted using a PerkinElmer MicroBeta Microplate Counter. IC<sub>50</sub> values for each compound were determined from dose–response curves, and <i>K</i><sub>i</sub> values were calculated using the Cheng–Prusoff equation;<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a><i>K</i><sub>d</sub> values for [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT were determined via separate homologous competitive binding experiments. When a complete inhibition could not be achieved at the highest tested concentrations, <i>K</i><sub>i</sub> values have been extrapolated by constraining the bottom of the dose–response curves (=0% residual specific binding) in the nonlinear regression analysis. These analyses were performed using GraphPad Prism version 6.00 for Macintosh (GraphPad Software, San Diego, CA). All results were rounded to the third significant figure. <i>K</i><sub>i</sub> values were determined from at least three independent experiments and are reported as the mean ± standard error of the mean (SEM).</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Phase I Metabolism in Rat Liver Microsomes</h3><div class="NLM_p">For phase I metabolism, the reactions were carried out with 100 mM potassium phosphate buffer, pH 7.4, in the presence of the NADPH regenerating system (1.3 mM NADPH, 3.3 mM glucose 6-phosphate, 3.3 mM MgCl<sub>2</sub>, 0.4 U/mL glucose-6-phosphate dehydrogenase, 50 μM sodium citrate). Reactions in triplicate were initiated by addition of the liver microsomes to the incubation mixture (compound final concentration was 10 μM; 0.5 mg/mL microsomes). Compound disappearance was monitored via LC/MS/MS. Chromatographic analysis was performed using an Accela ultra high-performance system consisting of an analytical pump and an autosampler coupled with TSQ Vantage mass spectrometer (Thermo Fisher Scientific Inc., Waltham MA). Separation of the analyte from the potentially interfering material was achieved at ambient temperature using an Agilent Eclipse Plus column (100 × 2.1 mm i.d.) packed with a 1.8 μm C18 stationary phase. The mobile phase used was composed of 0.1% formic acid in acetonitrile and 0.1% formic acid in water with gradient elution, starting with 10% (organic) linearly increasing to 99% up to 2.5 min and re-equilibrating to 10% by 2.7 min. The total run time for each analyte was 5.0 min.</div><div class="NLM_p last">Metabolite identification (MET-ID) was performed on a Dionex ultra high-performance LC system coupled with a Q Exactive Focus orbitrap mass spectrometer (Thermo Fisher Scientific Inc., Waltham MA). Separation was achieved using an Agilent Eclipse Plus column (100 × 2.1 mm i.d; maintained at 35 °C) packed with a 1.8 μm C18 stationary phase. The mobile phase consisted of 0.1% formic acid in water and 0.1% formic acid in acetonitrile. Pumps were operated at a flow rate of 0.3 mL/min for 7 min using gradient elution. The mass spectrometer controlled by Xcalibur software 4.0.27.13 (Thermo Scientific) was operated with a HESI ion source in the positive ionization mode. Metabolites were identified in the full-scan mode (from <i>m</i>/<i>z</i> 50 to 1600) by comparing <i>t</i> = 0 samples with <i>t</i> = 60 min samples, and structures were proposed based on the accurate mass information.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> X-ray Crystal Data on Compounds <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> and <b>(2<i>R</i>,5<i>S</i>)-23a</b></h3><div class="NLM_p">Single-crystal X-ray diffraction data on compound <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> were collected using Cu Kα radiation and a Bruker Photon 100 CMOS area detector. Single-crystal X-ray diffraction data on compound <b>(2<i>R</i>,5<i>S</i>)-23a</b> were collected using Mo Kα radiation and a Bruker APEX II area detector. The crystals were prepared for data collection by coating with high viscosity microscope oil. The oil-coated crystal was mounted on a micro-mesh mount (MiteGen, Inc.) and transferred to the diffractometer. The structures were dissolved by direct methods and refined by full-matrix least squares on <i>F</i><sup>2</sup> values using programs found in the SHELXL suite (Bruker, SHELXL v2014.7, 2014, Bruker AXS Inc., Madison, WI). Corrections were applied for Lorentz, polarization, and absorption effects. Parameters refined included atomic coordinates and anisotropic thermal parameters for all nonhydrogen atoms. The H atoms were included using a riding model. Complete information on data collection and refinement is available in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div class="NLM_p">The 0.331 × 0.105 × 0.020 mm<sup>3</sup> crystal of <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> was orthorhombic in space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, with unit cell dimensions <i>a</i> = 5.6918(2) Å, <i>b</i> = 6.2010(2) Å, <i>c</i> = 26.4447(10) Å, α = 90°, β = 90°, and γ = 90°. Data were collected at 150 K. Data were 98.13% complete to 67.7° θ (∼0.83 Å) with an average redundancy of 5.52. The final anisotropic full matrix least-squares refinement on <i>F</i><sup>2</sup> with 120 variables converged at <i>R</i><sub>1</sub> = 3.49% for the observed data and w<i>R</i><sub>2</sub> = 9.45% for all data.</div><div class="NLM_p last">The 0.294 × 0.099 × 0.054 mm<sup>3</sup> crystal of <b>(2<i>R</i>,5<i>S</i>)-23a</b> was monoclinic in space group <i>C</i>2, with unit cell dimensions <i>a</i> = 30.3306(18) Å, <i>b</i> = 5.4531(3) Å, <i>c</i> = 12.7310(7) Å, α = 90°, β = 99.926(2)°, and γ = 90°. Data were collected at 293 K. Data were 99.6% complete to 25.242° θ (∼0.83 Å) with an average redundancy of 2.71. The final anisotropic full matrix least-squares refinement on <i>F</i><sup>2</sup> with 261 variables converged at <i>R</i><sub>1</sub> = 4.26% for the observed data and w<i>R</i><sub>2</sub> = 10.42% for all data.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00702" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00702" class="ext-link">10.1021/acs.jmedchem.9b00702</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chiral HPLC analyses of final products, bidimensional <sup>1</sup>H NMR spectra of compounds <b>30</b> and <b>31</b>, analytical data summary of all final products, crystal structure and structure refinement of <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> and <b>(2<i>R</i>,5<i>S</i>)-23a</b>, and SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf">jm9b00702_si_001.pdf (1.47 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_002.csv">jm9b00702_si_002.csv (3.78 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00702" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Hauck Newman</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9065-4072" title="Orcid link">http://orcid.org/0000-0001-9065-4072</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#50313e35273d313e10393e2422317e3e3934317e3e39387e373f26"><span class="__cf_email__" data-cfemail="9afbf4ffedf7fbf4daf3f4eee8fbb4f4f3fefbb4f4f3f2b4fdf5ec">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessandro Bonifazi</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7306-0114" title="Orcid link">http://orcid.org/0000-0002-7306-0114</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5f3e333a2c2c3e313b2d30713d303136393e25366d1f31363771383029"><span class="__cf_email__" data-cfemail="7d1c11180e0e1c13190f12531f1213141b1c07144f3d131415531a120b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francisco
O. Battiti</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sophie L. Cemaj</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian M. Guerrero</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anver Basha Shaik</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenny Lam</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Johns
Hopkins Drug Discovery Program, Johns Hopkins
School of Medicine, 855
N. Wolfe Street, Baltimore, Maryland 21205, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rana Rais</span> - <span class="hlFld-Affiliation affiliation">Johns
Hopkins Drug Discovery Program, Johns Hopkins
School of Medicine, 855
N. Wolfe Street, Baltimore, Maryland 21205, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4059-2453" title="Orcid link">http://orcid.org/0000-0003-4059-2453</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara S. Slusher</span> - <span class="hlFld-Affiliation affiliation">Johns
Hopkins Drug Discovery Program, Johns Hopkins
School of Medicine, 855
N. Wolfe Street, Baltimore, Maryland 21205, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9814-4157" title="Orcid link">http://orcid.org/0000-0001-9814-4157</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffery R. Deschamps</span> - <span class="hlFld-Affiliation affiliation">Naval
Research Laboratory, Code 6910, 4555 Overlook Avenue, Washington,
DC 20375, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Greg H. Imler</span> - <span class="hlFld-Affiliation affiliation">Naval
Research Laboratory, Code 6910, 4555 Overlook Avenue, Washington,
DC 20375, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>F.O.B., S.L.C., and A.M.G. contributed equally to this work. A.B. and A.H.N. designed the project; A.B., A.H.N., and F.O.B. wrote the manuscript with input of all the authors; A.B., F.O.B., S.L.C., A.M.G., A.B.S., J.L., R.R., B.S.S., J.R.D., and A.H.N. designed and/or supervised the experiments and data analyses; A.B., F.O.B., S.L.C., A.M.G., A.B.S., G.H.I., and J.L. performed experiments.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This project was supported by National Institute on Drug Abuse—Intramural Research Program ZIA DA 000609. The authors thank Dr. Ludovic Muller from the Structural Biology Core at NIDA-IRP for high-resolution MS analyses. The X-ray crystallographic work was supported by NIDA through Interagency Agreement #Y1-DA1101 with the Naval Research Laboratory (NRL).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">OBS</td><td class="NLM_def"><p class="first last">orthosteric binding site</p></td></tr><tr><td class="NLM_term">SBP</td><td class="NLM_def"><p class="first last">secondary binding pocket</p></td></tr><tr><td class="NLM_term">PP</td><td class="NLM_def"><p class="first last">primary pharmacophore</p></td></tr><tr><td class="NLM_term">SP</td><td class="NLM_def"><p class="first last">secondary pharmacophore</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">DMP</td><td class="NLM_def"><p class="first last">Dess–Martin periodinane</p></td></tr><tr><td class="NLM_term">TBDMS</td><td class="NLM_def"><p class="first last">(<i>tert</i>-butyl)dimethylsilane</p></td></tr><tr><td class="NLM_term">STAB</td><td class="NLM_def"><p class="first last">sodium triacetoxyborohydride</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">DIP-Cl</td><td class="NLM_def"><p class="first last"><i>B</i>-chlorodiisopinocampheylborane</p></td></tr><tr><td class="NLM_term">7-OH-DPAT</td><td class="NLM_def"><p class="first last">7-hydroxy-<i>N</i>,<i>N</i>-dipropyl-2-aminotetralin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">The physiology, signaling, and pharmacology of dopamine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fpr.110.002642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=21303898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=182-217&author=J.-M.+Beaulieuauthor=R.+R.+Gainetdinov&title=The+physiology%2C+signaling%2C+and+pharmacology+of+dopamine+receptors&doi=10.1124%2Fpr.110.002642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, signaling, and pharmacology of dopamine receptors</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-217</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiol. functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension.  Pharmacol. agents targeting dopaminergic neurotransmission have been clin. used in the management of several neurol. and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD1), and Tourette's syndrome.  Numerous advances have occurred in understanding the general structural, biochem., and functional properties of dopamine receptors that have led to the development of multiple pharmacol. active compds. that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics.  Recent progress in understanding the complex biol. of dopamine receptor-related signal transduction mechanisms has revealed that, in addn. to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins.  One of the future directions in managing dopamine-related pathol. conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacol.  In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms.  In addn., we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacol. and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp84qmbSbA7Vg90H21EOLACvtfcHk0lgTqCVXZSKWiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D&md5=53e6841062c98abe60c732692109e498</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002642%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.-M.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DThe%2520physiology%252C%2520signaling%252C%2520and%2520pharmacology%2520of%2520dopamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D182%26epage%3D217%26doi%3D10.1124%2Fpr.110.002642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span> <span> </span><span class="NLM_article-title">Targeting the dopamine D3 receptor: an overview of drug design strategies</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1185413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1080%2F17460441.2016.1185413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27135354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=641-664&author=A.+Cort%C3%A9sauthor=E.+Morenoauthor=M.+Rodr%C3%ADguez-Ruizauthor=E.+I.+Canelaauthor=V.+Casad%C3%B3&title=Targeting+the+dopamine+D3+receptor%3A+an+overview+of+drug+design+strategies&doi=10.1080%2F17460441.2016.1185413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D3 receptor: an overview of drug design strategies</span></div><div class="casAuthors">Cortes, Antoni; Moreno, Estefania; Rodriguez-Ruiz, Mar; Canela, Enric I.; Casado, Vicent</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">641-664</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter widely distributed in both the periphery and the central nervous system (CNS).  Its physiol. effects are mediated by five closely related G protein-coupled receptors (GPCRs) that are divided into two major subclasses: the D1-like (D1, D5) and the D2-like (D2, D3, D4) receptors.  D3 receptors (D3Rs) have the highest d. in the limbic areas of the brain, which are assocd. with cognitive and emotional functions.  These receptors are therefore attractive targets for therapeutic management.  This review summarizes the functional and pharmacol. characteristics of D3Rs, including the design and clin. relevance of full agonists, partial agonists and antagonists, as well as the capacity of these receptors to form active homodimers, heterodimers or higher order receptor complexes as pharmacol. targets in several neurol. and neurodegenerative disorders.  The high sequence homol. between D3R and the D2-type challenges the development of D3R-selective compds.  The design of new D3R-preferential ligands with improved physicochem. properties should provide a better pharmacokinetic/bioavailability profile and lesser toxicity than is found with existing D3R ligands.  It is also essential to optimize D3R affinity and, esp., D3R vs.  D2-type binding and functional selectivity ratios.  Developing allosteric and bitopic ligands should help to improve the D3R selectivity of these drugs.  As most evidence points to the ability of GPCRs to form homomers and heteromers, the most promising therapeutic strategy in the future is likely to involve the application of heteromer-selective drugs.  These selective ligands would display different affinities for a given receptor depending on the receptor partners within the heteromer.  Therefore, designing novel compds. that specifically target and modulate D1R-D3R heteromers would be an interesting approach for the treatment of levodopa (L-DOPA)-induced dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE412vMxQCZ7Vg90H21EOLACvtfcHk0lgTqCVXZSKWiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D&md5=eda2d0b52e03bbca2d62f1b27b193360</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1185413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1185413%26sid%3Dliteratum%253Aachs%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez-Ruiz%26aufirst%3DM.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520dopamine%2520D3%2520receptor%253A%2520an%2520overview%2520of%2520drug%2520design%2520strategies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D641%26epage%3D664%26doi%3D10.1080%2F17460441.2016.1185413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Beyond Small-Molecule SAR</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1016/b978-0-12-420118-7.00007-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fb978-0-12-420118-7.00007-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=24484980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=267-300&author=T.+M.+Keckauthor=C.+Burzynskiauthor=L.+Shiauthor=A.+H.+Newman&title=Beyond+Small-Molecule+SAR&doi=10.1016%2Fb978-0-12-420118-7.00007-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design</span></div><div class="casAuthors">Keck, Thomas M.; Burzynski, Caitlin; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse</span>),
    <span class="NLM_cas:pages">267-300</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor is a target of pharmacotherapeutic interest in a variety of neurol. disorders including schizophrenia, restless leg syndrome, and drug addiction.  The high protein sequence homol. between the D3 and D2 receptors has posed a challenge to developing D3 receptor-selective ligands whose behavioral actions can be attributed to D3 receptor engagement, in vivo.  However, through primarily small-mol. structure-activity relationship (SAR) studies, a variety of chem. scaffolds have been discovered over the past two decades that have resulted in several D3 receptor-selective ligands with high affinity and in vivo activity.  Nevertheless, viable clin. candidates remain limited.  The recent detn. of the high-resoln. crystal structure of the D3 receptor has invigorated structure-based drug design, providing refinements to the mol. dynamic models and testable predictions about receptor-ligand interactions.  This chapter will highlight recent preclin. and clin. studies demonstrating potential utility of D3 receptor-selective ligands in the treatment of addiction.  In addn., new structure-based rational drug design strategies for D3 receptor-selective ligands that complement traditional small-mol. SAR to improve the selectivity and directed efficacy profiles are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbH7VLMIagF7Vg90H21EOLACvtfcHk0lhNKaxhcAmkag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D&md5=d266814a068e4528c70e200a860fab64</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fb978-0-12-420118-7.00007-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fb978-0-12-420118-7.00007-x%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DBeyond%2520Small-Molecule%2520SAR%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2014%26volume%3D69%26spage%3D267%26epage%3D300%26doi%3D10.1016%2Fb978-0-12-420118-7.00007-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+Won+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lhNKaxhcAmkag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWon%2BHan%26aufirst%3DG.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0lhNKaxhcAmkag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">D4 dopamine receptor high-resolution structures enable the discovery of selective agonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1126/science.aan5468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1126%2Fscience.aan5468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29051383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kns73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2017&pages=381-386&author=S.+Wangauthor=D.+Wackerauthor=A.+Levitauthor=T.+Cheauthor=R.+M.+Betzauthor=J.+D.+McCorvyauthor=A.+J.+Venkatakrishnanauthor=X.-P.+Huangauthor=R.+O.+Drorauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=D4+dopamine+receptor+high-resolution+structures+enable+the+discovery+of+selective+agonists&doi=10.1126%2Fscience.aan5468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">D4 dopamine receptor high-resolution structures enable the discovery of selective agonists</span></div><div class="casAuthors">Wang, Sheng; Wacker, Daniel; Levit, Anat; Che, Tao; Betz, Robin M.; McCorvy, John D.; Venkatakrishnan, A. J.; Huang, Xi-Ping; Dror, Ron O.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6361</span>),
    <span class="NLM_cas:pages">381-386</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine receptors are implicated in the pathogenesis and treatment of nearly every neuropsychiatric disorder.  Although thousands of drugs interact with these receptors, our mol. understanding of dopaminergic drug selectivity and design remains clouded.  To illuminate dopamine receptor structure, function, and ligand recognition, we detd. crystal structures of the D4 dopamine receptor in its inactive state bound to the antipsychotic drug nemonapride, with resolns. up to 1.95 angstroms.  These structures suggest a mechanism for the control of constitutive signaling, and their unusually high resoln. enabled a structure-based campaign for new agonists of the D4 dopamine receptor.  The ability to efficiently exploit structure for specific probe discovery-rapidly moving from elucidating receptor structure to discovering previously unrecognized, selective agonists-testifies to the power of structure-based approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8NDKhkv_ILbVg90H21EOLACvtfcHk0ljv39EW-UpM_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kns73I&md5=0bbb93e6bcb33577f9d9b7459273d896</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.aan5468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aan5468%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DD4%2520dopamine%2520receptor%2520high-resolution%2520structures%2520enable%2520the%2520discovery%2520of%2520selective%2520agonists%26jtitle%3DScience%26date%3D2017%26volume%3D358%26spage%3D381%26epage%3D386%26doi%3D10.1126%2Fscience.aan5468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, G. A.</span></span> <span> </span><span class="NLM_article-title">Abnormalities of dopamine D3 receptor signaling in the diseased brain</span>. <i>J. Cent. Nerv. Syst. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1179573517726335</span>, <span class="refDoi"> DOI: 10.1177/1179573517726335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1177%2F1179573517726335" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1179573517726335&author=G.+A.+Prieto&title=Abnormalities+of+dopamine+D3+receptor+signaling+in+the+diseased+brain&doi=10.1177%2F1179573517726335"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1177%2F1179573517726335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1179573517726335%26sid%3Dliteratum%253Aachs%26aulast%3DPrieto%26aufirst%3DG.%2BA.%26atitle%3DAbnormalities%2520of%2520dopamine%2520D3%2520receptor%2520signaling%2520in%2520the%2520diseased%2520brain%26jtitle%3DJ.%2520Cent.%2520Nerv.%2520Syst.%2520Dis.%26date%3D2017%26volume%3D9%26spage%3D1179573517726335%26doi%3D10.1177%2F1179573517726335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2010.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.tips.2010.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=21232805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=148-157&author=S.+L%C3%B6berauthor=H.+H%C3%BCbnerauthor=N.+Tschammerauthor=P.+Gmeiner&title=Recent+advances+in+the+search+for+D3-+and+D4-selective+drugs%3A+probes%2C+models+and+candidates&doi=10.1016%2Fj.tips.2010.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates</span></div><div class="casAuthors">Lober Stefan; Hubner Harald; Tschammer Nuska; Gmeiner Peter</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopamine D(2)-like receptors (including D(2), D(3) and D(4)) belong to the 'rhodopsin-like' family of G protein-coupled receptors (GPCRs), which represent the largest group of targets for bioactive molecules.  Due to their high sequence similarity, the design of subtype-selective ligands requires rational and effective strategies.  The general formula of 1,4-disubstituted aromatic piperidines and piperazines (1,4-DAPs) was extracted from classical dopaminergic drugs.  The biological properties of this compound family are encoded by an aromatic head group that controls intrinsic activity, an amine moiety and a lipophilic appendage.  D(3)- and D(4)-selective molecular probes and drug candidates were generated from the general formula of 1,4-DAP.  Formal structural rearrangement led to investigational drugs beyond the 1,4-DAP structure.  The very recent publication of the X-ray crystal structure of D(3) should facilitate efficient discovery of unprecedented chemotypes.  However, the development of D(3)-selective agonists, functionally selective ligands and the exploitation of homo- and heteromers remain challenging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJYDidIFGFwMjl5L8hwNX0fW6udTcc2eYpY2YDyFi1gLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D&md5=9b688525eaa75c6d965b634617c16d70</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DRecent%2520advances%2520in%2520the%2520search%2520for%2520D3-%2520and%2520D4-selective%2520drugs%253A%2520probes%252C%2520models%2520and%2520candidates%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D148%26epage%3D157%26doi%3D10.1016%2Fj.tips.2010.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platania, C. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">Current drug treatments targeting dopamine D3 receptor</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.pharmthera.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27343365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=164-177&author=G.+M.+Leggioauthor=C.+Bucoloauthor=C.+B.+M.+Plataniaauthor=S.+Salomoneauthor=F.+Drago&title=Current+drug+treatments+targeting+dopamine+D3+receptor&doi=10.1016%2Fj.pharmthera.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug treatments targeting dopamine D3 receptor</span></div><div class="casAuthors">Leggio, Gian Marco; Bucolo, Claudio; Platania, Chiara Bianca Maria; Salomone, Salvatore; Drago, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164-177</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dopamine receptors (DR) have been extensively studied, but only in recent years they became object of investigation to elucidate the specific role of different subtypes (D1R, D2R, D3R, D4R, D5R) in neural transmission and circuitry.  D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D2R and D4R) differ in signal transduction, binding profile, localization in the central nervous system and physiol. effects.  D3R is involved in a no. of pathol. conditions, including schizophrenia, Parkinson's disease, addiction, anxiety, depression and glaucoma.  Development of selective D3R ligands has been so far challenging, due to the high sequence identity and homol. shared by D2R and D3R.  As a consequence, despite a rational design of selective DR ligands has been carried out, none of currently available medicines selectively target a given D2-like receptor subtype.  The availability of the D3R ligand [11C]-(+)-PHNO for positron emission tomog. studies in animal models as well as in humans, allows researchers to est. the expression of D3R in vivo; displacement of [11C]-(+)-PHNO binding by concurrent drug treatments is used to est. the in vivo occupancy of D3R.  Here we provide an overview of studies indicating D3R as a target for pharmacol. therapy, and a review of market approved drugs endowed with significant affinity at D3R that are used to treat disorders where D3R plays a relevant role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripJ2xDVYRubVg90H21EOLACvtfcHk0lgF3n2gxwILiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF&md5=e29dffe5b17b48f68d33ec838ece35dc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DBucolo%26aufirst%3DC.%26aulast%3DPlatania%26aufirst%3DC.%2BB.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DCurrent%2520drug%2520treatments%2520targeting%2520dopamine%2520D3%2520receptor%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D164%26epage%3D177%26doi%3D10.1016%2Fj.pharmthera.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">11271</span>– <span class="NLM_lpage">11275</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.23.11271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1073%2Fpnas.91.23.11271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=7972046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11271-11275&author=A.+M.+Murrayauthor=H.+L.+Ryooauthor=E.+Gurevichauthor=J.+N.+Joyce&title=Localization+of+dopamine+D3+receptors+to+mesolimbic+and+D2+receptors+to+mesostriatal+regions+of+human+forebrain&doi=10.1073%2Fpnas.91.23.11271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain</span></div><div class="casAuthors">Murray, Angela M.; Ryoo, Han L.; Gurevich, Eugenia; Joyce, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11271-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We characterized the binding of [125I]epidepride to dopamine D2-like and D3-like receptors in tissue sections of human striatum.  The competition for binding of [125I]epidepride by domperidone, quinpirole, and 7-hydroxy-N,N-di(1-propyl)-2-aminotetralin (7-OH-DPAT) was best fit by assuming one site in the caudate but two sites in nucleus accumbens.  Guanosine 5'-[β,γ-imido]triphosphate showed a large modulatory influence in agonist inhibition of [125I]epidepride binding in caudate but not in nucleus accumbens.  The binding of [125I]epidepride in the presence of 7-OH-DPAT (1000-fold selective for D3-like vs. D2-like sites) and domperidone (20-fold selective for D2 vs. D3-like sites) was used to quantify the nos. of D2-like and D3-like receptors in areas of human brain.  The distribution of D2-like and D3-like receptors was largely nonoverlapping.  Binding of [125I]epidepride to D3-like receptors was negligible in the dorsal striatum but was concd. in islands of dense binding in the nucleus accumbens and ventral putamen that aligned with acetylcholinesterase-poor striosomes.  Binding to D3-like receptors was also enriched in the internal globus pallidus, ventral palladium, septum, islands of Calleja, nucleus basalis, amygdalostriatal transition nucleus of the amygdala, central nucleus of the amygdala, and ventral tegmental area.  Binding of [125I]epidepride to D2 but not D3 receptors was detected in cortex and hippocampus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXhwrtC4swVrVg90H21EOLACvtfcHk0lgF3n2gxwILiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D&md5=229c93d0b8695eb673e9c7265a1d574f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.23.11271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.23.11271%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DA.%2BM.%26aulast%3DRyoo%26aufirst%3DH.%2BL.%26aulast%3DGurevich%26aufirst%3DE.%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DLocalization%2520of%2520dopamine%2520D3%2520receptors%2520to%2520mesolimbic%2520and%2520D2%2520receptors%2520to%2520mesostriatal%2520regions%2520of%2520human%2520forebrain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D11271%26epage%3D11275%26doi%3D10.1073%2Fpnas.91.23.11271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7650</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7634-7650&author=V.+Kumarauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=E.+Pommierauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+Gardnerauthor=Z.-B.+Youauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Highly+selective+dopamine+D3+receptor+%28D3R%29+antagonists+and+partial+agonists+based+on+eticlopride+and+the+D3R+crystal+structure%3A+new+leads+for+opioid+dependence+treatment&doi=10.1021%2Facs.jmedchem.6b00860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment</span></div><div class="casAuthors">Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Pommier, Elie; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot; You, Zhi-Bing; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7634-7650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention.  Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clin. use for cocaine abuse.  Herein, the authors report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies.  Lead compd. I was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R vs. D2R binding selectivity, and its metabolic stability in mouse microsomes.  Compd. I inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.  In addn., pretreatment with I also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats.  These findings support the D3R as a target for opioid dependence treatment and compd. I as a new lead mol. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyb_lyL223q7Vg90H21EOLACvtfcHk0liG0RCIV13zvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN&md5=c352556630974f4205a8684b4fd29226</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00860%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520antagonists%2520and%2520partial%2520agonists%2520based%2520on%2520eticlopride%2520and%2520the%2520D3R%2520crystal%2520structure%253A%2520new%2520leads%2520for%2520opioid%2520dependence%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7634%26epage%3D7650%26doi%3D10.1021%2Facs.jmedchem.6b00860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1478-1494&author=V.+Kumarauthor=A.+E.+Moritzauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=C.+D.+Sibleyauthor=R.+B.+Freeauthor=L.+Shiauthor=J.+R.+Laneauthor=D.+R.+Sibleyauthor=A.+H.+Newman&title=Synthesis+and+pharmacological+characterization+of+novel+trans-cyclopropylmethyl-linked+bivalent+ligands+that+exhibit+selectivity+and+allosteric+pharmacology+at+the+dopamine+D3+receptor+%28D3R%29&doi=10.1021%2Facs.jmedchem.6b01688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)</span></div><div class="casAuthors">Kumar, Vivek; Moritz, Amy E.; Keck, Thomas M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Sibley, Christopher D.; Free, R. Benjamin; Shi, Lei; Lane, J. Robert; Sibley, David R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1478-1494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bitopic ligands directed toward D2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies.  The structural similarities between dopamine D3 receptor (D3R)-selective mols. that display bitopic or allosteric pharmacol. and those that are simply competitive antagonists are subtle and intriguing.  Herein the authors synthesized a series of mols. in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 and SB277011A whose structural similarity and pharmacol. disparity provided the perfect templates for SAR investigation.  Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, I and II, which further delineates SAR assocd. with allosterism at D3R and provides leads toward novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PUM_XBYBsLVg90H21EOLACvtfcHk0liG0RCIV13zvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D&md5=de385d8d9699e2d37a56974382989a19</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01688%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DSibley%26aufirst%3DC.%2BD.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520trans-cyclopropylmethyl-linked%2520bivalent%2520ligands%2520that%2520exhibit%2520selectivity%2520and%2520allosteric%2520pharmacology%2520at%2520the%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1478%26epage%3D1494%26doi%3D10.1021%2Facs.jmedchem.6b01688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward understanding the structural basis of partial agonism at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=580-593&author=M.+Michinoauthor=C.+A.+Boatengauthor=P.+Donthamsettiauthor=H.+Yanoauthor=O.+M.+Bakareauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=V.+Kumarauthor=C.+Zhuauthor=R.+Vermaauthor=J.+R.+Deschampsauthor=J.+A.+Javitchauthor=A.+H.+Newmanauthor=L.+Shi&title=Toward+understanding+the+structural+basis+of+partial+agonism+at+the+dopamine+D3+receptor&doi=10.1021%2Facs.jmedchem.6b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor</span></div><div class="casAuthors">Michino, Mayako; Boateng, Comfort A.; Donthamsetti, Prashant; Yano, Hideaki; Bakare, Oluyomi M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Kumar, Vivek; Zhu, Clare; Verma, Ravi; Deschamps, Jeffrey R.; Javitch, Jonathan A.; Newman, Amy Hauck; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders.  In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions.  Here, the authors report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious.  To investigate the structural basis of partial agonism, the authors performed comparative microsecond-scale mol. dynamics simulations starting from the inactive state of D3R in complex with these enantiomers.  Anal. of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations.  These receptor models bound with partial agonists may be useful for structure-based design of compds. with tailored efficacy profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELFqc0pAf8LVg90H21EOLACvtfcHk0liG0RCIV13zvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK&md5=91e378048c5dfd4c44fb54746a2e1df2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01148%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520partial%2520agonism%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D580%26epage%3D593%26doi%3D10.1021%2Facs.jmedchem.6b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5361</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+medication+targets+for+psychostimulant+addiction%3A+unraveling+the+dopamine+D3+receptor+hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0lgf8uVj5oxS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520medication%2520targets%2520for%2520psychostimulant%2520addiction%253A%2520unraveling%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maramai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">451</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.3389%2Ffnins.2016.00451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27761108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=451&author=S.+Maramaiauthor=S.+Gemmaauthor=S.+Brogiauthor=G.+Campianiauthor=S.+Butiniauthor=H.+Starkauthor=M.+Brindisi&title=Dopamine+D3+receptor+antagonists+as+potential+therapeutics+for+the+treatment+of+neurological+diseases&doi=10.3389%2Ffnins.2016.00451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases</span></div><div class="casAuthors">Maramai Samuele; Gemma Sandra; Brogi Simone; Campiani Giuseppe; Butini Stefania; Brindisi Margherita; Stark Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">D3 receptors represent a major focus of current drug design and development of therapeutics for dopamine-related pathological states.  Their close homology with the D2 receptor subtype makes the development of D3 selective antagonists a challenging task.  In this review, we explore the relevance and therapeutic utility of D3 antagonists or partial agonists endowed with multireceptor affinity profile in the field of central nervous system disorders such as schizophrenia and drug abuse.  In fact, the peculiar distribution and low brain abundance of D3 receptors make them a valuable target for the development of drugs devoid of motor side effects classically elicited by D2 antagonists.  Recent research efforts were devoted to the conception of chemical templates possibly endowed with a multi-target profile, especially with regards to other G-protein-coupled receptors (GPCRs).  A comprehensive overview of the recent literature in the field is herein provided.  In particular, the evolution of the chemical templates has been tracked, according to the growing advancements in both the structural information and the refinement of the key pharmacophoric elements.  The receptor/multireceptor affinity and functional profiles for the examined compounds have been covered, together with their most significant pharmacological applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdsZ2fFId2JDslzEEsg76ufW6udTcc2eb11oQGkm3Idbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D&md5=03b1e02b49ea48ab9331f5c9d38dfaf1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00451%26sid%3Dliteratum%253Aachs%26aulast%3DMaramai%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonists%2520as%2520potential%2520therapeutics%2520for%2520the%2520treatment%2520of%2520neurological%2520diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D451%26doi%3D10.3389%2Ffnins.2016.00451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders</span>. <i>Ann. N.Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1187</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05149.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1111%2Fj.1749-6632.2009.05149.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=20201845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=4-34&author=C.+A.+Heidbrederauthor=A.+H.+Newman&title=Current+perspectives+on+selective+dopamine+D%283%29+receptor+antagonists+as+pharmacotherapeutics+for+addictions+and+related+disorders&doi=10.1111%2Fj.1749-6632.2009.05149.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders</span></div><div class="casAuthors">Heidbreder, Christian A.; Newman, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">4-34</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Repeated exposure to drugs of abuse produces long-term mol. and neurochem. changes that may explain the core features of addiction, such as the compulsive seeking and taking of the drug, as well as the risk of relapse.  A growing no. of new mol. and cellular targets of addictive drugs have been identified, and rapid advances are being made in relating those targets to specific behavioral phenotypes in animal models of addiction.  In this context, the pattern of expression of the dopamine (DA) D3 receptor in the rodent and human brain and changes in this pattern in response to drugs of abuse have contributed primarily to direct research efforts toward the development of selective DA D3 receptor antagonists.  Growing preclin. evidence indicates that these compds. may actually regulate the motivation to self-administer drugs and disrupt drug-assocd. cue-induced craving.  This report will be divided into three parts.  First, preclin. evidence in support of the efficacy of selective DA D3 receptor antagonists in animal models of drug addiction will be reviewed.  The effects of mixed DA D2/D3 receptor antagonists will not be discussed here because most of these compds. have low selectivity at the D3 vs. D2 receptor, and their efficacy profile is related primarily to functional antagonism at D2 receptors and possibly interactions with other neurotransmitter systems.  Second, major advances in medicinal chem. for the identification and optimization of selective DA D3 receptor antagonists and partial agonists will be analyzed.  Third, translational research from preclin. efficacy studies to so-called proof-of-concept studies for drug addiction indications will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarcQYm33s6LVg90H21EOLACvtfcHk0lgf8uVj5oxS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D&md5=48ded12d27f36b8d77717b118ccfa869</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05149.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05149.x%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DCurrent%2520perspectives%2520on%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520antagonists%2520as%2520pharmacotherapeutics%2520for%2520addictions%2520and%2520related%2520disorders%26jtitle%3DAnn.%2520N.Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D4%26epage%3D34%26doi%3D10.1111%2Fj.1749-6632.2009.05149.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonsai, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendpara, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, G. M.</span></span> <span> </span><span class="NLM_article-title">Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure</span>. <i>J. Clin. Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1111/jcpt.12649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1111%2Fjcpt.12649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29119585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVyrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1-7&author=N.+H.+Gonsaiauthor=V.+H.+Aminauthor=C.+G.+Mendparaauthor=R.+Spethauthor=G.+M.+Hale&title=Effects+of+dopamine+receptor+antagonist+antipsychotic+therapy+on+blood+pressure&doi=10.1111%2Fjcpt.12649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure</span></div><div class="casAuthors">Gonsai, N. H.; Amin, V. H.; Mendpara, C. G.; Speth, R.; Hale, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacy and Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">JCPTED</span>;
        ISSN:<span class="NLM_cas:issn">0269-4727</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : What is known and Objective : Hypertension, a major risk factor for adverse cardiovascular events, such as stroke and myocardial infarction, affects 80 million American adults.  The etiol. of hypertension is multifaceted and difficult to identify.  Dopamine receptors, esp. those in the kidneys, play a role in blood pressure regulation, and alterations in their function can cause hypertension.  The objective of this review was to investigate the assocn. between the use of dopamine antagonists with hypertension focusing esp. on second-generation antipsychotics, like clozapine that is D4 receptor antagonist.  Methods : A literature review was conducted using MEDLINE, Ovid, Science Direct, Web of Science and Cochrane Database of Systematic Reviews databases with keywords:hypertension, hypotension, renin-angiotensin-aldosterone system, dopaminergic receptors, blood pressure, antipsychotics.  Inclusion criteria were human or animal studies, systematic reviews, meta-analyses, randomized controlled trials, case report/series, published in selected for inclusion.  Results and Discussion : All 5 dopamine receptor subtypes (ie D1, D2, D3, D4 and D5) regulate sodium excretion and BP.  The D1, D3 and D4 receptors interact directly with the renin-angiotensin-aldosterone system, whereas D2 and D5 receptors directly interact with the sympathetic nervous system to regulate BP.  Use of dopaminergic agonists or antagonists could therefore disturb the regulation of BP by dopamine receptors.  What is new and Conclusion : Based upon this review, individuals on antipsychotic agents, particularly clozapine, should be routinely monitored for hypertension, and addn. of antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is indicated if hypertension occurs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok3RAFZIuXabVg90H21EOLACvtfcHk0lgtQp5iYcnmpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVyrsA%253D%253D&md5=cdd41ab6527c9e2172168427c6f7ff0c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fjcpt.12649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcpt.12649%26sid%3Dliteratum%253Aachs%26aulast%3DGonsai%26aufirst%3DN.%2BH.%26aulast%3DAmin%26aufirst%3DV.%2BH.%26aulast%3DMendpara%26aufirst%3DC.%2BG.%26aulast%3DSpeth%26aufirst%3DR.%26aulast%3DHale%26aufirst%3DG.%2BM.%26atitle%3DEffects%2520of%2520dopamine%2520receptor%2520antagonist%2520antipsychotic%2520therapy%2520on%2520blood%2520pressure%26jtitle%3DJ.%2520Clin.%2520Pharm.%2520Ther.%26date%3D2018%26volume%3D43%26spage%3D1%26epage%3D7%26doi%3D10.1111%2Fjcpt.12649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charbit, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.151951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fjpet.109.151951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=19657051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=752-763&author=A.+R.+Charbitauthor=S.+Akermanauthor=P.+J.+Goadsby&title=Comparison+of+the+effects+of+central+and+peripheral+dopamine+receptor+activation+on+evoked+firing+in+the+trigeminocervical+complex&doi=10.1124%2Fjpet.109.151951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex</span></div><div class="casAuthors">Charbit, Annabelle R.; Akerman, Simon; Goadsby, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">752-763</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dopaminergic mechanisms have been suggested to play a role in migraine.  Here, electrophysiol. techniques were used to study the effects of i.v. administered centrally or peripherally active dopamine receptor agonists and antagonists on evoked firing in the trigeminocervical complex (TCC).  After establishing baseline firing evoked by elec. stimulation of the dural middle meningeal artery (MMA) and mech. noxious and innocuous stimulation of the ophthalmic dermatome, D1- or D2-like receptor agonists or antagonists were administered i.v. and the effect on firing was detd.  In addn., with use of intravital microscopy, we monitored changes in dural vessel diam. in response to varying doses of D1- or D2-like receptor agonists to det. whether their effects were related to blood vessel caliber.  The central D2-like receptor agonist quinpirole hydrochloride inhibited firing in the TCC evoked by stimulation of the MMA.  Conversely, the central D2-like receptor antagonists, eticlopride hydrochloride and remoxipride hydrochloride, facilitated MMA-evoked firing and also firing evoked by noxious and innocuous stimulation of the ophthalmic dermatome.  Both the peripheral D1-like receptor agonist fenoldopam and the central D1-like receptor agonists cis-(±)-1-(aminomethyl)-3,4-dihydro-3-phenyl-1H-2-benzopyran-5,6-diol hydrochloride (A68930 hydrochloride) and dihydrexidine facilitated innocuous brush-evoked firing, with A68930 hydrochloride having the greatest effect.  The data suggest that dopamine binding to peripheral D1-like receptors may play a role in peripheral sensitization, and that the inhibitory or excitatory effects seen with administration of dopamine receptor agonists are independent of blood vessel changes.  In addn., these studies maintain that central D2-like receptors inhibit trigeminocervical neurons, and may provide insight into the conflicting literature on the role of dopamine and its receptors in migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxU1a61nMZLrVg90H21EOLACvtfcHk0lgtQp5iYcnmpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7vM&md5=262ed2b419eb26447648a511c301fa13</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151951%26sid%3Dliteratum%253Aachs%26aulast%3DCharbit%26aufirst%3DA.%2BR.%26aulast%3DAkerman%26aufirst%3DS.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520central%2520and%2520peripheral%2520dopamine%2520receptor%2520activation%2520on%2520evoked%2520firing%2520in%2520the%2520trigeminocervical%2520complex%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D752%26epage%3D763%26doi%3D10.1124%2Fjpet.109.151951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballon, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajvani, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyberg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathophysiology of metabolic effects of antipsychotic medications</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2014.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.tem.2014.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=25190097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ntbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=593-600&author=J.+S.+Ballonauthor=U.+Pajvaniauthor=Z.+Freybergauthor=R.+L.+Leibelauthor=J.+A.+Lieberman&title=Molecular+pathophysiology+of+metabolic+effects+of+antipsychotic+medications&doi=10.1016%2Fj.tem.2014.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pathophysiology of metabolic effects of antipsychotic medications</span></div><div class="casAuthors">Ballon, Jacob S.; Pajvani, Utpal; Freyberg, Zachary; Leibel, Rudolph L.; Lieberman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">593-600</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Antipsychotic medications are assocd. with major metabolic changes that contribute to medical morbidity and a significantly shortened life span.  The mechanisms for these changes provide us with a broader understanding of central nervous and peripheral organ-mediated metabolic regulation.  This paper reviews an extensive literature regarding putative mechanisms for effects of antipsychotic medications on wt. regulation and glucose homeostasis as well as potential inherent metabolic risks of schizophrenia itself.  We present a model suggesting that peripheral antipsychotic targets play a crit. role in drug-induced wt. gain and diabetes.  We propose that a better understanding of these mechanisms will be crucial to developing improved treatments for serious mental illnesses as well as providing potentially novel therapeutic targets of metabolic disorders including diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUXmEXlYukObVg90H21EOLACvtfcHk0lgtQp5iYcnmpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ntbbP&md5=6072e0c11ad8cb6da738f707b0d1f4b0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2014.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2014.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DBallon%26aufirst%3DJ.%2BS.%26aulast%3DPajvani%26aufirst%3DU.%26aulast%3DFreyberg%26aufirst%3DZ.%26aulast%3DLeibel%26aufirst%3DR.%2BL.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520pathophysiology%2520of%2520metabolic%2520effects%2520of%2520antipsychotic%2520medications%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2014%26volume%3D25%26spage%3D593%26epage%3D600%26doi%3D10.1016%2Fj.tem.2014.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farino, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenstern, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Solis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiriyasermkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyberg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanoglou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorisio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inbar, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosharov, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellendonk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmauss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeltser, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyberg, Z.</span></span> <span> </span><span class="NLM_article-title">New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1038/s41380-018-0344-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fs41380-018-0344-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=30626912" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Z.+J.+Farinoauthor=T.+J.+Morgensternauthor=A.+Maffeiauthor=M.+Quickauthor=A.+J.+De+Solisauthor=P.+Wiriyasermkulauthor=R.+J.+Freybergauthor=D.+Aslanoglouauthor=D.+Sorisioauthor=B.+P.+Inbarauthor=R.+B.+Freeauthor=P.+Donthamsettiauthor=E.+V.+Mosharovauthor=C.+Kellendonkauthor=G.+J.+Schwartzauthor=D.+R.+Sibleyauthor=C.+Schmaussauthor=L.+M.+Zeltserauthor=H.+Mooreauthor=P.+E.+Harrisauthor=J.+A.+Javitchauthor=Z.+Freyberg&title=New+roles+for+dopamine+D2+and+D3+receptors+in+pancreatic+beta+cell+insulin+secretion&doi=10.1038%2Fs41380-018-0344-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fs41380-018-0344-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-018-0344-6%26sid%3Dliteratum%253Aachs%26aulast%3DFarino%26aufirst%3DZ.%2BJ.%26aulast%3DMorgenstern%26aufirst%3DT.%2BJ.%26aulast%3DMaffei%26aufirst%3DA.%26aulast%3DQuick%26aufirst%3DM.%26aulast%3DDe%2BSolis%26aufirst%3DA.%2BJ.%26aulast%3DWiriyasermkul%26aufirst%3DP.%26aulast%3DFreyberg%26aufirst%3DR.%2BJ.%26aulast%3DAslanoglou%26aufirst%3DD.%26aulast%3DSorisio%26aufirst%3DD.%26aulast%3DInbar%26aufirst%3DB.%2BP.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DMosharov%26aufirst%3DE.%2BV.%26aulast%3DKellendonk%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DG.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSchmauss%26aufirst%3DC.%26aulast%3DZeltser%26aufirst%3DL.%2BM.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DHarris%26aufirst%3DP.%2BE.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DFreyberg%26aufirst%3DZ.%26atitle%3DNew%2520roles%2520for%2520dopamine%2520D2%2520and%2520D3%2520receptors%2520in%2520pancreatic%2520beta%2520cell%2520insulin%2520secretion%26jtitle%3DMol.%2520Psychiatry%26date%3D2019%26doi%3D10.1038%2Fs41380-018-0344-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Epub ahead of print</p></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo Pich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor ligands for drug addiction treatment</span>. <i>Prog. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/b978-0-444-63425-2.00011-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fb978-0-444-63425-2.00011-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=24968784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2014&pages=255-275&author=B.+Le%0AFollauthor=G.+Colloauthor=E.+A.+Rabinerauthor=I.+Boileauauthor=E.+Merlo+Pichauthor=P.+Sokoloff&title=Dopamine+D3+receptor+ligands+for+drug+addiction+treatment&doi=10.1016%2Fb978-0-444-63425-2.00011-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor ligands for drug addiction treatment, update on recent findings</span></div><div class="casAuthors">Le Foll, Bernard; Collo, Ginetta; Rabiner, Eugenii A.; Boileau, Isabelle; Pich, Emilio Merlo; Sokoloff, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Dopamine</span>),
    <span class="NLM_cas:pages">255-275</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor is located in the limbic area and apparently mediates selective effects on motivation to take drugs and drug-seeking behaviors, so that there has been considerable interest on the possible use of D3 receptor ligands to treat drug addiction.  However, only recently selective tools allowing studying this receptor have been developed.  This chapter presents an overview of findings that were presented at a symposium on the conference Dopamine 2013 in Sardinia in May 2013.  Novel neurobiol. findings indicate that drugs of abuse can lead to significant structural plasticity in rodent brain and that this is dependent on the availability of functional dopamine D3 autoreceptor, whose activation increased phosphorylation in the ERK pathway and in the Akt/mTORC1 pathway indicating the parallel engagement of a series of intracellular signaling pathways all involved in cell growth and survival.  Preclin. findings using animal models of drug-seeking behaviors confirm that D3 antagonists have a promising profile to treat drug addiction across drugs of abuse type.  Imaging the D3 is now feasible in human subjects.  Notably, the development of (+)-4-propyl-9-hydroxynaphthoxazine ligand used in positron emission tomog. (PET) studies in humans allows to measure D3 and D2 receptors based on the area of the brain under study.  This PET ligand has been used to confirm up-regulation of D3 sites in psychostimulant users and to reveal that tobacco smoking produces elevation of dopamine at the level of D3 sites.  There are now novel antagonists being developed, but also old drugs such as buspirone, that are available to test the D3 hypothesis in humans.  The first results of clin. investigations are now being provided.  Overall, those recent findings support further exploration of D3 ligands to treat drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxIQ6SUa_NcrVg90H21EOLACvtfcHk0liyuyWwhvU4cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtLzP&md5=e997ab74bf84de9d62b9b734a585b949</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fb978-0-444-63425-2.00011-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fb978-0-444-63425-2.00011-8%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DCollo%26aufirst%3DG.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DMerlo%2BPich%26aufirst%3DE.%26aulast%3DSokoloff%26aufirst%3DP.%26atitle%3DDopamine%2520D3%2520receptor%2520ligands%2520for%2520drug%2520addiction%2520treatment%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2014%26volume%3D211%26spage%3D255%26epage%3D275%26doi%3D10.1016%2Fb978-0-444-63425-2.00011-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2007.00013.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1111%2Fj.1527-3458.2007.00013.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=17627675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsVCltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=240-259&author=Z.-X.+Xiauthor=E.+L.+Gardner&title=Pharmacological+actions+of+NGB+2904%2C+a+selective+dopamine+D3+receptor+antagonist%2C+in+animal+models+of+drug+addiction&doi=10.1111%2Fj.1527-3458.2007.00013.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction</span></div><div class="casAuthors">Xi, Zheng-Xiong; Gardner, Eliot L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-259</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  As a continuation of our work with SB-277011A, we have examd. the effects of another highly elective dopamine (DA) D3 receptor antagonist, N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-2-fluorenylcarboxamide (NGB 2904), in animal models of addiction.  Our results indicate that by systemic administration, NGB 2904 inhibits i.v. cocaine self-administration maintained under a progressive-ratio (PR) reinforcement schedule, cocaine- or cocaine cue-induced reinstatement of cocaine-seeking behavior, and cocaine- or other addictive drug-enhanced brain stimulation reward (BSR).  The action of NGB 2904 on PR cocaine self-administration was long-lasting (1-2 days) after a single injection, supporting its potential use in treatment of cocaine addiction.  The effects of NGB 2904 in the BSR paradigm were dose-dependent for both NGB 2904 and cocaine; i.e., only lower doses of NGB 2904 were effective, and their putative antiaddiction effect could be overcome by increasing the doses of cocaine or other addictive drugs.  A dopamine-dependent mechanism is proposed to explain the effects of NGB 2904 on cocaine's actions in these animal models of drug addiction.  The data reviewed in this paper suggest that NGB 2904 or other D3-selective antagonists may have potential in controlling motivation for drug-taking behavior or relapse to drug-seeking behavior, but may have a limited role in antagonizing the acute rewarding effects produced by cocaine or other addictive drugs.  In addn., NGB 2904 may also act as a useful tool to study the role of D3 receptors in drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomI_kosmBM37Vg90H21EOLACvtfcHk0liyuyWwhvU4cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsVCltbs%253D&md5=7ad95c59ffa9d51a3670fd66d63e1376</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2007.00013.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2007.00013.x%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26atitle%3DPharmacological%2520actions%2520of%2520NGB%25202904%252C%2520a%2520selective%2520dopamine%2520D3%2520receptor%2520antagonist%252C%2520in%2520animal%2520models%2520of%2520drug%2520addiction%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2007%26volume%3D13%26spage%3D240%26epage%3D259%26doi%3D10.1111%2Fj.1527-3458.2007.00013.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C.</span></span> <span> </span><span class="NLM_article-title">Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence</span>. <i>CNS Neurol. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.2174/187152708786927822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.2174%2F187152708786927822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=19128200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFansA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=410-421&author=C.+Heidbreder&title=Selective+antagonism+at+dopamine+D3+receptors+as+a+target+for+drug+addiction+pharmacotherapy%3A+a+review+of+preclinical+evidence&doi=10.2174%2F187152708786927822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence</span></div><div class="casAuthors">Heidbreder, Christian</div><div class="citationInfo"><span class="NLM_cas:title">CNS & Neurological Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">410-421</span>CODEN:
                <span class="NLM_cas:coden">CNDDA3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5273</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts.  This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclin. paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alc., methamphetamine, and heroin.  This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists.  Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand.  In addn., selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-assocd. stimuli that play a key role in reinstatement of drug-seeking behavior.  These preclin. findings will be discussed in the context of translational research relevant to the design of early clin. trials and hypothesis testing in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcM0jWAd6GHrVg90H21EOLACvtfcHk0lhVTShlrWU_ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFansA%253D%253D&md5=8f187ba70d486dc49f745562fe3f9408</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F187152708786927822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152708786927822%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%26atitle%3DSelective%2520antagonism%2520at%2520dopamine%2520D3%2520receptors%2520as%2520a%2520target%2520for%2520drug%2520addiction%2520pharmacotherapy%253A%2520a%2520review%2520of%2520preclinical%2520evidence%26jtitle%3DCNS%2520Neurol.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2008%26volume%3D7%26spage%3D410%26epage%3D421%26doi%3D10.2174%2F187152708786927822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanos, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence</span>. <i>Brain Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.brainresrev.2004.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.brainresrev.2004.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=15960988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Ghu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=77-105&author=C.+A.+Heidbrederauthor=E.+L.+Gardnerauthor=Z.-X.+Xiauthor=P.+K.+Thanosauthor=M.+Mugnainiauthor=J.+J.+Haganauthor=C.+R.+Ashby&title=The+role+of+central+dopamine+D3+receptors+in+drug+addiction%3A+a+review+of+pharmacological+evidence&doi=10.1016%2Fj.brainresrev.2004.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence</span></div><div class="casAuthors">Heidbreder, Christian A.; Gardner, Eliot L.; Xi, Zheng-Xiong; Thanos, Panayotis K.; Mugnaini, Manolo; Hagan, Jim J.; Ashby, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-105</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The cDNA for the dopamine D3 receptor was isolated and characterized in 1990.  Subsequent studies have indicated that D3 receptors, as well as D3 receptor mRNA, are primarily localized in limbic regions in mammals.  This finding led to the postulate that D3 receptors may be involved in drug dependence and addiction.  However, this hypothesis has been difficult to test due to the lack of compds. with high selectivity for central D3 receptors.  The interpretation of results from studies using mixed D2/D3 agonists and/or antagonists is problematic because these agents have low selectivity for D3 over D2 receptors and it is likely that their actions are primarily related to D2 receptor antagonism and possibly interaction with other neurotransmitter receptors.  Currently, with the synthesis and characterization of new highly selective D3 receptor antagonists such as SB-277011-A this difficulty has been surmounted.  The purpose of the present article is to review, for the first time, the effects of various putative D3 receptor selective compds. in animal models of drug dependence and addiction.  The results obtained with highly selective D3 receptor antagonists such as SB-277011-A, SB-414796, and NGB-2904 indicate that central D3 receptors may play an important role in drug-induced reward, drug-taking, and cue-, drug-, and stress-induced reinstatement of drug-seeking behavior.  Provided these results can be extrapolated to human drug addicts, they suggest that selective DA D3 receptor antagonists may prove effective as potential pharmacotherapeutic agents to manage drug dependence and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwzEJPprm60rVg90H21EOLACvtfcHk0lhVTShlrWU_ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Ghu7k%253D&md5=3e5948e0f94515fd240d1e3d18812028</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2004.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2004.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DThanos%26aufirst%3DP.%2BK.%26aulast%3DMugnaini%26aufirst%3DM.%26aulast%3DHagan%26aufirst%3DJ.%2BJ.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26atitle%3DThe%2520role%2520of%2520central%2520dopamine%2520D3%2520receptors%2520in%2520drug%2520addiction%253A%2520a%2520review%2520of%2520pharmacological%2520evidence%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2005%26volume%3D49%26spage%3D77%26epage%3D105%26doi%3D10.1016%2Fj.brainresrev.2004.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranaldi, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine D1 and D3 receptor interactions in cocaine reward and seeking in rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">3881</span>– <span class="NLM_lpage">3890</span>, <span class="refDoi"> DOI: 10.1007/s00213-016-4420-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1007%2Fs00213-016-4420-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27582181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCgsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2016&pages=3881-3890&author=E.+Galajauthor=W.+Hardingauthor=R.+Ranaldi&title=Dopamine+D1+and+D3+receptor+interactions+in+cocaine+reward+and+seeking+in+rats&doi=10.1007%2Fs00213-016-4420-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D1 and D3 receptor interactions in cocaine reward and seeking in rats</span></div><div class="casAuthors">Galaj, E.; Harding, W.; Ranaldi, R.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">3881-3890</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Animal research has demonstrated a role of dopamine D1 and D3 receptors in cocaine reward and seeking.  Purpose and methods: Here, we investigated the potential interaction of these two dopamine receptors in cue-induced reinstatement of cocaine seeking, cocaine conditioned place preference (CPP), and cocaine self-administration in rats.  Results: The co-administration of a D3 receptor antagonist, NGB 2904 and a D1 partial agonist, SKF 77434, of doses which when administered individually produced no significant effects, prior to reinstatement or CPP tests significantly reduced lever pressing and time spent in the cocaine-paired environment, suggesting synergistic effects of the combined compds. on cocaine seeking.  When given to rats self-administering cocaine under a progressive ratio schedule of reinforcement doses of NGB 2904 which were ineffective alone significantly enhanced the break point-reducing effects of SKF 77434.  Conclusions: Our results indicate that the combined treatment with a D1 receptor partial agonist and D3 receptor antagonist produces robust decreases in cocaine seeking and reward.  This suggests an interaction between dopamine D1 and D3 receptors in cocaine-related behaviors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7GjokU1Dv7Vg90H21EOLACvtfcHk0lhVTShlrWU_ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCgsLbF&md5=ea69a64f097986de74381bf03f04c4e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00213-016-4420-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-016-4420-9%26sid%3Dliteratum%253Aachs%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DW.%26aulast%3DRanaldi%26aufirst%3DR.%26atitle%3DDopamine%2520D1%2520and%2520D3%2520receptor%2520interactions%2520in%2520cocaine%2520reward%2520and%2520seeking%2520in%2520rats%26jtitle%3DPsychopharmacology%26date%3D2016%26volume%3D233%26spage%3D3881%26epage%3D3890%26doi%3D10.1007%2Fs00213-016-4420-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fjpet.115.224121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=26177654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=484-492&author=N.+M.+Appelauthor=S.-H.+Liauthor=T.+H.+Holmesauthor=J.+B.+Acri&title=Dopamine+D3+receptor+antagonist+%28GSK598809%29+potentiates+the+hypertensive+effects+of+cocaine+in+conscious%2C+freely-moving+dogs&doi=10.1124%2Fjpet.115.224121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span></div><div class="casAuthors">Appel, Nathan M.; Li, Shou-Hua; Holmes, Tyson H.; Acri, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-492</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chronic and relapsing nature of addiction presents unique challenges for ensuring the safety of a potential medication.  A patient may use cocaine, for example, while taking the medication or take more medication than prescribed.  Thus, a potential medication must be safe and not exacerbate the effects of cocaine.  Multiple published studies support antagonism of brain dopamine D3 receptor function as a potential mechanism of action for an anti-addiction medication.  Dopamine D3 receptors are widely distributed outside the central nervous system, however; for example, dopamine D3 receptors in the kidneys are implicated in regulating blood pressure.  The selective dopamine D3 receptor antagonist GSK598809 [1-(2-fluoro-4- trifluoromethyl-phenyl)-3-{3-[4-methyl-5-(4-methyl-oxazol-5- yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-propyl}-3-aza-bicyclo[3.1.0] hexane] has been proposed as a medication to treat cocaine and other substance use disorders.  The US Food and Drug Administration has established guidelines recommending safety studies to investigate potential undesirable pharmacodynamic effects of a substance in relation to exposure in the therapeutic range and above.  Hence, we assessed the interaction between this selective dopamine D3 receptor antagonist and cocaine on hemodynamics and cardiac function in freely-moving, telemetered dogs before conducting a clin. trial.  GSK598809 increased the hemodynamic effect of cocaine in this model.  Thus, the increase in blood pressure after i.v. cocaine was greater in animals that had been pretreated with GSK598809 compared with vehicle.  This finding suggests that GSK598809 in particular, and perhaps dopamine D3 receptor antagonists as a class, may produce unacceptable cardiovascular risks as medications to treat cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWq20sTq43bVg90H21EOLACvtfcHk0lixuj8-8BFdMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ&md5=6fd994c95c5bee2dd486b4c340564c73</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224121%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DS.-H.%26aulast%3DHolmes%26aufirst%3DT.%2BH.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonist%2520%2528GSK598809%2529%2520potentiates%2520the%2520hypertensive%2520effects%2520of%2520cocaine%2520in%2520conscious%252C%2520freely-moving%2520dogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D484%26epage%3D492%26doi%3D10.1124%2Fjpet.115.224121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1415</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0284-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fs41386-018-0284-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=30555159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1415&author=Z.-B.+Youauthor=G.-H.+Biauthor=E.+Galajauthor=V.+Kumarauthor=J.+Caoauthor=A.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+L.+Gardnerauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Dopamine+D3R+antagonist+VK4-116+attenuates+oxycodone+self-administration+and+reinstatement+without+compromising+its+antinociceptive+effects&doi=10.1038%2Fs41386-018-0284-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span></div><div class="casAuthors">You, Zhi-Bing; Bi, Guo-Hua; Galaj, Ewa; Kumar, Vivek; Cao, Jianjing; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot L.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prescription opioids such as oxycodone are highly effective analgesics for clin. pain management, but their misuse and abuse have led to the current opioid epidemic in the United States.  In order to ameliorate this public health crisis, the development of effective pharmacotherapies for the prevention and treatment of opioid abuse and addiction is essential and urgently required.  In this study, we evaluated-in lab. rats-the potential utility of VK4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and treatment of prescription opioid use disorders.  Pretreatment with VK4-116 (5-25 mg/kg, i.p.) dose-dependently inhibited the acquisition and maintenance of oxycodone self-administration.  VK4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxycodone-seeking behavior.  In addn., VK4-116 pretreatment dose-dependently enhanced the antinociceptive effects of oxycodone and reduced naloxone-pptd. conditioned place aversion in rats chronically treated with oxycodone.  In contrast, VK4-116 had little effect on oral sucrose self-administration.  Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3PmmEMo-frVg90H21EOLACvtfcHk0lixuj8-8BFdMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN&md5=dac3d9cbb6c0594cd06d3ec328aa519f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0284-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0284-5%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520D3R%2520antagonist%2520VK4-116%2520attenuates%2520oxycodone%2520self-administration%2520and%2520reinstatement%2520without%2520compromising%2520its%2520antinociceptive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1415%26doi%3D10.1038%2Fs41386-018-0284-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span> <span> </span><span class="NLM_article-title">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.neuropharm.2017.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=28888944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=190-199&author=Z.-B.+Youauthor=J.-T.+Gaoauthor=G.-H.+Biauthor=Y.+Heauthor=C.+Boatengauthor=J.+Caoauthor=E.+L.+Gardnerauthor=A.+H.+Newmanauthor=Z.-X.+Xi&title=The+novel+dopamine+D3+receptor+antagonists%2Fpartial+agonists+CAB2-015+and+BAK4-54+inhibit+oxycodone-taking+and+oxycodone-seeking+behavior+in+rats&doi=10.1016%2Fj.neuropharm.2017.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span></div><div class="casAuthors">You, Zhi-Bing; Gao, Jun-Tao; Bi, Guo-Hua; He, Yi; Boateng, Comfort; Cao, Jianjing; Gardner, Eliot L.; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190-199</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of prescription opioid analgesics, particularly oxycodone, has dramatically increased, and parallels escalated opioid abuse and drug-related deaths worldwide.  Understanding the mol. mechanisms underlying the development of opioid dependence and expanding treatment options to counter prescription opioid abuse has become a crit. public health matter.  In the present study, we first evaluated the reinforcing effects of oxycodone in a rat model of self-administration and then explored the potential utility of two novel high affinity dopamine D3 receptor (D3R) antagonists/partial agonists, CAB2-015 and BAK4-54, for treatment of prescription opioid abuse and dependence.  We found that rats acquired oxycodone self-administration rapidly within a range of unit doses that was similar to that for heroin, confirming that oxycodone has significant abuse potential.  Strikingly, pretreatment with either CAB2-015 or BAK4-54 (0.4-10 mg/kg, i.p.) dose-dependently decreased oxycodone self-administration, and shifted the oxycodone dose-response curve downward.  Repeated pretreatment with CAB2-015 or BAK4-54 (0.4-4 mg/kg) facilitated extinction and inhibited oxycodone-induced reinstatement of drug-seeking behavior.  In addn., pretreatment with CAB2-015 or BAK4-54 (4-10 mg/kg) also dose-dependently decreased oxycodone-enhanced locomotor activity, but only CAB2-015 decreased oral sucrose self-administration.  These data suggest that D3R antagonists may be suitable alternatives or adjunctive to opioid-based medications currently used clin. in treating opioid addiction and that the D3R-selective ligands (CAB2-015 or BAK4-54) provide new lead mols. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2yL76pWO8Z7Vg90H21EOLACvtfcHk0lixuj8-8BFdMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF&md5=a046de2818f1daf7029be110c5c0cc9b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DGao%26aufirst%3DJ.-T.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBoateng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.-X.%26atitle%3DThe%2520novel%2520dopamine%2520D3%2520receptor%2520antagonists%252Fpartial%2520agonists%2520CAB2-015%2520and%2520BAK4-54%2520inhibit%2520oxycodone-taking%2520and%2520oxycodone-seeking%2520behavior%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D126%26spage%3D190%26epage%3D199%26doi%3D10.1016%2Fj.neuropharm.2017.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">High affinity dopamine D3 receptor (D3R)-selective antagonists attenuate heroin self-administration in wild-type but not D3R knockout mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6213</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00776</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00776" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6195-6213&author=C.+A.+Boatengauthor=O.+M.+Bakareauthor=J.+Zhanauthor=A.+K.+Banalaauthor=C.+Burzynskiauthor=E.+Pommierauthor=T.+M.+Keckauthor=P.+Donthamsettiauthor=J.+A.+Javitchauthor=R.+Raisauthor=B.+S.+Slusherauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=High+affinity+dopamine+D3+receptor+%28D3R%29-selective+antagonists+attenuate+heroin+self-administration+in+wild-type+but+not+D3R+knockout+mice&doi=10.1021%2Facs.jmedchem.5b00776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice</span></div><div class="casAuthors">Boateng, Comfort A.; Bakare, Oluyomi M.; Zhan, Jia; Banala, Ashwini K.; Burzynski, Caitlin; Pommier, Elie; Keck, Thomas M.; Donthamsetti, Prashant; Javitch, Jonathan A.; Rais, Rana; Slusher, Barbara S.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6195-6213</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders.  Several D3R-selective antagonists are effective in animal models of drug abuse, esp. in models of relapse.  Nevertheless, poor bioavailability, metabolic instability, and/or predicted toxicity have impeded success in translating these drug candidates to clin. use.  Herein, the authors report a series of D3R-selective 4-phenylpiperazines with improved metabolic stability.  A subset of these compds. was evaluated for D3R functional efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with D3R has been obsd.  Several high affinity D3R antagonists, including compds. I (Ki = 0.12 nM) and II (Ki = 0.35 nM), showed improved metabolic stability compared to the parent compd., PG648.  Notably, I and the classic D3R antagonist SB277011A were effective in reducing self-administration of heroin in wild-type but not D3R knockout mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagzWQU_gPV7Vg90H21EOLACvtfcHk0lj414JUaWy1pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK&md5=1724065cac8ac51295cf4660a20ed734</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00776%26sid%3Dliteratum%253Aachs%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DZhan%26aufirst%3DJ.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHigh%2520affinity%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529-selective%2520antagonists%2520attenuate%2520heroin%2520self-administration%2520in%2520wild-type%2520but%2520not%2520D3R%2520knockout%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6195%26epage%3D6213%26doi%3D10.1021%2Facs.jmedchem.5b00776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 agonists in the treatment of Parkinson’s disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.2174/156802661510150328223428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.2174%2F156802661510150328223428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=25832718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=908-926&author=B.+Dasauthor=G.+Modiauthor=A.+Dutta&title=Dopamine+D3+agonists+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.2174%2F156802661510150328223428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Agonists in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Modi, Gyan; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">908-926</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is t he second most common form of neurodegenerative disorders that results from the progressive loss of dopaminergic neurons in the midbrain substantia nigra pars compacta (SNpc) triggering profound motor perturbation, as well as cognitive, sensory and mood deficits.  Although these symptoms can be improved using currently available dopamine replacement strategies, they are not able to slow the neurodegenerative process that underlies PD progression.  Following the discovery of the D3 receptor from mol. cloning, it has gained much attention as a potential therapeutic target for the treatment of PD due to their localization in the limbic regions of the brain as well as pharmacol. similarity to the D2 receptor subtype.  Of particular interest, D3 receptor- selective agonists appear to have neuroprotective effects apart from their ability to relieve PD symptoms.  Owing to the distinct significance of D3 receptor in mediating diverse neurol. effects, it represents a unique target for therapeutic intervention in PD with much less undesirable side effects.  Herein, we review progress in the development of D3 receptor selective agonist mols. having a broad spectrum of affinities, selectivities as well as unique pharmacol. properties directed at slowing the neurodegeneration process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vO7t50SK9rVg90H21EOLACvtfcHk0lj414JUaWy1pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D&md5=46885592d050d099cbad73ba7ef8e61b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F156802661510150328223428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661510150328223428%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DDopamine%2520D3%2520agonists%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D908%26epage%3D926%26doi%3D10.2174%2F156802661510150328223428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddaluna, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D4 receptor-selective compounds reveal structure-activity relationships that engender agonist efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3722</span>– <span class="NLM_lpage">3740</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3722-3740&author=T.+M.+Keckauthor=R.+B.+Freeauthor=M.+M.+Dayauthor=S.+L.+Brownauthor=M.+S.+Maddalunaauthor=G.+Fountainauthor=C.+Cooperauthor=B.+Fallonauthor=M.+Holmesauthor=C.+T.+Stangauthor=R.+Burkhardtauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=D.+R.+Sibleyauthor=C.+Wuauthor=C.+A.+Boateng&title=Dopamine+D4+receptor-selective+compounds+reveal+structure-activity+relationships+that+engender+agonist+efficacy&doi=10.1021%2Facs.jmedchem.9b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy</span></div><div class="casAuthors">Keck, Thomas M.; Free, R. Benjamin; Day, Marilyn M.; Brown, Sonvia L.; Maddaluna, Michele S.; Fountain, Griffin; Cooper, Charles; Fallon, Brooke; Holmes, Matthew; Stang, Christopher T.; Burkhardt, Russell; Bonifazi, Alessandro; Ellenberger, Michael P.; Newman, Amy H.; Sibley, David R.; Wu, Chun; Boateng, Comfort A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3722-3740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D4 receptor (D4R) plays important roles in cognition, attention, and decision making.  Novel D4R-selective ligands have promise in medication development for neuropsychiatric conditions, including Alzheimer's disease and substance use disorders.  To identify new D4R-selective ligands, and to understand the mol. determinants of agonist efficacy at D4R, we report a series of eighteen novel ligands based on the classical D4R agonist A-412997 (1, 2-(4-(pyridin-2-yl)piperidin-1-yl)-N-(m-tolyl)acetamide).  Compds. were profiled using radioligand binding displacement assays, β-arrestin recruitment assays, cAMP inhibition assays, and mol. dynamics computational modeling.  We identified several novel D4R-selective (Ki ≤ 4.3 nM and >100-fold vs other D2-like receptors) compds. with diverse partial agonist and antagonist profiles, falling into three structural groups.  These compds. highlight receptor-ligand interactions that control efficacy at D2-like receptors and may provide insights into targeted drug discovery, leading to a better understanding of the role of D4Rs in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtBRYg7sp8rVg90H21EOLACvtfcHk0lj414JUaWy1pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D&md5=f3f03df2f50a91030295d32d6b692f1c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00231%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDay%26aufirst%3DM.%2BM.%26aulast%3DBrown%26aufirst%3DS.%2BL.%26aulast%3DMaddaluna%26aufirst%3DM.%2BS.%26aulast%3DFountain%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DFallon%26aufirst%3DB.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DStang%26aufirst%3DC.%2BT.%26aulast%3DBurkhardt%26aufirst%3DR.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26atitle%3DDopamine%2520D4%2520receptor-selective%2520compounds%2520reveal%2520structure-activity%2520relationships%2520that%2520engender%2520agonist%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3722%26epage%3D3740%26doi%3D10.1021%2Facs.jmedchem.9b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweppe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) provide clues to dopamine D2/D3 receptor agonist selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2973</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01612</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01612" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2973-2988&author=M.-F.+Zouauthor=T.+M.+Keckauthor=V.+Kumarauthor=P.+Donthamsettiauthor=M.+Michinoauthor=C.+Burzynskiauthor=C.+Schweppeauthor=A.+Bonifaziauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=A.+Janowskyauthor=L.+Shiauthor=J.+A.+Javitchauthor=A.+H.+Newman&title=Novel+analogues+of+%28R%29-5-%28Methylamino%29-5%2C6-dihydro-4H-imidazo%5B4%2C5%2C1-ij%5Dquinolin-2%281H%29-one+%28Sumanirole%29+provide+clues+to+dopamine+D2%2FD3+receptor+agonist+selectivity&doi=10.1021%2Facs.jmedchem.5b01612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity</span></div><div class="casAuthors">Zou, Mu-Fa; Keck, Thomas M.; Kumar, Vivek; Donthamsetti, Prashant; Michino, Mayako; Burzynski, Caitlin; Schweppe, Catherine; Bonifazi, Alessandro; Free, R. Benjamin; Sibley, David R.; Janowsky, Aaron; Shi, Lei; Javitch, Jonathan A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2973-2988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 1-, 5-, and 8-substituted analogs of sumanirole (I), a dopamine D2/D3 receptor (D2R/D3R) agonist, were synthesized.  Binding affinities at both D2R and D3R were higher when detd. in competition with the agonist radioligand [3H]7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT) than with the antagonist radioligand [3H]N-methylspiperone.  Although I was confirmed as a D2R-preferential agonist, its selectivity in binding and functional studies was lower than previously reported.  All analogs were detd. to be D2R/D3R agonists in both GoBRET and mitogenesis functional assays.  Loss of efficacy was detected for the N-1-substituted analogs at D3R.  In contrast, the N-5-alkyl-substituted analogs, and notably the n-butyl-arylamides (II and III), all showed improved affinity at D2R over I with neither a loss of efficacy nor an increase in selectivity.  Computational modeling provided a structural basis for the D2R selectivity of I, illustrating how subtle differences in the highly homologous orthosteric binding site (OBS) differentially affect D2R/D3R affinity and functional efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCYS7hdbWljrVg90H21EOLACvtfcHk0lgoeD8-_il4zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D&md5=504e9fde86b9cef1a3b52fa4a3ef2063</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01612%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DM.-F.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DSchweppe%26aufirst%3DC.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520analogues%2520of%2520%2528R%2529-5-%2528Methylamino%2529-5%252C6-dihydro-4H-imidazo%255B4%252C5%252C1-ij%255Dquinolin-2%25281H%2529-one%2520%2528Sumanirole%2529%2520provide%2520clues%2520to%2520dopamine%2520D2%252FD3%2520receptor%2520agonist%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2973%26epage%3D2988%26doi%3D10.1021%2Facs.jmedchem.5b01612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5905</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1021/jm800471h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800471h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFaqtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5905-5908&author=J.+Chenauthor=G.+T.+Collinsauthor=J.+Zhangauthor=C.-Y.+Yangauthor=B.+Levantauthor=J.+Woodsauthor=S.+Wang&title=Design%2C+synthesis%2C+and+evaluation+of+potent+and+selective+ligands+for+the+dopamine+3+%28D3%29+receptor+with+a+novel+in+vivo+behavioral+profile&doi=10.1021%2Fjm800471h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Potent and Selective Ligands for the Dopamine 3 (D3) Receptor with a Novel in Vivo Behavioral Profile</span></div><div class="casAuthors">Chen, Jianyong; Collins, Gregory T.; Zhang, Jian; Yang, Chao-Yie; Levant, Beth; Woods, James; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5905-5908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. structurally related to pramipexole were designed, synthesized, and evaluated as ligands for the dopamine 3 (D3) receptor.  Compd. 12 (I) has a Ki value of 0.41 nM to D3 and a selectivity of >30000- and 800-fold over the D1-like and D2 receptors, resp.  Our in vivo functional assays showed that this compd. is a partial agonist at the D3 receptor with no detectable activity at the D2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZFzVrBCdRRbVg90H21EOLACvtfcHk0lgoeD8-_il4zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFaqtLbE&md5=6ea446427c46a43ac56870b2026f5751</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800471h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800471h%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520potent%2520and%2520selective%2520ligands%2520for%2520the%2520dopamine%25203%2520%2528D3%2529%2520receptor%2520with%2520a%2520novel%2520in%2520vivo%2520behavioral%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5905%26epage%3D5908%26doi%3D10.1021%2Fjm800471h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">CJ-1639: A potent and highly selective dopamine D3 receptor full agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1021/ml200100t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200100t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=620-625&author=J.+Chenauthor=G.+T.+Collinsauthor=B.+Levantauthor=J.+Woodsauthor=J.+R.+Deschampsauthor=S.+Wang&title=CJ-1639%3A+A+potent+and+highly+selective+dopamine+D3+receptor+full+agonist&doi=10.1021%2Fml200100t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist</span></div><div class="casAuthors">Chen, Jianyong; Collins, Gregory T.; Levant, Beth; Woods, James; Deschamps, Jeffrey R.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have identified several ligands with high binding affinities to the dopamine D3 receptor and excellent selectivity over the D2 and D1 receptors.  CJ-1639 (17) binds to the D3 receptor with a Ki value of 0.50 nM and displays a selectivity of >5000 times over D2 and D1 receptors in binding assays using dopamine receptors expressed in the native rat brain tissues.  CJ-1639 binds to human D3 receptor with a Ki value of 3.61 nM and displays over >1000-fold selectivity over human D1 and D2 receptors.  CJ-1639 is active at 0.01 mg/kg at the dopamine D3 receptor in the rat and only starts to show a modest D2 activity at doses as high as 10 mg/kg.  CJ-1639 is the most potent and selective D3 full agonist reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1_j_DTOKv47Vg90H21EOLACvtfcHk0lgufPpLaYc9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D&md5=563e24bd67062d01a456b6f03429329a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fml200100t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200100t%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DCJ-1639%253A%2520A%2520potent%2520and%2520highly%2520selective%2520dopamine%2520D3%2520receptor%2520full%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D620%26epage%3D625%26doi%3D10.1021%2Fml200100t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D2 receptor (D2R) biased agonism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2890-2907&author=A.+Bonifaziauthor=H.+Yanoauthor=M.+P.+Ellenbergerauthor=L.+Mullerauthor=V.+Kumarauthor=M.-F.+Zouauthor=N.+S.+Caiauthor=A.+M.+Guerreroauthor=A.+S.+Woodsauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+bivalent+ligands+based+on+the+sumanirole+pharmacophore+reveal+dopamine+D2+receptor+%28D2R%29+biased+agonism&doi=10.1021%2Facs.jmedchem.6b01875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Ellenberger, Michael P.; Muller, Ludovic; Kumar, Vivek; Zou, Mu-Fa; Cai, Ning Sheng; Guerrero, Adrian M.; Woods, Amina S.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2890-2907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype.  The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways.  Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore.  We found that substitutions in the N-1- and/or N-5-positions, physiochem. properties of those substituents, and secondary arom. pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment.  Compd. 19 was identified as a new lead for its selective D2 G-protein biased agonism with an EC50 in the subnanomolar range.  Structure-activity correlations were obsd. between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compds. to selectively activate G-proteins vs. β-arrestin recruitment in D2R-BRET functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprfScHokUgP7Vg90H21EOLACvtfcHk0lgufPpLaYc9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D&md5=24bf22a101756e44fbc8f8345d2c1fe4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01875%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DM.-F.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520bivalent%2520ligands%2520based%2520on%2520the%2520sumanirole%2520pharmacophore%2520reveal%2520dopamine%2520D2%2520receptor%2520%2528D2R%2529%2520biased%2520agonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2890%26epage%3D2907%26doi%3D10.1021%2Facs.jmedchem.6b01875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and potent dopamine D2 receptor Go-protein biased agonists</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.8b00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=52-65&author=A.+Bonifaziauthor=H.+Yanoauthor=A.+M.+Guerreroauthor=V.+Kumarauthor=A.+F.+Hoffmanauthor=C.+R.+Lupicaauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+and+potent+dopamine+D2+receptor+Go-protein+biased+agonists&doi=10.1021%2Facsptsci.8b00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Guerrero, Adrian M.; Kumar, Vivek; Hoffman, Alexander F.; Lupica, Carl R.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of functionally biased and physiol. beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D2 receptor (D2R) targeted mols. that may be therapeutically advantageous for the treatment of certain neuropsychiatric or basal ganglia related disorders.  Here we describe the synthesis of a novel series of D2R agonists linking the D2R unbiased agonist sumanirole with privileged secondary mol. fragments.  The resulting ligands demonstrate improved D2R affinity and selectivity over sumanirole.  Extensive in vitro functional studies and bias factor anal. led to the identification of a novel class of highly potent Go-protein biased full D2R agonists with more than 10-fold and 1000-fold bias selectivity toward activation of specific G-protein subtypes and β-arrestin, resp.  Intracellular electrophysiol. recordings from midbrain dopamine neurons demonstrated that Go-protein selective agonists can elicit prolonged ligand-induced GIRK activity via D2Rs, which may be beneficial in the treatment of dyskinesias assocd. with dopamine system dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNIFl-FnvXCrVg90H21EOLACvtfcHk0lgufPpLaYc9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D&md5=5b67e76002f6ceb85293c961f698722a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00060%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520potent%2520dopamine%2520D2%2520receptor%2520Go-protein%2520biased%2520agonists%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D2%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facsptsci.8b00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Chiral resolution and serendipitous fluorination reaction for the selective dopamine D3 receptor antagonist BAK2-66</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1021/ml500006v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500006v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=647-651&author=V.+Kumarauthor=A.+K.+Banalaauthor=E.+G.+Garciaauthor=J.+Caoauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=J.+R.+Deschampsauthor=A.+H.+Newman&title=Chiral+resolution+and+serendipitous+fluorination+reaction+for+the+selective+dopamine+D3+receptor+antagonist+BAK2-66&doi=10.1021%2Fml500006v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66</span></div><div class="casAuthors">Kumar, Vivek; Banala, Ashwini K.; Garcia, Erick G.; Cao, Jianjing; Keck, Thomas M.; Bonifazi, Alessandro; Deschamps, Jeffery R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-651</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The improved chiral synthesis of the selective dopamine D3 receptor (D3R) antagonist (R)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)1H-indole-2-carboxamide ((R)-PG648) is described.  The same chiral secondary alc. intermediate was used to prep. the enantiomers of a 3-F-benzofuranyl analog, BAK 2-66 (I).  The abs. configurations of the 3-F enantiomers were assigned from their X-ray crystal structures that confirmed retention of configuration during fluorination with N,N-diethylaminosulfur trifluoride (DAST).  (R)-I showed higher D3R affinity and selectivity than its (S)-enantiomer; however, it had lower D3R affinity and enantioselectivity than (R)-PG648.  Further, importance of the 4-atom linker length between the aryl amide and 4-phenylpiperazine was demonstrated with the 4-fluorobutyl-product (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTRVSlrPS4ybVg90H21EOLACvtfcHk0lgF0ChSeVkPjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D&md5=17ddfb3b45b6630f53c917281d76b620</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fml500006v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500006v%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DGarcia%26aufirst%3DE.%2BG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DChiral%2520resolution%2520and%2520serendipitous%2520fluorination%2520reaction%2520for%2520the%2520selective%2520dopamine%2520D3%2520receptor%2520antagonist%2520BAK2-66%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D647%26epage%3D651%26doi%3D10.1021%2Fml500006v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1208</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-19642-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fs41598-018-19642-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29352161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1208&author=C.+J.+Draper-Joyceauthor=R.+K.+Vermaauthor=M.+Michinoauthor=J.+Shonbergauthor=A.+Kopinathanauthor=C.+Klein+Herenbrinkauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=A.+M.+Abramyanauthor=D.+M.+Thalauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=L.+Shiauthor=J.+R.+Lane&title=The+action+of+a+negative+allosteric+modulator+at+the+dopamine+D2+receptor+is+dependent+upon+sodium+ions&doi=10.1038%2Fs41598-018-19642-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span></div><div class="casAuthors">Draper-Joyce Christopher J; Klein Herenbrink Carmen; Thal David M; Christopoulos Arthur; Lane J Robert; Verma Ravi Kumar; Michino Mayako; Abramyan Ara M; Shi Lei; Michino Mayako; Shonberg Jeremy; Kopinathan Anitha; Scammells Peter J; Capuano Ben; Javitch Jonathan A; Javitch Jonathan A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sodium ions (Na(+)) allosterically modulate the binding of orthosteric agonists and antagonists to many class A G protein-coupled receptors, including the dopamine D2 receptor (D2R).  Experimental and computational evidences have revealed that this effect is mediated by the binding of Na(+) to a conserved site located beneath the orthosteric binding site (OBS).  SB269652 acts as a negative allosteric modulator (NAM) of the D2R that adopts an extended bitopic pose, in which the tetrahydroisoquinoline moiety interacts with the OBS and the indole-2-carboxamide moiety occupies a secondary binding pocket (SBP).  In this study, we find that the presence of a Na(+) within the conserved Na(+)-binding pocket is required for the action of SB269652.  Using fragments of SB269652 and novel full-length analogues, we show that Na(+) is required for the high affinity binding of the tetrahydroisoquinoline moiety within the OBS, and that the interaction of the indole-2-carboxamide moiety with the SBP determines the degree of Na(+)-sensitivity.  Thus, we extend our understanding of the mode of action of this novel class of NAM by showing it acts synergistically with Na(+) to modulate the binding of orthosteric ligands at the D2R, providing opportunities for fine-tuning of modulatory effects in future allosteric drug design efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvIHTTptFmHTToTC3aBaesfW6udTcc2eaqRPIggSN1Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D&md5=7126d1cd2e69be311c508c596d81cc2f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-19642-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-19642-1%26sid%3Dliteratum%253Aachs%26aulast%3DDraper-Joyce%26aufirst%3DC.%2BJ.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520action%2520of%2520a%2520negative%2520allosteric%2520modulator%2520at%2520the%2520dopamine%2520D2%2520receptor%2520is%2520dependent%2520upon%2520sodium%2520ions%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D1208%26doi%3D10.1038%2Fs41598-018-19642-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e1005948</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1371%2Fjournal.pcbi.1005948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29337986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=e1005948&author=R.+K.+Vermaauthor=A.+M.+Abramyanauthor=M.+Michinoauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=L.+Shi&title=The+E2.65A+mutation+disrupts+dynamic+binding+poses+of+SB269652+at+the+dopamine+D2+and+D3+receptors&doi=10.1371%2Fjournal.pcbi.1005948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span></div><div class="casAuthors">Verma, Ravi Kumar; Abramyan, Ara M.; Michino, Mayako; Free, R. Benjamin; Sibley, David R.; Javitch, Jonathan A.; Lane, J. Robert; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1005948/1-e1005948/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The dopamine D2 and D3 receptors (D2R and D3R) are important targets for antipsychotics and for the treatment of drug abuse.  SB269652, a bitopic ligand that simultaneously binds both the orthosteric binding site (OBS) and a secondary binding pocket (SBP) in both D2R and D3R, was found to be a neg. allosteric modulator.  Previous studies identified Glu2.65 in the SBP to be a key determinant of both the affinity of SB269652 and the magnitude of its cooperativity with orthosteric ligands, as the E2.  A mutation decreased both of these parameters.  However, the proposed hydrogen bond (H-bond) between Glu2.65 and the indole moiety of SB269652 is not a strong interaction, and a structure activity relationship study of SB269652 indicates that this H-bond may not be the only element that dets. its allosteric properties.  To understand the structural basis of the obsd. phenotype of E2.65A, we carried out mol. dynamics simulations with a cumulative length of ∼77 μs of D2R and D3R wild-type and their E2.65A mutants bound to SB269652.  In combination with Markov state model anal. and by characterizing the equil. of ligand binding modes in different conditions, we found that in both D2R and D3R, whereas the tetrahydroisoquinoline moiety of SB269652 is stably bound in the OBS, the indole-2-carboxamide moiety is dynamic and only intermittently forms H-bonds with Glu2.65.  Our results also indicate that the E2.65A mutation significantly affects the overall shape and size of the SBP, as well as the conformation of the N terminus.  Thus, our findings suggest that the key role of Glu2.65 in mediating the allosteric properties of SB269652 extends beyond a direct interaction with SB269652, and provide structural insights for rational design of SB269652 derivs. that may retain its allosteric properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg1JueDgCVDrVg90H21EOLACvtfcHk0lgF0ChSeVkPjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ&md5=e7ff0bcc58a78f0292a5c1f1c820c151</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005948%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DThe%2520E2.65A%2520mutation%2520disrupts%2520dynamic%2520binding%2520poses%2520of%2520SB269652%2520at%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3De1005948%26doi%3D10.1371%2Fjournal.pcbi.1005948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein
Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.bcp.2018.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29325769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosl2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=315-328&author=C.+J.+Draper-Joyceauthor=M.+Michinoauthor=R.+K.+Vermaauthor=C.+Klein%0AHerenbrinkauthor=J.+Shonbergauthor=A.+Kopinathanauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=D.+M.+Thalauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=L.+Shiauthor=J.+R.+Lane&title=The+structural+determinants+of+the+bitopic+binding+mode+of+a+negative+allosteric+modulator+of+the+dopamine+D2+receptor&doi=10.1016%2Fj.bcp.2018.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor</span></div><div class="casAuthors">Draper-Joyce, Christopher J.; Michino, Mayako; Verma, Ravi Kumar; Klein Herenbrink, Carmen; Shonberg, Jeremy; Kopinathan, Anitha; Scammells, Peter J.; Capuano, Ben; Thal, David M.; Javitch, Jonathan A.; Christopoulos, Arthur; Shi, Lei; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-328</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SB269652 is a neg. allosteric modulator of the dopamine D2 receptor (D2R) yet possesses structural similarity to ligands with a competitive mode of interaction.  In this study, we aimed to understand the ligand-receptor interactions that confer its allosteric action.  We combined site-directed mutagenesis with mol. dynamics simulations using both SB269652 and derivs. from our previous structure activity studies.  We identify residues within the conserved orthosteric binding site (OBS) and a secondary binding pocket (SBP) that det. affinity and cooperativity.  Our results indicate that interaction with the SBP is a requirement for allosteric pharmacol., but that both competitive and allosteric derivs. of SB269652 can display sensitivity to the mutation of a glutamate residue (E952.65) within the SBP.  Our findings provide the mol. basis for the differences in affinity between SB269652 derivs., and reveal how changes to interactions made by the primary pharmacophore of SB269652 in the orthosteric pocket can confer changes in the interactions made by the secondary pharmacophore in the SBP.  Our insights provide a structure-activity framework towards rational optimization of bitopic ligands for D2R with tailored competitive vs. allosteric properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcW9XzMctE47Vg90H21EOLACvtfcHk0lhJ9Qu1JQ6XDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosl2luw%253D%253D&md5=a8c520e48173145a1f1a999312c724dc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DDraper-Joyce%26aufirst%3DC.%2BJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520structural%2520determinants%2520of%2520the%2520bitopic%2520binding%2520mode%2520of%2520a%2520negative%2520allosteric%2520modulator%2520of%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D148%26spage%3D315%26epage%3D328%26doi%3D10.1016%2Fj.bcp.2018.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Dai, D.</span>; <span class="NLM_string-name">Cai, J.</span>; <span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Hua, W.</span>; <span class="NLM_string-name">Jia, N.</span>; <span class="NLM_string-name">Li, M.</span>; <span class="NLM_string-name">Gu, L.</span></span> <span> </span><span class="NLM_article-title">Preparation Of Fused-Tricyclic Compounds For Treatment Of Central Nervous System Diseases</span>. CN <span class="NLM_patent">1948315</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Ji&author=D.+Dai&author=J.+Cai&author=Y.+Dai&author=W.+Hua&author=N.+Jia&author=M.+Li&author=L.+Gu&title=Preparation+Of+Fused-Tricyclic+Compounds+For+Treatment+Of+Central+Nervous+System+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DM.%26atitle%3DPreparation%2520Of%2520Fused-Tricyclic%2520Compounds%2520For%2520Treatment%2520Of%2520Central%2520Nervous%2520System%2520Diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allerton, C. M. N.</span>; <span class="NLM_string-name">Cook, A. S.</span>; <span class="NLM_string-name">Hepworth, D.</span>; <span class="NLM_string-name">Miller, D. C.</span></span> <span> </span><span class="NLM_article-title">Aminopyridine Derivatives As Selective Dopamine D3 Agonists</span>. WO <span class="NLM_patent">115985 Al</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=C.+M.+N.+Allerton&author=A.+S.+Cook&author=D.+Hepworth&author=D.+C.+Miller&title=Aminopyridine+Derivatives+As+Selective+Dopamine+D3+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllerton%26aufirst%3DC.%2BM.%2BN.%26atitle%3DAminopyridine%2520Derivatives%2520As%2520Selective%2520Dopamine%2520D3%2520Agonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span> <span> </span><span class="NLM_article-title">Morpholine Dopamine Agonists For The Treatment Of Pain</span>. WO <span class="NLM_patent">087512 A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=M.+A.+Ackley&title=Morpholine+Dopamine+Agonists+For+The+Treatment+Of+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAckley%26aufirst%3DM.%2BA.%26atitle%3DMorpholine%2520Dopamine%2520Agonists%2520For%2520The%2520Treatment%2520Of%2520Pain%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. H.</span>; <span class="NLM_string-name">Wyvratt, M. J.</span></span> <span> </span><span class="NLM_article-title">Morpholine Derivatives Compositions And Use</span>. U.S. Patent <span class="NLM_patent">5,124,328 A</span>, <span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=M.+H.+Fisher&author=M.+J.+Wyvratt&title=Morpholine+Derivatives+Compositions+And+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BH.%26atitle%3DMorpholine%2520Derivatives%2520Compositions%2520And%2520Use%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn-Sims, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawreen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugolenski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majchrzak, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormos, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A. N.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00297</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1eltr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=165-177&author=T.+T.+Wagerauthor=T.+Chappieauthor=D.+Hortonauthor=R.+Y.+Chandrasekaranauthor=B.+Samasauthor=E.+R.+Dunn-Simsauthor=C.+Hsuauthor=N.+Nawreenauthor=M.+A.+Vanase-Frawleyauthor=R.+E.+O%E2%80%99Connorauthor=C.+J.+Schmidtauthor=K.+Dlugolenskiauthor=N.+C.+Stratmanauthor=M.+J.+Majchrzakauthor=B.+L.+Kormosauthor=D.+P.+Nguyenauthor=A.+Sawant-Basakauthor=A.+N.+Mead&title=Dopamine+D3%2FD2+receptor+antagonist+PF-4363467+attenuates+opioid+drug-seeking+behavior+without+concomitant+D2+side+effects&doi=10.1021%2Facschemneuro.6b00297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects</span></div><div class="casAuthors">Wager, Travis T.; Chappie, Thomas; Horton, David; Chandrasekaran, Ramalakshmi Y.; Samas, Brian; Dunn-Sims, Elizabeth R.; Hsu, Cathleen; Nawreen, Nawshaba; Vanase-Frawley, Michelle A.; O'Connor, Rebecca E.; Schmidt, Christopher J.; Dlugolenski, Keith; Stratman, Nancy C.; Majchrzak, Mark J.; Kormos, Bethany L.; Nguyen, David P.; Sawant-Basak, Aarti; Mead, Andy N.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-177</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine receptor antagonism is a compelling mol. target for the treatment of a range of psychiatric disorders, including substance use disorders.  From the authors' corporate compd. file the authors identified a structurally unique D3 receptor (D3R) antagonist scaffold, PNU-177864.  Through a hybrid approach, the authors merged key pharmacophore elements from PNU-177864 and D3 agonist PF-592379 to yield the novel D3R/D2R antagonist PF-4363467.  PF-4363467 was designed to possess CNS drug-like properties as defined by its CNS MPO desirability score (≥4/6).  In addn. to good physicochem. properties, PF-4363467 exhibited low nanomolar affinity for the D3R (D3 Ki = 3.2 nM), good subtype selectivity over D2R (D2 Ki = 692 nM), and high selectivity for D3R vs. other biogenic amine receptors.  In vivo, PF-4363467 dose-dependently attenuated opioid self-administration and opioid drug-seeking behavior in a rat operant reinstatement model using animals trained to self-administer fentanyl.  Further, traditional extrapyramidal symptoms (EPS), adverse side effects arising from D2R antagonism, were not obsd. despite high D2 receptor occupancy (RO) in rodents, suggesting that compd. PF-4363467 has a unique in vivo profile.  Collectively, the authors' data support further investigation of dual D3R and D2R antagonists for the treatment of drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkblTSt1t8cbVg90H21EOLACvtfcHk0ljVB77swGFBgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1eltr7M&md5=abd6262987e08cb98b00d8057a52dc4f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00297%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DChappie%26aufirst%3DT.%26aulast%3DHorton%26aufirst%3DD.%26aulast%3DChandrasekaran%26aufirst%3DR.%2BY.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DDunn-Sims%26aufirst%3DE.%2BR.%26aulast%3DHsu%26aufirst%3DC.%26aulast%3DNawreen%26aufirst%3DN.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DDlugolenski%26aufirst%3DK.%26aulast%3DStratman%26aufirst%3DN.%2BC.%26aulast%3DMajchrzak%26aufirst%3DM.%2BJ.%26aulast%3DKormos%26aufirst%3DB.%2BL.%26aulast%3DNguyen%26aufirst%3DD.%2BP.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%2BN.%26atitle%3DDopamine%2520D3%252FD2%2520receptor%2520antagonist%2520PF-4363467%2520attenuates%2520opioid%2520drug-seeking%2520behavior%2520without%2520concomitant%2520D2%2520side%2520effects%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D165%26epage%3D177%26doi%3D10.1021%2Facschemneuro.6b00297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attkins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heatherington, A. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.3109/00498254.2010.514961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.3109%2F00498254.2010.514961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=20836725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OgsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=730-742&author=N.+Attkinsauthor=A.+Bettsauthor=D.+Hepworthauthor=A.+C.+Heatherington&title=Pharmacokinetics+and+elucidation+of+the+rates+and+routes+of+N-glucuronidation+of+PF-592379%2C+an+oral+dopamine+3+agonist+in+rat%2C+dog%2C+and+human&doi=10.3109%2F00498254.2010.514961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human</span></div><div class="casAuthors">Attkins, Neil; Betts, Alison; Hepworth, David; Heatherington, Anne C.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">730-742</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">PF-592379 is a potent, selective agonist of the dopamine 3 receptor, for the treatment of male erectile dysfunction and female sexual dysfunction.  In vivo, PF-592379 has low-moderate clearance relative to liver blood flow of 6.3 and 8.5 mL/min/kg in dog and 44.8 and 58.2 mL/min/kg in rat.  It has high permeability in Caco-2 cells and was completely absorbed in rat and dog pharmacokinetic studies with an oral bioavailability of 28% in both rats and 61 and 87% in the dogs.  These data are consistent with the physicochem. properties of PF-592379, which indicate complete absorption by the transcellular route.  Elimination of PF-592379 was predominantly metabolic in nature.  In vitro routes of metab. studies indicate that metab. in the rat is a combination of P 450 mechanisms and N-glucuronidation, whereas in dog and human, N-glucuronidation is the major route.  NMR anal. indicates that N-glucuronidation is non-quaternary in nature and occurs on both the pyridyl amine and ring nitrogen.  Rates of clearance via N-glucuronidation were predicted to be low in humans compared with acyl or phenolic glucuronidation.  PF-592379 was predicted to have complete absorption from the gastrointestinal tract and an oral bioavailability of >60% in the clinic.  Clin. data verified that PF-592379 is a low clearance compd. in human, with a mean oral clearance of 6.5 mL/min/kg following a 200 mg oral dose. PF-592379 has ideal pharmacokinetic properties for an oral D3 agonist, intended for on demand dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOuUcyl_LeyLVg90H21EOLACvtfcHk0ljVB77swGFBgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OgsbnL&md5=6fe4382d8c39ed1887f2bc0289252f0a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3109%2F00498254.2010.514961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2010.514961%26sid%3Dliteratum%253Aachs%26aulast%3DAttkins%26aufirst%3DN.%26aulast%3DBetts%26aufirst%3DA.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHeatherington%26aufirst%3DA.%2BC.%26atitle%3DPharmacokinetics%2520and%2520elucidation%2520of%2520the%2520rates%2520and%2520routes%2520of%2520N-glucuronidation%2520of%2520PF-592379%252C%2520an%2520oral%2520dopamine%25203%2520agonist%2520in%2520rat%252C%2520dog%252C%2520and%2520human%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D40%26spage%3D730%26epage%3D742%26doi%3D10.3109%2F00498254.2010.514961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberhofer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, S. B.</span></span> <span> </span><span class="NLM_article-title">Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1097/fbp.0b013e3283536d21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1097%2Ffbp.0b013e3283536d21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=22470105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=280-291&author=G.+T.+Collinsauthor=P.+Butlerauthor=C.+Waymanauthor=S.+Ratcliffeauthor=P.+Guptaauthor=G.+Oberhoferauthor=S.+B.+Caine&title=Lack+of+abuse+potential+in+a+highly+selective+dopamine+D3+agonist%2C+PF-592%2C379%2C+in+drug+self-administration+and+drug+discrimination+in+rats&doi=10.1097%2Ffbp.0b013e3283536d21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats</span></div><div class="casAuthors">Collins, Gregory T.; Butler, Paul; Wayman, Chris; Ratcliffe, Sian; Gupta, Paul; Oberhofer, Geoffrey; Caine, S. Barak</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-291</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Dopamine D3-preferring agonists are commonly used to treat Parkinson's disease and restless leg syndrome; however, lab. animal studies suggest that they may possess a moderate abuse potential.  These studies aimed to compare the highly selective, full D3 agonist PF-592,379 to the less selective D3 agonist 7-OH-DPAT, and the indirect dopamine agonist cocaine in drug self-administration and discrimination assays.  Although rats readily acquired high rates of fixed ratio (FR)1 responding for cocaine, exptl. naive rats failed to acquire responding when 7-OH-DPAT or PF-592,379 was made available during an 18-session acquisition period.  Cocaine also maintained dose-dependent levels of responding when available under a FR5 or a progressive ratio (PR) schedule of reinforcement.  Although 7-OH-DPAT maintained modest levels of responding when substituted under a FR5, it failed to maintain significant levels of PR responding.  PF-592,379 maintained saline-like rates of responding when substituted under FR5 or PR schedules of reinforcement.  Similar behavioral profiles were obsd. in cocaine discrimination assays, with 7-OH-DPAT partially substituting for cocaine, and PF-592,379 producing saline-like effects over a wide range of doses.  Together, the results of these studies predict that highly selective D3 agonists, such as PF-592,379, will have low abuse potential in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRBvTK9AL8fbVg90H21EOLACvtfcHk0ljVB77swGFBgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oisrg%253D&md5=bf0671e1e1174cbcd5143a4dfeb20c84</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1097%2Ffbp.0b013e3283536d21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Ffbp.0b013e3283536d21%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DButler%26aufirst%3DP.%26aulast%3DWayman%26aufirst%3DC.%26aulast%3DRatcliffe%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DOberhofer%26aufirst%3DG.%26aulast%3DCaine%26aufirst%3DS.%2BB.%26atitle%3DLack%2520of%2520abuse%2520potential%2520in%2520a%2520highly%2520selective%2520dopamine%2520D3%2520agonist%252C%2520PF-592%252C379%252C%2520in%2520drug%2520self-administration%2520and%2520drug%2520discrimination%2520in%2520rats%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2012%26volume%3D23%26spage%3D280%26epage%3D291%26doi%3D10.1097%2Ffbp.0b013e3283536d21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, S. B.</span></span> <span> </span><span class="NLM_article-title">Effects of acute and chronic treatments with dopamine D2 and D3 receptor ligands on cocaine versus food choice in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.241141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fjpet.117.241141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=28473458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=161-176&author=M.+Thomsenauthor=A.+C.+Barrettauthor=P.+Butlerauthor=S.+S.+Negusauthor=S.+B.+Caine&title=Effects+of+acute+and+chronic+treatments+with+dopamine+D2+and+D3+receptor+ligands+on+cocaine+versus+food+choice+in+rats&doi=10.1124%2Fjpet.117.241141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of acute and chronic treatments with dopamine D2 and D3 receptor ligands on cocaine versus food choice in rats</span></div><div class="casAuthors">Thomsen, Morgane; Barrett, Andrew C.; Butler, Paul; Negus, S. Stevens; Caine, S. Barak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-176</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dopamine D3 receptor ligands are potential medications for psychostimulant addiction.  Medication assessment may benefit from preclin. studies that evaluate chronic medication effects on choice between an abused drug and an alternative, nondrug reinforcer.  This study compared acute and chronic effects of dopamine D2- and D3-preferring ligands on choice between i.v. cocaine and palatable food in rats.  Under baseline conditions, cocaine maintained dose-dependent increases in cocaine choice and reciprocal decreases in food choice.  Acutely, the D2 agonist R-(-)-norpropylapomorphine (NPA) and antagonist L-741,626 [3-[[4-(4-chlorophenyl)-4-hydroxypiperidin-l-yl]methyl-1H-indole]] produced leftward and rightward shifts in cocaine dose-effect curves, resp., whereas the partial agonist terguride had no effect.  All three drugs dose-dependently decreased food-maintained responding.  Chronically, the effects of R-(-)-norpropylapomorphine and L-741,626 on cocaine self-administration showed marked tolerance, whereas suppression of food-reinforced behavior persisted.  Acute effects of the D3 ligands were less systematic and most consistent with nonselective decreases in cocaine- and food-maintained responding.  Chronically, the D3 agonist PF-592,379 [5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine] increased cocaine choice, whereas an intermediate dose of the D3 antagonist PG01037 [N-[(E)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-pyridin-2-ylbenzamide] produced a therapeutically desirable decrease in cocaine choice early in treatment; however, tolerance to this effect developed, and lower and higher doses were ineffective.  D3 ligands failed to significantly modify total cocaine intake but caused persistent decreases in food intake.  Thus, D2-and D3-preferring ligands showed distinct profiles, consistent with different pharmacol. actions.  In addn., these results highlight the role of acute vs. chronic treatment as a determinant of test drug effects.  With the possible exception of the D3 antagonist PG01037, no ligand was promising in terms of cocaine addiction treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7F9zB3ud9_rVg90H21EOLACvtfcHk0ljzMKHyCWYyig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbzN&md5=581bbdcd95f3ca589db0dc67e1b1ccaa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241141%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DA.%2BC.%26aulast%3DButler%26aufirst%3DP.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DCaine%26aufirst%3DS.%2BB.%26atitle%3DEffects%2520of%2520acute%2520and%2520chronic%2520treatments%2520with%2520dopamine%2520D2%2520and%2520D3%2520receptor%2520ligands%2520on%2520cocaine%2520versus%2520food%2520choice%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D161%26epage%3D176%26doi%3D10.1124%2Fjpet.117.241141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElveen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1021/jm049465g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049465g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=839-848&author=P.+Grundtauthor=E.+E.+Carlsonauthor=J.+Caoauthor=C.+J.+Bennettauthor=E.+McElveenauthor=M.+Taylorauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Novel+heterocyclic+trans+olefin+analogues+of+N-%7B4-%5B4-%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dbutyl%7Darylcarboxamides+as+selective+probes+with+high+affinity+for+the+dopamine+D3+receptor&doi=10.1021%2Fjm049465g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor</span></div><div class="casAuthors">Grundt, Peter; Carlson, Erin E.; Cao, Jianjing; Bennett, Christina J.; McElveen, Elizabeth; Taylor, Michelle; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine.  However, definitive pharmacol. investigations have been hampered by the lack of highly D3 receptor selective compds. that can be used in vivo.  To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl}-amide, Ki (hD3) = 2.0 nM, Ki (hD2L) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chem. modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity.  A series of >30 novel analogs were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2L, D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist 125I-IABN.  Structural diversity in the aryl amide end of the mol. was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine.  Several analogs demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand.  Compd. 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide) displayed the most promising pharmacol. profile (Ki (hD3) = 0.7 nM, Ki (hD2L) = 93.3 nM, D2/D3 selectivity ratio of 133).  In addn., this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM.  Compd. 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM).  Moreover, a decrease in c log D value of ∼2 orders of magnitude was detd. for this novel D3-receptor-preferring ligand, compared to 1.  In summary, chem. modification of 1 has resulted in compds. with high affinity and selectivity for D3 receptors.  The most promising candidate, compd. 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofDgtp4SPuC7Vg90H21EOLACvtfcHk0ljzMKHyCWYyig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D&md5=080af9d0e167912621f35c40020c534b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049465g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049465g%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCarlson%26aufirst%3DE.%2BE.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DC.%2BJ.%26aulast%3DMcElveen%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520heterocyclic%2520trans%2520olefin%2520analogues%2520of%2520N-%257B4-%255B4-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dbutyl%257Darylcarboxamides%2520as%2520selective%2520probes%2520with%2520high%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D839%26epage%3D848%26doi%3D10.1021%2Fjm049465g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">The “cyclopropyl fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8712</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8712-8756&author=T.+T.+Talele&title=The+%E2%80%9Ccyclopropyl+fragment%E2%80%9D+is+a+versatile+player+that+frequently+appears+in+preclinical%2Fclinical+drug+molecules&doi=10.1021%2Facs.jmedchem.6b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8712-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclin. to clin. stage.  Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes.  The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs contg. it.  Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflux ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIJAG1XVRG7Vg90H21EOLACvtfcHk0ljzMKHyCWYyig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D&md5=b5586458ec4ab5e2d7586f5739663d1f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DThe%2520%25E2%2580%259Ccyclopropyl%2520fragment%25E2%2580%259D%2520is%2520a%2520versatile%2520player%2520that%2520frequently%2520appears%2520in%2520preclinical%252Fclinical%2520drug%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8712%26epage%3D8756%26doi%3D10.1021%2Facs.jmedchem.6b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongetti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBounty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of selectivity and efficacy at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6699</span>, <span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+determinants+of+selectivity+and+efficacy+at+the+dopamine+D3+receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0lh0Sq2yvEPsSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520determinants%2520of%2520selectivity%2520and%2520efficacy%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dijkstra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, T. B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollema, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der
Weide, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, A. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2178</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1021/jm00119a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00119a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL1cXlvFSgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=2178-2182&author=D.+Dijkstraauthor=T.+B.+A.+Mulderauthor=H.+Rollemaauthor=P.+G.+Tepperauthor=J.+Van+der%0AWeideauthor=A.+S.+Horn&title=Synthesis+and+pharmacology+of+trans-4-n-propyl-3%2C4%2C4a%2C10b-tetrahydro-2H%2C5H-1-benzopyrano%5B4%2C3-b+%5D-1%2C4-oxazin-7-+and+-9-ols%3A+the+significance+of+nitrogen+pKa+values+for+central+dopamine+receptor+activation&doi=10.1021%2Fjm00119a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b]1,4-oxazin-7- and -9-ols.  The significance of nitrogen pka values for central dopamine receptor activation</span></div><div class="casAuthors">Dijkstra, Durk; Mulder, Theo B. A.; Rollema, Hans; Tepper, Pieter G.; Van der Weide, Jan; Horn, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2178-82</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The 6-oxa analogs I (X = O, R = OH, R = 1H; R = H, R1 = OH) of potent dopamine agonists, hexahydronaphthoxazines I (X = CH2, R = OH, R1 = H; R = H, R1 = OH) were tested for dopamine receptor binding and stimulating activity, and were almost inactive.  PKa value detns. indicated that I (X = O) are protonated to ∼2%, while potent compds. are protonated to a much greater extent.  These results strongly support the assumption that the protonated forms of dopamine agonists are the active species at the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofF_Dd2wqo0LVg90H21EOLACvtfcHk0lh0Sq2yvEPsSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlvFSgsbg%253D&md5=b3ba385865eb357aba2228dc418bd134</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm00119a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00119a020%26sid%3Dliteratum%253Aachs%26aulast%3DDijkstra%26aufirst%3DD.%26aulast%3DMulder%26aufirst%3DT.%2BB.%2BA.%26aulast%3DRollema%26aufirst%3DH.%26aulast%3DTepper%26aufirst%3DP.%2BG.%26aulast%3DVan%2Bder%2BWeide%26aufirst%3DJ.%26aulast%3DHorn%26aufirst%3DA.%2BS.%26atitle%3DSynthesis%2520and%2520pharmacology%2520of%2520trans-4-n-propyl-3%252C4%252C4a%252C10b-tetrahydro-2H%252C5H-1-benzopyrano%255B4%252C3-b%2520%255D-1%252C4-oxazin-7-%2520and%2520-9-ols%253A%2520the%2520significance%2520of%2520nitrogen%2520pKa%2520values%2520for%2520central%2520dopamine%2520receptor%2520activation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D2178%26epage%3D2182%26doi%3D10.1021%2Fjm00119a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devries, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and dopaminergic activity of a new oxygen isostere of the 2-aminotetralins: N, N-dipropyl-8-hydroxy-3-chromanamine</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/0223-5234(88)90203-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2F0223-5234%2888%2990203-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL1MXhtFClsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1988&pages=325-328&author=A.+Hornauthor=B.+Kapteinauthor=N.+Vermueauthor=J.+Devriesauthor=T.+Mulder&title=Synthesis+and+dopaminergic+activity+of+a+new+oxygen+isostere+of+the+2-aminotetralins%3A+N%2C+N-dipropyl-8-hydroxy-3-chromanamine&doi=10.1016%2F0223-5234%2888%2990203-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and dopaminergic activity of a new oxygen isostere of the 2-aminotetralins:  N,N-dipropyl-8-hydroxy-3-chromanamine</span></div><div class="casAuthors">Horn, Alan S.; Kaptein, Bernard; Vermue, Niek A.; De Vries, Jan B.; Mulder, Theo B. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">325-8</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">The synthesis of N,N-dipropyl-8-hydroxy-3-chromanamine (I) from 8-methoxy-4-chromanone oxime in 7 steps is described.  This compd. is an oxygen isostere of the dopamine (DA) receptor agonist N,N-dipropyl-5-hydroxy-2-aminotetralin.  In in vitro and in vivo tests of dopaminergic activity showed I to be a more potent DA agonist than apomorphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcokbwXgnKUrVg90H21EOLACvtfcHk0lh0Sq2yvEPsSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtFClsbg%253D&md5=3df5601efeba8701ba745a537cabcf6e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0223-5234%2888%2990203-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0223-5234%252888%252990203-6%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DA.%26aulast%3DKaptein%26aufirst%3DB.%26aulast%3DVermue%26aufirst%3DN.%26aulast%3DDevries%26aufirst%3DJ.%26aulast%3DMulder%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520dopaminergic%2520activity%2520of%2520a%2520new%2520oxygen%2520isostere%2520of%2520the%25202-aminotetralins%253A%2520N%252C%2520N-dipropyl-8-hydroxy-3-chromanamine%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1988%26volume%3D23%26spage%3D325%26epage%3D328%26doi%3D10.1016%2F0223-5234%2888%2990203-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hembre, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J. R.</span></span> <span> </span><span class="NLM_article-title">Conversion of olefins to ditriflates by .mu.-oxobis[(trifluoromethanesulfonato)(phenyl)iodine]</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3650</span>– <span class="NLM_lpage">3654</span>, <span class="refDoi"> DOI: 10.1021/jo00392a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00392a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL2sXltFCqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1987&pages=3650-3654&author=R.+T.+Hembreauthor=C.+P.+Scottauthor=J.+R.+Norton&title=Conversion+of+olefins+to+ditriflates+by+.mu.-oxobis%5B%28trifluoromethanesulfonato%29%28phenyl%29iodine%5D&doi=10.1021%2Fjo00392a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of olefins to ditriflates by μ-oxobis[(trifluoromethanesulfonato)(phenyl)iodine]</span></div><div class="casAuthors">Hembre, Robert T.; Scott, Carl P.; Norton, Jack R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3650-4</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">(CF3SO3IPh)2O (I) was prepd. from iodosobenzene and triflic anhydride and used for the mild, single-step conversion of olefins to vicinal ditriflates and of dienes to 1,4-ditriflates.  The reaction of I with cyclohexene and cis- and trans-ethylene-1,2-d2 results in syn addn.  In the latter case, 3JHH from the 13C sidebands in the [2H]1H NMR shows that the ditriflates from the use of I have the same stereochem. as those prepd. from cis- and trans-ethylene-1,2-d2 via catalytic OsO4 oxidn.  The obsd. temp. dependence of the 13C sidebands of these ditriflates is consistent with greater stability of the rotamer contg. gauche triflate groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2U9ijxT9067Vg90H21EOLACvtfcHk0lh0Sq2yvEPsSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltFCqu7o%253D&md5=bf04de02729dcd93cdd2bfec9698af42</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjo00392a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00392a028%26sid%3Dliteratum%253Aachs%26aulast%3DHembre%26aufirst%3DR.%2BT.%26aulast%3DScott%26aufirst%3DC.%2BP.%26aulast%3DNorton%26aufirst%3DJ.%2BR.%26atitle%3DConversion%2520of%2520olefins%2520to%2520ditriflates%2520by%2520.mu.-oxobis%255B%2528trifluoromethanesulfonato%2529%2528phenyl%2529iodine%255D%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1987%26volume%3D52%26spage%3D3650%26epage%3D3654%26doi%3D10.1021%2Fjo00392a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevatt, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresca, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4146</span>, <span class="refDoi"> DOI: 10.1021/jm0704200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0704200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVWitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4135-4146&author=P.+Grundtauthor=K.+M.+Prevattauthor=J.+Caoauthor=M.+Taylorauthor=C.+Z.+Florescaauthor=J.-K.+Choiauthor=B.+G.+Jenkinsauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Heterocyclic+analogues+of+N-%284-%284-%282%2C3-dichlorophenyl%29piperazin-1-yl%29butyl%29arylcarboxamides+with+functionalized+linking+chains+as+novel+dopamine+D3+receptor+ligands%3A+potential+substance+abuse+therapeutic+agents&doi=10.1021%2Fjm0704200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclic Analogues of N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with Functionalized Linking Chains as Novel Dopamine D3 Receptor Ligands: Potential Substance Abuse Therapeutic Agents</span></div><div class="casAuthors">Grundt, Peter; Prevatt, Katherine M.; Cao, Jianjing; Taylor, Michelle; Floresca, Christina Z.; Choi, Ji-Kyung; Jenkins, Bruce G.; Luedtke, Robert R.; Hauck Newman, Amy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4135-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor antagonists and partial agonists have been shown to modulate drug-seeking effects induced by cocaine and other abused substances.  Compd. 6 [PG01037, (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-trans-but-2-enyl)-4-pyridine-2-ylbenzamide)] and related analogs are currently being evaluated in animal models of drug addiction.  In these studies, a discrepancy between in vitro binding affinity, in vivo occupancy, and behavioral potency has been obsd.  The purpose of this study was to examine (1) modifications of the 2-pyridylphenyl moiety of 6 and (2) hydroxyl, acetyl, and cyclopropyl substitutions on the butylamide linking chain systematically coupled with 2-fluorenylamide or 2-pyridylphenylamide and 2-methoxy- or 2,3-dichloro-substituted phenylpiperazines to measure the impact on binding affinity, D2/D3 selectivity, lipophilicity, and function.  In general, these modifications were well tolerated at the human dopamine D3 (hD3) receptor (Ki = 1-5 nM) as measured in competition binding assays.  Several analogs showed >100-fold selectivity for dopamine D3 over D2 and D4 receptors.  In addn., while all the derivs. with an olefinic linker were antagonists, in quinpirole-stimulated mitogenesis at hD3 receptors, several of the hydroxybutyl-linked analogs (16, 17, 21) showed partial agonist activity.  Finally, several structural modifications reduced lipophilicities while retaining the desired binding profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVBkV6gsuYUrVg90H21EOLACvtfcHk0lh9hdB_Ql9Vlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVWitLY%253D&md5=594bd5ab15004fbdf521ddaee4698b96</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm0704200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0704200%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DPrevatt%26aufirst%3DK.%2BM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DFloresca%26aufirst%3DC.%2BZ.%26aulast%3DChoi%26aufirst%3DJ.-K.%26aulast%3DJenkins%26aufirst%3DB.%2BG.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHeterocyclic%2520analogues%2520of%2520N-%25284-%25284-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%2529butyl%2529arylcarboxamides%2520with%2520functionalized%2520linking%2520chains%2520as%2520novel%2520dopamine%2520D3%2520receptor%2520ligands%253A%2520potential%2520substance%2520abuse%2520therapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4135%26epage%3D4146%26doi%3D10.1021%2Fjm0704200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurer, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, H. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiherpetic activity of (.+-.)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2304</span>– <span class="NLM_lpage">2315</span>, <span class="refDoi"> DOI: 10.1021/jm00120a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00120a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL1MXisVahtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=2304-2315&author=W.+T.+Ashtonauthor=L.+C.+Meurerauthor=C.+L.+Cantoneauthor=A.+K.+Fieldauthor=J.+Hannahauthor=J.+D.+Karkasauthor=R.+Liouauthor=G.+F.+Patelauthor=H.+C.+Perry&title=Synthesis+and+antiherpetic+activity+of+%28.%2B-.%29-9-%5B%5B%28Z%29-2-%28hydroxymethyl%29cyclopropyl%5Dmethyl%5Dguanine+and+related+compounds&doi=10.1021%2Fjm00120a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiherpetic activity of (±)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds</span></div><div class="casAuthors">Ashton, Wallace T.; Meurer, Laura Canning; Cantone, Christine L.; Field, A. Kirk; Hannah, John; Karkas, John D.; Liou, Richard; Patel, Gool F.; Perry, Helen C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2304-15</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of analogs of acyclovir and ganciclovir were prepd. in which conformational constraints were imposed by incorporation of a cyclopropane ring or unsatn. into the side chain.  In addn., several related base-modified compds. were synthesized.  These acyclonucleosides were evaluated for enzymic phosphorylation and DNA polymerase inhibition in a staggered assay and for inhibitory activity against herpes simplex virus types 1 and 2 in vitro.  Certain of the guanine or 8-azaguanine derivs. were good substrates for the viral thymidine kinase and were further converted to triphosphate, but none was a potent inhibitor of the viral DNA polymerase.  Nevertheless, one member of this group, (±)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine (I), displayed significant antiherpetic activity in vitro, superior to that of the corresponding cis olefin II.  Another group, typified by (±)-9-[[(E[)-2-(hydroxymethyl)cyclopropyl]methyl]adenine, possessed modest antiviral activity despite an apparent inability to be enzymically phosphorylated.  The relationship of side-chain conformation and flexibility to biol. activity in this series is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEZAxB9bZ67bVg90H21EOLACvtfcHk0lhScCGhvXR_PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXisVahtg%253D%253D&md5=ef49d6f68f24bd6f9f0e49d329ba3fa3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm00120a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00120a010%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DW.%2BT.%26aulast%3DMeurer%26aufirst%3DL.%2BC.%26aulast%3DCantone%26aufirst%3DC.%2BL.%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DHannah%26aufirst%3DJ.%26aulast%3DKarkas%26aufirst%3DJ.%2BD.%26aulast%3DLiou%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DG.%2BF.%26aulast%3DPerry%26aufirst%3DH.%2BC.%26atitle%3DSynthesis%2520and%2520antiherpetic%2520activity%2520of%2520%2528.%252B-.%2529-9-%255B%255B%2528Z%2529-2-%2528hydroxymethyl%2529cyclopropyl%255Dmethyl%255Dguanine%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D2304%26epage%3D2315%26doi%3D10.1021%2Fjm00120a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span> <span> </span><span class="NLM_article-title">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fmol.115.101808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=26843180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=457-466&author=M.+Sanchez-Sotoauthor=A.+Bonifaziauthor=N.+S.+Caiauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=S.+Ferreauthor=H.+Yano&title=Evidence+for+noncanonical+neurotransmitter+activation%3A+norepinephrine+as+a+dopamine+D2-like+receptor+agonist&doi=10.1124%2Fmol.115.101808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span></div><div class="casAuthors">Sanchez-Soto, Marta; Bonifazi, Alessandro; Cai, Ning Sheng; Ellenberger, Michael P.; Newman, Amy Hauck; Ferre, Sergi; Yano, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-466</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Gαi/o-coupled dopamine D2-like receptor family comprises three subtypes: the D2 receptor (D2R), with short and long isoform variants (D2SR and D2LR), D3 receptor (D3R), and D4 receptor (D4R), with several polymorphic variants.  The common overlap of norepinephrine innervation and D2-like receptor expression patterns prompts the question of a possible noncanonical action by norepinephrine.  In fact, previous studies have suggested that norepinephrine can functionally interact with D4R.  To our knowledge, significant interactions between norepinephrine and D2R or D3R receptors have not been demonstrated.  By using radioligand binding and bioluminescent resonance energy transfer (BRET) assays in transfected cells, the present study attempted a careful comparison between dopamine and norepinephrine in their possible activation of all D2-like receptors, including the two D2R isoforms and the most common D4R polymorphic variants.  Functional BRET assays included activation of G proteins with all Gαi/o subunits, adenylyl cyclase inhibition, and β arrestin recruitment.  Norepinephrine acted as a potent agonist for all D2-like receptor subtypes, with the general rank order of potency of D3R > D4R ≥ D2SR ≥ D2L.  However, for both dopamine and norepinephrine, differences depended on the Gαi/o protein subunit involved.  The most striking differenceswere obsd. with Gαi2, where the rank order of potencies for both dopamine and norepinephrine were D4R > D2SR = D2LR >> D3R.  Furthermore the results do not support the existence of differences in the ability of dopamine and norepinephrine to activate different human D4R variants.  The potency of norepinephrine for adrenergic α2A receptor was only about 20-fold higher compared with D3R and D4R across the three functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbXqWDRdlAsrVg90H21EOLACvtfcHk0lhScCGhvXR_PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN&md5=df11300a8c0bb71ef35b5d2917bee471</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101808%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Soto%26aufirst%3DM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DH.%26atitle%3DEvidence%2520for%2520noncanonical%2520neurotransmitter%2520activation%253A%2520norepinephrine%2520as%2520a%2520dopamine%2520D2-like%2520receptor%2520agonist%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D457%26epage%3D466%26doi%3D10.1124%2Fmol.115.101808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urs, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span> <span> </span><span class="NLM_article-title">Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E8178</span>– <span class="NLM_lpage">E8186</span>, <span class="refDoi"> DOI: 10.1073/pnas.1614347113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1073%2Fpnas.1614347113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27911814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOgs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E8178-E8186&author=N.+M.+Ursauthor=S.+M.+Geeauthor=T.+F.+Packauthor=J.+D.+McCorvyauthor=T.+Evronauthor=J.+C.+Snyderauthor=X.+Yangauthor=R.+M.+Rodriguizauthor=E.+Borrelliauthor=W.+C.+Wetselauthor=J.+Jinauthor=B.+L.+Rothauthor=P.+O%E2%80%99Donnellauthor=M.+G.+Caron&title=Distinct+cortical+and+striatal+actions+of+a+beta-arrestin-biased+dopamine+D2+receptor+ligand+reveal+unique+antipsychotic-like+properties&doi=10.1073%2Fpnas.1614347113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties</span></div><div class="casAuthors">Urs, Nikhil M.; Gee, Steven M.; Pack, Thomas F.; McCorvy, John D.; Evron, Tama; Snyder, Joshua C.; Yang, Xiaobao; Rodriguiz, Ramona M.; Borrelli, Emiliana; Wetsel, William C.; Jin, Jian; Roth, Bryan L.; O'Donnell, Patricio; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">E8178-E8186</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The current dopamine (DA) hypothesis of schizophrenia postulates striatal hyperdopaminergia and cortical hypodopaminergia.  Although partial agonists at DA D2 receptors (D2Rs), like aripiprazole, were developed to simultaneously target both phenomena, they do not effectively improve cortical dysfunction.  In this study, we investigate the potential for newly developed β-arrestin2 (βarr2)-biased D2R partial agonists to simultaneously target hyper- and hypodopaminergia.  Using neuron-specific βarr2-KO mice, we show that the antipsychotic-like effects of a βarr2-biased D2R ligand are driven through both striatal antagonism and cortical agonism of D2R-βarr2 signaling.  Furthermore, βarr2-biased D2R agonism enhances firing of cortical fast-spiking interneurons.  This enhanced cortical agonism of the biased ligand can be attributed to a lack of G-protein signaling and elevated expression of βarr2 and G protein-coupled receptor (GPCR) kinase 2 in the cortex vs. the striatum.  Therefore, we propose that βarr2-biased D2R ligands that exert region-selective actions could provide a path to develop more effective antipsychotic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8kMnf0ZjPbVg90H21EOLACvtfcHk0ljMYy7YVRmFVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOgs7rL&md5=872fc6c6026a01fa4d48bad545f51b61</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1614347113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1614347113%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DGee%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DEvron%26aufirst%3DT.%26aulast%3DSnyder%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DBorrelli%26aufirst%3DE.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDistinct%2520cortical%2520and%2520striatal%2520actions%2520of%2520a%2520beta-arrestin-biased%2520dopamine%2520D2%2520receptor%2520ligand%2520reveal%2520unique%2520antipsychotic-like%2520properties%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE8178%26epage%3DE8186%26doi%3D10.1073%2Fpnas.1614347113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D(2) receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7141</span>– <span class="NLM_lpage">7153</span>, <span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-functional+selectivity+relationship+studies+of+beta-arrestin-biased+dopamine+D%282%29+receptor+agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D2 Receptor Agonists</span></div><div class="casAuthors">Chen, Xin; Sassano, Maria F.; Zheng, Lianyou; Setola, Vincent; Chen, Meng; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7141-7153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side effects of drugs.  However, few such ligands have been created, and very little purposeful attention has been devoted to studying what we term: "structure-functional selectivity relationships" (SFSR).  We recently disclosed the first β-arrestin-biased dopamine D2 receptor (D2R) agonists UNC9975 (44) and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities.  Here we report the first comprehensive SFSR studies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery of these β-arrestin-biased D2R agonists.  These studies provide a successful proof-of-concept for how functionally selective ligands can be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoG1fasQ6GLVg90H21EOLACvtfcHk0ljMYy7YVRmFVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK&md5=00b0613e62ce7b5a4c98cb5212fea3b5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-functional%2520selectivity%2520relationship%2520studies%2520of%2520beta-arrestin-biased%2520dopamine%2520D%25282%2529%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armarego, W. L. F.</span>; <span class="NLM_string-name">Chai, C.</span></span> <i>Purification of Laboratory Chemicals</i>, <span class="NLM_edition">6</span>th ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Burlington</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2FB978-1-85617-567-8.50011-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.+L.+F.+Armarego&author=C.+Chai&title=Purification+of+Laboratory+Chemicals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FB978-1-85617-567-8.50011-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-1-85617-567-8.50011-1%26sid%3Dliteratum%253Aachs%26aulast%3DArmarego%26aufirst%3DW.%2BL.%2BF.%26btitle%3DPurification%2520of%2520Laboratory%2520Chemicals%26pub%3DElsevier%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung-Chi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Alessandro Bonifazi, Francisco O. Battiti, Julie Sanchez, Saheem A. Zaidi, Eric Bow, Mariia Makarova, Jianjing Cao, Anver Basha Shaik, Agnieszka Sulima, Kenner C. Rice, Vsevolod Katritch, Meritxell Canals, J. Robert Lane, <span class="NLM_string-name hlFld-ContribAuthor">Amy Hauck Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7778-7808. <a href="https://doi.org/10.1021/acs.jmedchem.1c00611" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00611</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00611%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BDual-Target%252B%2525CE%2525BC-Opioid%252BReceptor%252Band%252BDopamine%252BD3%252BReceptor%252BLigands%252Bas%252BPotential%252BNonaddictive%252BPharmacotherapeutics%252Bfor%252BPain%252BManagement%26aulast%3DBonifazi%26aufirst%3DAlessandro%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D02042021%26date%3D20052021%26volume%3D64%26issue%3D11%26spage%3D7778%26epage%3D7808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Femke A. Meijer, Guido J.M. Oerlemans, <span class="NLM_string-name hlFld-ContribAuthor">Luc Brunsveld</span>. </span><span class="cited-content_cbyCitation_article-title">Orthosteric and Allosteric Dual Targeting of the Nuclear Receptor RORγt with a Bitopic Ligand. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 510-519. <a href="https://doi.org/10.1021/acschembio.0c00941" title="DOI URL">https://doi.org/10.1021/acschembio.0c00941</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.0c00941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.0c00941%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DOrthosteric%252Band%252BAllosteric%252BDual%252BTargeting%252Bof%252Bthe%252BNuclear%252BReceptor%252BROR%2525CE%2525B3t%252Bwith%252Ba%252BBitopic%252BLigand%26aulast%3DMeijer%26aufirst%3DFemke%2BA.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D06122020%26date%3D08022021%26date%3D17022021%26volume%3D16%26issue%3D3%26spage%3D510%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amy E. Moritz, Alessandro Bonifazi, Adrian M. Guerrero, Vivek Kumar, R. Benjamin Free, J. Robert Lane, Ravi Kumar Verma, Lei Shi, Amy Hauck Newman, <span class="NLM_string-name hlFld-ContribAuthor">David R. Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D3 Dopamine Receptor. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (20)
                                     , 3309-3320. <a href="https://doi.org/10.1021/acschemneuro.0c00425" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00425%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DEvidence%252Bfor%252Ba%252BStereoselective%252BMechanism%252Bfor%252BBitopic%252BActivity%252Bby%252BExtended-Length%252BAntagonists%252Bof%252Bthe%252BD3%252BDopamine%252BReceptor%26aulast%3DMoritz%26aufirst%3DAmy%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09072020%26date%3D24092020%26date%3D05102020%26date%3D24092020%26volume%3D11%26issue%3D20%26spage%3D3309%26epage%3D3320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Francisco O. Battiti, Amy Hauck Newman, <span class="NLM_string-name hlFld-ContribAuthor">Alessandro Bonifazi</span>. </span><span class="cited-content_cbyCitation_article-title">Exception That Proves the Rule: Investigation of Privileged Stereochemistry in Designing Dopamine D3R Bitopic Agonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1956-1964. <a href="https://doi.org/10.1021/acsmedchemlett.9b00660" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00660</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00660%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DException%252BThat%252BProves%252Bthe%252BRule%25253A%252BInvestigation%252Bof%252BPrivileged%252BStereochemistry%252Bin%252BDesigning%252BDopamine%252BD3R%252BBitopic%252BAgonists%26aulast%3DBattiti%26aufirst%3DFrancisco%2BO.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D30122019%26date%3D28022020%26date%3D03032020%26date%3D28022020%26volume%3D11%26issue%3D10%26spage%3D1956%26epage%3D1964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amy E. Moritz, R. Benjamin Free, Warren S. Weiner, Emmanuel O. Akano, Disha Gandhi, Ara Abramyan, Thomas M. Keck, Marc Ferrer, Xin Hu, Noel Southall, Joseph Steiner, Jeffrey Aubé, Lei Shi, Kevin J. Frankowski, <span class="NLM_string-name hlFld-ContribAuthor">David R. Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5526-5567. <a href="https://doi.org/10.1021/acs.jmedchem.0c00424" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00424%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252BOptimization%25252C%252Band%252BCharacterization%252Bof%252BML417%25253A%252BA%252BNovel%252Band%252BHighly%252BSelective%252BD3%252BDopamine%252BReceptor%252BAgonist%26aulast%3DMoritz%26aufirst%3DAmy%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18032020%26date%3D12052020%26date%3D28042020%26volume%3D63%26issue%3D10%26spage%3D5526%26epage%3D5567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liang Tan, Qingtong Zhou, Wenzhong Yan, Jian Sun, Alan P. Kozikowski, Suwen Zhao, Xi-Ping Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4579-4602. <a href="https://doi.org/10.1021/acs.jmedchem.9b01835" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01835</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01835%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BBitopic%252B2-Phenylcyclopropylmethylamine%252B%252528PCPMA%252529%252BDerivatives%252Bas%252BSelective%252BDopamine%252BD3%252BReceptor%252BLigands%26aulast%3DTan%26aufirst%3DLiang%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18112019%26date%3D23042020%26date%3D13042020%26volume%3D63%26issue%3D9%26spage%3D4579%26epage%3D4602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amy Hauck Newman, Francisco O. Battiti, <span class="NLM_string-name hlFld-ContribAuthor">Alessandro Bonifazi</span>. </span><span class="cited-content_cbyCitation_article-title">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 1779-1797. <a href="https://doi.org/10.1021/acs.jmedchem.9b01105" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2016%252BPhilip%252BS.%252BPortoghese%252BMedicinal%252BChemistry%252BLectureship%25253A%252BDesigning%252BBivalent%252Bor%252BBitopic%252BMolecules%252Bfor%252BG-Protein%252BCoupled%252BReceptors.%252BThe%252BWhole%252BIs%252BGreater%252BThan%252Bthe%252BSum%252Bof%252BIts%252BParts%26aulast%3DNewman%26aufirst%3DAmy%2BHauck%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D09072019%26date%3D24092019%26date%3D09092019%26volume%3D63%26issue%3D5%26spage%3D1779%26epage%3D1797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pramisha  Adhikari</span>, <span class="hlFld-ContribAuthor ">Bing  Xie</span>, <span class="hlFld-ContribAuthor ">Ana  Semeano</span>, <span class="hlFld-ContribAuthor ">Alessandro  Bonifazi</span>, <span class="hlFld-ContribAuthor ">Francisco O.  Battiti</span>, <span class="hlFld-ContribAuthor ">Amy H.  Newman</span>, <span class="hlFld-ContribAuthor ">Hideaki  Yano</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (4)
                                     , 570. <a href="https://doi.org/10.3390/biom11040570" title="DOI URL">https://doi.org/10.3390/biom11040570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11040570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11040570%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DChirality%252Bof%252BNovel%252BBitopic%252BAgonists%252BDetermines%252BUnique%252BPharmacology%252Bat%252Bthe%252BDopamine%252BD3%252BReceptor%26aulast%3DAdhikari%26aufirst%3DPramisha%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D4%26spage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roland  Kallenborn</span>, <span class="hlFld-ContribAuthor ">Heinrich  Hühnerfuss</span>, <span class="hlFld-ContribAuthor ">Hassan Y.  Aboul-Enein</span>, <span class="hlFld-ContribAuthor ">Imran  Ali</span>. </span><span class="cited-content_cbyCitation_article-title">Chirality in Environmental Toxicity and Fate Assessments. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 279-305. <a href="https://doi.org/10.1007/978-3-030-62456-9_10" title="DOI URL">https://doi.org/10.1007/978-3-030-62456-9_10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-62456-9_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-62456-9_10%26sid%3Dliteratum%253Aachs%26atitle%3DChirality%252Bin%252BEnvironmental%252BToxicity%252Band%252BFate%252BAssessments%26aulast%3DKallenborn%26aufirst%3DRoland%26date%3D2021%26date%3D2021%26spage%3D279%26epage%3D305%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DChiral%252BEnvironmental%252BPollutants%26aulast%3DKallenborn%26aufirst%3DRoland%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tibor  Stark</span>, <span class="hlFld-ContribAuthor ">Martina  Di Bartolomeo</span>, <span class="hlFld-ContribAuthor ">Roberta  Di Marco</span>, <span class="hlFld-ContribAuthor ">Eva  Drazanova</span>, <span class="hlFld-ContribAuthor ">Chiara Bianca Maria  Platania</span>, <span class="hlFld-ContribAuthor ">Fabio Arturo  Iannotti</span>, <span class="hlFld-ContribAuthor ">Jana  Ruda-Kucerova</span>, <span class="hlFld-ContribAuthor ">Claudio  D'Addario</span>, <span class="hlFld-ContribAuthor ">Lucie  Kratka</span>, <span class="hlFld-ContribAuthor ">Vladimir  Pekarik</span>, <span class="hlFld-ContribAuthor ">Fabiana  Piscitelli</span>, <span class="hlFld-ContribAuthor ">Zuzana  Babinska</span>, <span class="hlFld-ContribAuthor ">Julia  Fedotova</span>, <span class="hlFld-ContribAuthor ">Giovanni  Giurdanella</span>, <span class="hlFld-ContribAuthor ">Salvatore  Salomone</span>, <span class="hlFld-ContribAuthor ">Alexandra  Sulcova</span>, <span class="hlFld-ContribAuthor ">Claudio  Bucolo</span>, <span class="hlFld-ContribAuthor ">Carsten T.  Wotjak</span>, <span class="hlFld-ContribAuthor ">Zenon  Starcuk</span>, <span class="hlFld-ContribAuthor ">Filippo  Drago</span>, <span class="hlFld-ContribAuthor ">Raphael  Mechoulam</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Di Marzo</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Micale</span>. </span><span class="cited-content_cbyCitation_article-title">Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>, 114004. <a href="https://doi.org/10.1016/j.bcp.2020.114004" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114004%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DAltered%252Bdopamine%252BD3%252Breceptor%252Bgene%252Bexpression%252Bin%252BMAM%252Bmodel%252Bof%252Bschizophrenia%252Bis%252Breversed%252Bby%252Bperipubertal%252Bcannabidiol%252Btreatment%26aulast%3DStark%26aufirst%3DTibor%26date%3D2020%26volume%3D177%26spage%3D114004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bitopic drug design based on <b>1</b> as the PP scaffold. The PPs are highlighted in red, the linker portion of the new bitopic analogues is highlighted in green, and all different SPs are highlighted in blue. The SAR studies were focused on (i) O-alkylation of the phenolic region of <b>1</b>, (ii) structural simplification of the PP via removal of the morpholine ring, (iii) preparation of <b>15</b> and subsequent <i>N</i>-alkylation at the morpholine nitrogen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Bitopic drug design based on PP scaffold <b>2</b>. The PP is highlighted in magenta, the linker portions of the new bitopic analogues are highlighted in green, and all the different SPs are highlighted in blue. The structural modifications of the PP focused on <i>N</i>-<i>n</i>-dipropylation at the aniline nitrogen, preparation of the nor-diastereoisomers, and subsequent <i>N</i>-alkylation at the morpholine nitrogen with different linkers and SPs. The linkers used in the SAR studies, to combine PP and SPs, included: (i) <i>n</i>-butyl, (ii) <i>E</i>-butenyl, (iii) <i>cis</i>- and <i>trans</i>-(methyl)cyclopropyl-methyl, and (iv) <i>trans</i>-(methyl)cyclopropyl-ethyl. When necessary, to further investigate SAR, all stereochemical combinations of diastereoisomers and/or enantiomers were prepared.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, KI, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (b) NH<sub>2</sub>NH<sub>2</sub>, EtOH, reflux; (c) DIPEA, EDC, HOBt, ArCOOH, 0 °C to RT; (d) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, KI, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (4-Bromobutoxy)(<i>tert</i>-butyl)dimethylsilane, K<sub>2</sub>CO<sub>3</sub>, EtOH, reflux; (b) 1 M TBAF, THF, RT; (c) DMP, DCM, 0 °C to RT; (d) (i) BrCN, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, microwave 120 °C, 275 psi, 75 W; (ii) 37% HCl/H<sub>2</sub>O (e) cat. AcOH, Na(OAc)<sub>3</sub>BH, <b>14</b>.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 48% HBr in water, reflux; (b) AcOH, Na(OAc)<sub>3</sub>BH, <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> DCE, RT.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) X-ray crystal structure of <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> [C8(<i>R</i>)–C6(<i>S</i>)]; (B) X-ray crystal structure of <b>23a</b>. The assigned absolute configuration for <b>(2<i>R</i>,5<i>S</i>)-23a</b> [C8(<i>R</i>)–C11(<i>S</i>)] and its spectroscopic data matches with the literature.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) AcOH, Na(OAc)<sub>3</sub>BH, propionaldehyde, ACN, reflux; (b) resolution via flash chromatography; (c) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, KI (cat.), K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (d) AcOH, Na(OAc)<sub>3</sub>BH, <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> DCE, RT.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) HG-II Grubb’s catalyst, DCM; (b) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, KI, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (c) <b>23a</b> or <b>23b</b>, K<sub>2</sub>CO<sub>3</sub>, ACN, reflux.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) LiAlH<sub>4</sub>, THF, 0 °C to RT; (b) indole-2-carboxylic acid, DIPEA, EDC, HOBt, DCM, 0 °C to RT; (c) diastereoisomer separation via flash chromatography; (d) DMP, DCM, 0 °C to RT; (e) cat. AcOH, Na(OAc)<sub>3</sub>BH, <b>23a</b> or <b>23b</b>, DCE; (f) chiral resolution via preparative chiral HPLC (AD-H column) or flash chromatography.</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>a) CH<sub>3</sub>NO<sub>2</sub>, <i>t</i>-BuOLi, <i>t</i>-BuOH/THF, 0 °C to RT; (b) MsCl, TEA, DCM, 0 °C to RT, followed by preparative chiral HPLC resolution; (c) LAH, THF, 0 °C to reflux; (d) EDC, HOBt, DIPEA, THF, 0 °C to RT; (e) DMP, DCM, RT.</p></p></figure><figure data-id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (+)-DIP, <sup><i>t</i></sup>BuOMe/THF (7:3), −40 °C to RT; (b) K<sub>2</sub>CO<sub>3</sub>, ACN, reflux; (c) (<i>S</i>)-2-aminopropan-1-ol, toluene, reflux; (d) <i>N</i>-(benzyloxycarbonyloxy)succinimide, THF, −40 °C to RT; (e) DIAD, PPh<sub>3</sub>, toluene, RT; (f) hydroxylamine hydrochloride (NH<sub>2</sub>OH·HCl), EtOH, reflux; (g) H<sub>2</sub> (50 psi), Pd(OH)<sub>2</sub>/C; (h) cat. AcOH, Na(OAc)<sub>3</sub>BH, <i>N</i>-(2-(2-formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref12 ref36'); return false;" href="javascript:void(0);" class="ref ref12 ref36">(12,36)</a> DCE; (i) chiral resolution via preparative chiral HPLC-ADH; (j) chiral resolution via preparative chiral HPLC-ADH; (k) DMP, DCM, 0 °C to RT; (l) cat. AcOH, Na(OAc)<sub>3</sub>BH.</p></p></figure><figure data-id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) K<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-DMF, 90 °C.</p></p></figure><figure data-id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/medium/jm-2019-00702u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Metabolic stability of <b>53</b>. The compound shows moderate instability to phase I metabolism in rat liver microsomes fortified with NADPH. Compound <b>53</b> shows complete stability in the negative control without NADPH. (B) Metabolite Identification of <b>53</b> following phase I metabolic stability using high-resolution MS. The major phase I metabolite was determined to be the hydroxylated product (<i>m</i>/<i>z</i> = 450.2498; *note the position assigned to the hydroxyl group is arbitrary). Minor metabolites were identified to be N-dealkylation (<i>m</i>/<i>z</i> = 194.1288) and the oxidation (<i>m</i>/<i>z</i> = 432.2293) products.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00702/20190705/images/large/jm-2019-00702u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00702&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45648" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45648" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">The physiology, signaling, and pharmacology of dopamine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fpr.110.002642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=21303898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=182-217&author=J.-M.+Beaulieuauthor=R.+R.+Gainetdinov&title=The+physiology%2C+signaling%2C+and+pharmacology+of+dopamine+receptors&doi=10.1124%2Fpr.110.002642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, signaling, and pharmacology of dopamine receptors</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-217</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiol. functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension.  Pharmacol. agents targeting dopaminergic neurotransmission have been clin. used in the management of several neurol. and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD1), and Tourette's syndrome.  Numerous advances have occurred in understanding the general structural, biochem., and functional properties of dopamine receptors that have led to the development of multiple pharmacol. active compds. that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics.  Recent progress in understanding the complex biol. of dopamine receptor-related signal transduction mechanisms has revealed that, in addn. to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins.  One of the future directions in managing dopamine-related pathol. conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacol.  In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms.  In addn., we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacol. and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp84qmbSbA7Vg90H21EOLACvtfcHk0lgvavroKCO8Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D&md5=53e6841062c98abe60c732692109e498</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002642%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.-M.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DThe%2520physiology%252C%2520signaling%252C%2520and%2520pharmacology%2520of%2520dopamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D182%26epage%3D217%26doi%3D10.1124%2Fpr.110.002642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span> <span> </span><span class="NLM_article-title">Targeting the dopamine D3 receptor: an overview of drug design strategies</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1185413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1080%2F17460441.2016.1185413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27135354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=641-664&author=A.+Cort%C3%A9sauthor=E.+Morenoauthor=M.+Rodr%C3%ADguez-Ruizauthor=E.+I.+Canelaauthor=V.+Casad%C3%B3&title=Targeting+the+dopamine+D3+receptor%3A+an+overview+of+drug+design+strategies&doi=10.1080%2F17460441.2016.1185413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D3 receptor: an overview of drug design strategies</span></div><div class="casAuthors">Cortes, Antoni; Moreno, Estefania; Rodriguez-Ruiz, Mar; Canela, Enric I.; Casado, Vicent</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">641-664</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter widely distributed in both the periphery and the central nervous system (CNS).  Its physiol. effects are mediated by five closely related G protein-coupled receptors (GPCRs) that are divided into two major subclasses: the D1-like (D1, D5) and the D2-like (D2, D3, D4) receptors.  D3 receptors (D3Rs) have the highest d. in the limbic areas of the brain, which are assocd. with cognitive and emotional functions.  These receptors are therefore attractive targets for therapeutic management.  This review summarizes the functional and pharmacol. characteristics of D3Rs, including the design and clin. relevance of full agonists, partial agonists and antagonists, as well as the capacity of these receptors to form active homodimers, heterodimers or higher order receptor complexes as pharmacol. targets in several neurol. and neurodegenerative disorders.  The high sequence homol. between D3R and the D2-type challenges the development of D3R-selective compds.  The design of new D3R-preferential ligands with improved physicochem. properties should provide a better pharmacokinetic/bioavailability profile and lesser toxicity than is found with existing D3R ligands.  It is also essential to optimize D3R affinity and, esp., D3R vs.  D2-type binding and functional selectivity ratios.  Developing allosteric and bitopic ligands should help to improve the D3R selectivity of these drugs.  As most evidence points to the ability of GPCRs to form homomers and heteromers, the most promising therapeutic strategy in the future is likely to involve the application of heteromer-selective drugs.  These selective ligands would display different affinities for a given receptor depending on the receptor partners within the heteromer.  Therefore, designing novel compds. that specifically target and modulate D1R-D3R heteromers would be an interesting approach for the treatment of levodopa (L-DOPA)-induced dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE412vMxQCZ7Vg90H21EOLACvtfcHk0lgvavroKCO8Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D&md5=eda2d0b52e03bbca2d62f1b27b193360</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1185413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1185413%26sid%3Dliteratum%253Aachs%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez-Ruiz%26aufirst%3DM.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520dopamine%2520D3%2520receptor%253A%2520an%2520overview%2520of%2520drug%2520design%2520strategies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D641%26epage%3D664%26doi%3D10.1080%2F17460441.2016.1185413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Beyond Small-Molecule SAR</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1016/b978-0-12-420118-7.00007-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fb978-0-12-420118-7.00007-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=24484980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=267-300&author=T.+M.+Keckauthor=C.+Burzynskiauthor=L.+Shiauthor=A.+H.+Newman&title=Beyond+Small-Molecule+SAR&doi=10.1016%2Fb978-0-12-420118-7.00007-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design</span></div><div class="casAuthors">Keck, Thomas M.; Burzynski, Caitlin; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse</span>),
    <span class="NLM_cas:pages">267-300</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor is a target of pharmacotherapeutic interest in a variety of neurol. disorders including schizophrenia, restless leg syndrome, and drug addiction.  The high protein sequence homol. between the D3 and D2 receptors has posed a challenge to developing D3 receptor-selective ligands whose behavioral actions can be attributed to D3 receptor engagement, in vivo.  However, through primarily small-mol. structure-activity relationship (SAR) studies, a variety of chem. scaffolds have been discovered over the past two decades that have resulted in several D3 receptor-selective ligands with high affinity and in vivo activity.  Nevertheless, viable clin. candidates remain limited.  The recent detn. of the high-resoln. crystal structure of the D3 receptor has invigorated structure-based drug design, providing refinements to the mol. dynamic models and testable predictions about receptor-ligand interactions.  This chapter will highlight recent preclin. and clin. studies demonstrating potential utility of D3 receptor-selective ligands in the treatment of addiction.  In addn., new structure-based rational drug design strategies for D3 receptor-selective ligands that complement traditional small-mol. SAR to improve the selectivity and directed efficacy profiles are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbH7VLMIagF7Vg90H21EOLACvtfcHk0lias5RbfzLAhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D&md5=d266814a068e4528c70e200a860fab64</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fb978-0-12-420118-7.00007-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fb978-0-12-420118-7.00007-x%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DBeyond%2520Small-Molecule%2520SAR%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2014%26volume%3D69%26spage%3D267%26epage%3D300%26doi%3D10.1016%2Fb978-0-12-420118-7.00007-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+Won+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lias5RbfzLAhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWon%2BHan%26aufirst%3DG.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0lias5RbfzLAhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">D4 dopamine receptor high-resolution structures enable the discovery of selective agonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1126/science.aan5468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1126%2Fscience.aan5468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29051383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kns73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2017&pages=381-386&author=S.+Wangauthor=D.+Wackerauthor=A.+Levitauthor=T.+Cheauthor=R.+M.+Betzauthor=J.+D.+McCorvyauthor=A.+J.+Venkatakrishnanauthor=X.-P.+Huangauthor=R.+O.+Drorauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=D4+dopamine+receptor+high-resolution+structures+enable+the+discovery+of+selective+agonists&doi=10.1126%2Fscience.aan5468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">D4 dopamine receptor high-resolution structures enable the discovery of selective agonists</span></div><div class="casAuthors">Wang, Sheng; Wacker, Daniel; Levit, Anat; Che, Tao; Betz, Robin M.; McCorvy, John D.; Venkatakrishnan, A. J.; Huang, Xi-Ping; Dror, Ron O.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6361</span>),
    <span class="NLM_cas:pages">381-386</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine receptors are implicated in the pathogenesis and treatment of nearly every neuropsychiatric disorder.  Although thousands of drugs interact with these receptors, our mol. understanding of dopaminergic drug selectivity and design remains clouded.  To illuminate dopamine receptor structure, function, and ligand recognition, we detd. crystal structures of the D4 dopamine receptor in its inactive state bound to the antipsychotic drug nemonapride, with resolns. up to 1.95 angstroms.  These structures suggest a mechanism for the control of constitutive signaling, and their unusually high resoln. enabled a structure-based campaign for new agonists of the D4 dopamine receptor.  The ability to efficiently exploit structure for specific probe discovery-rapidly moving from elucidating receptor structure to discovering previously unrecognized, selective agonists-testifies to the power of structure-based approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8NDKhkv_ILbVg90H21EOLACvtfcHk0lg542MRB6fMmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kns73I&md5=0bbb93e6bcb33577f9d9b7459273d896</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.aan5468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aan5468%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DD4%2520dopamine%2520receptor%2520high-resolution%2520structures%2520enable%2520the%2520discovery%2520of%2520selective%2520agonists%26jtitle%3DScience%26date%3D2017%26volume%3D358%26spage%3D381%26epage%3D386%26doi%3D10.1126%2Fscience.aan5468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, G. A.</span></span> <span> </span><span class="NLM_article-title">Abnormalities of dopamine D3 receptor signaling in the diseased brain</span>. <i>J. Cent. Nerv. Syst. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1179573517726335</span>, <span class="refDoi"> DOI: 10.1177/1179573517726335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1177%2F1179573517726335" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1179573517726335&author=G.+A.+Prieto&title=Abnormalities+of+dopamine+D3+receptor+signaling+in+the+diseased+brain&doi=10.1177%2F1179573517726335"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1177%2F1179573517726335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1179573517726335%26sid%3Dliteratum%253Aachs%26aulast%3DPrieto%26aufirst%3DG.%2BA.%26atitle%3DAbnormalities%2520of%2520dopamine%2520D3%2520receptor%2520signaling%2520in%2520the%2520diseased%2520brain%26jtitle%3DJ.%2520Cent.%2520Nerv.%2520Syst.%2520Dis.%26date%3D2017%26volume%3D9%26spage%3D1179573517726335%26doi%3D10.1177%2F1179573517726335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2010.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.tips.2010.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=21232805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=148-157&author=S.+L%C3%B6berauthor=H.+H%C3%BCbnerauthor=N.+Tschammerauthor=P.+Gmeiner&title=Recent+advances+in+the+search+for+D3-+and+D4-selective+drugs%3A+probes%2C+models+and+candidates&doi=10.1016%2Fj.tips.2010.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates</span></div><div class="casAuthors">Lober Stefan; Hubner Harald; Tschammer Nuska; Gmeiner Peter</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopamine D(2)-like receptors (including D(2), D(3) and D(4)) belong to the 'rhodopsin-like' family of G protein-coupled receptors (GPCRs), which represent the largest group of targets for bioactive molecules.  Due to their high sequence similarity, the design of subtype-selective ligands requires rational and effective strategies.  The general formula of 1,4-disubstituted aromatic piperidines and piperazines (1,4-DAPs) was extracted from classical dopaminergic drugs.  The biological properties of this compound family are encoded by an aromatic head group that controls intrinsic activity, an amine moiety and a lipophilic appendage.  D(3)- and D(4)-selective molecular probes and drug candidates were generated from the general formula of 1,4-DAP.  Formal structural rearrangement led to investigational drugs beyond the 1,4-DAP structure.  The very recent publication of the X-ray crystal structure of D(3) should facilitate efficient discovery of unprecedented chemotypes.  However, the development of D(3)-selective agonists, functionally selective ligands and the exploitation of homo- and heteromers remain challenging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJYDidIFGFwMjl5L8hwNX0fW6udTcc2eZxDn45FMuZTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D&md5=9b688525eaa75c6d965b634617c16d70</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DRecent%2520advances%2520in%2520the%2520search%2520for%2520D3-%2520and%2520D4-selective%2520drugs%253A%2520probes%252C%2520models%2520and%2520candidates%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D148%26epage%3D157%26doi%3D10.1016%2Fj.tips.2010.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platania, C. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">Current drug treatments targeting dopamine D3 receptor</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.pharmthera.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27343365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=164-177&author=G.+M.+Leggioauthor=C.+Bucoloauthor=C.+B.+M.+Plataniaauthor=S.+Salomoneauthor=F.+Drago&title=Current+drug+treatments+targeting+dopamine+D3+receptor&doi=10.1016%2Fj.pharmthera.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug treatments targeting dopamine D3 receptor</span></div><div class="casAuthors">Leggio, Gian Marco; Bucolo, Claudio; Platania, Chiara Bianca Maria; Salomone, Salvatore; Drago, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164-177</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dopamine receptors (DR) have been extensively studied, but only in recent years they became object of investigation to elucidate the specific role of different subtypes (D1R, D2R, D3R, D4R, D5R) in neural transmission and circuitry.  D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D2R and D4R) differ in signal transduction, binding profile, localization in the central nervous system and physiol. effects.  D3R is involved in a no. of pathol. conditions, including schizophrenia, Parkinson's disease, addiction, anxiety, depression and glaucoma.  Development of selective D3R ligands has been so far challenging, due to the high sequence identity and homol. shared by D2R and D3R.  As a consequence, despite a rational design of selective DR ligands has been carried out, none of currently available medicines selectively target a given D2-like receptor subtype.  The availability of the D3R ligand [11C]-(+)-PHNO for positron emission tomog. studies in animal models as well as in humans, allows researchers to est. the expression of D3R in vivo; displacement of [11C]-(+)-PHNO binding by concurrent drug treatments is used to est. the in vivo occupancy of D3R.  Here we provide an overview of studies indicating D3R as a target for pharmacol. therapy, and a review of market approved drugs endowed with significant affinity at D3R that are used to treat disorders where D3R plays a relevant role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripJ2xDVYRubVg90H21EOLACvtfcHk0liOwKddXh1K0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF&md5=e29dffe5b17b48f68d33ec838ece35dc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DBucolo%26aufirst%3DC.%26aulast%3DPlatania%26aufirst%3DC.%2BB.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DCurrent%2520drug%2520treatments%2520targeting%2520dopamine%2520D3%2520receptor%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D164%26epage%3D177%26doi%3D10.1016%2Fj.pharmthera.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">11271</span>– <span class="NLM_lpage">11275</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.23.11271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1073%2Fpnas.91.23.11271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=7972046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11271-11275&author=A.+M.+Murrayauthor=H.+L.+Ryooauthor=E.+Gurevichauthor=J.+N.+Joyce&title=Localization+of+dopamine+D3+receptors+to+mesolimbic+and+D2+receptors+to+mesostriatal+regions+of+human+forebrain&doi=10.1073%2Fpnas.91.23.11271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain</span></div><div class="casAuthors">Murray, Angela M.; Ryoo, Han L.; Gurevich, Eugenia; Joyce, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11271-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We characterized the binding of [125I]epidepride to dopamine D2-like and D3-like receptors in tissue sections of human striatum.  The competition for binding of [125I]epidepride by domperidone, quinpirole, and 7-hydroxy-N,N-di(1-propyl)-2-aminotetralin (7-OH-DPAT) was best fit by assuming one site in the caudate but two sites in nucleus accumbens.  Guanosine 5'-[β,γ-imido]triphosphate showed a large modulatory influence in agonist inhibition of [125I]epidepride binding in caudate but not in nucleus accumbens.  The binding of [125I]epidepride in the presence of 7-OH-DPAT (1000-fold selective for D3-like vs. D2-like sites) and domperidone (20-fold selective for D2 vs. D3-like sites) was used to quantify the nos. of D2-like and D3-like receptors in areas of human brain.  The distribution of D2-like and D3-like receptors was largely nonoverlapping.  Binding of [125I]epidepride to D3-like receptors was negligible in the dorsal striatum but was concd. in islands of dense binding in the nucleus accumbens and ventral putamen that aligned with acetylcholinesterase-poor striosomes.  Binding to D3-like receptors was also enriched in the internal globus pallidus, ventral palladium, septum, islands of Calleja, nucleus basalis, amygdalostriatal transition nucleus of the amygdala, central nucleus of the amygdala, and ventral tegmental area.  Binding of [125I]epidepride to D2 but not D3 receptors was detected in cortex and hippocampus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXhwrtC4swVrVg90H21EOLACvtfcHk0liOwKddXh1K0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D&md5=229c93d0b8695eb673e9c7265a1d574f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.23.11271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.23.11271%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DA.%2BM.%26aulast%3DRyoo%26aufirst%3DH.%2BL.%26aulast%3DGurevich%26aufirst%3DE.%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DLocalization%2520of%2520dopamine%2520D3%2520receptors%2520to%2520mesolimbic%2520and%2520D2%2520receptors%2520to%2520mesostriatal%2520regions%2520of%2520human%2520forebrain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D11271%26epage%3D11275%26doi%3D10.1073%2Fpnas.91.23.11271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7650</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7634-7650&author=V.+Kumarauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=E.+Pommierauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+Gardnerauthor=Z.-B.+Youauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Highly+selective+dopamine+D3+receptor+%28D3R%29+antagonists+and+partial+agonists+based+on+eticlopride+and+the+D3R+crystal+structure%3A+new+leads+for+opioid+dependence+treatment&doi=10.1021%2Facs.jmedchem.6b00860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment</span></div><div class="casAuthors">Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Pommier, Elie; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot; You, Zhi-Bing; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7634-7650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention.  Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clin. use for cocaine abuse.  Herein, the authors report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies.  Lead compd. I was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R vs. D2R binding selectivity, and its metabolic stability in mouse microsomes.  Compd. I inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.  In addn., pretreatment with I also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats.  These findings support the D3R as a target for opioid dependence treatment and compd. I as a new lead mol. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyb_lyL223q7Vg90H21EOLACvtfcHk0liOwKddXh1K0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN&md5=c352556630974f4205a8684b4fd29226</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00860%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520antagonists%2520and%2520partial%2520agonists%2520based%2520on%2520eticlopride%2520and%2520the%2520D3R%2520crystal%2520structure%253A%2520new%2520leads%2520for%2520opioid%2520dependence%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7634%26epage%3D7650%26doi%3D10.1021%2Facs.jmedchem.6b00860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1478-1494&author=V.+Kumarauthor=A.+E.+Moritzauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=C.+D.+Sibleyauthor=R.+B.+Freeauthor=L.+Shiauthor=J.+R.+Laneauthor=D.+R.+Sibleyauthor=A.+H.+Newman&title=Synthesis+and+pharmacological+characterization+of+novel+trans-cyclopropylmethyl-linked+bivalent+ligands+that+exhibit+selectivity+and+allosteric+pharmacology+at+the+dopamine+D3+receptor+%28D3R%29&doi=10.1021%2Facs.jmedchem.6b01688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)</span></div><div class="casAuthors">Kumar, Vivek; Moritz, Amy E.; Keck, Thomas M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Sibley, Christopher D.; Free, R. Benjamin; Shi, Lei; Lane, J. Robert; Sibley, David R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1478-1494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bitopic ligands directed toward D2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies.  The structural similarities between dopamine D3 receptor (D3R)-selective mols. that display bitopic or allosteric pharmacol. and those that are simply competitive antagonists are subtle and intriguing.  Herein the authors synthesized a series of mols. in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 and SB277011A whose structural similarity and pharmacol. disparity provided the perfect templates for SAR investigation.  Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, I and II, which further delineates SAR assocd. with allosterism at D3R and provides leads toward novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PUM_XBYBsLVg90H21EOLACvtfcHk0lio0Nq3EG_0QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D&md5=de385d8d9699e2d37a56974382989a19</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01688%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DSibley%26aufirst%3DC.%2BD.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520trans-cyclopropylmethyl-linked%2520bivalent%2520ligands%2520that%2520exhibit%2520selectivity%2520and%2520allosteric%2520pharmacology%2520at%2520the%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1478%26epage%3D1494%26doi%3D10.1021%2Facs.jmedchem.6b01688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward understanding the structural basis of partial agonism at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=580-593&author=M.+Michinoauthor=C.+A.+Boatengauthor=P.+Donthamsettiauthor=H.+Yanoauthor=O.+M.+Bakareauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=V.+Kumarauthor=C.+Zhuauthor=R.+Vermaauthor=J.+R.+Deschampsauthor=J.+A.+Javitchauthor=A.+H.+Newmanauthor=L.+Shi&title=Toward+understanding+the+structural+basis+of+partial+agonism+at+the+dopamine+D3+receptor&doi=10.1021%2Facs.jmedchem.6b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor</span></div><div class="casAuthors">Michino, Mayako; Boateng, Comfort A.; Donthamsetti, Prashant; Yano, Hideaki; Bakare, Oluyomi M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Kumar, Vivek; Zhu, Clare; Verma, Ravi; Deschamps, Jeffrey R.; Javitch, Jonathan A.; Newman, Amy Hauck; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders.  In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions.  Here, the authors report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious.  To investigate the structural basis of partial agonism, the authors performed comparative microsecond-scale mol. dynamics simulations starting from the inactive state of D3R in complex with these enantiomers.  Anal. of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations.  These receptor models bound with partial agonists may be useful for structure-based design of compds. with tailored efficacy profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELFqc0pAf8LVg90H21EOLACvtfcHk0lio0Nq3EG_0QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK&md5=91e378048c5dfd4c44fb54746a2e1df2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01148%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520partial%2520agonism%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D580%26epage%3D593%26doi%3D10.1021%2Facs.jmedchem.6b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5361</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+medication+targets+for+psychostimulant+addiction%3A+unraveling+the+dopamine+D3+receptor+hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0ljMipo0gOdQSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520medication%2520targets%2520for%2520psychostimulant%2520addiction%253A%2520unraveling%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maramai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">451</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.3389%2Ffnins.2016.00451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27761108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=451&author=S.+Maramaiauthor=S.+Gemmaauthor=S.+Brogiauthor=G.+Campianiauthor=S.+Butiniauthor=H.+Starkauthor=M.+Brindisi&title=Dopamine+D3+receptor+antagonists+as+potential+therapeutics+for+the+treatment+of+neurological+diseases&doi=10.3389%2Ffnins.2016.00451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases</span></div><div class="casAuthors">Maramai Samuele; Gemma Sandra; Brogi Simone; Campiani Giuseppe; Butini Stefania; Brindisi Margherita; Stark Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">D3 receptors represent a major focus of current drug design and development of therapeutics for dopamine-related pathological states.  Their close homology with the D2 receptor subtype makes the development of D3 selective antagonists a challenging task.  In this review, we explore the relevance and therapeutic utility of D3 antagonists or partial agonists endowed with multireceptor affinity profile in the field of central nervous system disorders such as schizophrenia and drug abuse.  In fact, the peculiar distribution and low brain abundance of D3 receptors make them a valuable target for the development of drugs devoid of motor side effects classically elicited by D2 antagonists.  Recent research efforts were devoted to the conception of chemical templates possibly endowed with a multi-target profile, especially with regards to other G-protein-coupled receptors (GPCRs).  A comprehensive overview of the recent literature in the field is herein provided.  In particular, the evolution of the chemical templates has been tracked, according to the growing advancements in both the structural information and the refinement of the key pharmacophoric elements.  The receptor/multireceptor affinity and functional profiles for the examined compounds have been covered, together with their most significant pharmacological applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdsZ2fFId2JDslzEEsg76ufW6udTcc2eZaQfqVUJze67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D&md5=03b1e02b49ea48ab9331f5c9d38dfaf1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00451%26sid%3Dliteratum%253Aachs%26aulast%3DMaramai%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonists%2520as%2520potential%2520therapeutics%2520for%2520the%2520treatment%2520of%2520neurological%2520diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D451%26doi%3D10.3389%2Ffnins.2016.00451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders</span>. <i>Ann. N.Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1187</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05149.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1111%2Fj.1749-6632.2009.05149.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=20201845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=4-34&author=C.+A.+Heidbrederauthor=A.+H.+Newman&title=Current+perspectives+on+selective+dopamine+D%283%29+receptor+antagonists+as+pharmacotherapeutics+for+addictions+and+related+disorders&doi=10.1111%2Fj.1749-6632.2009.05149.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders</span></div><div class="casAuthors">Heidbreder, Christian A.; Newman, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">4-34</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Repeated exposure to drugs of abuse produces long-term mol. and neurochem. changes that may explain the core features of addiction, such as the compulsive seeking and taking of the drug, as well as the risk of relapse.  A growing no. of new mol. and cellular targets of addictive drugs have been identified, and rapid advances are being made in relating those targets to specific behavioral phenotypes in animal models of addiction.  In this context, the pattern of expression of the dopamine (DA) D3 receptor in the rodent and human brain and changes in this pattern in response to drugs of abuse have contributed primarily to direct research efforts toward the development of selective DA D3 receptor antagonists.  Growing preclin. evidence indicates that these compds. may actually regulate the motivation to self-administer drugs and disrupt drug-assocd. cue-induced craving.  This report will be divided into three parts.  First, preclin. evidence in support of the efficacy of selective DA D3 receptor antagonists in animal models of drug addiction will be reviewed.  The effects of mixed DA D2/D3 receptor antagonists will not be discussed here because most of these compds. have low selectivity at the D3 vs. D2 receptor, and their efficacy profile is related primarily to functional antagonism at D2 receptors and possibly interactions with other neurotransmitter systems.  Second, major advances in medicinal chem. for the identification and optimization of selective DA D3 receptor antagonists and partial agonists will be analyzed.  Third, translational research from preclin. efficacy studies to so-called proof-of-concept studies for drug addiction indications will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarcQYm33s6LVg90H21EOLACvtfcHk0ljMipo0gOdQSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D&md5=48ded12d27f36b8d77717b118ccfa869</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05149.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05149.x%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DCurrent%2520perspectives%2520on%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520antagonists%2520as%2520pharmacotherapeutics%2520for%2520addictions%2520and%2520related%2520disorders%26jtitle%3DAnn.%2520N.Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D4%26epage%3D34%26doi%3D10.1111%2Fj.1749-6632.2009.05149.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonsai, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendpara, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, G. M.</span></span> <span> </span><span class="NLM_article-title">Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure</span>. <i>J. Clin. Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1111/jcpt.12649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1111%2Fjcpt.12649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29119585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVyrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1-7&author=N.+H.+Gonsaiauthor=V.+H.+Aminauthor=C.+G.+Mendparaauthor=R.+Spethauthor=G.+M.+Hale&title=Effects+of+dopamine+receptor+antagonist+antipsychotic+therapy+on+blood+pressure&doi=10.1111%2Fjcpt.12649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure</span></div><div class="casAuthors">Gonsai, N. H.; Amin, V. H.; Mendpara, C. G.; Speth, R.; Hale, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacy and Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">JCPTED</span>;
        ISSN:<span class="NLM_cas:issn">0269-4727</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : What is known and Objective : Hypertension, a major risk factor for adverse cardiovascular events, such as stroke and myocardial infarction, affects 80 million American adults.  The etiol. of hypertension is multifaceted and difficult to identify.  Dopamine receptors, esp. those in the kidneys, play a role in blood pressure regulation, and alterations in their function can cause hypertension.  The objective of this review was to investigate the assocn. between the use of dopamine antagonists with hypertension focusing esp. on second-generation antipsychotics, like clozapine that is D4 receptor antagonist.  Methods : A literature review was conducted using MEDLINE, Ovid, Science Direct, Web of Science and Cochrane Database of Systematic Reviews databases with keywords:hypertension, hypotension, renin-angiotensin-aldosterone system, dopaminergic receptors, blood pressure, antipsychotics.  Inclusion criteria were human or animal studies, systematic reviews, meta-analyses, randomized controlled trials, case report/series, published in selected for inclusion.  Results and Discussion : All 5 dopamine receptor subtypes (ie D1, D2, D3, D4 and D5) regulate sodium excretion and BP.  The D1, D3 and D4 receptors interact directly with the renin-angiotensin-aldosterone system, whereas D2 and D5 receptors directly interact with the sympathetic nervous system to regulate BP.  Use of dopaminergic agonists or antagonists could therefore disturb the regulation of BP by dopamine receptors.  What is new and Conclusion : Based upon this review, individuals on antipsychotic agents, particularly clozapine, should be routinely monitored for hypertension, and addn. of antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is indicated if hypertension occurs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok3RAFZIuXabVg90H21EOLACvtfcHk0ljfw_Ytnx2q5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVyrsA%253D%253D&md5=cdd41ab6527c9e2172168427c6f7ff0c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fjcpt.12649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcpt.12649%26sid%3Dliteratum%253Aachs%26aulast%3DGonsai%26aufirst%3DN.%2BH.%26aulast%3DAmin%26aufirst%3DV.%2BH.%26aulast%3DMendpara%26aufirst%3DC.%2BG.%26aulast%3DSpeth%26aufirst%3DR.%26aulast%3DHale%26aufirst%3DG.%2BM.%26atitle%3DEffects%2520of%2520dopamine%2520receptor%2520antagonist%2520antipsychotic%2520therapy%2520on%2520blood%2520pressure%26jtitle%3DJ.%2520Clin.%2520Pharm.%2520Ther.%26date%3D2018%26volume%3D43%26spage%3D1%26epage%3D7%26doi%3D10.1111%2Fjcpt.12649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charbit, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.151951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fjpet.109.151951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=19657051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=752-763&author=A.+R.+Charbitauthor=S.+Akermanauthor=P.+J.+Goadsby&title=Comparison+of+the+effects+of+central+and+peripheral+dopamine+receptor+activation+on+evoked+firing+in+the+trigeminocervical+complex&doi=10.1124%2Fjpet.109.151951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex</span></div><div class="casAuthors">Charbit, Annabelle R.; Akerman, Simon; Goadsby, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">752-763</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dopaminergic mechanisms have been suggested to play a role in migraine.  Here, electrophysiol. techniques were used to study the effects of i.v. administered centrally or peripherally active dopamine receptor agonists and antagonists on evoked firing in the trigeminocervical complex (TCC).  After establishing baseline firing evoked by elec. stimulation of the dural middle meningeal artery (MMA) and mech. noxious and innocuous stimulation of the ophthalmic dermatome, D1- or D2-like receptor agonists or antagonists were administered i.v. and the effect on firing was detd.  In addn., with use of intravital microscopy, we monitored changes in dural vessel diam. in response to varying doses of D1- or D2-like receptor agonists to det. whether their effects were related to blood vessel caliber.  The central D2-like receptor agonist quinpirole hydrochloride inhibited firing in the TCC evoked by stimulation of the MMA.  Conversely, the central D2-like receptor antagonists, eticlopride hydrochloride and remoxipride hydrochloride, facilitated MMA-evoked firing and also firing evoked by noxious and innocuous stimulation of the ophthalmic dermatome.  Both the peripheral D1-like receptor agonist fenoldopam and the central D1-like receptor agonists cis-(±)-1-(aminomethyl)-3,4-dihydro-3-phenyl-1H-2-benzopyran-5,6-diol hydrochloride (A68930 hydrochloride) and dihydrexidine facilitated innocuous brush-evoked firing, with A68930 hydrochloride having the greatest effect.  The data suggest that dopamine binding to peripheral D1-like receptors may play a role in peripheral sensitization, and that the inhibitory or excitatory effects seen with administration of dopamine receptor agonists are independent of blood vessel changes.  In addn., these studies maintain that central D2-like receptors inhibit trigeminocervical neurons, and may provide insight into the conflicting literature on the role of dopamine and its receptors in migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxU1a61nMZLrVg90H21EOLACvtfcHk0ljfw_Ytnx2q5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7vM&md5=262ed2b419eb26447648a511c301fa13</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151951%26sid%3Dliteratum%253Aachs%26aulast%3DCharbit%26aufirst%3DA.%2BR.%26aulast%3DAkerman%26aufirst%3DS.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520central%2520and%2520peripheral%2520dopamine%2520receptor%2520activation%2520on%2520evoked%2520firing%2520in%2520the%2520trigeminocervical%2520complex%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D752%26epage%3D763%26doi%3D10.1124%2Fjpet.109.151951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballon, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajvani, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyberg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathophysiology of metabolic effects of antipsychotic medications</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2014.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.tem.2014.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=25190097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ntbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=593-600&author=J.+S.+Ballonauthor=U.+Pajvaniauthor=Z.+Freybergauthor=R.+L.+Leibelauthor=J.+A.+Lieberman&title=Molecular+pathophysiology+of+metabolic+effects+of+antipsychotic+medications&doi=10.1016%2Fj.tem.2014.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pathophysiology of metabolic effects of antipsychotic medications</span></div><div class="casAuthors">Ballon, Jacob S.; Pajvani, Utpal; Freyberg, Zachary; Leibel, Rudolph L.; Lieberman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">593-600</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Antipsychotic medications are assocd. with major metabolic changes that contribute to medical morbidity and a significantly shortened life span.  The mechanisms for these changes provide us with a broader understanding of central nervous and peripheral organ-mediated metabolic regulation.  This paper reviews an extensive literature regarding putative mechanisms for effects of antipsychotic medications on wt. regulation and glucose homeostasis as well as potential inherent metabolic risks of schizophrenia itself.  We present a model suggesting that peripheral antipsychotic targets play a crit. role in drug-induced wt. gain and diabetes.  We propose that a better understanding of these mechanisms will be crucial to developing improved treatments for serious mental illnesses as well as providing potentially novel therapeutic targets of metabolic disorders including diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUXmEXlYukObVg90H21EOLACvtfcHk0ljfw_Ytnx2q5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ntbbP&md5=6072e0c11ad8cb6da738f707b0d1f4b0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2014.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2014.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DBallon%26aufirst%3DJ.%2BS.%26aulast%3DPajvani%26aufirst%3DU.%26aulast%3DFreyberg%26aufirst%3DZ.%26aulast%3DLeibel%26aufirst%3DR.%2BL.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520pathophysiology%2520of%2520metabolic%2520effects%2520of%2520antipsychotic%2520medications%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2014%26volume%3D25%26spage%3D593%26epage%3D600%26doi%3D10.1016%2Fj.tem.2014.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farino, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenstern, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Solis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiriyasermkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyberg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanoglou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorisio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inbar, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosharov, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellendonk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmauss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeltser, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyberg, Z.</span></span> <span> </span><span class="NLM_article-title">New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1038/s41380-018-0344-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fs41380-018-0344-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=30626912" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Z.+J.+Farinoauthor=T.+J.+Morgensternauthor=A.+Maffeiauthor=M.+Quickauthor=A.+J.+De+Solisauthor=P.+Wiriyasermkulauthor=R.+J.+Freybergauthor=D.+Aslanoglouauthor=D.+Sorisioauthor=B.+P.+Inbarauthor=R.+B.+Freeauthor=P.+Donthamsettiauthor=E.+V.+Mosharovauthor=C.+Kellendonkauthor=G.+J.+Schwartzauthor=D.+R.+Sibleyauthor=C.+Schmaussauthor=L.+M.+Zeltserauthor=H.+Mooreauthor=P.+E.+Harrisauthor=J.+A.+Javitchauthor=Z.+Freyberg&title=New+roles+for+dopamine+D2+and+D3+receptors+in+pancreatic+beta+cell+insulin+secretion&doi=10.1038%2Fs41380-018-0344-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fs41380-018-0344-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-018-0344-6%26sid%3Dliteratum%253Aachs%26aulast%3DFarino%26aufirst%3DZ.%2BJ.%26aulast%3DMorgenstern%26aufirst%3DT.%2BJ.%26aulast%3DMaffei%26aufirst%3DA.%26aulast%3DQuick%26aufirst%3DM.%26aulast%3DDe%2BSolis%26aufirst%3DA.%2BJ.%26aulast%3DWiriyasermkul%26aufirst%3DP.%26aulast%3DFreyberg%26aufirst%3DR.%2BJ.%26aulast%3DAslanoglou%26aufirst%3DD.%26aulast%3DSorisio%26aufirst%3DD.%26aulast%3DInbar%26aufirst%3DB.%2BP.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DMosharov%26aufirst%3DE.%2BV.%26aulast%3DKellendonk%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DG.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSchmauss%26aufirst%3DC.%26aulast%3DZeltser%26aufirst%3DL.%2BM.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DHarris%26aufirst%3DP.%2BE.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DFreyberg%26aufirst%3DZ.%26atitle%3DNew%2520roles%2520for%2520dopamine%2520D2%2520and%2520D3%2520receptors%2520in%2520pancreatic%2520beta%2520cell%2520insulin%2520secretion%26jtitle%3DMol.%2520Psychiatry%26date%3D2019%26doi%3D10.1038%2Fs41380-018-0344-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Epub ahead of print</p></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo Pich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor ligands for drug addiction treatment</span>. <i>Prog. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/b978-0-444-63425-2.00011-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fb978-0-444-63425-2.00011-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=24968784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2014&pages=255-275&author=B.+Le%0AFollauthor=G.+Colloauthor=E.+A.+Rabinerauthor=I.+Boileauauthor=E.+Merlo+Pichauthor=P.+Sokoloff&title=Dopamine+D3+receptor+ligands+for+drug+addiction+treatment&doi=10.1016%2Fb978-0-444-63425-2.00011-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor ligands for drug addiction treatment, update on recent findings</span></div><div class="casAuthors">Le Foll, Bernard; Collo, Ginetta; Rabiner, Eugenii A.; Boileau, Isabelle; Pich, Emilio Merlo; Sokoloff, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Dopamine</span>),
    <span class="NLM_cas:pages">255-275</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor is located in the limbic area and apparently mediates selective effects on motivation to take drugs and drug-seeking behaviors, so that there has been considerable interest on the possible use of D3 receptor ligands to treat drug addiction.  However, only recently selective tools allowing studying this receptor have been developed.  This chapter presents an overview of findings that were presented at a symposium on the conference Dopamine 2013 in Sardinia in May 2013.  Novel neurobiol. findings indicate that drugs of abuse can lead to significant structural plasticity in rodent brain and that this is dependent on the availability of functional dopamine D3 autoreceptor, whose activation increased phosphorylation in the ERK pathway and in the Akt/mTORC1 pathway indicating the parallel engagement of a series of intracellular signaling pathways all involved in cell growth and survival.  Preclin. findings using animal models of drug-seeking behaviors confirm that D3 antagonists have a promising profile to treat drug addiction across drugs of abuse type.  Imaging the D3 is now feasible in human subjects.  Notably, the development of (+)-4-propyl-9-hydroxynaphthoxazine ligand used in positron emission tomog. (PET) studies in humans allows to measure D3 and D2 receptors based on the area of the brain under study.  This PET ligand has been used to confirm up-regulation of D3 sites in psychostimulant users and to reveal that tobacco smoking produces elevation of dopamine at the level of D3 sites.  There are now novel antagonists being developed, but also old drugs such as buspirone, that are available to test the D3 hypothesis in humans.  The first results of clin. investigations are now being provided.  Overall, those recent findings support further exploration of D3 ligands to treat drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxIQ6SUa_NcrVg90H21EOLACvtfcHk0lhVKSuSfGOQUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtLzP&md5=e997ab74bf84de9d62b9b734a585b949</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fb978-0-444-63425-2.00011-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fb978-0-444-63425-2.00011-8%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DCollo%26aufirst%3DG.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DMerlo%2BPich%26aufirst%3DE.%26aulast%3DSokoloff%26aufirst%3DP.%26atitle%3DDopamine%2520D3%2520receptor%2520ligands%2520for%2520drug%2520addiction%2520treatment%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2014%26volume%3D211%26spage%3D255%26epage%3D275%26doi%3D10.1016%2Fb978-0-444-63425-2.00011-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2007.00013.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1111%2Fj.1527-3458.2007.00013.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=17627675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsVCltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=240-259&author=Z.-X.+Xiauthor=E.+L.+Gardner&title=Pharmacological+actions+of+NGB+2904%2C+a+selective+dopamine+D3+receptor+antagonist%2C+in+animal+models+of+drug+addiction&doi=10.1111%2Fj.1527-3458.2007.00013.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction</span></div><div class="casAuthors">Xi, Zheng-Xiong; Gardner, Eliot L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-259</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  As a continuation of our work with SB-277011A, we have examd. the effects of another highly elective dopamine (DA) D3 receptor antagonist, N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-2-fluorenylcarboxamide (NGB 2904), in animal models of addiction.  Our results indicate that by systemic administration, NGB 2904 inhibits i.v. cocaine self-administration maintained under a progressive-ratio (PR) reinforcement schedule, cocaine- or cocaine cue-induced reinstatement of cocaine-seeking behavior, and cocaine- or other addictive drug-enhanced brain stimulation reward (BSR).  The action of NGB 2904 on PR cocaine self-administration was long-lasting (1-2 days) after a single injection, supporting its potential use in treatment of cocaine addiction.  The effects of NGB 2904 in the BSR paradigm were dose-dependent for both NGB 2904 and cocaine; i.e., only lower doses of NGB 2904 were effective, and their putative antiaddiction effect could be overcome by increasing the doses of cocaine or other addictive drugs.  A dopamine-dependent mechanism is proposed to explain the effects of NGB 2904 on cocaine's actions in these animal models of drug addiction.  The data reviewed in this paper suggest that NGB 2904 or other D3-selective antagonists may have potential in controlling motivation for drug-taking behavior or relapse to drug-seeking behavior, but may have a limited role in antagonizing the acute rewarding effects produced by cocaine or other addictive drugs.  In addn., NGB 2904 may also act as a useful tool to study the role of D3 receptors in drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomI_kosmBM37Vg90H21EOLACvtfcHk0lhVKSuSfGOQUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsVCltbs%253D&md5=7ad95c59ffa9d51a3670fd66d63e1376</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2007.00013.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2007.00013.x%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26atitle%3DPharmacological%2520actions%2520of%2520NGB%25202904%252C%2520a%2520selective%2520dopamine%2520D3%2520receptor%2520antagonist%252C%2520in%2520animal%2520models%2520of%2520drug%2520addiction%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2007%26volume%3D13%26spage%3D240%26epage%3D259%26doi%3D10.1111%2Fj.1527-3458.2007.00013.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C.</span></span> <span> </span><span class="NLM_article-title">Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence</span>. <i>CNS Neurol. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.2174/187152708786927822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.2174%2F187152708786927822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=19128200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFansA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=410-421&author=C.+Heidbreder&title=Selective+antagonism+at+dopamine+D3+receptors+as+a+target+for+drug+addiction+pharmacotherapy%3A+a+review+of+preclinical+evidence&doi=10.2174%2F187152708786927822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence</span></div><div class="casAuthors">Heidbreder, Christian</div><div class="citationInfo"><span class="NLM_cas:title">CNS & Neurological Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">410-421</span>CODEN:
                <span class="NLM_cas:coden">CNDDA3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5273</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts.  This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclin. paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alc., methamphetamine, and heroin.  This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists.  Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand.  In addn., selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-assocd. stimuli that play a key role in reinstatement of drug-seeking behavior.  These preclin. findings will be discussed in the context of translational research relevant to the design of early clin. trials and hypothesis testing in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcM0jWAd6GHrVg90H21EOLACvtfcHk0lhVKSuSfGOQUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFansA%253D%253D&md5=8f187ba70d486dc49f745562fe3f9408</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F187152708786927822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152708786927822%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%26atitle%3DSelective%2520antagonism%2520at%2520dopamine%2520D3%2520receptors%2520as%2520a%2520target%2520for%2520drug%2520addiction%2520pharmacotherapy%253A%2520a%2520review%2520of%2520preclinical%2520evidence%26jtitle%3DCNS%2520Neurol.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2008%26volume%3D7%26spage%3D410%26epage%3D421%26doi%3D10.2174%2F187152708786927822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanos, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence</span>. <i>Brain Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.brainresrev.2004.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.brainresrev.2004.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=15960988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Ghu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=77-105&author=C.+A.+Heidbrederauthor=E.+L.+Gardnerauthor=Z.-X.+Xiauthor=P.+K.+Thanosauthor=M.+Mugnainiauthor=J.+J.+Haganauthor=C.+R.+Ashby&title=The+role+of+central+dopamine+D3+receptors+in+drug+addiction%3A+a+review+of+pharmacological+evidence&doi=10.1016%2Fj.brainresrev.2004.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence</span></div><div class="casAuthors">Heidbreder, Christian A.; Gardner, Eliot L.; Xi, Zheng-Xiong; Thanos, Panayotis K.; Mugnaini, Manolo; Hagan, Jim J.; Ashby, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-105</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The cDNA for the dopamine D3 receptor was isolated and characterized in 1990.  Subsequent studies have indicated that D3 receptors, as well as D3 receptor mRNA, are primarily localized in limbic regions in mammals.  This finding led to the postulate that D3 receptors may be involved in drug dependence and addiction.  However, this hypothesis has been difficult to test due to the lack of compds. with high selectivity for central D3 receptors.  The interpretation of results from studies using mixed D2/D3 agonists and/or antagonists is problematic because these agents have low selectivity for D3 over D2 receptors and it is likely that their actions are primarily related to D2 receptor antagonism and possibly interaction with other neurotransmitter receptors.  Currently, with the synthesis and characterization of new highly selective D3 receptor antagonists such as SB-277011-A this difficulty has been surmounted.  The purpose of the present article is to review, for the first time, the effects of various putative D3 receptor selective compds. in animal models of drug dependence and addiction.  The results obtained with highly selective D3 receptor antagonists such as SB-277011-A, SB-414796, and NGB-2904 indicate that central D3 receptors may play an important role in drug-induced reward, drug-taking, and cue-, drug-, and stress-induced reinstatement of drug-seeking behavior.  Provided these results can be extrapolated to human drug addicts, they suggest that selective DA D3 receptor antagonists may prove effective as potential pharmacotherapeutic agents to manage drug dependence and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwzEJPprm60rVg90H21EOLACvtfcHk0lgUDuUQZtS1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Ghu7k%253D&md5=3e5948e0f94515fd240d1e3d18812028</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2004.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2004.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DThanos%26aufirst%3DP.%2BK.%26aulast%3DMugnaini%26aufirst%3DM.%26aulast%3DHagan%26aufirst%3DJ.%2BJ.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26atitle%3DThe%2520role%2520of%2520central%2520dopamine%2520D3%2520receptors%2520in%2520drug%2520addiction%253A%2520a%2520review%2520of%2520pharmacological%2520evidence%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2005%26volume%3D49%26spage%3D77%26epage%3D105%26doi%3D10.1016%2Fj.brainresrev.2004.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranaldi, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine D1 and D3 receptor interactions in cocaine reward and seeking in rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">3881</span>– <span class="NLM_lpage">3890</span>, <span class="refDoi"> DOI: 10.1007/s00213-016-4420-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1007%2Fs00213-016-4420-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27582181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCgsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2016&pages=3881-3890&author=E.+Galajauthor=W.+Hardingauthor=R.+Ranaldi&title=Dopamine+D1+and+D3+receptor+interactions+in+cocaine+reward+and+seeking+in+rats&doi=10.1007%2Fs00213-016-4420-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D1 and D3 receptor interactions in cocaine reward and seeking in rats</span></div><div class="casAuthors">Galaj, E.; Harding, W.; Ranaldi, R.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">3881-3890</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Animal research has demonstrated a role of dopamine D1 and D3 receptors in cocaine reward and seeking.  Purpose and methods: Here, we investigated the potential interaction of these two dopamine receptors in cue-induced reinstatement of cocaine seeking, cocaine conditioned place preference (CPP), and cocaine self-administration in rats.  Results: The co-administration of a D3 receptor antagonist, NGB 2904 and a D1 partial agonist, SKF 77434, of doses which when administered individually produced no significant effects, prior to reinstatement or CPP tests significantly reduced lever pressing and time spent in the cocaine-paired environment, suggesting synergistic effects of the combined compds. on cocaine seeking.  When given to rats self-administering cocaine under a progressive ratio schedule of reinforcement doses of NGB 2904 which were ineffective alone significantly enhanced the break point-reducing effects of SKF 77434.  Conclusions: Our results indicate that the combined treatment with a D1 receptor partial agonist and D3 receptor antagonist produces robust decreases in cocaine seeking and reward.  This suggests an interaction between dopamine D1 and D3 receptors in cocaine-related behaviors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7GjokU1Dv7Vg90H21EOLACvtfcHk0lgUDuUQZtS1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCgsLbF&md5=ea69a64f097986de74381bf03f04c4e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00213-016-4420-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-016-4420-9%26sid%3Dliteratum%253Aachs%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DW.%26aulast%3DRanaldi%26aufirst%3DR.%26atitle%3DDopamine%2520D1%2520and%2520D3%2520receptor%2520interactions%2520in%2520cocaine%2520reward%2520and%2520seeking%2520in%2520rats%26jtitle%3DPsychopharmacology%26date%3D2016%26volume%3D233%26spage%3D3881%26epage%3D3890%26doi%3D10.1007%2Fs00213-016-4420-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fjpet.115.224121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=26177654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=484-492&author=N.+M.+Appelauthor=S.-H.+Liauthor=T.+H.+Holmesauthor=J.+B.+Acri&title=Dopamine+D3+receptor+antagonist+%28GSK598809%29+potentiates+the+hypertensive+effects+of+cocaine+in+conscious%2C+freely-moving+dogs&doi=10.1124%2Fjpet.115.224121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span></div><div class="casAuthors">Appel, Nathan M.; Li, Shou-Hua; Holmes, Tyson H.; Acri, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-492</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chronic and relapsing nature of addiction presents unique challenges for ensuring the safety of a potential medication.  A patient may use cocaine, for example, while taking the medication or take more medication than prescribed.  Thus, a potential medication must be safe and not exacerbate the effects of cocaine.  Multiple published studies support antagonism of brain dopamine D3 receptor function as a potential mechanism of action for an anti-addiction medication.  Dopamine D3 receptors are widely distributed outside the central nervous system, however; for example, dopamine D3 receptors in the kidneys are implicated in regulating blood pressure.  The selective dopamine D3 receptor antagonist GSK598809 [1-(2-fluoro-4- trifluoromethyl-phenyl)-3-{3-[4-methyl-5-(4-methyl-oxazol-5- yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-propyl}-3-aza-bicyclo[3.1.0] hexane] has been proposed as a medication to treat cocaine and other substance use disorders.  The US Food and Drug Administration has established guidelines recommending safety studies to investigate potential undesirable pharmacodynamic effects of a substance in relation to exposure in the therapeutic range and above.  Hence, we assessed the interaction between this selective dopamine D3 receptor antagonist and cocaine on hemodynamics and cardiac function in freely-moving, telemetered dogs before conducting a clin. trial.  GSK598809 increased the hemodynamic effect of cocaine in this model.  Thus, the increase in blood pressure after i.v. cocaine was greater in animals that had been pretreated with GSK598809 compared with vehicle.  This finding suggests that GSK598809 in particular, and perhaps dopamine D3 receptor antagonists as a class, may produce unacceptable cardiovascular risks as medications to treat cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWq20sTq43bVg90H21EOLACvtfcHk0lgUDuUQZtS1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ&md5=6fd994c95c5bee2dd486b4c340564c73</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224121%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DS.-H.%26aulast%3DHolmes%26aufirst%3DT.%2BH.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonist%2520%2528GSK598809%2529%2520potentiates%2520the%2520hypertensive%2520effects%2520of%2520cocaine%2520in%2520conscious%252C%2520freely-moving%2520dogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D484%26epage%3D492%26doi%3D10.1124%2Fjpet.115.224121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1415</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0284-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fs41386-018-0284-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=30555159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1415&author=Z.-B.+Youauthor=G.-H.+Biauthor=E.+Galajauthor=V.+Kumarauthor=J.+Caoauthor=A.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+L.+Gardnerauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Dopamine+D3R+antagonist+VK4-116+attenuates+oxycodone+self-administration+and+reinstatement+without+compromising+its+antinociceptive+effects&doi=10.1038%2Fs41386-018-0284-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span></div><div class="casAuthors">You, Zhi-Bing; Bi, Guo-Hua; Galaj, Ewa; Kumar, Vivek; Cao, Jianjing; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot L.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prescription opioids such as oxycodone are highly effective analgesics for clin. pain management, but their misuse and abuse have led to the current opioid epidemic in the United States.  In order to ameliorate this public health crisis, the development of effective pharmacotherapies for the prevention and treatment of opioid abuse and addiction is essential and urgently required.  In this study, we evaluated-in lab. rats-the potential utility of VK4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and treatment of prescription opioid use disorders.  Pretreatment with VK4-116 (5-25 mg/kg, i.p.) dose-dependently inhibited the acquisition and maintenance of oxycodone self-administration.  VK4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxycodone-seeking behavior.  In addn., VK4-116 pretreatment dose-dependently enhanced the antinociceptive effects of oxycodone and reduced naloxone-pptd. conditioned place aversion in rats chronically treated with oxycodone.  In contrast, VK4-116 had little effect on oral sucrose self-administration.  Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3PmmEMo-frVg90H21EOLACvtfcHk0lhBTzdNymRGhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN&md5=dac3d9cbb6c0594cd06d3ec328aa519f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0284-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0284-5%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520D3R%2520antagonist%2520VK4-116%2520attenuates%2520oxycodone%2520self-administration%2520and%2520reinstatement%2520without%2520compromising%2520its%2520antinociceptive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1415%26doi%3D10.1038%2Fs41386-018-0284-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span> <span> </span><span class="NLM_article-title">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.neuropharm.2017.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=28888944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=190-199&author=Z.-B.+Youauthor=J.-T.+Gaoauthor=G.-H.+Biauthor=Y.+Heauthor=C.+Boatengauthor=J.+Caoauthor=E.+L.+Gardnerauthor=A.+H.+Newmanauthor=Z.-X.+Xi&title=The+novel+dopamine+D3+receptor+antagonists%2Fpartial+agonists+CAB2-015+and+BAK4-54+inhibit+oxycodone-taking+and+oxycodone-seeking+behavior+in+rats&doi=10.1016%2Fj.neuropharm.2017.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span></div><div class="casAuthors">You, Zhi-Bing; Gao, Jun-Tao; Bi, Guo-Hua; He, Yi; Boateng, Comfort; Cao, Jianjing; Gardner, Eliot L.; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190-199</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of prescription opioid analgesics, particularly oxycodone, has dramatically increased, and parallels escalated opioid abuse and drug-related deaths worldwide.  Understanding the mol. mechanisms underlying the development of opioid dependence and expanding treatment options to counter prescription opioid abuse has become a crit. public health matter.  In the present study, we first evaluated the reinforcing effects of oxycodone in a rat model of self-administration and then explored the potential utility of two novel high affinity dopamine D3 receptor (D3R) antagonists/partial agonists, CAB2-015 and BAK4-54, for treatment of prescription opioid abuse and dependence.  We found that rats acquired oxycodone self-administration rapidly within a range of unit doses that was similar to that for heroin, confirming that oxycodone has significant abuse potential.  Strikingly, pretreatment with either CAB2-015 or BAK4-54 (0.4-10 mg/kg, i.p.) dose-dependently decreased oxycodone self-administration, and shifted the oxycodone dose-response curve downward.  Repeated pretreatment with CAB2-015 or BAK4-54 (0.4-4 mg/kg) facilitated extinction and inhibited oxycodone-induced reinstatement of drug-seeking behavior.  In addn., pretreatment with CAB2-015 or BAK4-54 (4-10 mg/kg) also dose-dependently decreased oxycodone-enhanced locomotor activity, but only CAB2-015 decreased oral sucrose self-administration.  These data suggest that D3R antagonists may be suitable alternatives or adjunctive to opioid-based medications currently used clin. in treating opioid addiction and that the D3R-selective ligands (CAB2-015 or BAK4-54) provide new lead mols. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2yL76pWO8Z7Vg90H21EOLACvtfcHk0lhBTzdNymRGhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF&md5=a046de2818f1daf7029be110c5c0cc9b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DGao%26aufirst%3DJ.-T.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBoateng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.-X.%26atitle%3DThe%2520novel%2520dopamine%2520D3%2520receptor%2520antagonists%252Fpartial%2520agonists%2520CAB2-015%2520and%2520BAK4-54%2520inhibit%2520oxycodone-taking%2520and%2520oxycodone-seeking%2520behavior%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D126%26spage%3D190%26epage%3D199%26doi%3D10.1016%2Fj.neuropharm.2017.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">High affinity dopamine D3 receptor (D3R)-selective antagonists attenuate heroin self-administration in wild-type but not D3R knockout mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6213</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00776</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00776" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6195-6213&author=C.+A.+Boatengauthor=O.+M.+Bakareauthor=J.+Zhanauthor=A.+K.+Banalaauthor=C.+Burzynskiauthor=E.+Pommierauthor=T.+M.+Keckauthor=P.+Donthamsettiauthor=J.+A.+Javitchauthor=R.+Raisauthor=B.+S.+Slusherauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=High+affinity+dopamine+D3+receptor+%28D3R%29-selective+antagonists+attenuate+heroin+self-administration+in+wild-type+but+not+D3R+knockout+mice&doi=10.1021%2Facs.jmedchem.5b00776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice</span></div><div class="casAuthors">Boateng, Comfort A.; Bakare, Oluyomi M.; Zhan, Jia; Banala, Ashwini K.; Burzynski, Caitlin; Pommier, Elie; Keck, Thomas M.; Donthamsetti, Prashant; Javitch, Jonathan A.; Rais, Rana; Slusher, Barbara S.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6195-6213</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders.  Several D3R-selective antagonists are effective in animal models of drug abuse, esp. in models of relapse.  Nevertheless, poor bioavailability, metabolic instability, and/or predicted toxicity have impeded success in translating these drug candidates to clin. use.  Herein, the authors report a series of D3R-selective 4-phenylpiperazines with improved metabolic stability.  A subset of these compds. was evaluated for D3R functional efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with D3R has been obsd.  Several high affinity D3R antagonists, including compds. I (Ki = 0.12 nM) and II (Ki = 0.35 nM), showed improved metabolic stability compared to the parent compd., PG648.  Notably, I and the classic D3R antagonist SB277011A were effective in reducing self-administration of heroin in wild-type but not D3R knockout mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagzWQU_gPV7Vg90H21EOLACvtfcHk0lhBTzdNymRGhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK&md5=1724065cac8ac51295cf4660a20ed734</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00776%26sid%3Dliteratum%253Aachs%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DZhan%26aufirst%3DJ.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHigh%2520affinity%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529-selective%2520antagonists%2520attenuate%2520heroin%2520self-administration%2520in%2520wild-type%2520but%2520not%2520D3R%2520knockout%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6195%26epage%3D6213%26doi%3D10.1021%2Facs.jmedchem.5b00776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 agonists in the treatment of Parkinson’s disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.2174/156802661510150328223428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.2174%2F156802661510150328223428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=25832718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=908-926&author=B.+Dasauthor=G.+Modiauthor=A.+Dutta&title=Dopamine+D3+agonists+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.2174%2F156802661510150328223428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Agonists in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Modi, Gyan; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">908-926</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is t he second most common form of neurodegenerative disorders that results from the progressive loss of dopaminergic neurons in the midbrain substantia nigra pars compacta (SNpc) triggering profound motor perturbation, as well as cognitive, sensory and mood deficits.  Although these symptoms can be improved using currently available dopamine replacement strategies, they are not able to slow the neurodegenerative process that underlies PD progression.  Following the discovery of the D3 receptor from mol. cloning, it has gained much attention as a potential therapeutic target for the treatment of PD due to their localization in the limbic regions of the brain as well as pharmacol. similarity to the D2 receptor subtype.  Of particular interest, D3 receptor- selective agonists appear to have neuroprotective effects apart from their ability to relieve PD symptoms.  Owing to the distinct significance of D3 receptor in mediating diverse neurol. effects, it represents a unique target for therapeutic intervention in PD with much less undesirable side effects.  Herein, we review progress in the development of D3 receptor selective agonist mols. having a broad spectrum of affinities, selectivities as well as unique pharmacol. properties directed at slowing the neurodegeneration process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vO7t50SK9rVg90H21EOLACvtfcHk0lhhKsmKsDMAQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D&md5=46885592d050d099cbad73ba7ef8e61b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F156802661510150328223428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661510150328223428%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DDopamine%2520D3%2520agonists%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D908%26epage%3D926%26doi%3D10.2174%2F156802661510150328223428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddaluna, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D4 receptor-selective compounds reveal structure-activity relationships that engender agonist efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3722</span>– <span class="NLM_lpage">3740</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3722-3740&author=T.+M.+Keckauthor=R.+B.+Freeauthor=M.+M.+Dayauthor=S.+L.+Brownauthor=M.+S.+Maddalunaauthor=G.+Fountainauthor=C.+Cooperauthor=B.+Fallonauthor=M.+Holmesauthor=C.+T.+Stangauthor=R.+Burkhardtauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=D.+R.+Sibleyauthor=C.+Wuauthor=C.+A.+Boateng&title=Dopamine+D4+receptor-selective+compounds+reveal+structure-activity+relationships+that+engender+agonist+efficacy&doi=10.1021%2Facs.jmedchem.9b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy</span></div><div class="casAuthors">Keck, Thomas M.; Free, R. Benjamin; Day, Marilyn M.; Brown, Sonvia L.; Maddaluna, Michele S.; Fountain, Griffin; Cooper, Charles; Fallon, Brooke; Holmes, Matthew; Stang, Christopher T.; Burkhardt, Russell; Bonifazi, Alessandro; Ellenberger, Michael P.; Newman, Amy H.; Sibley, David R.; Wu, Chun; Boateng, Comfort A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3722-3740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D4 receptor (D4R) plays important roles in cognition, attention, and decision making.  Novel D4R-selective ligands have promise in medication development for neuropsychiatric conditions, including Alzheimer's disease and substance use disorders.  To identify new D4R-selective ligands, and to understand the mol. determinants of agonist efficacy at D4R, we report a series of eighteen novel ligands based on the classical D4R agonist A-412997 (1, 2-(4-(pyridin-2-yl)piperidin-1-yl)-N-(m-tolyl)acetamide).  Compds. were profiled using radioligand binding displacement assays, β-arrestin recruitment assays, cAMP inhibition assays, and mol. dynamics computational modeling.  We identified several novel D4R-selective (Ki ≤ 4.3 nM and >100-fold vs other D2-like receptors) compds. with diverse partial agonist and antagonist profiles, falling into three structural groups.  These compds. highlight receptor-ligand interactions that control efficacy at D2-like receptors and may provide insights into targeted drug discovery, leading to a better understanding of the role of D4Rs in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtBRYg7sp8rVg90H21EOLACvtfcHk0lhhKsmKsDMAQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D&md5=f3f03df2f50a91030295d32d6b692f1c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00231%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDay%26aufirst%3DM.%2BM.%26aulast%3DBrown%26aufirst%3DS.%2BL.%26aulast%3DMaddaluna%26aufirst%3DM.%2BS.%26aulast%3DFountain%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DFallon%26aufirst%3DB.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DStang%26aufirst%3DC.%2BT.%26aulast%3DBurkhardt%26aufirst%3DR.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26atitle%3DDopamine%2520D4%2520receptor-selective%2520compounds%2520reveal%2520structure-activity%2520relationships%2520that%2520engender%2520agonist%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3722%26epage%3D3740%26doi%3D10.1021%2Facs.jmedchem.9b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweppe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) provide clues to dopamine D2/D3 receptor agonist selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2973</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01612</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01612" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2973-2988&author=M.-F.+Zouauthor=T.+M.+Keckauthor=V.+Kumarauthor=P.+Donthamsettiauthor=M.+Michinoauthor=C.+Burzynskiauthor=C.+Schweppeauthor=A.+Bonifaziauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=A.+Janowskyauthor=L.+Shiauthor=J.+A.+Javitchauthor=A.+H.+Newman&title=Novel+analogues+of+%28R%29-5-%28Methylamino%29-5%2C6-dihydro-4H-imidazo%5B4%2C5%2C1-ij%5Dquinolin-2%281H%29-one+%28Sumanirole%29+provide+clues+to+dopamine+D2%2FD3+receptor+agonist+selectivity&doi=10.1021%2Facs.jmedchem.5b01612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity</span></div><div class="casAuthors">Zou, Mu-Fa; Keck, Thomas M.; Kumar, Vivek; Donthamsetti, Prashant; Michino, Mayako; Burzynski, Caitlin; Schweppe, Catherine; Bonifazi, Alessandro; Free, R. Benjamin; Sibley, David R.; Janowsky, Aaron; Shi, Lei; Javitch, Jonathan A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2973-2988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 1-, 5-, and 8-substituted analogs of sumanirole (I), a dopamine D2/D3 receptor (D2R/D3R) agonist, were synthesized.  Binding affinities at both D2R and D3R were higher when detd. in competition with the agonist radioligand [3H]7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT) than with the antagonist radioligand [3H]N-methylspiperone.  Although I was confirmed as a D2R-preferential agonist, its selectivity in binding and functional studies was lower than previously reported.  All analogs were detd. to be D2R/D3R agonists in both GoBRET and mitogenesis functional assays.  Loss of efficacy was detected for the N-1-substituted analogs at D3R.  In contrast, the N-5-alkyl-substituted analogs, and notably the n-butyl-arylamides (II and III), all showed improved affinity at D2R over I with neither a loss of efficacy nor an increase in selectivity.  Computational modeling provided a structural basis for the D2R selectivity of I, illustrating how subtle differences in the highly homologous orthosteric binding site (OBS) differentially affect D2R/D3R affinity and functional efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCYS7hdbWljrVg90H21EOLACvtfcHk0lhhKsmKsDMAQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D&md5=504e9fde86b9cef1a3b52fa4a3ef2063</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01612%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DM.-F.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DSchweppe%26aufirst%3DC.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520analogues%2520of%2520%2528R%2529-5-%2528Methylamino%2529-5%252C6-dihydro-4H-imidazo%255B4%252C5%252C1-ij%255Dquinolin-2%25281H%2529-one%2520%2528Sumanirole%2529%2520provide%2520clues%2520to%2520dopamine%2520D2%252FD3%2520receptor%2520agonist%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2973%26epage%3D2988%26doi%3D10.1021%2Facs.jmedchem.5b01612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5905</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1021/jm800471h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800471h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFaqtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5905-5908&author=J.+Chenauthor=G.+T.+Collinsauthor=J.+Zhangauthor=C.-Y.+Yangauthor=B.+Levantauthor=J.+Woodsauthor=S.+Wang&title=Design%2C+synthesis%2C+and+evaluation+of+potent+and+selective+ligands+for+the+dopamine+3+%28D3%29+receptor+with+a+novel+in+vivo+behavioral+profile&doi=10.1021%2Fjm800471h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Potent and Selective Ligands for the Dopamine 3 (D3) Receptor with a Novel in Vivo Behavioral Profile</span></div><div class="casAuthors">Chen, Jianyong; Collins, Gregory T.; Zhang, Jian; Yang, Chao-Yie; Levant, Beth; Woods, James; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5905-5908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. structurally related to pramipexole were designed, synthesized, and evaluated as ligands for the dopamine 3 (D3) receptor.  Compd. 12 (I) has a Ki value of 0.41 nM to D3 and a selectivity of >30000- and 800-fold over the D1-like and D2 receptors, resp.  Our in vivo functional assays showed that this compd. is a partial agonist at the D3 receptor with no detectable activity at the D2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZFzVrBCdRRbVg90H21EOLACvtfcHk0lgH_-lEEUoQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFaqtLbE&md5=6ea446427c46a43ac56870b2026f5751</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800471h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800471h%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520potent%2520and%2520selective%2520ligands%2520for%2520the%2520dopamine%25203%2520%2528D3%2529%2520receptor%2520with%2520a%2520novel%2520in%2520vivo%2520behavioral%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5905%26epage%3D5908%26doi%3D10.1021%2Fjm800471h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">CJ-1639: A potent and highly selective dopamine D3 receptor full agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1021/ml200100t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200100t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=620-625&author=J.+Chenauthor=G.+T.+Collinsauthor=B.+Levantauthor=J.+Woodsauthor=J.+R.+Deschampsauthor=S.+Wang&title=CJ-1639%3A+A+potent+and+highly+selective+dopamine+D3+receptor+full+agonist&doi=10.1021%2Fml200100t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist</span></div><div class="casAuthors">Chen, Jianyong; Collins, Gregory T.; Levant, Beth; Woods, James; Deschamps, Jeffrey R.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have identified several ligands with high binding affinities to the dopamine D3 receptor and excellent selectivity over the D2 and D1 receptors.  CJ-1639 (17) binds to the D3 receptor with a Ki value of 0.50 nM and displays a selectivity of >5000 times over D2 and D1 receptors in binding assays using dopamine receptors expressed in the native rat brain tissues.  CJ-1639 binds to human D3 receptor with a Ki value of 3.61 nM and displays over >1000-fold selectivity over human D1 and D2 receptors.  CJ-1639 is active at 0.01 mg/kg at the dopamine D3 receptor in the rat and only starts to show a modest D2 activity at doses as high as 10 mg/kg.  CJ-1639 is the most potent and selective D3 full agonist reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1_j_DTOKv47Vg90H21EOLACvtfcHk0lgH_-lEEUoQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D&md5=563e24bd67062d01a456b6f03429329a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fml200100t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200100t%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DCJ-1639%253A%2520A%2520potent%2520and%2520highly%2520selective%2520dopamine%2520D3%2520receptor%2520full%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D620%26epage%3D625%26doi%3D10.1021%2Fml200100t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D2 receptor (D2R) biased agonism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2890-2907&author=A.+Bonifaziauthor=H.+Yanoauthor=M.+P.+Ellenbergerauthor=L.+Mullerauthor=V.+Kumarauthor=M.-F.+Zouauthor=N.+S.+Caiauthor=A.+M.+Guerreroauthor=A.+S.+Woodsauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+bivalent+ligands+based+on+the+sumanirole+pharmacophore+reveal+dopamine+D2+receptor+%28D2R%29+biased+agonism&doi=10.1021%2Facs.jmedchem.6b01875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Ellenberger, Michael P.; Muller, Ludovic; Kumar, Vivek; Zou, Mu-Fa; Cai, Ning Sheng; Guerrero, Adrian M.; Woods, Amina S.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2890-2907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype.  The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways.  Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore.  We found that substitutions in the N-1- and/or N-5-positions, physiochem. properties of those substituents, and secondary arom. pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment.  Compd. 19 was identified as a new lead for its selective D2 G-protein biased agonism with an EC50 in the subnanomolar range.  Structure-activity correlations were obsd. between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compds. to selectively activate G-proteins vs. β-arrestin recruitment in D2R-BRET functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprfScHokUgP7Vg90H21EOLACvtfcHk0lgH_-lEEUoQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D&md5=24bf22a101756e44fbc8f8345d2c1fe4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01875%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DM.-F.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520bivalent%2520ligands%2520based%2520on%2520the%2520sumanirole%2520pharmacophore%2520reveal%2520dopamine%2520D2%2520receptor%2520%2528D2R%2529%2520biased%2520agonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2890%26epage%3D2907%26doi%3D10.1021%2Facs.jmedchem.6b01875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and potent dopamine D2 receptor Go-protein biased agonists</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.8b00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=52-65&author=A.+Bonifaziauthor=H.+Yanoauthor=A.+M.+Guerreroauthor=V.+Kumarauthor=A.+F.+Hoffmanauthor=C.+R.+Lupicaauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+and+potent+dopamine+D2+receptor+Go-protein+biased+agonists&doi=10.1021%2Facsptsci.8b00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Guerrero, Adrian M.; Kumar, Vivek; Hoffman, Alexander F.; Lupica, Carl R.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of functionally biased and physiol. beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D2 receptor (D2R) targeted mols. that may be therapeutically advantageous for the treatment of certain neuropsychiatric or basal ganglia related disorders.  Here we describe the synthesis of a novel series of D2R agonists linking the D2R unbiased agonist sumanirole with privileged secondary mol. fragments.  The resulting ligands demonstrate improved D2R affinity and selectivity over sumanirole.  Extensive in vitro functional studies and bias factor anal. led to the identification of a novel class of highly potent Go-protein biased full D2R agonists with more than 10-fold and 1000-fold bias selectivity toward activation of specific G-protein subtypes and β-arrestin, resp.  Intracellular electrophysiol. recordings from midbrain dopamine neurons demonstrated that Go-protein selective agonists can elicit prolonged ligand-induced GIRK activity via D2Rs, which may be beneficial in the treatment of dyskinesias assocd. with dopamine system dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNIFl-FnvXCrVg90H21EOLACvtfcHk0lhtMqO5Mroupg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D&md5=5b67e76002f6ceb85293c961f698722a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00060%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520potent%2520dopamine%2520D2%2520receptor%2520Go-protein%2520biased%2520agonists%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D2%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facsptsci.8b00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Chiral resolution and serendipitous fluorination reaction for the selective dopamine D3 receptor antagonist BAK2-66</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1021/ml500006v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500006v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=647-651&author=V.+Kumarauthor=A.+K.+Banalaauthor=E.+G.+Garciaauthor=J.+Caoauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=J.+R.+Deschampsauthor=A.+H.+Newman&title=Chiral+resolution+and+serendipitous+fluorination+reaction+for+the+selective+dopamine+D3+receptor+antagonist+BAK2-66&doi=10.1021%2Fml500006v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66</span></div><div class="casAuthors">Kumar, Vivek; Banala, Ashwini K.; Garcia, Erick G.; Cao, Jianjing; Keck, Thomas M.; Bonifazi, Alessandro; Deschamps, Jeffery R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-651</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The improved chiral synthesis of the selective dopamine D3 receptor (D3R) antagonist (R)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)1H-indole-2-carboxamide ((R)-PG648) is described.  The same chiral secondary alc. intermediate was used to prep. the enantiomers of a 3-F-benzofuranyl analog, BAK 2-66 (I).  The abs. configurations of the 3-F enantiomers were assigned from their X-ray crystal structures that confirmed retention of configuration during fluorination with N,N-diethylaminosulfur trifluoride (DAST).  (R)-I showed higher D3R affinity and selectivity than its (S)-enantiomer; however, it had lower D3R affinity and enantioselectivity than (R)-PG648.  Further, importance of the 4-atom linker length between the aryl amide and 4-phenylpiperazine was demonstrated with the 4-fluorobutyl-product (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTRVSlrPS4ybVg90H21EOLACvtfcHk0lhtMqO5Mroupg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D&md5=17ddfb3b45b6630f53c917281d76b620</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fml500006v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500006v%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DGarcia%26aufirst%3DE.%2BG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DChiral%2520resolution%2520and%2520serendipitous%2520fluorination%2520reaction%2520for%2520the%2520selective%2520dopamine%2520D3%2520receptor%2520antagonist%2520BAK2-66%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D647%26epage%3D651%26doi%3D10.1021%2Fml500006v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1208</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-19642-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1038%2Fs41598-018-19642-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29352161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1208&author=C.+J.+Draper-Joyceauthor=R.+K.+Vermaauthor=M.+Michinoauthor=J.+Shonbergauthor=A.+Kopinathanauthor=C.+Klein+Herenbrinkauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=A.+M.+Abramyanauthor=D.+M.+Thalauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=L.+Shiauthor=J.+R.+Lane&title=The+action+of+a+negative+allosteric+modulator+at+the+dopamine+D2+receptor+is+dependent+upon+sodium+ions&doi=10.1038%2Fs41598-018-19642-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span></div><div class="casAuthors">Draper-Joyce Christopher J; Klein Herenbrink Carmen; Thal David M; Christopoulos Arthur; Lane J Robert; Verma Ravi Kumar; Michino Mayako; Abramyan Ara M; Shi Lei; Michino Mayako; Shonberg Jeremy; Kopinathan Anitha; Scammells Peter J; Capuano Ben; Javitch Jonathan A; Javitch Jonathan A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sodium ions (Na(+)) allosterically modulate the binding of orthosteric agonists and antagonists to many class A G protein-coupled receptors, including the dopamine D2 receptor (D2R).  Experimental and computational evidences have revealed that this effect is mediated by the binding of Na(+) to a conserved site located beneath the orthosteric binding site (OBS).  SB269652 acts as a negative allosteric modulator (NAM) of the D2R that adopts an extended bitopic pose, in which the tetrahydroisoquinoline moiety interacts with the OBS and the indole-2-carboxamide moiety occupies a secondary binding pocket (SBP).  In this study, we find that the presence of a Na(+) within the conserved Na(+)-binding pocket is required for the action of SB269652.  Using fragments of SB269652 and novel full-length analogues, we show that Na(+) is required for the high affinity binding of the tetrahydroisoquinoline moiety within the OBS, and that the interaction of the indole-2-carboxamide moiety with the SBP determines the degree of Na(+)-sensitivity.  Thus, we extend our understanding of the mode of action of this novel class of NAM by showing it acts synergistically with Na(+) to modulate the binding of orthosteric ligands at the D2R, providing opportunities for fine-tuning of modulatory effects in future allosteric drug design efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvIHTTptFmHTToTC3aBaesfW6udTcc2eZqjeCG8_iHK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D&md5=7126d1cd2e69be311c508c596d81cc2f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-19642-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-19642-1%26sid%3Dliteratum%253Aachs%26aulast%3DDraper-Joyce%26aufirst%3DC.%2BJ.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520action%2520of%2520a%2520negative%2520allosteric%2520modulator%2520at%2520the%2520dopamine%2520D2%2520receptor%2520is%2520dependent%2520upon%2520sodium%2520ions%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D1208%26doi%3D10.1038%2Fs41598-018-19642-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e1005948</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1371%2Fjournal.pcbi.1005948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29337986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=e1005948&author=R.+K.+Vermaauthor=A.+M.+Abramyanauthor=M.+Michinoauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=L.+Shi&title=The+E2.65A+mutation+disrupts+dynamic+binding+poses+of+SB269652+at+the+dopamine+D2+and+D3+receptors&doi=10.1371%2Fjournal.pcbi.1005948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span></div><div class="casAuthors">Verma, Ravi Kumar; Abramyan, Ara M.; Michino, Mayako; Free, R. Benjamin; Sibley, David R.; Javitch, Jonathan A.; Lane, J. Robert; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1005948/1-e1005948/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The dopamine D2 and D3 receptors (D2R and D3R) are important targets for antipsychotics and for the treatment of drug abuse.  SB269652, a bitopic ligand that simultaneously binds both the orthosteric binding site (OBS) and a secondary binding pocket (SBP) in both D2R and D3R, was found to be a neg. allosteric modulator.  Previous studies identified Glu2.65 in the SBP to be a key determinant of both the affinity of SB269652 and the magnitude of its cooperativity with orthosteric ligands, as the E2.  A mutation decreased both of these parameters.  However, the proposed hydrogen bond (H-bond) between Glu2.65 and the indole moiety of SB269652 is not a strong interaction, and a structure activity relationship study of SB269652 indicates that this H-bond may not be the only element that dets. its allosteric properties.  To understand the structural basis of the obsd. phenotype of E2.65A, we carried out mol. dynamics simulations with a cumulative length of ∼77 μs of D2R and D3R wild-type and their E2.65A mutants bound to SB269652.  In combination with Markov state model anal. and by characterizing the equil. of ligand binding modes in different conditions, we found that in both D2R and D3R, whereas the tetrahydroisoquinoline moiety of SB269652 is stably bound in the OBS, the indole-2-carboxamide moiety is dynamic and only intermittently forms H-bonds with Glu2.65.  Our results also indicate that the E2.65A mutation significantly affects the overall shape and size of the SBP, as well as the conformation of the N terminus.  Thus, our findings suggest that the key role of Glu2.65 in mediating the allosteric properties of SB269652 extends beyond a direct interaction with SB269652, and provide structural insights for rational design of SB269652 derivs. that may retain its allosteric properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg1JueDgCVDrVg90H21EOLACvtfcHk0lgUithO5D4q7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ&md5=e7ff0bcc58a78f0292a5c1f1c820c151</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005948%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DThe%2520E2.65A%2520mutation%2520disrupts%2520dynamic%2520binding%2520poses%2520of%2520SB269652%2520at%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3De1005948%26doi%3D10.1371%2Fjournal.pcbi.1005948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein
Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2Fj.bcp.2018.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=29325769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosl2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=315-328&author=C.+J.+Draper-Joyceauthor=M.+Michinoauthor=R.+K.+Vermaauthor=C.+Klein%0AHerenbrinkauthor=J.+Shonbergauthor=A.+Kopinathanauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=D.+M.+Thalauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=L.+Shiauthor=J.+R.+Lane&title=The+structural+determinants+of+the+bitopic+binding+mode+of+a+negative+allosteric+modulator+of+the+dopamine+D2+receptor&doi=10.1016%2Fj.bcp.2018.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor</span></div><div class="casAuthors">Draper-Joyce, Christopher J.; Michino, Mayako; Verma, Ravi Kumar; Klein Herenbrink, Carmen; Shonberg, Jeremy; Kopinathan, Anitha; Scammells, Peter J.; Capuano, Ben; Thal, David M.; Javitch, Jonathan A.; Christopoulos, Arthur; Shi, Lei; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-328</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SB269652 is a neg. allosteric modulator of the dopamine D2 receptor (D2R) yet possesses structural similarity to ligands with a competitive mode of interaction.  In this study, we aimed to understand the ligand-receptor interactions that confer its allosteric action.  We combined site-directed mutagenesis with mol. dynamics simulations using both SB269652 and derivs. from our previous structure activity studies.  We identify residues within the conserved orthosteric binding site (OBS) and a secondary binding pocket (SBP) that det. affinity and cooperativity.  Our results indicate that interaction with the SBP is a requirement for allosteric pharmacol., but that both competitive and allosteric derivs. of SB269652 can display sensitivity to the mutation of a glutamate residue (E952.65) within the SBP.  Our findings provide the mol. basis for the differences in affinity between SB269652 derivs., and reveal how changes to interactions made by the primary pharmacophore of SB269652 in the orthosteric pocket can confer changes in the interactions made by the secondary pharmacophore in the SBP.  Our insights provide a structure-activity framework towards rational optimization of bitopic ligands for D2R with tailored competitive vs. allosteric properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcW9XzMctE47Vg90H21EOLACvtfcHk0lgUithO5D4q7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosl2luw%253D%253D&md5=a8c520e48173145a1f1a999312c724dc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DDraper-Joyce%26aufirst%3DC.%2BJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520structural%2520determinants%2520of%2520the%2520bitopic%2520binding%2520mode%2520of%2520a%2520negative%2520allosteric%2520modulator%2520of%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D148%26spage%3D315%26epage%3D328%26doi%3D10.1016%2Fj.bcp.2018.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Dai, D.</span>; <span class="NLM_string-name">Cai, J.</span>; <span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Hua, W.</span>; <span class="NLM_string-name">Jia, N.</span>; <span class="NLM_string-name">Li, M.</span>; <span class="NLM_string-name">Gu, L.</span></span> <span> </span><span class="NLM_article-title">Preparation Of Fused-Tricyclic Compounds For Treatment Of Central Nervous System Diseases</span>. CN <span class="NLM_patent">1948315</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Ji&author=D.+Dai&author=J.+Cai&author=Y.+Dai&author=W.+Hua&author=N.+Jia&author=M.+Li&author=L.+Gu&title=Preparation+Of+Fused-Tricyclic+Compounds+For+Treatment+Of+Central+Nervous+System+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DM.%26atitle%3DPreparation%2520Of%2520Fused-Tricyclic%2520Compounds%2520For%2520Treatment%2520Of%2520Central%2520Nervous%2520System%2520Diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allerton, C. M. N.</span>; <span class="NLM_string-name">Cook, A. S.</span>; <span class="NLM_string-name">Hepworth, D.</span>; <span class="NLM_string-name">Miller, D. C.</span></span> <span> </span><span class="NLM_article-title">Aminopyridine Derivatives As Selective Dopamine D3 Agonists</span>. WO <span class="NLM_patent">115985 Al</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=C.+M.+N.+Allerton&author=A.+S.+Cook&author=D.+Hepworth&author=D.+C.+Miller&title=Aminopyridine+Derivatives+As+Selective+Dopamine+D3+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllerton%26aufirst%3DC.%2BM.%2BN.%26atitle%3DAminopyridine%2520Derivatives%2520As%2520Selective%2520Dopamine%2520D3%2520Agonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span> <span> </span><span class="NLM_article-title">Morpholine Dopamine Agonists For The Treatment Of Pain</span>. WO <span class="NLM_patent">087512 A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=M.+A.+Ackley&title=Morpholine+Dopamine+Agonists+For+The+Treatment+Of+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAckley%26aufirst%3DM.%2BA.%26atitle%3DMorpholine%2520Dopamine%2520Agonists%2520For%2520The%2520Treatment%2520Of%2520Pain%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. H.</span>; <span class="NLM_string-name">Wyvratt, M. J.</span></span> <span> </span><span class="NLM_article-title">Morpholine Derivatives Compositions And Use</span>. U.S. Patent <span class="NLM_patent">5,124,328 A</span>, <span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=M.+H.+Fisher&author=M.+J.+Wyvratt&title=Morpholine+Derivatives+Compositions+And+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BH.%26atitle%3DMorpholine%2520Derivatives%2520Compositions%2520And%2520Use%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn-Sims, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawreen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugolenski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majchrzak, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormos, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A. N.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00297</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1eltr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=165-177&author=T.+T.+Wagerauthor=T.+Chappieauthor=D.+Hortonauthor=R.+Y.+Chandrasekaranauthor=B.+Samasauthor=E.+R.+Dunn-Simsauthor=C.+Hsuauthor=N.+Nawreenauthor=M.+A.+Vanase-Frawleyauthor=R.+E.+O%E2%80%99Connorauthor=C.+J.+Schmidtauthor=K.+Dlugolenskiauthor=N.+C.+Stratmanauthor=M.+J.+Majchrzakauthor=B.+L.+Kormosauthor=D.+P.+Nguyenauthor=A.+Sawant-Basakauthor=A.+N.+Mead&title=Dopamine+D3%2FD2+receptor+antagonist+PF-4363467+attenuates+opioid+drug-seeking+behavior+without+concomitant+D2+side+effects&doi=10.1021%2Facschemneuro.6b00297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects</span></div><div class="casAuthors">Wager, Travis T.; Chappie, Thomas; Horton, David; Chandrasekaran, Ramalakshmi Y.; Samas, Brian; Dunn-Sims, Elizabeth R.; Hsu, Cathleen; Nawreen, Nawshaba; Vanase-Frawley, Michelle A.; O'Connor, Rebecca E.; Schmidt, Christopher J.; Dlugolenski, Keith; Stratman, Nancy C.; Majchrzak, Mark J.; Kormos, Bethany L.; Nguyen, David P.; Sawant-Basak, Aarti; Mead, Andy N.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-177</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine receptor antagonism is a compelling mol. target for the treatment of a range of psychiatric disorders, including substance use disorders.  From the authors' corporate compd. file the authors identified a structurally unique D3 receptor (D3R) antagonist scaffold, PNU-177864.  Through a hybrid approach, the authors merged key pharmacophore elements from PNU-177864 and D3 agonist PF-592379 to yield the novel D3R/D2R antagonist PF-4363467.  PF-4363467 was designed to possess CNS drug-like properties as defined by its CNS MPO desirability score (≥4/6).  In addn. to good physicochem. properties, PF-4363467 exhibited low nanomolar affinity for the D3R (D3 Ki = 3.2 nM), good subtype selectivity over D2R (D2 Ki = 692 nM), and high selectivity for D3R vs. other biogenic amine receptors.  In vivo, PF-4363467 dose-dependently attenuated opioid self-administration and opioid drug-seeking behavior in a rat operant reinstatement model using animals trained to self-administer fentanyl.  Further, traditional extrapyramidal symptoms (EPS), adverse side effects arising from D2R antagonism, were not obsd. despite high D2 receptor occupancy (RO) in rodents, suggesting that compd. PF-4363467 has a unique in vivo profile.  Collectively, the authors' data support further investigation of dual D3R and D2R antagonists for the treatment of drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkblTSt1t8cbVg90H21EOLACvtfcHk0li84GW5evYyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1eltr7M&md5=abd6262987e08cb98b00d8057a52dc4f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00297%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DChappie%26aufirst%3DT.%26aulast%3DHorton%26aufirst%3DD.%26aulast%3DChandrasekaran%26aufirst%3DR.%2BY.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DDunn-Sims%26aufirst%3DE.%2BR.%26aulast%3DHsu%26aufirst%3DC.%26aulast%3DNawreen%26aufirst%3DN.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DDlugolenski%26aufirst%3DK.%26aulast%3DStratman%26aufirst%3DN.%2BC.%26aulast%3DMajchrzak%26aufirst%3DM.%2BJ.%26aulast%3DKormos%26aufirst%3DB.%2BL.%26aulast%3DNguyen%26aufirst%3DD.%2BP.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%2BN.%26atitle%3DDopamine%2520D3%252FD2%2520receptor%2520antagonist%2520PF-4363467%2520attenuates%2520opioid%2520drug-seeking%2520behavior%2520without%2520concomitant%2520D2%2520side%2520effects%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D165%26epage%3D177%26doi%3D10.1021%2Facschemneuro.6b00297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attkins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heatherington, A. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.3109/00498254.2010.514961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.3109%2F00498254.2010.514961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=20836725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OgsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=730-742&author=N.+Attkinsauthor=A.+Bettsauthor=D.+Hepworthauthor=A.+C.+Heatherington&title=Pharmacokinetics+and+elucidation+of+the+rates+and+routes+of+N-glucuronidation+of+PF-592379%2C+an+oral+dopamine+3+agonist+in+rat%2C+dog%2C+and+human&doi=10.3109%2F00498254.2010.514961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human</span></div><div class="casAuthors">Attkins, Neil; Betts, Alison; Hepworth, David; Heatherington, Anne C.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">730-742</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">PF-592379 is a potent, selective agonist of the dopamine 3 receptor, for the treatment of male erectile dysfunction and female sexual dysfunction.  In vivo, PF-592379 has low-moderate clearance relative to liver blood flow of 6.3 and 8.5 mL/min/kg in dog and 44.8 and 58.2 mL/min/kg in rat.  It has high permeability in Caco-2 cells and was completely absorbed in rat and dog pharmacokinetic studies with an oral bioavailability of 28% in both rats and 61 and 87% in the dogs.  These data are consistent with the physicochem. properties of PF-592379, which indicate complete absorption by the transcellular route.  Elimination of PF-592379 was predominantly metabolic in nature.  In vitro routes of metab. studies indicate that metab. in the rat is a combination of P 450 mechanisms and N-glucuronidation, whereas in dog and human, N-glucuronidation is the major route.  NMR anal. indicates that N-glucuronidation is non-quaternary in nature and occurs on both the pyridyl amine and ring nitrogen.  Rates of clearance via N-glucuronidation were predicted to be low in humans compared with acyl or phenolic glucuronidation.  PF-592379 was predicted to have complete absorption from the gastrointestinal tract and an oral bioavailability of >60% in the clinic.  Clin. data verified that PF-592379 is a low clearance compd. in human, with a mean oral clearance of 6.5 mL/min/kg following a 200 mg oral dose. PF-592379 has ideal pharmacokinetic properties for an oral D3 agonist, intended for on demand dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOuUcyl_LeyLVg90H21EOLACvtfcHk0li84GW5evYyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OgsbnL&md5=6fe4382d8c39ed1887f2bc0289252f0a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3109%2F00498254.2010.514961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2010.514961%26sid%3Dliteratum%253Aachs%26aulast%3DAttkins%26aufirst%3DN.%26aulast%3DBetts%26aufirst%3DA.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHeatherington%26aufirst%3DA.%2BC.%26atitle%3DPharmacokinetics%2520and%2520elucidation%2520of%2520the%2520rates%2520and%2520routes%2520of%2520N-glucuronidation%2520of%2520PF-592379%252C%2520an%2520oral%2520dopamine%25203%2520agonist%2520in%2520rat%252C%2520dog%252C%2520and%2520human%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D40%26spage%3D730%26epage%3D742%26doi%3D10.3109%2F00498254.2010.514961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberhofer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, S. B.</span></span> <span> </span><span class="NLM_article-title">Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1097/fbp.0b013e3283536d21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1097%2Ffbp.0b013e3283536d21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=22470105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=280-291&author=G.+T.+Collinsauthor=P.+Butlerauthor=C.+Waymanauthor=S.+Ratcliffeauthor=P.+Guptaauthor=G.+Oberhoferauthor=S.+B.+Caine&title=Lack+of+abuse+potential+in+a+highly+selective+dopamine+D3+agonist%2C+PF-592%2C379%2C+in+drug+self-administration+and+drug+discrimination+in+rats&doi=10.1097%2Ffbp.0b013e3283536d21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats</span></div><div class="casAuthors">Collins, Gregory T.; Butler, Paul; Wayman, Chris; Ratcliffe, Sian; Gupta, Paul; Oberhofer, Geoffrey; Caine, S. Barak</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-291</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Dopamine D3-preferring agonists are commonly used to treat Parkinson's disease and restless leg syndrome; however, lab. animal studies suggest that they may possess a moderate abuse potential.  These studies aimed to compare the highly selective, full D3 agonist PF-592,379 to the less selective D3 agonist 7-OH-DPAT, and the indirect dopamine agonist cocaine in drug self-administration and discrimination assays.  Although rats readily acquired high rates of fixed ratio (FR)1 responding for cocaine, exptl. naive rats failed to acquire responding when 7-OH-DPAT or PF-592,379 was made available during an 18-session acquisition period.  Cocaine also maintained dose-dependent levels of responding when available under a FR5 or a progressive ratio (PR) schedule of reinforcement.  Although 7-OH-DPAT maintained modest levels of responding when substituted under a FR5, it failed to maintain significant levels of PR responding.  PF-592,379 maintained saline-like rates of responding when substituted under FR5 or PR schedules of reinforcement.  Similar behavioral profiles were obsd. in cocaine discrimination assays, with 7-OH-DPAT partially substituting for cocaine, and PF-592,379 producing saline-like effects over a wide range of doses.  Together, the results of these studies predict that highly selective D3 agonists, such as PF-592,379, will have low abuse potential in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRBvTK9AL8fbVg90H21EOLACvtfcHk0liWIovlbU1ZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oisrg%253D&md5=bf0671e1e1174cbcd5143a4dfeb20c84</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1097%2Ffbp.0b013e3283536d21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Ffbp.0b013e3283536d21%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DButler%26aufirst%3DP.%26aulast%3DWayman%26aufirst%3DC.%26aulast%3DRatcliffe%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DOberhofer%26aufirst%3DG.%26aulast%3DCaine%26aufirst%3DS.%2BB.%26atitle%3DLack%2520of%2520abuse%2520potential%2520in%2520a%2520highly%2520selective%2520dopamine%2520D3%2520agonist%252C%2520PF-592%252C379%252C%2520in%2520drug%2520self-administration%2520and%2520drug%2520discrimination%2520in%2520rats%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2012%26volume%3D23%26spage%3D280%26epage%3D291%26doi%3D10.1097%2Ffbp.0b013e3283536d21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, S. B.</span></span> <span> </span><span class="NLM_article-title">Effects of acute and chronic treatments with dopamine D2 and D3 receptor ligands on cocaine versus food choice in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.241141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fjpet.117.241141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=28473458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=161-176&author=M.+Thomsenauthor=A.+C.+Barrettauthor=P.+Butlerauthor=S.+S.+Negusauthor=S.+B.+Caine&title=Effects+of+acute+and+chronic+treatments+with+dopamine+D2+and+D3+receptor+ligands+on+cocaine+versus+food+choice+in+rats&doi=10.1124%2Fjpet.117.241141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of acute and chronic treatments with dopamine D2 and D3 receptor ligands on cocaine versus food choice in rats</span></div><div class="casAuthors">Thomsen, Morgane; Barrett, Andrew C.; Butler, Paul; Negus, S. Stevens; Caine, S. Barak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-176</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dopamine D3 receptor ligands are potential medications for psychostimulant addiction.  Medication assessment may benefit from preclin. studies that evaluate chronic medication effects on choice between an abused drug and an alternative, nondrug reinforcer.  This study compared acute and chronic effects of dopamine D2- and D3-preferring ligands on choice between i.v. cocaine and palatable food in rats.  Under baseline conditions, cocaine maintained dose-dependent increases in cocaine choice and reciprocal decreases in food choice.  Acutely, the D2 agonist R-(-)-norpropylapomorphine (NPA) and antagonist L-741,626 [3-[[4-(4-chlorophenyl)-4-hydroxypiperidin-l-yl]methyl-1H-indole]] produced leftward and rightward shifts in cocaine dose-effect curves, resp., whereas the partial agonist terguride had no effect.  All three drugs dose-dependently decreased food-maintained responding.  Chronically, the effects of R-(-)-norpropylapomorphine and L-741,626 on cocaine self-administration showed marked tolerance, whereas suppression of food-reinforced behavior persisted.  Acute effects of the D3 ligands were less systematic and most consistent with nonselective decreases in cocaine- and food-maintained responding.  Chronically, the D3 agonist PF-592,379 [5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine] increased cocaine choice, whereas an intermediate dose of the D3 antagonist PG01037 [N-[(E)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-pyridin-2-ylbenzamide] produced a therapeutically desirable decrease in cocaine choice early in treatment; however, tolerance to this effect developed, and lower and higher doses were ineffective.  D3 ligands failed to significantly modify total cocaine intake but caused persistent decreases in food intake.  Thus, D2-and D3-preferring ligands showed distinct profiles, consistent with different pharmacol. actions.  In addn., these results highlight the role of acute vs. chronic treatment as a determinant of test drug effects.  With the possible exception of the D3 antagonist PG01037, no ligand was promising in terms of cocaine addiction treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7F9zB3ud9_rVg90H21EOLACvtfcHk0liWIovlbU1ZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbzN&md5=581bbdcd95f3ca589db0dc67e1b1ccaa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241141%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DA.%2BC.%26aulast%3DButler%26aufirst%3DP.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DCaine%26aufirst%3DS.%2BB.%26atitle%3DEffects%2520of%2520acute%2520and%2520chronic%2520treatments%2520with%2520dopamine%2520D2%2520and%2520D3%2520receptor%2520ligands%2520on%2520cocaine%2520versus%2520food%2520choice%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D161%26epage%3D176%26doi%3D10.1124%2Fjpet.117.241141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElveen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1021/jm049465g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049465g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=839-848&author=P.+Grundtauthor=E.+E.+Carlsonauthor=J.+Caoauthor=C.+J.+Bennettauthor=E.+McElveenauthor=M.+Taylorauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Novel+heterocyclic+trans+olefin+analogues+of+N-%7B4-%5B4-%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dbutyl%7Darylcarboxamides+as+selective+probes+with+high+affinity+for+the+dopamine+D3+receptor&doi=10.1021%2Fjm049465g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor</span></div><div class="casAuthors">Grundt, Peter; Carlson, Erin E.; Cao, Jianjing; Bennett, Christina J.; McElveen, Elizabeth; Taylor, Michelle; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine.  However, definitive pharmacol. investigations have been hampered by the lack of highly D3 receptor selective compds. that can be used in vivo.  To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl}-amide, Ki (hD3) = 2.0 nM, Ki (hD2L) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chem. modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity.  A series of >30 novel analogs were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2L, D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist 125I-IABN.  Structural diversity in the aryl amide end of the mol. was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine.  Several analogs demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand.  Compd. 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide) displayed the most promising pharmacol. profile (Ki (hD3) = 0.7 nM, Ki (hD2L) = 93.3 nM, D2/D3 selectivity ratio of 133).  In addn., this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM.  Compd. 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM).  Moreover, a decrease in c log D value of ∼2 orders of magnitude was detd. for this novel D3-receptor-preferring ligand, compared to 1.  In summary, chem. modification of 1 has resulted in compds. with high affinity and selectivity for D3 receptors.  The most promising candidate, compd. 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofDgtp4SPuC7Vg90H21EOLACvtfcHk0liWIovlbU1ZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D&md5=080af9d0e167912621f35c40020c534b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049465g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049465g%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCarlson%26aufirst%3DE.%2BE.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DC.%2BJ.%26aulast%3DMcElveen%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520heterocyclic%2520trans%2520olefin%2520analogues%2520of%2520N-%257B4-%255B4-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dbutyl%257Darylcarboxamides%2520as%2520selective%2520probes%2520with%2520high%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D839%26epage%3D848%26doi%3D10.1021%2Fjm049465g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">The “cyclopropyl fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8712</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8712-8756&author=T.+T.+Talele&title=The+%E2%80%9Ccyclopropyl+fragment%E2%80%9D+is+a+versatile+player+that+frequently+appears+in+preclinical%2Fclinical+drug+molecules&doi=10.1021%2Facs.jmedchem.6b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8712-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclin. to clin. stage.  Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes.  The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs contg. it.  Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflux ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIJAG1XVRG7Vg90H21EOLACvtfcHk0liWIovlbU1ZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D&md5=b5586458ec4ab5e2d7586f5739663d1f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DThe%2520%25E2%2580%259Ccyclopropyl%2520fragment%25E2%2580%259D%2520is%2520a%2520versatile%2520player%2520that%2520frequently%2520appears%2520in%2520preclinical%252Fclinical%2520drug%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8712%26epage%3D8756%26doi%3D10.1021%2Facs.jmedchem.6b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongetti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBounty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of selectivity and efficacy at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6699</span>, <span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+determinants+of+selectivity+and+efficacy+at+the+dopamine+D3+receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0lgAPph-rrw2cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520determinants%2520of%2520selectivity%2520and%2520efficacy%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dijkstra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, T. B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollema, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der
Weide, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, A. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2178</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1021/jm00119a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00119a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL1cXlvFSgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=2178-2182&author=D.+Dijkstraauthor=T.+B.+A.+Mulderauthor=H.+Rollemaauthor=P.+G.+Tepperauthor=J.+Van+der%0AWeideauthor=A.+S.+Horn&title=Synthesis+and+pharmacology+of+trans-4-n-propyl-3%2C4%2C4a%2C10b-tetrahydro-2H%2C5H-1-benzopyrano%5B4%2C3-b+%5D-1%2C4-oxazin-7-+and+-9-ols%3A+the+significance+of+nitrogen+pKa+values+for+central+dopamine+receptor+activation&doi=10.1021%2Fjm00119a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b]1,4-oxazin-7- and -9-ols.  The significance of nitrogen pka values for central dopamine receptor activation</span></div><div class="casAuthors">Dijkstra, Durk; Mulder, Theo B. A.; Rollema, Hans; Tepper, Pieter G.; Van der Weide, Jan; Horn, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2178-82</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The 6-oxa analogs I (X = O, R = OH, R = 1H; R = H, R1 = OH) of potent dopamine agonists, hexahydronaphthoxazines I (X = CH2, R = OH, R1 = H; R = H, R1 = OH) were tested for dopamine receptor binding and stimulating activity, and were almost inactive.  PKa value detns. indicated that I (X = O) are protonated to ∼2%, while potent compds. are protonated to a much greater extent.  These results strongly support the assumption that the protonated forms of dopamine agonists are the active species at the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofF_Dd2wqo0LVg90H21EOLACvtfcHk0lgAPph-rrw2cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlvFSgsbg%253D&md5=b3ba385865eb357aba2228dc418bd134</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm00119a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00119a020%26sid%3Dliteratum%253Aachs%26aulast%3DDijkstra%26aufirst%3DD.%26aulast%3DMulder%26aufirst%3DT.%2BB.%2BA.%26aulast%3DRollema%26aufirst%3DH.%26aulast%3DTepper%26aufirst%3DP.%2BG.%26aulast%3DVan%2Bder%2BWeide%26aufirst%3DJ.%26aulast%3DHorn%26aufirst%3DA.%2BS.%26atitle%3DSynthesis%2520and%2520pharmacology%2520of%2520trans-4-n-propyl-3%252C4%252C4a%252C10b-tetrahydro-2H%252C5H-1-benzopyrano%255B4%252C3-b%2520%255D-1%252C4-oxazin-7-%2520and%2520-9-ols%253A%2520the%2520significance%2520of%2520nitrogen%2520pKa%2520values%2520for%2520central%2520dopamine%2520receptor%2520activation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D2178%26epage%3D2182%26doi%3D10.1021%2Fjm00119a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devries, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and dopaminergic activity of a new oxygen isostere of the 2-aminotetralins: N, N-dipropyl-8-hydroxy-3-chromanamine</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/0223-5234(88)90203-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2F0223-5234%2888%2990203-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL1MXhtFClsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1988&pages=325-328&author=A.+Hornauthor=B.+Kapteinauthor=N.+Vermueauthor=J.+Devriesauthor=T.+Mulder&title=Synthesis+and+dopaminergic+activity+of+a+new+oxygen+isostere+of+the+2-aminotetralins%3A+N%2C+N-dipropyl-8-hydroxy-3-chromanamine&doi=10.1016%2F0223-5234%2888%2990203-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and dopaminergic activity of a new oxygen isostere of the 2-aminotetralins:  N,N-dipropyl-8-hydroxy-3-chromanamine</span></div><div class="casAuthors">Horn, Alan S.; Kaptein, Bernard; Vermue, Niek A.; De Vries, Jan B.; Mulder, Theo B. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">325-8</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">The synthesis of N,N-dipropyl-8-hydroxy-3-chromanamine (I) from 8-methoxy-4-chromanone oxime in 7 steps is described.  This compd. is an oxygen isostere of the dopamine (DA) receptor agonist N,N-dipropyl-5-hydroxy-2-aminotetralin.  In in vitro and in vivo tests of dopaminergic activity showed I to be a more potent DA agonist than apomorphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcokbwXgnKUrVg90H21EOLACvtfcHk0lgAPph-rrw2cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtFClsbg%253D&md5=3df5601efeba8701ba745a537cabcf6e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0223-5234%2888%2990203-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0223-5234%252888%252990203-6%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DA.%26aulast%3DKaptein%26aufirst%3DB.%26aulast%3DVermue%26aufirst%3DN.%26aulast%3DDevries%26aufirst%3DJ.%26aulast%3DMulder%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520dopaminergic%2520activity%2520of%2520a%2520new%2520oxygen%2520isostere%2520of%2520the%25202-aminotetralins%253A%2520N%252C%2520N-dipropyl-8-hydroxy-3-chromanamine%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1988%26volume%3D23%26spage%3D325%26epage%3D328%26doi%3D10.1016%2F0223-5234%2888%2990203-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hembre, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J. R.</span></span> <span> </span><span class="NLM_article-title">Conversion of olefins to ditriflates by .mu.-oxobis[(trifluoromethanesulfonato)(phenyl)iodine]</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3650</span>– <span class="NLM_lpage">3654</span>, <span class="refDoi"> DOI: 10.1021/jo00392a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00392a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL2sXltFCqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1987&pages=3650-3654&author=R.+T.+Hembreauthor=C.+P.+Scottauthor=J.+R.+Norton&title=Conversion+of+olefins+to+ditriflates+by+.mu.-oxobis%5B%28trifluoromethanesulfonato%29%28phenyl%29iodine%5D&doi=10.1021%2Fjo00392a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of olefins to ditriflates by μ-oxobis[(trifluoromethanesulfonato)(phenyl)iodine]</span></div><div class="casAuthors">Hembre, Robert T.; Scott, Carl P.; Norton, Jack R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3650-4</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">(CF3SO3IPh)2O (I) was prepd. from iodosobenzene and triflic anhydride and used for the mild, single-step conversion of olefins to vicinal ditriflates and of dienes to 1,4-ditriflates.  The reaction of I with cyclohexene and cis- and trans-ethylene-1,2-d2 results in syn addn.  In the latter case, 3JHH from the 13C sidebands in the [2H]1H NMR shows that the ditriflates from the use of I have the same stereochem. as those prepd. from cis- and trans-ethylene-1,2-d2 via catalytic OsO4 oxidn.  The obsd. temp. dependence of the 13C sidebands of these ditriflates is consistent with greater stability of the rotamer contg. gauche triflate groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2U9ijxT9067Vg90H21EOLACvtfcHk0ljtEOVWrDsdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltFCqu7o%253D&md5=bf04de02729dcd93cdd2bfec9698af42</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjo00392a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00392a028%26sid%3Dliteratum%253Aachs%26aulast%3DHembre%26aufirst%3DR.%2BT.%26aulast%3DScott%26aufirst%3DC.%2BP.%26aulast%3DNorton%26aufirst%3DJ.%2BR.%26atitle%3DConversion%2520of%2520olefins%2520to%2520ditriflates%2520by%2520.mu.-oxobis%255B%2528trifluoromethanesulfonato%2529%2528phenyl%2529iodine%255D%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1987%26volume%3D52%26spage%3D3650%26epage%3D3654%26doi%3D10.1021%2Fjo00392a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevatt, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresca, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4146</span>, <span class="refDoi"> DOI: 10.1021/jm0704200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0704200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVWitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4135-4146&author=P.+Grundtauthor=K.+M.+Prevattauthor=J.+Caoauthor=M.+Taylorauthor=C.+Z.+Florescaauthor=J.-K.+Choiauthor=B.+G.+Jenkinsauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Heterocyclic+analogues+of+N-%284-%284-%282%2C3-dichlorophenyl%29piperazin-1-yl%29butyl%29arylcarboxamides+with+functionalized+linking+chains+as+novel+dopamine+D3+receptor+ligands%3A+potential+substance+abuse+therapeutic+agents&doi=10.1021%2Fjm0704200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclic Analogues of N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with Functionalized Linking Chains as Novel Dopamine D3 Receptor Ligands: Potential Substance Abuse Therapeutic Agents</span></div><div class="casAuthors">Grundt, Peter; Prevatt, Katherine M.; Cao, Jianjing; Taylor, Michelle; Floresca, Christina Z.; Choi, Ji-Kyung; Jenkins, Bruce G.; Luedtke, Robert R.; Hauck Newman, Amy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4135-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor antagonists and partial agonists have been shown to modulate drug-seeking effects induced by cocaine and other abused substances.  Compd. 6 [PG01037, (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-trans-but-2-enyl)-4-pyridine-2-ylbenzamide)] and related analogs are currently being evaluated in animal models of drug addiction.  In these studies, a discrepancy between in vitro binding affinity, in vivo occupancy, and behavioral potency has been obsd.  The purpose of this study was to examine (1) modifications of the 2-pyridylphenyl moiety of 6 and (2) hydroxyl, acetyl, and cyclopropyl substitutions on the butylamide linking chain systematically coupled with 2-fluorenylamide or 2-pyridylphenylamide and 2-methoxy- or 2,3-dichloro-substituted phenylpiperazines to measure the impact on binding affinity, D2/D3 selectivity, lipophilicity, and function.  In general, these modifications were well tolerated at the human dopamine D3 (hD3) receptor (Ki = 1-5 nM) as measured in competition binding assays.  Several analogs showed >100-fold selectivity for dopamine D3 over D2 and D4 receptors.  In addn., while all the derivs. with an olefinic linker were antagonists, in quinpirole-stimulated mitogenesis at hD3 receptors, several of the hydroxybutyl-linked analogs (16, 17, 21) showed partial agonist activity.  Finally, several structural modifications reduced lipophilicities while retaining the desired binding profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVBkV6gsuYUrVg90H21EOLACvtfcHk0ljtEOVWrDsdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVWitLY%253D&md5=594bd5ab15004fbdf521ddaee4698b96</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm0704200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0704200%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DPrevatt%26aufirst%3DK.%2BM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DFloresca%26aufirst%3DC.%2BZ.%26aulast%3DChoi%26aufirst%3DJ.-K.%26aulast%3DJenkins%26aufirst%3DB.%2BG.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHeterocyclic%2520analogues%2520of%2520N-%25284-%25284-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%2529butyl%2529arylcarboxamides%2520with%2520functionalized%2520linking%2520chains%2520as%2520novel%2520dopamine%2520D3%2520receptor%2520ligands%253A%2520potential%2520substance%2520abuse%2520therapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4135%26epage%3D4146%26doi%3D10.1021%2Fjm0704200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurer, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, H. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiherpetic activity of (.+-.)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2304</span>– <span class="NLM_lpage">2315</span>, <span class="refDoi"> DOI: 10.1021/jm00120a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00120a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADyaL1MXisVahtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=2304-2315&author=W.+T.+Ashtonauthor=L.+C.+Meurerauthor=C.+L.+Cantoneauthor=A.+K.+Fieldauthor=J.+Hannahauthor=J.+D.+Karkasauthor=R.+Liouauthor=G.+F.+Patelauthor=H.+C.+Perry&title=Synthesis+and+antiherpetic+activity+of+%28.%2B-.%29-9-%5B%5B%28Z%29-2-%28hydroxymethyl%29cyclopropyl%5Dmethyl%5Dguanine+and+related+compounds&doi=10.1021%2Fjm00120a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiherpetic activity of (±)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds</span></div><div class="casAuthors">Ashton, Wallace T.; Meurer, Laura Canning; Cantone, Christine L.; Field, A. Kirk; Hannah, John; Karkas, John D.; Liou, Richard; Patel, Gool F.; Perry, Helen C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2304-15</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of analogs of acyclovir and ganciclovir were prepd. in which conformational constraints were imposed by incorporation of a cyclopropane ring or unsatn. into the side chain.  In addn., several related base-modified compds. were synthesized.  These acyclonucleosides were evaluated for enzymic phosphorylation and DNA polymerase inhibition in a staggered assay and for inhibitory activity against herpes simplex virus types 1 and 2 in vitro.  Certain of the guanine or 8-azaguanine derivs. were good substrates for the viral thymidine kinase and were further converted to triphosphate, but none was a potent inhibitor of the viral DNA polymerase.  Nevertheless, one member of this group, (±)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine (I), displayed significant antiherpetic activity in vitro, superior to that of the corresponding cis olefin II.  Another group, typified by (±)-9-[[(E[)-2-(hydroxymethyl)cyclopropyl]methyl]adenine, possessed modest antiviral activity despite an apparent inability to be enzymically phosphorylated.  The relationship of side-chain conformation and flexibility to biol. activity in this series is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEZAxB9bZ67bVg90H21EOLACvtfcHk0liEr_FV-KeZ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXisVahtg%253D%253D&md5=ef49d6f68f24bd6f9f0e49d329ba3fa3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm00120a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00120a010%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DW.%2BT.%26aulast%3DMeurer%26aufirst%3DL.%2BC.%26aulast%3DCantone%26aufirst%3DC.%2BL.%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DHannah%26aufirst%3DJ.%26aulast%3DKarkas%26aufirst%3DJ.%2BD.%26aulast%3DLiou%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DG.%2BF.%26aulast%3DPerry%26aufirst%3DH.%2BC.%26atitle%3DSynthesis%2520and%2520antiherpetic%2520activity%2520of%2520%2528.%252B-.%2529-9-%255B%255B%2528Z%2529-2-%2528hydroxymethyl%2529cyclopropyl%255Dmethyl%255Dguanine%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D2304%26epage%3D2315%26doi%3D10.1021%2Fjm00120a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span> <span> </span><span class="NLM_article-title">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1124%2Fmol.115.101808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=26843180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=457-466&author=M.+Sanchez-Sotoauthor=A.+Bonifaziauthor=N.+S.+Caiauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=S.+Ferreauthor=H.+Yano&title=Evidence+for+noncanonical+neurotransmitter+activation%3A+norepinephrine+as+a+dopamine+D2-like+receptor+agonist&doi=10.1124%2Fmol.115.101808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span></div><div class="casAuthors">Sanchez-Soto, Marta; Bonifazi, Alessandro; Cai, Ning Sheng; Ellenberger, Michael P.; Newman, Amy Hauck; Ferre, Sergi; Yano, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-466</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Gαi/o-coupled dopamine D2-like receptor family comprises three subtypes: the D2 receptor (D2R), with short and long isoform variants (D2SR and D2LR), D3 receptor (D3R), and D4 receptor (D4R), with several polymorphic variants.  The common overlap of norepinephrine innervation and D2-like receptor expression patterns prompts the question of a possible noncanonical action by norepinephrine.  In fact, previous studies have suggested that norepinephrine can functionally interact with D4R.  To our knowledge, significant interactions between norepinephrine and D2R or D3R receptors have not been demonstrated.  By using radioligand binding and bioluminescent resonance energy transfer (BRET) assays in transfected cells, the present study attempted a careful comparison between dopamine and norepinephrine in their possible activation of all D2-like receptors, including the two D2R isoforms and the most common D4R polymorphic variants.  Functional BRET assays included activation of G proteins with all Gαi/o subunits, adenylyl cyclase inhibition, and β arrestin recruitment.  Norepinephrine acted as a potent agonist for all D2-like receptor subtypes, with the general rank order of potency of D3R > D4R ≥ D2SR ≥ D2L.  However, for both dopamine and norepinephrine, differences depended on the Gαi/o protein subunit involved.  The most striking differenceswere obsd. with Gαi2, where the rank order of potencies for both dopamine and norepinephrine were D4R > D2SR = D2LR >> D3R.  Furthermore the results do not support the existence of differences in the ability of dopamine and norepinephrine to activate different human D4R variants.  The potency of norepinephrine for adrenergic α2A receptor was only about 20-fold higher compared with D3R and D4R across the three functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbXqWDRdlAsrVg90H21EOLACvtfcHk0liEr_FV-KeZ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN&md5=df11300a8c0bb71ef35b5d2917bee471</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101808%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Soto%26aufirst%3DM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DH.%26atitle%3DEvidence%2520for%2520noncanonical%2520neurotransmitter%2520activation%253A%2520norepinephrine%2520as%2520a%2520dopamine%2520D2-like%2520receptor%2520agonist%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D457%26epage%3D466%26doi%3D10.1124%2Fmol.115.101808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urs, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span> <span> </span><span class="NLM_article-title">Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E8178</span>– <span class="NLM_lpage">E8186</span>, <span class="refDoi"> DOI: 10.1073/pnas.1614347113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1073%2Fpnas.1614347113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=27911814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOgs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E8178-E8186&author=N.+M.+Ursauthor=S.+M.+Geeauthor=T.+F.+Packauthor=J.+D.+McCorvyauthor=T.+Evronauthor=J.+C.+Snyderauthor=X.+Yangauthor=R.+M.+Rodriguizauthor=E.+Borrelliauthor=W.+C.+Wetselauthor=J.+Jinauthor=B.+L.+Rothauthor=P.+O%E2%80%99Donnellauthor=M.+G.+Caron&title=Distinct+cortical+and+striatal+actions+of+a+beta-arrestin-biased+dopamine+D2+receptor+ligand+reveal+unique+antipsychotic-like+properties&doi=10.1073%2Fpnas.1614347113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties</span></div><div class="casAuthors">Urs, Nikhil M.; Gee, Steven M.; Pack, Thomas F.; McCorvy, John D.; Evron, Tama; Snyder, Joshua C.; Yang, Xiaobao; Rodriguiz, Ramona M.; Borrelli, Emiliana; Wetsel, William C.; Jin, Jian; Roth, Bryan L.; O'Donnell, Patricio; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">E8178-E8186</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The current dopamine (DA) hypothesis of schizophrenia postulates striatal hyperdopaminergia and cortical hypodopaminergia.  Although partial agonists at DA D2 receptors (D2Rs), like aripiprazole, were developed to simultaneously target both phenomena, they do not effectively improve cortical dysfunction.  In this study, we investigate the potential for newly developed β-arrestin2 (βarr2)-biased D2R partial agonists to simultaneously target hyper- and hypodopaminergia.  Using neuron-specific βarr2-KO mice, we show that the antipsychotic-like effects of a βarr2-biased D2R ligand are driven through both striatal antagonism and cortical agonism of D2R-βarr2 signaling.  Furthermore, βarr2-biased D2R agonism enhances firing of cortical fast-spiking interneurons.  This enhanced cortical agonism of the biased ligand can be attributed to a lack of G-protein signaling and elevated expression of βarr2 and G protein-coupled receptor (GPCR) kinase 2 in the cortex vs. the striatum.  Therefore, we propose that βarr2-biased D2R ligands that exert region-selective actions could provide a path to develop more effective antipsychotic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8kMnf0ZjPbVg90H21EOLACvtfcHk0liEr_FV-KeZ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOgs7rL&md5=872fc6c6026a01fa4d48bad545f51b61</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1614347113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1614347113%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DGee%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DEvron%26aufirst%3DT.%26aulast%3DSnyder%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DBorrelli%26aufirst%3DE.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDistinct%2520cortical%2520and%2520striatal%2520actions%2520of%2520a%2520beta-arrestin-biased%2520dopamine%2520D2%2520receptor%2520ligand%2520reveal%2520unique%2520antipsychotic-like%2520properties%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE8178%26epage%3DE8186%26doi%3D10.1073%2Fpnas.1614347113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D(2) receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7141</span>– <span class="NLM_lpage">7153</span>, <span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-functional+selectivity+relationship+studies+of+beta-arrestin-biased+dopamine+D%282%29+receptor+agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D2 Receptor Agonists</span></div><div class="casAuthors">Chen, Xin; Sassano, Maria F.; Zheng, Lianyou; Setola, Vincent; Chen, Meng; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7141-7153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side effects of drugs.  However, few such ligands have been created, and very little purposeful attention has been devoted to studying what we term: "structure-functional selectivity relationships" (SFSR).  We recently disclosed the first β-arrestin-biased dopamine D2 receptor (D2R) agonists UNC9975 (44) and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities.  Here we report the first comprehensive SFSR studies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery of these β-arrestin-biased D2R agonists.  These studies provide a successful proof-of-concept for how functionally selective ligands can be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoG1fasQ6GLVg90H21EOLACvtfcHk0liAR1iTTblZRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK&md5=00b0613e62ce7b5a4c98cb5212fea3b5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-functional%2520selectivity%2520relationship%2520studies%2520of%2520beta-arrestin-biased%2520dopamine%2520D%25282%2529%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armarego, W. L. F.</span>; <span class="NLM_string-name">Chai, C.</span></span> <i>Purification of Laboratory Chemicals</i>, <span class="NLM_edition">6</span>th ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Burlington</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2FB978-1-85617-567-8.50011-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.+L.+F.+Armarego&author=C.+Chai&title=Purification+of+Laboratory+Chemicals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FB978-1-85617-567-8.50011-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-1-85617-567-8.50011-1%26sid%3Dliteratum%253Aachs%26aulast%3DArmarego%26aufirst%3DW.%2BL.%2BF.%26btitle%3DPurification%2520of%2520Laboratory%2520Chemicals%26pub%3DElsevier%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung-Chi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i74"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00702">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32371"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00702">10.1021/acs.jmedchem.9b00702</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chiral HPLC analyses of final products, bidimensional <sup>1</sup>H NMR spectra of compounds <b>30</b> and <b>31</b>, analytical data summary of all final products, crystal structure and structure refinement of <b>(−)-(1<i>R</i>,2<i>S</i>)-41a</b> and <b>(2<i>R</i>,5<i>S</i>)-23a</b>, and SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_001.pdf">jm9b00702_si_001.pdf (1.47 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00702/suppl_file/jm9b00702_si_002.csv">jm9b00702_si_002.csv (3.78 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00702" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00702" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679972b358423d8e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
